

Appendix A: Detailed Electronic Database Search Strategies

PubMed Strategy

Search	String
#1	"kidney failure, chronic"[mh]
#2	Renal[tiab]
#3	Kidney[tiab]
#4	Dialysis[tiab]
#5	Hemodialysis[tiab]
#6	Haemodialysis[tiab]
#7	#1 OR #2 OR #3 OR #4 OR #5 OR #6
#8	"acute coronary syndrome"[mh]
#9	"acute coronary syndrome"[tiab] OR "acute coronary syndromes"[tiab]
#10	"angina, unstable"[mh]
#11	"unstable angina"[tiab]
#12	"myocardial infarction"[tiab]
#13	"Non-ST-segment elevation"[tiab] OR "non-ST-elevation"[tiab] OR "non-ST elevation"[tiab] OR "ST-segment elevation"[tiab] OR "ST-elevation"[tiab] OR "ST elevation"[tiab] OR (elevation[tiab] AND (ST[tiab] OR "S-T"[tiab] OR "ST-segment"[tiab]))
#14	Acute[tiab]
#15	#12 AND (#13 OR #14)
#16	#8 OR #9 OR #10 OR #11 OR #15
#17	"Troponin I"[mh] OR "Troponin T"[mh]
#18	Troponin*[tiab]
#19	#17 OR #18
#20	(#7 AND #16) OR (#7 AND #19)
#21	(animal[mh] NOT human [mh])
#22	Addresses[pt] OR Autobiography[pt] OR Bibliography[pt] OR Biography[pt] OR "Case Reports"[pt] OR "Classical Article"[pt] OR "Clinical Conference"[pt] OR "Collected Works"[pt] OR Comment[pt] OR Congresses[pt] OR "Consensus Development Conference"[pt] OR "Consensus Development Conference, NIH"[pt] OR Dictionary[pt] OR Directory[pt] OR Editorial[pt] OR "Legal Cases"[pt] OR Legislation[pt] OR News[pt] OR "Newspaper Article"[pt] OR Portraits[pt]
#23	#20 NOT #21 NOT #22 Publication date from 1990/01/01

EMBASE Strategy

Search	String	Hits
#1	'chronic kidney failure'/exp	54230
#2	"Renal":ti,ab	525969
#3	"Kidney":ti,ab	330513
#4	"Dialysis":ti,ab	96520
#5	"Hemodialysis":ti,ab	55567
#6	"Haemodialysis":ti,ab	14180
#7	#1 OR #2 OR #3 OR #4 OR #5 OR #6	822852
#8	'acute coronary syndrome'/exp	26253
#9	"acute coronary syndrome":ti,ab OR "acute coronary syndromes":ti,ab	23742
#10	'unstable angina pectoris'/exp	16558
#11	"unstable angina":ti,ab	13871
#12	"myocardial infarction":ti,ab	13871
#13	"Non-ST-segment elevation":ti,ab OR "non-ST-elevation":ti,ab OR "non-ST elevation":ti,ab OR "ST-segment elevation":ti,ab OR "ST-elevation":ti,ab OR "ST elevation":ti,ab OR ("elevation":ti,ab AND ("ST":ti,ab OR "S-T":ti,ab OR "ST-segment":ti,ab))	22318
#14	"acute":ti,ab	1009558
#15	#12 AND (#13 OR #14)	83038
#16	#8 OR #9 OR #10 OR #11 OR #15	116007
#17	'Troponin i'/exp OR 'Troponin T'/exp	18483
#18	Troponin*:ti,ab	19501
#19	#17 OR #18	24191
#20	(#7 AND #16) OR (#7 AND #19)	6618
#21	([animals]/lim NOT [humans]/lim)	4534849
#22	'conference abstracts':it OR 'conference paper':it OR 'conference reviews':it OR editorial:it OR erratum:it OR letter:it OR note:it	2578437
#23	#20 NOT #21 NOT #22	6172
#24	Publication date from 1990	5831

Cochrane Strategy

Search	String	Hits
#1	"kidney failure, chronic":ti,ab,kw	3704
#2	Renal:ti,ab,kw	22257
#3	Kidney:ti,ab,kw	17529
#4	Dialysis:ti,ab,kw	6781
#5	Hemodialysis:ti,ab,kw	3612
#6	Haemodialysis:ti,ab,kw	1015
#7	#1 OR #2 OR #3 OR #4 OR #5 OR #6	28862
#8	"acute coronary syndrome":ti,ab,kw	1026
#9	"acute coronary syndrome":ti,ab,kw OR "acute coronary syndromes":ti,ab,kw	1706
#10	"angina, unstable":ti,ab,kw	882
#11	"unstable angina":ti,ab,kw	1797
#12	"myocardial infarction":ti,ab,kw	13540
#13	"Non-ST-segment elevation":ti,ab,kw OR "non-ST-elevation":ti,ab,kw OR "non-ST elevation":ti,ab,kw OR "ST-segment elevation":ti,ab,kw OR "ST-elevation":ti,ab,kw OR "ST elevation":ti,ab,kw OR (elevation:ti,ab,kw AND (ST:ti,ab,kw OR "S-T":ti,ab,kw OR "ST-segment":ti,ab,kw))	1876
#14	Acute:ti,ab,kw	54681
#15	#12 AND (#13 OR #14)	7163
#16	#8 OR #9 OR #10 OR #11 OR #15	8958
#17	"Troponin I":ti,ab,kw OR "Troponin T":ti,ab,kw	911
#18	Troponin*:ti,ab,kw	1006
#19	#17 OR #18	1012
#20	(#7 AND #16) OR (#7 AND #19)	274
	Publication date from 1990/01/01 and only trials	244

Appendix B: Forms

Title Review

Refid: 12, Skateboards: Are they really perilous? A retrospective study from a district hospital.
Rethnam U, Yesupalan RS, Sinha A.

and go to or Skip to Next

Is this article POTENTIALLY relevant to our review? Yes No Clear Response

and go to or Skip to Next

Abstract Review

Refid: 12, Skateboards: Are they really perilous? A retrospective study from a district hospital.
Rethnam U, Yesupalan RS, Sinha A.

BACKGROUND: Skateboarding has been a popular sport among teenagers even with its attendant associated risks. The literature is packed with articles regarding the perils of skateboards. Is the skateboard as dangerous as has been portrayed?

METHODS: This was a retrospective study conducted over a 5 year period. All skateboard related injuries seen in the Orthopaedic unit were identified and data collated on patient demographics, mechanism & location of injury, annual incidence, type of injury, treatment needed including hospitalisation.

RESULTS: We encountered 50 patients with skateboard related injuries. Most patients were males and under the age of 15. The annual incidence has remained low at about 10. The upper limb was predominantly involved with most injuries being fractures. Most injuries occurred during summer. The commonest treatment modality was plaster immobilisation. The distal radius was the commonest bone to be fractured. There were no head & neck injuries, open fractures or injuries requiring surgical intervention.

CONCLUSION: Despite its negative image among the medical fraternity, the skateboard does not appear to be a dangerous sport with a low incidence and injuries encountered being not severe. Skateboarding should be restricted to supervised skateboard parks and skateboarders should wear protective gear. These measures would reduce the number of skateboarders injured in motor vehicle collisions, reduce the personal injuries among skateboarders, and reduce the number of pedestrians injured in collisions with skateboarders.

and go to or Skip to Next

Troponin Systematic Review Abstract Review Form

1. *Exclude* article if: (check the first response that applies)

- No **original** data (e.g., review article, commentary, editorial)
- Conference **abstract**
- Only includes patients with **normal renal function**
- Case report**
- Does not apply to the **key questions**
- No **human** subjects
- Published prior to **1990**
- Other** reason for exclusion (specify):

2. *Unclear*

- Unclear- pull article for review
- Unclear if Troponin included as a biomarker

3. *Include*

- Include article for review

5. Handsearch

- Exclude article from review, but pull for handsearching (i.e. systematic review published since 2000)

Comments (please limit to 250 characters):

and go to or Skip to Next

Article Review

Refid: 12, Skateboards: Are they really perilous? A retrospective study from a district hospital.

Rethnam U, Yesupalan RS, Sinha A.

BACKGROUND: Skateboarding has been a popular sport among teenagers even with its attendant associated risks. The literature is packed with articles regarding the perils of skateboards. Is the skateboard as dangerous as has been portrayed?

METHODS: This was a retrospective study conducted over a 5 year period. All skateboard related injuries seen in the Orthopaedic unit were identified and data collated on patient demographics, mechanism & location of injury, annual incidence, type of injury, treatment needed including hospitalisation.

RESULTS: We encountered 50 patients with skateboard related injuries. Most patients were males and under the age of 15. The annual incidence has remained low at about 10. The upper limb was predominantly involved with most injuries being fractures. Most injuries occurred during summer. The commonest treatment modality was plaster immobilisation. The distal radius was the commonest bone to be fractured. There were no head & neck injuries, open fractures or injuries requiring surgical intervention.

CONCLUSION: Despite its negative image among the medical fraternity, the skateboard does not appear to be a dangerous sport with a low incidence and injuries encountered being not severe. Skateboarding should be restricted to supervised skateboard parks and skateboarders should wear protective gear. These measures would reduce the number of skateboarders injured in motor vehicle collisions, reduce the personal injuries among skateboarders, and reduce the number of pedestrians injured in collisions with skateboarders.

and go to or Skip to Next

Troponin Systematic Review Article Review Form

1. Exclude article if. (check the first response that applies)

- No **original data** (e.g., review article, commentary, editorial)
- Meeting abstract
- Published prior to **1990**
- Does not include patients with **chronic kidney disease or end-stage renal disease**
- Does not evaluate **troponin I or T levels**
- Troponin & CKD results not presented separately
- No **human** subjects
- Does not evaluate a **comparison of interest**
- Does not evaluate an **outcome of interest**
- Does not apply to a **key question**
- Other reason for exclusion (specify):

2. Include article for review (indicate the main intervention of interest):

- KQ1 (diagnostic performance of troponin testing for detection of ACS in patients with CKD)
- KQ2 (do troponin levels improve management in patients with ACS and CKD)
- KQ3 (troponin and prognostication of patients with ACS and CKD)
- KQ4 (troponin help risk stratification in adults with CKD and no ACS symptoms)

3. Reference

- Exclude article from review, but pull for handsearching (i.e. systematic review published since 2000)
- Flag for background (i.e. discusses troponin prevalence for clearance in CKD population)

Comments (limit 250 characters)

and go to or Skip to Next

Study Design

Refid: 12, Skateboards: Are they really perilous? A retrospective study from a district hospital.
Rethnam U, Yesupalan RS, Sinha A.

and go to or Skip to Next

Troponin EPC Study Design Form

1. Where did the study occur?

- United States
- Canada
- Europe
- Worldwide
- Other (specify):

2. When was the study enrollment? (Enter the 4-digit year for the start and end dates)

- Start date:
- End date:
- Not reported

3. What was the length of followup?

- Days (mean):
- Days (median):
- Weeks (mean):
- Weeks (median):
- Months (mean):
- Months (median):
- Years (mean):
- Years (median):
- Maximum followup time
- Not reported

4. What was the total number at enrollment or cohort inception?

- Total:
- CKD Patients:
- Not reported

5. What study design was used?

- Post-hoc analysis of an RCT
 - Prospective cohort
 - Retrospective cohort
 - Case control
 - Other study design (specify):
- Clear Response

6. What was the setting?

- Outpatient
- Emergency department
- Hospital
- Other (specify):

7. Did the study include patients presenting with symptoms of acute coronary syndrome?

- Yes
 - No
 - Not reported
- Clear Response

8. How was acute coronary syndrome defined?

- ICD-9 codes
- Adjudicated (e.g. panel of physicians adjudicated cases)
- Other method (specify):

9. Was a cardiologist involved in the adjudication?

- Yes
- No
- Not reported
- [Clear Response](#)

10. How was it adjudicated?

- Single adjudicator
- Panel adjudicator (specify number):
- Not specified
- [Clear Response](#)

11. What definition was used to adjudicate?

- Global consensus on MI
- ACC/AHA
- Other (specified):
- Not reported

12. What stages of chronic kidney disease were included?

- CKD (combined stages 1-4)
- Stage 1 (eGFR: 90+)
- Stage 2 (eGFR: 60-89)
- Stage 3 (eGFR: 30-59)
- Stage 4 (eGFR: 15-29)
- Stage 5 (eGFR: <15)
- Dialysis
- Kidney transplant patients
- Creatinine level <
- Creatinine level >
- Other (specify):
- Not reported

13. What equation was used to define GFR?

- MDRD
- CKD Epi formula
- Creatinine available, but GFR not provided
- Cockcroft-Gault
- Other (specify):
- Not reported

14. Other exclusion criteria

- Age <
- Age >
- Other (specify):
- Other (specify):
- Other (specify):
- Other (specify):
- Not reported

15. Did the study present a subgroup analysis on:

- Gender
- Age
- Ethnicity
- Stage of kidney disease
- Dialysis status
- Status post renal transplant
- Presence of baseline or prior elevated troponins
- Presence of ischemic EKG changes
- 10-year CHD risk
- History of CAD
- No subgroups

16. Comments

and go to or Skip to Next

Population characteristics

Refid: 12, Skateboards: Are they really perilous? A retrospective study from a district hospital.
Rethnam U, Yesupalan RS, Sinha A.

[Submit Form](#) and go to or Skip to Next

Troponin EPC Population Characteristics Form

Please record baseline characteristics for each group below.

Assign groups in the following order:

- TBD

	Group 1	Group 2	Group 3
Group Name	<input type="checkbox"/> Total Sample <input type="checkbox"/> Other (specify): <input type="text"/>	<input type="radio"/> Other: <input type="text"/> Clear Response	<input type="radio"/> Other: <input type="text"/> Clear Response
Number enrolled	<input type="text"/>	<input type="text"/>	<input type="text"/>
Age <input type="radio"/> Age not reported Clear Response	<input type="checkbox"/> Mean: <input type="text"/> <input type="checkbox"/> Median: <input type="text"/>	<input type="checkbox"/> Mean: <input type="text"/> <input type="checkbox"/> Median: <input type="text"/>	<input type="checkbox"/> Mean: <input type="text"/> <input type="checkbox"/> Median: <input type="text"/>
Gender <input type="radio"/> Gender not reported Clear Response	<input type="checkbox"/> Male, n: <input type="text"/> <input type="checkbox"/> Male, %: <input type="text"/>	<input type="checkbox"/> Male, n: <input type="text"/> <input type="checkbox"/> Male, %: <input type="text"/>	<input type="checkbox"/> Male, n: <input type="text"/> <input type="checkbox"/> Male, %: <input type="text"/>
Dialysis status <input type="radio"/> Dialysis status not reported Clear Response	<input type="checkbox"/> On dialysis, n: <input type="text"/> <input type="checkbox"/> On dialysis, %: <input type="text"/>	<input type="checkbox"/> On dialysis, n: <input type="text"/> <input type="checkbox"/> On dialysis, %: <input type="text"/>	<input type="checkbox"/> On dialysis, n: <input type="text"/> <input type="checkbox"/> On dialysis, %: <input type="text"/>
Known CAD <input type="radio"/> Known CAD not reported Clear Response	<input type="checkbox"/> Known CAD, n: <input type="text"/> <input type="checkbox"/> Known CAD, %: <input type="text"/>	<input type="checkbox"/> Known CAD, n: <input type="text"/> <input type="checkbox"/> Known CAD, %: <input type="text"/>	<input type="checkbox"/> Known CAD, n: <input type="text"/> <input type="checkbox"/> Known CAD, %: <input type="text"/>
Stage of Kidney Disease <input type="radio"/> Stage kidney disease not reported Clear Response	<input type="checkbox"/> 1, n: <input type="text"/> <input type="checkbox"/> 1, %: <input type="text"/> <input type="checkbox"/> 2, n: <input type="text"/> <input type="checkbox"/> 2, %: <input type="text"/> <input type="checkbox"/> 3, n: <input type="text"/> <input type="checkbox"/> 3, %: <input type="text"/> <input type="checkbox"/> 4, n: <input type="text"/> <input type="checkbox"/> 4, %: <input type="text"/> <input type="checkbox"/> 5, n: <input type="text"/> <input type="checkbox"/> 5, %: <input type="text"/>	<input type="checkbox"/> 1, n: <input type="text"/> <input type="checkbox"/> 1, %: <input type="text"/> <input type="checkbox"/> 2, n: <input type="text"/> <input type="checkbox"/> 2, %: <input type="text"/> <input type="checkbox"/> 3, n: <input type="text"/> <input type="checkbox"/> 3, %: <input type="text"/> <input type="checkbox"/> 4, n: <input type="text"/> <input type="checkbox"/> 4, %: <input type="text"/> <input type="checkbox"/> 5, n: <input type="text"/> <input type="checkbox"/> 5, %: <input type="text"/>	<input type="checkbox"/> 1, n: <input type="text"/> <input type="checkbox"/> 1, %: <input type="text"/> <input type="checkbox"/> 2, n: <input type="text"/> <input type="checkbox"/> 2, %: <input type="text"/> <input type="checkbox"/> 3, n: <input type="text"/> <input type="checkbox"/> 3, %: <input type="text"/> <input type="checkbox"/> 4, n: <input type="text"/> <input type="checkbox"/> 4, %: <input type="text"/> <input type="checkbox"/> 5, n: <input type="text"/> <input type="checkbox"/> 5, %: <input type="text"/>
GFR levels <input type="radio"/> GFR not reported Clear Response	<input type="checkbox"/> Mean: <input type="text"/> <input type="checkbox"/> Median: <input type="text"/>	<input type="checkbox"/> Mean: <input type="text"/> <input type="checkbox"/> Median: <input type="text"/>	<input type="checkbox"/> Mean: <input type="text"/> <input type="checkbox"/> Median: <input type="text"/>
Race/Ethnicity <input type="radio"/> Not reported Clear Response	<input type="checkbox"/> White, n: <input type="text"/> <input type="checkbox"/> White, %: <input type="text"/> <input type="checkbox"/> African American, n: <input type="text"/> <input type="checkbox"/> African American, %: <input type="text"/> <input type="checkbox"/> Hispanic, n: <input type="text"/> <input type="checkbox"/> Hispanic, %: <input type="text"/> <input type="checkbox"/> Other, n: <input type="text"/> <input type="checkbox"/> Other, %: <input type="text"/>	<input type="checkbox"/> White, n: <input type="text"/> <input type="checkbox"/> White, %: <input type="text"/> <input type="checkbox"/> African American, n: <input type="text"/> <input type="checkbox"/> African American, %: <input type="text"/> <input type="checkbox"/> Hispanic, n: <input type="text"/> <input type="checkbox"/> Hispanic, %: <input type="text"/> <input type="checkbox"/> Other, n: <input type="text"/> <input type="checkbox"/> Other, %: <input type="text"/>	<input type="checkbox"/> White, n: <input type="text"/> <input type="checkbox"/> White, %: <input type="text"/> <input type="checkbox"/> African American, n: <input type="text"/> <input type="checkbox"/> African American, %: <input type="text"/> <input type="checkbox"/> Hispanic, n: <input type="text"/> <input type="checkbox"/> Hispanic, %: <input type="text"/> <input type="checkbox"/> Other, n: <input type="text"/> <input type="checkbox"/> Other, %: <input type="text"/>

Comments:

Comments:

[Submit Form](#) and go to or Skip to Next

Key Question 1 Outcomes

Refid: 12, Skateboards: Are they really perilous? A retrospective study from a district hospital.
 Rethnam U, Yesupalan RS, Sinha A.

and go to or Skip to Next

Troponin EPC Outcomes Form-KQ1

Please describe only one outcome and one reference group per form

This is data for:

- Total sample
 Subgroup (specify):

Describe the characteristics of the index test(s)

Index test #	Assay	Manufacturer	Assay used	Cut-off value for normal	Timing	99th upper reference
Index test #1	<input type="button" value="Select an Answer"/>					
Index test #2	<input type="button" value="Select an Answer"/>					

1. How was acute coronary syndrome defined?

- ICD-9 codes
 Adjudicated (e.g. panel of physicians adjudicated cases)
 Other method (specify):

2. How was it adjudicated?

- Single adjudicator
 Panel adjudicator (specify number):
 Not specified

3. Was a cardiologist involved in the adjudication?

- Yes
 No
 Not reported

4. What definition was used to adjudicate?

- Global Consensus on MI
 ACC/AHA
 Other (specified):
 Not reported

	Reference standard (+)	Reference standard (-)	Total
Index test (+ elevated troponin)	True positives (A) <input type="text"/>	False positives (B) <input type="text"/>	A + B <input type="text"/>
Index test (- normal troponin)	False negative (C) <input type="text"/>	True negative (D) <input type="text"/>	C + D <input type="text"/>
Total	A + C <input type="text"/>	B + D <input type="text"/>	N <input type="text"/>

PLEASE NOTE: FORMULAS ARE PROVIDED FOR YOUR REFERENCE. PLEASE DO NOT MANUALLY CALCULATE ANY VALUES

	Value	Measure of variability	95% Confidence Interval
		<input type="button" value="Select an Answer"/>	

Sensitivity A / (A+C)	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> UL <input type="text"/> <input type="checkbox"/> LL <input type="text"/>
Specificity D / (B+D)	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> UL <input type="text"/> <input type="checkbox"/> LL <input type="text"/>
% positive agreement A / (A+ C)	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> UL <input type="text"/> <input type="checkbox"/> LL <input type="text"/>
% negative agreement D / (B+D)	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> UL <input type="text"/> <input type="checkbox"/> LL <input type="text"/>
Positive likelihood ratio	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> UL <input type="text"/> <input type="checkbox"/> LL <input type="text"/>
Negative likelihood ratio	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> UL <input type="text"/> <input type="checkbox"/> LL <input type="text"/>
Positive predictive value	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> UL <input type="text"/> <input type="checkbox"/> LL <input type="text"/>
Negative predictive value	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> UL <input type="text"/> <input type="checkbox"/> LL <input type="text"/>
AUC	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> UL <input type="text"/> <input type="checkbox"/> LL <input type="text"/>
% false-positive tests B / (B+D)	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> UL <input type="text"/> <input type="checkbox"/> LL <input type="text"/>
% false-negative tests C / (A+C)	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> UL <input type="text"/> <input type="checkbox"/> LL <input type="text"/>
Test accuracy	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> UL <input type="text"/> <input type="checkbox"/> LL <input type="text"/>

Comments

and go to or Skip to Next

Key Question 2-4 Outcomes

Refid: 12, Skateboards: Are they really perilous? A retrospective study from a district hospital.
Rethnam U, Yesupalan RS, Sinha A.

and go to or Skip to Next

Troponin EPC
Outcomes Form-KQ2-4

Please describe only one outcome per form

This is data for:

- Total sample
- Subgroup (specify):
- Clear Response

Please indicate the outcome being reported

Outcome	Adjudicated	Definition	Followup
All-cause mortality <input type="radio"/> select Clear Response	Select an Answer <input type="button" value="v"/>	<input type="radio"/> Define: <input type="text"/> <input type="radio"/> Not specified Clear Response	<input type="checkbox"/> days <input type="text"/> <input type="checkbox"/> weeks <input type="text"/> <input type="checkbox"/> months <input type="text"/> <input type="checkbox"/> years <input type="text"/> <input type="checkbox"/> Not reported
Cardiovascular mortality <input type="radio"/> select Clear Response	Select an Answer <input type="button" value="v"/>	<input type="radio"/> Define: <input type="text"/> <input type="radio"/> Not specified Clear Response	<input type="checkbox"/> days <input type="text"/> <input type="checkbox"/> weeks <input type="text"/> <input type="checkbox"/> months <input type="text"/> <input type="checkbox"/> years <input type="text"/> <input type="checkbox"/> Not reported
Subsequent myocardial infarction <input type="radio"/> select Clear Response	Select an Answer <input type="button" value="v"/>	<input type="radio"/> Define: <input type="text"/> <input type="radio"/> Not specified Clear Response	<input type="checkbox"/> days <input type="text"/> <input type="checkbox"/> weeks <input type="text"/> <input type="checkbox"/> months <input type="text"/> <input type="checkbox"/> years <input type="text"/> <input type="checkbox"/> Not reported
Stroke <input type="radio"/> select Clear Response	Select an Answer <input type="button" value="v"/>	<input type="radio"/> Define: <input type="text"/> <input type="radio"/> Not specified Clear Response	<input type="checkbox"/> days <input type="text"/> <input type="checkbox"/> weeks <input type="text"/> <input type="checkbox"/> months <input type="text"/> <input type="checkbox"/> years <input type="text"/> <input type="checkbox"/> Not reported
Hospital readmission rate <input type="radio"/> select Clear Response	Select an Answer <input type="button" value="v"/>	<input type="radio"/> Define: <input type="text"/> <input type="radio"/> Not specified Clear Response	<input type="checkbox"/> days <input type="text"/> <input type="checkbox"/> weeks <input type="text"/> <input type="checkbox"/> months <input type="text"/> <input type="checkbox"/> years <input type="text"/> <input type="checkbox"/> Not reported
Composite outcome (check all that apply) <input type="checkbox"/> ≥ 1 year MACE rates <input type="checkbox"/> < 1 year MACE rate <input type="checkbox"/> Revascularization	Select an Answer <input type="button" value="v"/>	<input type="radio"/> Define: <input type="text"/> <input type="radio"/> Not specified Clear Response	<input type="checkbox"/> days <input type="text"/> <input type="checkbox"/> weeks <input type="text"/> <input type="checkbox"/> months <input type="text"/> <input type="checkbox"/> years <input type="text"/> <input type="checkbox"/> Not reported
Other major adverse event (select one) Select an Answer <input type="button" value="v"/>	Select an Answer <input type="button" value="v"/>	<input type="radio"/> Define: <input type="text"/> <input type="radio"/> Not specified Clear Response	<input type="checkbox"/> days <input type="text"/> <input type="checkbox"/> weeks <input type="text"/> <input type="checkbox"/> months <input type="text"/>

			<input type="checkbox"/> years <input type="text"/> <input type="checkbox"/> Not reported
--	--	--	--

Please record how the troponin was categorized

Group	Assay	Manufacturer	Assay used	Troponin Level
Group 1	Select an Answer	Select an Answer	Select an Answer	<input type="checkbox"/> > __ng/L <input type="text"/> <input type="checkbox"/> < __ng/L <input type="text"/> <input type="checkbox"/> > __ug/L <input type="text"/> <input type="checkbox"/> < __ug/L <input type="text"/> <input type="checkbox"/> Other: <input type="text"/> <input type="checkbox"/> Other: <input type="text"/>
Group 2	Select an Answer	Select an Answer	Select an Answer	<input type="checkbox"/> > __ng/L <input type="text"/> <input type="checkbox"/> < __ng/L <input type="text"/> <input type="checkbox"/> > __ug/L <input type="text"/> <input type="checkbox"/> < __ug/L <input type="text"/> <input type="checkbox"/> Other: <input type="text"/> <input type="checkbox"/> Other: <input type="text"/>
Group 3	Select an Answer	Select an Answer	Select an Answer	<input type="checkbox"/> > __ng/L <input type="text"/> <input type="checkbox"/> < __ng/L <input type="text"/> <input type="checkbox"/> > __ug/L <input type="text"/> <input type="checkbox"/> < __ug/L <input type="text"/> <input type="checkbox"/> Other: <input type="text"/> <input type="checkbox"/> Other: <input type="text"/>
Group 4	Select an Answer	Select an Answer	Select an Answer	<input type="checkbox"/> > __ng/L <input type="text"/> <input type="checkbox"/> < __ng/L <input type="text"/> <input type="checkbox"/> > __ug/L <input type="text"/> <input type="checkbox"/> < __ug/L <input type="text"/> <input type="checkbox"/> Other: <input type="text"/> <input type="checkbox"/> Other: <input type="text"/>
Group 5	Select an Answer	Select an Answer	Select an Answer	<input type="checkbox"/> > __ng/L <input type="text"/> <input type="checkbox"/> < __ng/L <input type="text"/> <input type="checkbox"/> > __ug/L <input type="text"/> <input type="checkbox"/> < __ug/L <input type="text"/> <input type="checkbox"/> Other: <input type="text"/> <input type="checkbox"/> Other: <input type="text"/>

Table 1. Incidence of Outcome

Group	N for analysis	Outcome measure	Denominator	p-value	Reference group
Group 1	<input type="text"/>	<input type="checkbox"/> # of patients with one or more events: <input type="text"/> <input type="checkbox"/> % of patients with one or more events: <input type="text"/> <input type="checkbox"/> # of events: <input type="text"/>	Select an Answer	<input type="text"/>	Select an Answer
Group 2	<input type="text"/>	<input type="checkbox"/> # of patients with one or more events: <input type="text"/> <input type="checkbox"/> % of patients with one or more events: <input type="text"/> <input type="checkbox"/> # of events: <input type="text"/>	Select an Answer	<input type="text"/>	Select an Answer
Group 3	<input type="text"/>	<input type="checkbox"/> # of patients with one or more events: <input type="text"/> <input type="checkbox"/> % of patients with one or more events: <input type="text"/> <input type="checkbox"/> # of events: <input type="text"/>	Select an Answer	<input type="text"/>	Select an Answer

Group 4	<input type="text"/>	<input type="checkbox"/> # of patients with one or more events: <input type="text"/> <input type="checkbox"/> % of patients with one or more events: <input type="text"/> <input type="checkbox"/> # of events: <input type="text"/>	Select an Answer ▾	<input type="text"/>
Group 5	<input type="text"/>	<input type="checkbox"/> # of patients with one or more events: <input type="text"/> <input type="checkbox"/> % of patients with one or more events: <input type="text"/> <input type="checkbox"/> # of events: <input type="text"/>	Select an Answer ▾	<input type="text"/>

Table 2. Measure of Association

Group	N for analysis	Point estimate	Measure of variability	95% CI	P-value
		Select an Answer ▾	Select an Answer ▾		
Group 1	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> UL <input type="text"/> <input type="checkbox"/> LL <input type="text"/>	<input type="text"/>
Group 2	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> UL <input type="text"/> <input type="checkbox"/> LL <input type="text"/>	<input type="text"/>
Group 3	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> UL <input type="text"/> <input type="checkbox"/> LL <input type="text"/>	<input type="text"/>
Group 4	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> UL <input type="text"/> <input type="checkbox"/> LL <input type="text"/>	<input type="text"/>
Group 5	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> UL <input type="text"/> <input type="checkbox"/> LL <input type="text"/>	<input type="text"/>

Is the above data adjusted?

- Yes, adjusted
 No, not adjusted
 Clear Response

If a multivariable analysis, what other variables were adjusted for in the model?

- Age
 Sex
 Race/ethnicity
 History of coronary artery disease
 Other
 Other
 Other
 Other
 Other
 Other

Table 3. AUC values

	Value	P-value	95% Confidence Interval
AUC Value	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> UL <input type="text"/> <input type="checkbox"/> LL <input type="text"/>
Sensitivity	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> UL <input type="text"/> <input type="checkbox"/> LL <input type="text"/>
Specificity	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> UL <input type="text"/> <input type="checkbox"/> LL <input type="text"/>

Comments

and go to or Skip to Next

Study Quality

Refid: 12, Skateboards: Are they really perilous? A retrospective study from a district hospital.

Rethnam U, Yesupalan RS, Sinha A.

and go to or Skip to Next

Troponin EPC Downs and Black Checklist for Measuring Study Quality

REPORTING

1. Is the hypothesis/aim/objective of the study clearly described?

- Yes
 No
[Clear Response](#)

2. Are the main outcomes to be measured clearly described in the Introduction or Methods section?

If the main outcomes are first mentioned in the Results section, the question should be answered 'no.'

- Yes
 No
[Clear Response](#)

3. Are the characteristics of the subjects included in the study clearly described?

In trials, inclusion and/or exclusion criteria should be given.

- Yes
 No
[Clear Response](#)

4. Are the tests of interest clearly described?

Tests results (where relevant) that are to be compared should be clearly described.

- Yes
 No
[Clear Response](#)

5. Are the distributions of principal confounders in each group of subjects to be compared clearly described?

A list of principal confounders is provided.

- Yes
 No
[Clear Response](#)

6. Are the main findings of the study clearly described?

Simple outcome data (including denominators and numerators) should be reported for all major findings so that the reader can check the major analyses and conclusions. (This question does not cover statistical tests which are considered below).

- Yes
 No
[Clear Response](#)

7. Does the study provide estimates of the random variability in the data for the main outcomes?

In non-normally distributed data the inter-quartile range of results should be reported. In normally distributed data the standard error, standard deviation or confidence intervals should be reported. If the distribution of the data is not described, it must be assumed that the estimates used were appropriate and the question should be answered 'yes.'

- Yes
 No
[Clear Response](#)

8. Have the characteristics of subjects lost to follow-up been described?

This should be answered 'yes' where there were no losses to follow-up or where losses to follow-up were so small that findings would be unaffected by their inclusion. This should be answered 'no' where a study does not report the number of patients lost to follow-up.

- Yes
 No
[Clear Response](#)

9. Have actual probability values been reported (e.g. 0.035 rather than <0.05) for the main

outcomes except where the probability value is less than 0.001?

- Yes
 No
[Clear Response](#)

EXTERNAL VALIDITY

10. Were the subjects asked to participate in the study representative of the entire population from which they were recruited?

The study must identify the source population for patients and describe how the patients were selected. Subjects would be representative if they comprised the entire source population, an unselected sample of consecutive patients, or a random sample. Random sampling is only feasible where a list of all members of the relevant population exists. Where a study does not report the proportion of the source population from which the subjects are derived, the question should be answered 'unable to determine.'

- Yes
 No
 Unable to determine
[Clear Response](#)

11. Were those subjects who were prepared to participate representative of the entire population from which they were recruited?

The proportion of those asked who agreed should be stated. Validation that the sample was representative would include demonstrating that the distribution of the main confounding factors was the same in the study sample and the source population.

- Yes
 No
 Unable to determine
[Clear Response](#)

12. Were the staff, places, and facilities where the subjects were treated/tested representative of the testing the majority of subjects receive?

For the question to be answered 'yes' the study should demonstrate that the testing was representative of that in use in the source population. The question should be answered 'no' if, for example, the testing was undertaken in a specialist center unrepresentative of the hospitals most of the source population would attend.

- Yes
 No
 Unable to determine
[Clear Response](#)

INTERNAL VALIDITY-BIAS

13. Was an attempt made to blind those measuring the main outcomes of the testing strategy?

- Yes
 No
 Unable to determine
 Not feasible
[Clear Response](#)

14. If any of the results of the study were based on "data dredging", was this made clear?

Any analyses that had not been planned at the outset of the study should be clearly indicated. If no retrospective unplanned subgroup analyses were reported, then answer 'yes.'

- Yes
 No
 Unable to determine
[Clear Response](#)

15. In trials and cohort studies, do the analyses adjust for different lengths of follow-up of patients?

Where follow-up was the same for all study participants the answer should be 'yes.' If different lengths of follow-up were adjusted, for example, by survival analysis, the answer should be 'yes.' Studies where differences in follow-up are ignored should be answered 'no.'

- Yes
 No
 Unable to determine
 Not applicable (i.e. no followup for this type of study)
[Clear Response](#)

16. Were the statistical tests used to assess the main outcomes appropriate?

The statistical techniques used must be appropriate to the data. For example nonparametric methods should be used for small sample sizes. Where little statistical analysis has been undertaken but where there is no evidence of bias, the question should be answered 'yes.' If the distribution of the data (normal or not) is not described it must be assumed that the estimates used were appropriate and the question should be answered 'yes.'

- Yes
 No
 Unable to determine
[Clear Response](#)

17. Were the main outcome measures used accurate (valid and reliable)?

For studies where the outcome measures are clearly described, the question should be answered 'yes.' For studies which refer to other work or that demonstrates the outcome measures are accurate, the question should be answered 'yes.'

- Yes
- No
- Unable to determine

[Clear Response](#)

INTERNAL VALIDITY- CONFOUNDING AND SELECTION BIAS

18. Were the subjects in different intervention groups (trials and cohort studies) or were the cases and controls (case-control studies) recruited from the same population?

For example, subjects for all comparison groups should be selected from the same school. The question should be answered unable to determine for cohort where there is no information concerning the source of subjects included in the study.

- Yes
- No
- Unable to determine

[Clear Response](#)

19. Were study subjects in different testing groups groups (trials and cohort studies) or were the cases and controls (case-control studies) recruited over the same period of time?

For a study which does not specify the time period over which patients were recruited, the question should be answered as unable to determine.

- Yes
- No
- Unable to determine

[Clear Response](#)

20. Was there adequate adjustment for confounding in the analyses from which the main findings were drawn?

This question should be answered 'no' for trials if: the main conclusions of the study were based on analyses of treatment rather than intention to treat; the distribution of known confounders in the different treatment groups was not described; or the distribution of known confounders differed between the treatment groups but was not taken into account in the analyses. In non-randomized studies, if the effect of the main confounders was not investigated or confounding was demonstrated but no adjustment was made in the final analyses the question should be answered 'no.' "Yes" for adjusted for all major confounders (demographic and common comorbidities) and "Yes, some" if some, not all major confounders were adjusted for.

- Yes (adjusted for all confounders)
- Yes, some (adjusted for some confounders)
- No (did not adjust for confounders)
- Unable to determine
- Not applicable (i.e. diagnostic test paper)

[Clear Response](#)

21. Were losses of subjects to follow-up taken into account?

If the numbers of subjects lost to follow-up are not reported, the question should be answered 'unable to determine.' If the proportion lost to follow-up was too small to affect the main findings, the question should be answered 'yes.'

- Yes
- No
- Unable to determine
- Not applicable (i.e. no followup period such as KQ1)

[Clear Response](#)

POWER

22. Did they report a power calculation?

- Yes
- No

[Clear Response](#)

23. Was the study supported by industry?

- Yes (e.g. supported financially by industry, treatment provided by industry, co-author involved with industry)
- No (sources of funding provided by non-industry sponsors such as government, etc.)
- Not reported

[Clear Response](#)

24. What was the overall quality of the study?

- **Good** (low risk of bias). These studies had the least bias, and the results were considered valid. These studies adhered to the commonly held concepts of high quality, including the following: a clear description of the population, setting, interventions, and comparison groups; appropriate measurement of outcomes; appropriate statistical and analytic methods and reporting; no reporting errors; a low dropout rate; and clear reporting of dropouts.
- **Fair**. These studies were susceptible to some bias, but not enough to invalidate the results. They did not meet all the criteria required for a rating of good quality because they had some deficiencies, but no flaw was likely to cause major bias. The study may have been missing information, making it difficult to assess limitations and potential problems.
- **Poor** (high risk of bias). These studies had significant flaws that might have invalidated the results. They had serious errors in design, analysis, or reporting; large amounts of missing information; or discrepancies in reporting.

- Good
- Fair
- Poor

[Clear Response](#)

25. For Questions 1-9, how many were answered "no"?

26. Is the number in question 25 greater than or equal to 5?

- Yes (sum is 5 or more)
 No (sum is 4 or less)
Clear Response

27. For questions 10-12, how many questions were answered "no"?

28. Is the number in question 27 greater than or equal to 2?

- Yes (sum is 2 or more)
 No (sum is 1 or 0)
Clear Response

29. For questions 13-22, how many were answered "no"?

30. Is the number in question 29 greater than or equal to 5?

- Yes (sum is 5 or more)
 No (sum is 4 or less)
Clear Response

Comments:

and go to or Skip to Next

Appendix C: Exclusion Report

No Original Data

1. Bodor GS. Cardiac troponin-I: A highly specific biochemical marker for myocardial infarction. *Journal of Clinical Immunoassay*. 1994;17(1):40-4.
2. Capodanno D, Angiolillo DJ. Antithrombotic therapy in patients with chronic kidney disease. *Circulation*. 2012;125(21):2649-61.
3. Celik T, Iyisoy A, Yilmaz MI, et al. Another battlefield for drug-eluting coronary stents: Chronic kidney disease. *Int J Cardiol*. 2009;133(2):245-6.
4. Chen P, Tanasijevic M. Use of serum cardiac troponin-I levels in dialysis patients. *Semin Dial*. 2000 Jan-Feb;13(1):58-9. PMID: 10740676.
5. Chen BH. Cardiac troponin T levels in patients with renal failure. *CMAJ*. 2002 Sep 17;167(6):671. PMID: 12358205.

6. Dehoux M, Provenchere S, Benessiano J, et al. Utility of cardiac troponin measurement after cardiac surgery. *Clin Chim Acta*. 2001 Sep 15;311(1):41-4. PMID: 11557251.
7. Dewantoro O, Harun S. Troponin in heart disorder and chronic renal failure. *Acta Med Indones*. 2005 Oct-Dec;37(4):218-23. PMID: 16317219.
8. Foussas SG, Tsiaousis GZ. Coronary revascularisation in patients with chronic renal disease. *Hellenic Journal of Cardiology*. 2007;48(4):218-27.
9. Herzog CA. Dismal long-term survival of dialysis patients after acute myocardial infarction: Can we alter the outcome? *Nephrology Dialysis Transplantation*. 2002;17(1):7-10.
10. Johnston N, Dargie H, Jardine A. Diagnosis and treatment of coronary artery

disease in patients with chronic kidney disease. *Heart*. 2008;94(8):1080-8.

11. Kavsak PA. Serial cardiac troponin T measurements in haemodialysis patients: absolute versus changing concentrations? *Ann Clin Biochem*. 2010 Jan;47(Pt 1):97. PMID: 19900984.

12. Rabelink TJ, Truin G, de Jaegere P. Treatment of coronary artery disease in patients with renal failure. *Nephrology Dialysis Transplantation*. 2000;15(SUPPL. 5):117-21.

13. Rifkin DE, Sarnak MJ. Chronic kidney disease: Absence of evidence or evidence of absence? ACS treatment in CKD. *Nature Reviews Nephrology*. 2010;6(8):449-50.

14. Watine J. [Troponins: diagnostic and prognostic value in patients with renal failure]. *Ann Biol Clin (Paris)*. 2005 Jul-Aug;63(4):434-5. PMID: 16104063.

15. Widimsky P, Rychlik I. Renal disease and acute coronary syndrome. *Heart*. 2010 Jan;96(1):86-92. PMID: 20019214.

Abstract Only

16. Acharji S, Nikolsky E, Weisz G, et al. Impact of troponin elevation on outcomes of patients with acute coronary syndromes and chronic renal insufficiency. *J Am Coll Cardiol*. 2010;55(10):A118.E1108.

17. Adib K, Yacoub R, Gupta V, et al. The clinical significance of serial cardiac markers (Troponin I) measurements in hospitalized patients study (stop-IT study). *J Am Coll Cardiol*. 2011;57(14):E1105.

18. Akerblom A, Wallentin L, Siegbahn A, et al. Serial cystatin C measurements and changes in glomerular filtration rate as predictors for death or myocardial infarction in ACS patients. *Eur Heart J*. 2012;33:135.

19. Aoyama T, Ishii H, Takahashi H, et al. Elevated cardiac troponin T and C-reactive protein interactively increased cardiovascular and all-cause mortality risk

in chronic hemodialysis patients -10-year prospective study. *Eur Heart J*. 2011;32:646.

20. Assa S, Witte EC, Gansevoort RT, et al. Determinants of pre-dialysis levels and intra-dialytic rises of cardiac troponin T (cTnT) levels. *Blood Purif*. 2009;28(4):306-7.

21. Avdoshina S, Villevalde S, Tyukhmenov E, et al. Acute kidney injury in patients with non-st-elevation acute coronary syndrome. *Nephrology Dialysis Transplantation*. 2012;27:ii358.

22. Baber U, Mehran R, Brener S, et al. Impact of chronic kidney disease on myocardial infarct size and adverse events in ST-elevation myocardial infarction: Results from the INFUSE-AMI trial. *J Am Coll Cardiol*. 2012;60:B43.

23. Bahrman P, Bahrman A, Christ M, et al. Performance of high-sensitivity troponin T in the early diagnosis of non-ST-elevation myocardial infarction in elderly patients presenting to an emergency department. *Eur Heart J*. 2012;33:909.

24. Ballo P, Chechi T, Spaziani G, et al. Risk stratification by estimated glomerular filtration rate in patients with non ST-elevation acute coronary syndrome: Which method is best? *Eur Heart J*. 2010;31:339.

25. Barra SNC, Silva J, Gomes P, et al. The role of glomerular filtration rate in acute cardiac patients: STEMI vs NSTEMI. *European Heart Journal, Supplement*. 2010;12:F44-F5.

26. Barra SNC, Providencia R, Gomes P, et al. Predicting risk of stroke following a myocardial infarction. *European Journal of Cardiovascular Prevention and Rehabilitation*. 2010;17:S98.

27. Barthelemy O, Helft G, Silvain J, et al. One year clinical outcomes after percutaneous coronary intervention with drug-eluting stent in patients with chronic renal failure. *Eur Heart J*. 2009;30:787.

28. Barthelemy O, Cayla G, Silvain J, et al. Is there an optimal time for catheterization

- in NSTEMI-ACS patients with renal failure? Insights from the ABOARD study. *Eur Heart J*. 2010;31:340.
29. Bashardoost B, Ghaemian N. Impact of troponin i level and left ventricular hypertrophy on long term risk of mortality in patients on hemodialysis. *NDT Plus*. 2010;3:iii493.
30. Berton G, Cordiano R, Palmieri R, et al. Clinical predictors of ten-year event-free survival after myocardial infarction. *Eur Heart J*. 2011;32:883.
31. Bianco H, Helfenstein T, Izar MC, et al. Predictors of long-term cardiovascular outcomes in patients with type 2 diabetes mellitus. *Eur Heart J*. 2012;33:893.
32. Bosselmann HS, Rossing K, Egstrup M, et al. The association between renal function and mortality risk is attenuated by pro-adrenomedullin and troponin T in outpatients with systolic heart failure: A long term follow up study. *Eur Heart J*. 2011;32:476.
33. Bossola M, Colacicco L, Scribano D, et al. Reactive Oxygen Metabolites (ROMS) are associated with cardiovascular disease and new cardiovascular events in chronic hemodialysis patients. *Nephrology Dialysis Transplantation*. 2012;27:ii239.
34. Britt EB, Wu Y, Hazen SL, et al. Prediction of future cardiovascular risk by detecting subclinical myocardial necrosis in stable patients with diabetes mellitus. *J Card Fail*. 2011;17(8):S30-S1.
35. Brouwers FPJ, De Boer RA, Van Der Harst P, et al. Incident heart failure with preserved ejection fraction in the general population. *Eur Heart J*. 2012;33:939.
36. Brunner NW, Scheuermeyer F, Grafstein E, et al. Prognosis of patients discharged from the emergency department with a positive troponin: A retrospective cohort study. *Canadian Journal of Cardiology*. 2011;27(5):S142.
37. Buchholz S, Nojournian A, Hoo SS, et al. Incidence, risk factors, and in-hospital mortality of contrast-induced nephropathy in field triaged patients with acute myocardial infarction. *Heart Lung and Circulation*. 2010;19:S133.
38. Cabanas Grandio P, Alvarez Alvarez B, Gonzalez Cambeiro C, et al. Cockcroft-gault, modification of diet in renal disease or chronic kidney disease epidemiology collaboration in renal disease and acute coronary syndromes? *Eur Heart J*. 2012;33:1086.
39. Caetano AFSMA, Barra S, Silva J, et al. Cardiorenal syndrome in ischemic cardiomyopathy: Can cystatin-C predict it? *European Heart Journal, Supplement*. 2010;12:F66.
40. Caetano F, Almeida I, Seca L, et al. The best predictor of cardiorenal syndrome in ischemic cardiomyopathy. *Intensive Care Med*. 2011;37:S240.
41. Campard S, Bielefeld M, Richard C, et al. High preoperative troponin before elective surgery is associated with a poor prognosis. *Eur Heart J*. 2011;32:538-9.
42. Campbell NG, Varaganam M, Sawhney V, et al. Mild pre-procedural renal impairment is associated with increased mortality after emergency catheter laboratory admission in a contemporary population with ST-segment elevation myocardial infarction. *Eur Heart J*. 2010;31:211.
43. Charpentier S, Ducasse JL, Cournot M, et al. Clinical assessment of ischemia modified albumin and heart-fatty acid binding protein in early diagnosis of non ST elevation acute coronary syndrome in emergency department. *Eur Heart J*. 2009;30:188.
44. Chen Y, Chen H. High sensitivity creatinine protein levels at admission can not be used to predict inhospital mortality in patients with acute myocardial infarction a retrospective study. *Heart*. 2010;96:A133.
45. Chitalia N, Rahman S, Farrell N, et al. Elevated pulse pressure is associated with

increased cardiovascular events in patients on maintenance dialysis. *NDT Plus*. 2010;3:iii347.

46. Choi JC, Cha KS, Ahn JH, et al. The incidence and clinical predictors of persistent renal dysfunction in patients with acute myocardial infarction undergoing percutaneous coronary intervention: Results from the Korea working group on myocardial infarction. *Circulation*. 2012;126(21).

47. Chong C, Van Gaal W, Profitis K, et al. Electrocardiograph changes and correlation to troponin levels and cardiac complications after orthopaedic surgery. *Intern Med J*. 2010;40:10.

48. Chorianopoulos E, Krumsdorf U, Pleger S, et al. Prognostic value of preinterventional troponin t levels in patients with severe aortic stenosis undergoing TAVR. *J Am Coll Cardiol*. 2012;60:B247-B8.

49. Chou MT, Chieng CC, Wang TC. Acute coronary syndrome on end-stage renal disease dialysis patients:taiwan national cohort study. *Eur Heart J*. 2012;33:1085.

50. Chow KV, Roberts MA, Lerino FL. Cardiac troponin T as a predictor of long term mortality in patients undergoing haemodialysis. *Nephrology*. 2011;16:70.

51. Chu CY, Lin TH, Su HM, et al. Influences of the early invasive strategy on patients with chronic kidney diseases in non-ST segment elevation acute coronary syndrome, a population-based study from north of Taiwan. *American Journal of Cardiology*. 2012;109(7):62S.

52. Cieszynski K, Kaczmarek A, Grzegorzewska AE. High-sensitivity cardiac troponin T (HS-CTNT) in stable dialysis patients. *Hemodialysis International*. 2012;16(1):147-8.

53. Clark D, Mok M, Charter K, et al. Is measurement of troponin-I (Tn-I) post-elective percutaneous coronary intervention

(PCI) required to predict adverse events? *Heart Lung and Circulation*. 2011;20:S131.

54. Coats W, Pak Y, Chan E, et al. Are there clinical predictors of nonobstructive coronary artery disease among patients with end-stage renal disease on dialysis referred for coronary angiography? *Hemodialysis International*. 2011;15(1):135-6.

55. Cordeiro Da Rocha AS, Pittella FJM, Dutra Da Silva PR, et al. High-sensitivity C-reactive protein: New marker of operative risk in coronary artery bypass graft surgery? *Eur Heart J*. 2011;32:1049.

56. Covic A, Besarab A, Provenzano R, et al. Relationship between cardiovascular (CV) events and hemoglobin (HB) level or Hb rate of change in hemodialysis (HD) patients on peginesatide. *Nephrology Dialysis Transplantation*. 2012;27:ii133-ii4.

57. Cudjoe TK, Clavell AL, Olson LJ, et al. Predictors of outcome in an elderly population presenting with acute decompensated heart failure. *J Am Coll Cardiol*. 2009;53(10):A237-A8.

58. Dai K, Ishihara M, Inoue I, et al. Impact of chronic kidney disease and anemia on 5-year mortality after acute myocardial infarction. *J Am Coll Cardiol*. 2010;55(10):A102.E956.

59. Daniels LB, Laughlin GA, Maisel AS, et al. Galectin-3 is independently associated with cardiovascular disease in community-dwelling older adults: The rancho bernardo study. *Circulation*. 2012;126(21).

60. Dankovtseva EN, Evdokimova MA, Reznichenko NE, et al. Cystatin C associates with unfavorable outcome after acute coronary syndrome in patients with high level of BNP-fragment of brain natriuretic peptide and normal renal function. *European Journal of Heart Failure, Supplement*. 2011;10:S51.

61. De Lima JGG, Gowdak LHW, De Paula FJ, et al. Cardioprotective drugs and acute coronary syndrome in patients on the waiting list for renal transplantation.

American Journal of Transplantation. 2012;12:100.

62. Desai AS, Jarolim P, Uno H, et al. Serum levels of N-terminal pro-B-type natriuretic peptide and cardiac troponin T predict renal disease progression in patients with diabetes mellitus, anemia, and chronic kidney disease. *Eur Heart J*. 2010;31:449-50.

63. Desai M, Hegazi A, Campbell L, et al. Coronary heart disease is associated with renal impairment in HIV positive patients. *HIV Medicine*. 2012;13:3.

64. Drueke T, Clyne N, Eckardt K, et al. Diagnostic value of nt-probnp and cardiac troponin t in chronic kidney disease patients: correlation with baseline characteristics in the CREATE study [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal; 2004. p. 85.

65. Echols MR, Kontos MC, Prather K, et al. Predictive value of ejection fraction and renal function in high risk acute coronary syndrome patients: Results from the synergy trial. *J Am Coll Cardiol*. 2010;55(10):A141.E1323.

66. Edwards M, Matsuura AC, Robey J, et al. Relationship between kidney disease and outcomes in emergency department patients presenting with potential acute coronary syndromes. *Academic Emergency Medicine*. 2011;18(5):S42.

67. El Boukhrissi F, Balouch L, Benseddik N, et al. Interest of cardiac troponin T dosage in hemodialysis patients. *Clinical Chemistry and Laboratory Medicine*. 2012;50(4):A103.

68. Eubanks AM, Raza F, Alkhouli M, et al. Troponins predict long term outcomes in DKA patients without acute coronary syndrome. *J Am Coll Cardiol*. 2011;57(14):E934.

69. Fabbian F, Pala M, De Giorgi A, et al. Mortality for myocardial infarction and pulmonary embolism in chronic kidney

disease patients. A study on the emilia-romagna regional database of hospital admissions. *G Ital Cardiol*. 2011;12(12):e54.

70. Faes D, Jamart J, Chenu P, et al. Differential impact of bleeding complications on in-hospital outcome at the time of PCI. *Eur Heart J*. 2009;30:537.

71. Fakheri S, Contreras R, Mansukhani P, et al. Prognostic implications of minor troponin i elevation in the setting of renal insufficiency: Results from the troponin I in the emergency room (TiER) study. *J Am Coll Cardiol*. 2010;56(13):B72.

72. Fakheri S, Shen A, Khan S, et al. Determining a troponin i threshold for predicting 30-day mortality: Results from the troponin i in the emergency room (TiER) study. *J Am Coll Cardiol*. 2011;58(20):B109.

73. Fan W, Ping Y, Leiming L, et al. Association of glomerular filtration rate with high-sensitivity cardiac troponin t in a community-based population study in Beijing. *Heart*. 2011;97:A94-A5.

74. Faria R, Trigo J, Gago P, et al. Association between kidney function and mortality in patients with acute coronary syndromes without ST elevation undergoing catheterization. *European Heart Journal, Supplement*. 2010;12:F26.

75. Felker GM, Tang WHW, Hernandez AF, et al. High sensitivity troponin I in acute decompensated heart failure: Insights from the ASCEND-HF study. *Circulation*. 2011;124(21).

76. Feres MC, Rizzi C, Lorenzon P, et al. Evaluation of the role of biomarkers for prediction of cardiovascular risk in patients with obstructive sleep apnoea and dyslipidaemia. *Journal of Sleep Research*. 2010;19:164.

77. Ferrieres J, Berkenboom G, Coufal Z, et al. Risk of cardiovascular and bleeding events and mortality in patients with chronic kidney disease and ACS undergoing PCI:

Results from the APTOR-II study. *Eur Heart J*. 2011;32:188.

78. Fischer L, Shiv kumar J, Sudhakar S, et al. Comparison of drug-eluting stents with bare-metal stents in patients with mild and moderate chronic kidney disease undergoing primary percutaneous coronary intervention. *American Journal of Cardiology*. 2010;105(9):33B.

79. Flu WJ, Van Kuijk JP, Hoeks SE, et al. Intima media-thickness of the common carotid artery in major vascular surgery patients: A predictor of postoperative and late cardiovascular events. *Eur Heart J*. 2009;30:348.

80. Ford ML, Smith ER, Tomlinson LA, et al. Plasma osteoprotegerin and proteinuria are independently associated with highly sensitive troponin t in chronic kidney disease (ckd) stages 3 & 4. *Artery Research*. 2010;4(4):152.

81. Frank D, Stark S, Lutz M, et al. High-sensitive troponin t levels independently predict survival in tavi patients. *Circulation*. 2012;126(21).

82. Gago M, Semret M, Pelikka PA, et al. Survival of kidney transplant candidates and recipients with diabetes (DM). Stratification of risk using cardiac troponin T (cTNT). *American Journal of Transplantation*. 2010;10:69.

83. Gallagher S, Jones D, Rathod K, et al. Baseline renal dysfunction is associated with worse outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. *J Am Coll Cardiol*. 2011;58(20):B136.

84. Gallagher S, Hassan S, Jones D, et al. Is contrast-induced nephropathy following primary PCI for STEMI associated with increased long-term mortality? *EuroIntervention*. 2012;8:N37.

85. Garcia Gonzalez MJ, Arroyo Ucar E, Hernandez Garcia C, et al. Impact of impaired renal function on admission and reduced left ventricular function on in-

hospital outcome of acute coronary syndrome in clinical practice. Results of a single center registry. *Eur Heart J*. 2010;31:340-1.

86. Gashi M, Korca H, Kocinaj D, et al. Clinical manifestations of coronary heart disease in endstage renal disease (hemodialysis). *International Journal of Artificial Organs*. 2010;33:466.

87. Genereux P, Bernard S, Palmerini T, et al. Incidence, predictors and impact of stroke in acute coronary syndrome: Insights from the acuity trial. *J Am Coll Cardiol*. 2012;59(13):E378.

88. Giannini F, Perkan A, Vitrella G, et al. The impact of renal insufficiency on mortality and role of abciximab in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. *G Ital Cardiol*. 2011;12(5):107S.

89. Gierlotka M, Gasior M, Tajstra M, et al. Invasive treatment of patients with non-ST-segment elevation myocardial infarction and severe renal dysfunction - Early and 12-month outcomes from the PL-ACS registry. *J Am Coll Cardiol*. 2011;58(20):B138.

90. Goncalves S, Ferreira Santos J, Amador P, et al. Impact of renal failure on the bleeding risk of patients with non-ST acute coronary syndromes submitted to percutaneous coronary intervention. *Eur Heart J*. 2010;31:56.

91. Gonzalez MJG, Ucar EA, Garcia CH, et al. ST elevation acute myocardial infarction: Impact of renal dysfunction on management and in-hospital outcome in clinical practice. *European Heart Journal, Supplement*. 2010;12:F43.

92. Gonzalez MA, Collins SD, Ben-Dor I, et al. The contribution of renal failure and diabetes mellitus to the prognosis of patients with acute myocardial infarction undergoing percutaneous coronary intervention. *J Am Coll Cardiol*. 2010;55(10):A119.E1113.

93. Gowdak LHW, De Paula FJ, Cesar LAM, et al. The null General Cardiovascular Disease Risk Score null underestimates the risk of cardiovascular events in patients with end-stage renal disease. *Eur Heart J*. 2011;32:94.
94. Gruberg L, Parikh PB, Jeremias A, et al. Higher mortality rates after percutaneous coronary intervention in female patients on hemodialysis. *J Am Coll Cardiol*. 2010;55(10):A210.E1986.
95. Grundeken MJD, Damman P, Kikkert WJ, et al. Gender difference in the prognostic value of estimated glomerular filtration rate at admission in ST-segment elevation myocardial infarction. *Eur Heart J*. 2011;32:737-8.
96. Grygier M, Janus M, Araszkievicz A, et al. Combined treatment with ascorbic acid and N-acetylcysteine prevents contrast-induced nephropathy in patients with acute coronary syndrome undergoing coronary intervention. *Eur Heart J*. 2009;30:529.
97. Gupta S, Figueredo V. Effects of renal function on outcomes of patients with non-ST elevation myocardial infarction (NSTEMI) treated with early invasive strategy. *Crit Care Med*. 2009;37(12):A459.
98. Guttmann OP, Rathod K, Rathod B, et al. Prognostic value of baseline renal function on long term outcome in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. *Heart*. 2011;97:A31.
99. Ha SJ, Woo SH, Kim W, et al. Triple versus dual antiplatelet therapy in acute myocardial infarction in relation to renal function: Data from the Korean acute myocardial infarction registry: Data from the Korean acute myocardial. *Eur Heart J*. 2011;32:877.
100. Hao T, Jingguo W, Jia X, et al. The anticoagulant therapy of haemodialysis patients with acute coronary syndrome. *Heart*. 2012;98:E199.
101. Hashimoto T, Ishii J, Okumura M, et al. Prognostic value of high-sensitivity cardiac troponin i in patients with chronic kidney disease. *J Card Fail*. 2011;17(9):S164.
102. Helvig A, Naess H. Troponin in 574 patients with acute ischemic stroke. *European Journal of Neurology*. 2010;17:28.
103. Hira RS, Shenoy M, Fatemi O, et al. Troponin I is chronically and persistently elevated in hospitalized heart failure patients and is associated with increased mortality over five years. *J Am Coll Cardiol*. 2010;55(10):A17.E162.
104. Hochholzer W, Valina CM, Stratz C, et al. Utility of high-sensitivity cardiac troponin T in patients undergoing elective coronary angiography. *Eur Heart J*. 2012;33:776.
105. Hogg K, Hinchliffe E, Haslam S, et al. Biomarkers in mortality prediction after venous thromboembolism. *Journal of Thrombosis and Haemostasis*. 2011;9:865.
106. Holmes D, Abizaid A, Banning A, et al. The use of the Sirolimus-eluting CYPHER Select plus coronary stent in patients with renal failure, 1-year results from the e-SELECT registry. *EuroIntervention*. 2010;6.
107. Hong YJ, Mintz GS, Jeong MH, et al. Coronary plaque characteristics according to renal function in patients with acute myocardial infarction: An intravascular ultrasound analysis. *American Journal of Cardiology*. 2010;105(9):29B.
108. Hussien A, Battah A, Ashraf M, et al. Electrocardiography as a predictor of left main or three-vessel disease in patients with non-ST segment elevation acute coronary syndrome. *Egyptian Heart Journal*. 2011;63(2):103-7.
109. Hutchison A, Barns S, Barton T, et al. Mortality in patients with coronary and non coronary causes of an elevated Troponin. *Heart Lung and Circulation*. 2011;20:S209.
110. Inoue T, Arasaki O, Kajiwara K, et al. The impact of elevated heart rate and chronic kidney disease on all-cause death

- and cardiovascular events in coronary artery disease patients with type II diabetes. *Eur Heart J.* 2012;33:449.
111. Irfan A, Reichlin T, Twerenbold R, et al. Prevalence and determinants of elevated high-sensitive cardiac troponin T levels among patients with non-cardiac cause of chest pain. *Eur Heart J.* 2011;32:99-100.
 112. Ishii J, Hashimoto T, Naruse H, et al. Prognostic value of combination of cystatin C with BNP and cardiac troponin T for cardiac mortality in acute heart failure without advanced renal impairment. *J Mol Cell Cardiol.* 2010;48(5):S69-S70.
 113. Ishii J, Okuyama R, Hashimoto T, et al. Interaction of b-type natriuretic peptide and cardiac troponin t improves the prediction of mortality in patients on hemodialysis. *Circulation.* 2012;126(21).
 114. Itaya H, Hara H, Takagi T, et al. Impact of disappeared circadian variation on acute coronary syndrome to the patients with chronic kidney disease. *Eur Heart J.* 2010;31:982.
 115. Iwasaki Y, Yamada T, Okuyama Y, et al. Usefulness of anticoagulant therapy for atrial fibrillation in chronic kidney disease patients after percutaneous coronary intervention with stenting. *J Am Coll Cardiol.* 2010;55(10):A54.E513.
 116. Jarai R, Pavlovic I, Farhan S, et al. Prediction of acute heart failure by lactate dehydrogenase (LDH): An old player among the new stars. *European Heart Journal, Supplement.* 2010;12:F49.
 117. Jarai R, Leherbauer L, Farhan S, et al. Blood urea nitrogen (BUN) predicts all-cause mortality in chronic stable heart failure in addition to plasma Nt-proBNP and troponin T. *Eur Heart J.* 2010;31:132.
 118. Jin HY, Jung SR, Seo JS, et al. The prognostic value of admission serum creatinine for contrast induced nephropathy and 12 months mortality in patients with acute ST elevation myocardial infarction underwent primary percutaneous coronary intervention. *J Am Coll Cardiol.* 2011;58(20):B135-B6.
 119. Jin HY, Choi KN, Seo JS, et al. The impact of admission serum creatinine on contrast induced nephropathy and 1 year mortality in patients with ST elevation myocardial infarction underwent primary percutaneous coronary intervention. *Eur Heart J.* 2012;33:630.
 120. Joki N, Iwasaki M, Tanaka Y, et al. The best cut-off value for diagnosing of acute coronary syndrome at emergency room in patients with end stage kidney disease. *Nephrology Dialysis Transplantation.* 2012;27:ii238-ii9.
 121. Josefsson A, Fu M, Bjornsson E, et al. Pretransplant renal impairment predicts post transplant cardiac events in patients with liver cirrhosis. *Gastroenterology.* 2011;140(5):S901-S2.
 122. Kasiske BL, Snyder JJ, Skeans MA, et al. Predicting coronary heart disease after kidney transplant. *American Journal of Transplantation.* 2009;9:362-3.
 123. Kato H, Kubota S, Takasawa Y, et al. Strain of the left ventricular myocardium by 2D speckle tracking echocardiography predicts cardiac events and mortality in patients with advanced chronic kidney disease: A 3-year follow-up study. *Eur Heart J.* 2012;33:16.
 124. Keddis MT, El Ters M, Rodrigo E, et al. Cardiac troponin T (CTNT) before and after kidney transplantation (KTx): Cardiovascular (CV) risk and patient survival. *American Journal of Transplantation.* 2012;12:32.
 125. Khan J, Kingree R, Thameem D, et al. Predictors of hospital and postdischarge mortality among patients with pulmonary embolism. *Chest.* 2010;138(4).
 126. Khan MF, Shah N, Torabi A, et al. Impact of revascularisation on longer term survival of patients presenting with troponin positive acute coronary syndrome: A real

world experience. *EuroIntervention*. 2011;7:M9.

127. Khandekar A, Khandge J. Incidence of Cardiovascular Disease (CVD) in chronic kidney disease subjects (PRE-DIALYSIS): The role of plasma high sensitivity C-reactive protein (HS-CRP), homocysteine (HCY), carotid intima media thickness (CIMT) and left ventricular hypertrophy (LVH). *Nephrology Dialysis Transplantation*. 2012;27:ii246.
128. Kim IC, Kim HT, Cho YK, et al. The impact of renal insufficiency on clinical outcomes after percutaneous coronary intervention in acute myocardial infarction. *American Journal of Cardiology*. 2009;103(9):1B.
129. Kim W, Woo JS, Kim WS, et al. Triple versus dual antiplatelet therapy in acute myocardial infarction in relation to renal function. *Circulation*. 2011;124(21).
130. Kim D, Jeong MH, Ahn Y, et al. Benefit of statin therapy in acute myocardial infarction and renal insufficiency from the korea acute myocardial infarction registry. *American Journal of Cardiology*. 2012;109(7):115S-6S.
131. Kim D, Jeong MH, Ahn Y, et al. Comparison between drug-eluting stent and bare-metal stent in ischemic cardiomyopathy combined with renal insufficiency. *American Journal of Cardiology*. 2012;109(7):102S.
132. Kohsaka S, Endo Y, Koide K, et al. Impact of serum biomarkers by the presence or absence of kidney disease in predicting long-term outcome among advanced systolic heart failure patients. *J Mol Cell Cardiol*. 2010;48(5):S68.
133. Kokubu N, Otsuka Y, Yamane T, et al. Impacts of metabolic syndrome and chronic kidney disease on short-and long-term outcomes of patients after acute myocardial infarction. *American Journal of Cardiology*. 2009;104(6):128D.

134. Kokubu N, Otsuka Y, Oe Y, et al. Short- and long-term prognostic impacts of metabolic syndrome and chronic kidney disease in patients after acute myocardial infarction. *J Am Coll Cardiol*. 2010;55(10):A198.E1863.
135. Komarov A, Shakhmatova O, Chuvilina M, et al. Renal impairment as a risk factor of cardiovascular events in patients with stable coronary artery disease: The results of 4 years follow-up. *Eur Heart J*. 2009;30:781.
136. Konishi M, Suzuki H, Okada K, et al. The prevalence and comorbidity of nonspecific troponin elevation detected by highly sensitive assay in patients with acute chest pain. *Circulation*. 2011;124(21).
137. Kooiman J, Spaans B, Van Beers CJ, et al. Increased arterial thrombo-embolic events and major bleeding in patients with atrial fibrillation and chronic kidney disease on vitamin K-antagonist treatment. *Circulation*. 2012;126(21).
138. Kostrubiec M, Labyk A, Pedowska-Wloszek J, et al. Renal function improves troponin-based short term prognosis in patients with acute pulmonary embolism. *Eur Heart J*. 2009;30:106.
139. Kosuge M, Kimura K, Kojima S, et al. Differential impact of renal dysfunction on mortality following first acute myocardial infarction in nonelderly and elderly patients. *J Am Coll Cardiol*. 2010;55(10):A119.E1115.
140. Kotwal SS, Ranasinghe I, Gallagher MP, et al. The impact of chronic kidney disease on clinical outcomes in patients admitted with acute myocardial infarction in an Australian setting. *Circulation*. 2012;126(21).
141. Kozhukhov S, Parkhomenko A. Renal effects of intravenous lipoxigenase inhibitor Quercetin in patients with acute myocardial infarction: Prospective randomized study. *Eur Heart J*. 2009;30:469.
142. Krishnaswami A, Leong TK, Hlatky M, et al. Predictors of death following coronary

- artery bypass surgery in adults with endstage renal disease. *J Am Coll Cardiol.* 2012;59(13):E510.
143. Kuster N, Patrier L, Bargnoux AS, et al. Does high sensitivity troponin T modify long term risk stratification in dialysis patients? *Nephrology Dialysis Transplantation.* 2012;27:ii291.
144. Kyuichi F, Hideki I, Hiroshi T, et al. Multiple biomarkers improve the prediction of cardiovascular mortality in patients on chronic hemodialysis. *Circulation.* 2011;124(21).
145. Lai H, Patil A, Aronow W, et al. Causes of increased cardiac troponin i levels in hospitalized patients without coronary artery disease. *Chest.* 2011;140(4).
146. Lankeit M, Jimenez D, Kostrubiec M, et al. Validation of NT-proBNP cut-off values for risk stratification of acute non-high-risk pulmonary embolism. *Eur Heart J.* 2012;33:412.
147. Lazaros G, Tsiachris D, Patialiakas A, et al. Worsening renal function but not baseline creatinine levels adversely affects one year mortality in patients with myocardial infarction. The HEROES registry. *Eur Heart J.* 2009;30:42.
148. Lazaros G, Tsiachris D, Patialiakas A, et al. Acute kidney injury is a stronger predictor of one-year mortality than chronic kidney disease in patients with acute myocardial infarction. the HEROES study. *Eur Heart J.* 2011;32:97.
149. Lazaros G, Tsiachris D, Patialiakas A, et al. Admission white blood cell count predicts acute kidney injury in patients with acute myocardial infarction. *Eur Heart J.* 2012;33:785.
150. Lee EA, Stone GW, Mehran R, et al. The predictive value of CRP on 30-day and 1-year mortality in acute coronary syndromes: An analysis from the ACUTY trial. *American Journal of Cardiology.* 2009;104(6):108D.
151. Lee S, Lee SR, Rhee K, et al. Echocardiographic and laboratory indicators of in-hospital and all-cause mortality in end-stage renal disease patients. *European Journal of Heart Failure, Supplement.* 2010;9:S71-S2.
152. Lee JK, Yu WC, Lin SJ, et al. Multiple-biomarkers assessment offers additive risk prediction in patients with acute coronary syndrome. *Eur Heart J.* 2011;32:729.
153. Lee T, Kakuta T, Murai T, et al. Association between increased levels of cardiac troponin before elective stenting and optical coherence tomography findings in stable angina pectoris. *Eur Heart J.* 2012;33:776-7.
154. Lee JH, Kang JK, Jang SY, et al. Prognostic value of occult renal failure in patients with acute myocardial infarction. *Eur Heart J.* 2012;33:1085.
155. Lee JE, Moon SJ, Choi KH, et al. Noninvasive detection of coronary artery stenosis with multidetector row computed tomography in chronic kidney disease patients at the initiation of renal replacement therapy. *Nephrology Dialysis Transplantation.* 2012;27:ii246-ii7.
156. Lee JH, Kim KH, Choi WS, et al. Prognostic value of N-terminal pro-brain natriuretic peptide in patients with acute myocardial infarction and chronic kidney disease. *J Am Coll Cardiol.* 2012;59(13):E397.
157. Lekston A, Gasior M, Hudzik B, et al. Impact of multivessel coronary artery disease on the outcomes of patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. 5-year follow-up. *Eur Heart J.* 2009;30:928-9.
158. Levin A, Madore F, Rigatto C, et al. Canpredict: Canadian study for the prediction of dialysis, death and cardiovascular risk in CKD patients. *NDT Plus.* 2010;3:iii373.

159. Levin A, Rigatto C, Barrett B, et al. Canadian study of prediction of death, dialysis and interim cardiovascular events: Canpredict: Biomarkers improve prediction of one year outcomes in chronic kidney cohort. *Nephrology Dialysis Transplantation*. 2012;27:ii63.
160. Li H, Wang SX. Analysis of death causes and its related factors in young patients on maintenance hemodialysis. *Blood Purif*. 2012;33(4):247-8.
161. Lim SY, Bae EH, Kim SW, et al. Statin use decreased short-term and long-term major adverse cardiac events in acute myocardial infarction in patients with renal insufficiency. *EuroIntervention*. 2012;8:N157.
162. Linnemann B, Sutter T, Sixt S, et al. Troponin T and renal function indicate worse in-hospital outcome in patients with acute limb ischemia. *Vasa - Journal of Vascular Diseases*. 2010;39:53-4.
163. Liu YW, Su CT, Huang YY, et al. Evidence of subtle left ventricular systolic dysfunction and worse prognosis in asymptomatic hemodialysis patients with preserved left ventricular ejection fraction and elevated cardiac troponin T. *Eur Heart J*. 2011;32:289-90.
164. Liu YW, Su CT, Yang CS, et al. Left ventricular systolic dysfunction in high risk hemodialysis patients with preserved left ventricular ejection fraction. *Journal of the American Society of Echocardiography*. 2011;24(5):B5.
165. Liu YW. Longitudinal strain as a novel predictor of all-cause and cardiovascular mortality in asymptomatic hemodialysis patients with preserved left ventricular ejection fraction. *Circulation*. 2012;126(21).
166. Loh J, Kitabata H, Barbash I, et al. The impact of first-versus second-generation drug-eluting stents on immediate-and intermediate-term outcomes in a complex st-segment elevation myocardial infarction population. *J Am Coll Cardiol*. 2012;60:B136.
167. Lopes RD, White JA, Atar D, et al. Antithrombotic use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. *Circulation*. 2011;124(21).
168. Lotze U, Lemm H, Heyer A, et al. Combined determination of troponin T high sensitive and copeptin for early rule out of acute myocardial infarction: First experience in a general emergency department. *Eur Heart J*. 2011;32:1063.
169. Luo L. Incidence of cardiac events in patients undergoing renal transplantation with left ventricular dystolic dysfunction versus normal left-ventricular function. *European Heart Journal, Supplement*. 2009;11:S30.
170. Manzano Fernandez S, Bonaque-Gonzalez JC, Munoz-Esparza C, et al. Usefulness of beta-trace protein and cystatin c to predict outcomes in patients with acute heart failure. *European Journal of Heart Failure, Supplement*. 2010;9:S234-S5.
171. Matsue Y, Suzuki M, Nagahori W, et al. Head-to-head comparison of cardiac high-sensitive troponin I, high-sensitive troponin T and NT-proBNP for risk stratification in asymptomatic patients with end-stage renal disease. *Eur Heart J*. 2012;33:128.
172. Mehran R, Nikolsky E, Lansky A, et al. Impact of chronic kidney disease on one-year outcomes of patients with acute myocardial infarction undergoing primary angioplasty: Results from the HORIZONS AMI trial. *J Am Coll Cardiol*. 2009;53(10):A74-A5.
173. Milicic D, Ljubas J, Skoric B, et al. Predictors of mortality and clinical usefulness of NT-proBNP, troponin T and C-reactive protein in follow-up after heart transplantation. *Eur Heart J*. 2009;30:389.
174. Miyajima E, Nishijima H, Murakami N, et al. Cardiac troponin levels before labour predict complications with proteinuria in the

- postpartum period. *Eur Heart J*. 2012;33:452.
175. Miyata M, Kusumoto A, Tei C. The role of natriuretic peptides and highly sensitive troponin t in heart failure. *J Card Fail*. 2011;17(9):S129.
176. Mohamad T, Mahajan N, Kondur A, et al. Impact of renal insufficiency on percutaneous coronary interventions outcomes in octogenarians: A single tertiary center experience. *Catheterization and Cardiovascular Interventions*. 2011;77:S47-S8.
177. Monteiro S, Antonio N, Lourenco C, et al. Combining renal function and glucose metabolism data: A more efficient way to assess outcomes in acute coronary syndromes patients. *J Am Coll Cardiol*. 2009;53(10):A336.
178. Moral JAU, Llergo JT, Rodriguez RS, et al. Predictors of in-hospital mortality in patients with cardiogenic shock complicating acute coronary syndrome, treated with urgent percutaneous coronary intervention. *European Heart Journal, Supplement*. 2010;12:F46.
179. Moreira A, Souza A, Costa R, et al. Incidence and predictors of major adverse cardiac events(MACE) following drug-eluting stents implantation in patients with chronic kidney disease. Insights from the DESIRE (drug-eluting stents in the real world) Registry. *J Am Coll Cardiol*. 2010;56(13):B65.
180. Moretz C, Robinson SB, Johnson B. Validation of high-sensitivity troponin I method in ACS patients. *Crit Pathw Cardiol*. 2012;11(3):166.
181. Munoz Jimenez LD, Cabrera Calandria AM, Munoz Bono J, et al. Elevated troponin levels predictive role in coronary revascularization surgery postoperative management. *Intensive Care Med*. 2010;36:S266.
182. Munoz-Jimenez LD, Cabrera-Calandria AM, Urbano-Carrillo CA, et al. Short-term outcomes and post-operative management of patients underwent off-pump coronary artery bypass. *Intensive Care Med*. 2009;35:S77.
183. Nabais S, Gaspar A, Rocha S, et al. Estimation of renal function in acute coronary syndromes: MDRD or Cockcroft-Gault? *Eur Heart J*. 2009;30:171-2.
184. Nair SB, Chacko SM, Dixit A, et al. Comparison of patients' demographics, in-hospital and 3-year mortality rates and independent predictors of death in ST-elevation vs non-ST elevation myocardial infarction-an interventional centre experience. *Heart*. 2010;96:A71-A2.
185. Nakachi T, Kosuge M, Hibi K, et al. Renal dysfunction and rapid coronary artery disease progression in patients with non-ST-segment elevation acute coronary syndrome. *J Am Coll Cardiol*. 2009;53(10):A353-A4.
186. Nakachi T, Fukui K, Nakagawa T, et al. Renal function and coronary artery disease progression in patients with acute coronary syndrome. *Circulation*. 2011;124(21).
187. Nakatani D, Sakata Y, Suna S, et al. Independent and combined effect of heart failure and renal dysfunction on one-year mortality in patients with acute myocardial infarction. *Circulation*. 2012;126(21).
188. Naruse H, Ishii J, Hashimoto T, et al. Prognostic ability of combination of cystatin C, BNP and troponin t in acute heart failure patients without advanced renal impairment. *J Card Fail*. 2011;17(9):S147-S8.
189. Naruse H, Ishii J, Okuyama R, et al. Prognostic value of combination of ultra-sensitive troponin i and b-type natriuretic peptide in outpatients with chronic kidney disease. *Circulation*. 2012;126(21).
190. Ng A, Chow V, Yong A, et al. Elevated troponin T predicts both short and long-term mortality after pulmonary embolism. *Heart Lung and Circulation*. 2010;19:S216-S7.
191. Nishimura M, Tokoro T, Nishida M, et al. Coexistence of impaired myocardial fatty acid metabolism and insulin resistance predicts cardiac death of hemodialysis

- patients with normal coronary arteries. *NDT Plus*. 2010;3:iii557.
192. Nishimura M, Okamoto Y, Tokoro T, et al. Risk stratification of cardiac death in hemodialysis patients without coronary artery disease by myocardial fatty acid imaging. *Nephrology Dialysis Transplantation*. 2012;27:ii59-ii60.
193. Nishimura M, Okamoto Y, Tokoro T, et al. Oral nicorandil to reduce sudden cardiac death of hemodialysis patients with left ventricular hypertrophy. *Nephrology Dialysis Transplantation*. 2012;27:ii232-ii3.
194. Ntalianis A, Cuisset T, Hamilos M, et al. PCI-related myocardial infarction in patients with renal insufficiency reloaded with clopidogrel; an open-label multicenter registry. *Eur Heart J*. 2011;32:1039.
195. Ogando RA, Luis CH, Fuentes MGS, et al. Prognostic factors of clinical outcome and mortality in patients with Acute Coronary Syndrome requiring Mechanical Ventilation. *European Heart Journal, Supplement*. 2010;12:F116.
196. Ohsawa M, Itai K, Tanno K, et al. Relative risks for total mortality, incident myocardial infarction and incident stroke among Japanese hemodialysis patients. *Eur Heart J*. 2009;30:964.
197. Ouzouni A, Miari F, Mademtzoglou S, et al. The predictive value of cardiac troponin t in hemodialysis patients: A two year prospective study. *NDT Plus*. 2010;3:iii498.
198. Oyake N, Suzuki K, Tanabe K, et al. A pivotal link between hepatocyte growth factor and cardiovascular damage in end-stage renal disease. *NDT Plus*. 2010;3:iii494.
199. Pages PA, Aboyans V, Tanguy B, et al. Renal function degradation before coronary artery bypass surgery is associated with long-term mortality. *Eur Heart J*. 2012;33:70.
200. Parissis JT, Nikolaou M, Mebazaa A, et al. Prognostic markers in acute pulmonary oedema: Data from ALARM-HF registry. *Eur Heart J*. 2009;30:612.
201. Parissis JT, Delgado J, Mebazaa A, et al. Predictors of in-hospital mortality in acute heart failure syndromes: A sub-analysis of ALARM-HF survey. *European Journal of Heart Failure, Supplement*. 2009;8:ii473-ii4.
202. Parsa AFZ, Sedaghti M, Abdolahi A, et al. The impact of chronic kidney disease on cardiac biomarkers and left ventricular function. *Eur J Intern Med*. 2011;22:S101.
203. Pathak R, Alasady M, Talaulikar G, et al. Clinical variables predictive of mortality in ESRD patients. *Heart Lung and Circulation*. 2011;20:S203-S4.
204. Patiakas S, Charalampous C, Basiliou E. Risk of coronary heart disease in patients with chronic renal failure - Evaluation study. *Atherosclerosis Supplements*. 2010;11(2):167.
205. Patsourakos N, Zairis M, Nini S, et al. Evaluating the prognostic value of glomerular filtration rate added to the TIMI risk score in patients with acute coronary syndromes. *Eur Heart J*. 2010;31:342.
206. Peacock W, Hoekstra J, Krucoff M, et al. Early objective identification of chest pain patients at very low risk of 30-day adverse outcomes. *Ann Emerg Med*. 2009;54(3):S2.
207. Pereg D, Benderly M, Behar S, et al. Decreased renal function associated with incident adverse cardiovascular outcomes in patients with acute coronary syndromes. *Eur Heart J*. 2009;30:468.
208. Perna E, Valle R, Canella JPC, et al. The relevance of troponin and natriuretic peptides as prognostic markers in patients with acute pulmonary edema and preserved left ventricular systolic function: A report from ciast-HF study. *J Am Coll Cardiol*. 2011;57(14):E367.
209. Persic V, Kovac J, Marn-Pernat A, et al. Troponin I levels in chronic hemodialysis

- patients. *International Journal of Artificial Organs*. 2010;33:487.
210. Petrovic D, Obrenovic R, Trbojevic-Stankovic J, et al. Cardiovascular mortality in hemodialysis patients: Clinical and epidemiological analysis. *Journal of Medical Biochemistry*. 2011;30(4):302-8.
211. Piegas L, Avezum A, Guimaraes HP, et al. How different is the management? Results from the brazilian acute coronary syndrome registry. *Eur Heart J*. 2011;32:883.
212. Planer D, Ohman EM, White H, et al. Prognosis of patients presenting with non ST-segment elevation myocardial infarction and non-obstructive coronary artery disease: Propensity score matched cohort from the acuity trial. *J Am Coll Cardiol*. 2012;60:B136.
213. Podolecki T, Lenarczyk R, Kowalczyk J, et al. Risk of stroke in patients with acute myocardial infarction treated invasively. *Eur Heart J*. 2010;31:885.
214. Pugliese G, Penno G, Bonora E, et al. Association of normoalbuminuric renal impairment with cardiovascular disease. *Diabetologia*. 2011;54:S23.
215. Rahman A, Kirchner HL, Sartorius J, et al. Risk factors for 30-day hospital readmission among patients with non-dialysis dependent CKD. *American Journal of Kidney Diseases*. 2011;57(4):A81.
216. Ramchand J, Barlis P, Mehta N, et al. Acute reduction in renal function and cardiovascular risk in acute coronary syndromes. *European Heart Journal, Supplement*. 2010;12:S1.
217. Rampat R, Liew R, Suliman A, et al. The relation between haemoglobin concentration and eight year mortality rates after acute coronary syndromes. *Eur Heart J*. 2010;31:350-1.
218. Rastan A, Mohr M, Dege A, et al. Risk analysis of patients with acute myocardial infarction complicated by deep cardiogenic shock receiving emergency coronary artery bypass grafting and perioperative ECMO support. *Thoracic and Cardiovascular Surgeon*. 2011;58.
219. Raval J, Deshmukh T, Reece G, et al. Primary diagnoses in patients admitted to intensive care or coronary care units with an elevated troponin level but no clinical or ECG evidence of myocardial ischaemia. *Heart Lung and Circulation*. 2011;20:S39.
220. Robson R. The use of bivalirudin in patients with renal impairment. *J Invasive Cardiol*. 2000 Dec;12 Suppl F:33F-6. PMID: 11156732.
221. Rubin J, Matsushita K, Ballantyne CM, et al. Association of cardiovascular risk factors with minimally elevated cardiac troponin T detected by a novel highly sensitive assay. *Circulation*. 2011;124(21).
222. Rumenjak V, Brajkovic-Bralic M, Oranullanic-Braic D, et al. N-terminal proBNP and high sensitivity cardiac troponin I concentrations in haemodialysis patients. *Clinical Chemistry and Laboratory Medicine*. 2011;49:S572.
223. Saltzman AJ, Claessen BE, Narula A, et al. Impact of chronic kidney disease on long-term outcomes in ST-elevation myocardial infarction patients treated with primary percutaneous coronary intervention and alternative antithrombotic treatment strategies: A HORIZONS-AMI substudy. *J Am Coll Cardiol*. 2011;57(14):E904.
224. Sammut EC, Jones DA, Rathod K, et al. Prognostic value of baseline renal function on long term outcome in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. *Eur Heart J*. 2011;32:188.
225. Sanchez-Perales C, Vazquez E, Segura P, et al. Acute myocardial infarction in incident dialysis patients. *Nephrology Dialysis Transplantation*. 2012;27:ii248.
226. Sanchez-Perales C, Vazquez E, Merino E, et al. Valvular calcification predicts atrial fibrillation on chronic dialysis patients.

- Nephrology Dialysis Transplantation. 2012;27:ii228.
227. Sanganalmath P, Sohail H, Durairaj S. Can troponin-I be a good indicator for severity assessment and determine the length of stay in patients with diagnosis of pulmonary embolism?-A retrospective study done in south east of england. *Am J Respir Crit Care Med.* 2011;183(1).
228. Santos N, Serrao M, Cafe H, et al. Prognostic value of glomerular filtration rate in the context of acute myocardial infarction with ST-segment elevation. *Eur Heart J.* 2010;31:343.
229. Santos AR, Picarra B, Celeiro M, et al. Influence of chronic kidney disease on the acute therapy, in-hospital events and mortality in patients with acute myocardial infarction. *Eur Heart J.* 2012;33:1085-6.
230. Sato K, Fukuda H, Kunimasa T, et al. Predictive importance of prior history of coronary artery disease and current myocardial ischemia in patients with hemodialysis. *Circulation.* 2010;122(2):e251.
231. Savic L, Mrdovic I, Krljanac G, et al. The prognostic significance of combined left ventricular systolic dysfunction and chronic kidney disease in patients treated with primary percutaneous coronary intervention. *European Journal of Heart Failure, Supplement.* 2011;10:S145.
232. Sbarzaglia P, Savonitto S, Violini R, et al. Impact of isolated troponin elevations after PCI on two-year mortality. *Eur Heart J.* 2009;30:525.
233. Schmidt N, Woodle ES, Alloway RR, et al. Cardiovascular events and cardiovascular-related mortality after renal transplantation: Effect of maintenance steroid therapy. *American Journal of Transplantation.* 2011;11:36.
234. Schouten O, Winkel TA, Flu WJ, et al. Asymptomatic postoperative troponin release is associated with poor long-term outcome after vascular surgery. *Eur Heart J.* 2009;30:158.
235. Schouten O, Winkel TA, Welten GMJM, et al. Asymptomatic perioperative myocardial damage is associated with poor long-term outcome after vascular surgery. *J Vasc Surg.* 2009;49(5):7S-8S.
236. Semret M, Gago M, Pellikka PA, et al. Using cardiac troponin T (cTNT) to stratify the risks and benefits of kidney transplantation (KTx) in patients without diabetes (DM). *American Journal of Transplantation.* 2010;10:69.
237. Serpytis P, Rucinskas K, Kalinauskas A, et al. Risk factors for operation and inhospital mortality of patients with acute cardiac syndrome. *European Heart Journal, Supplement.* 2010;12:F45-F6.
238. Setsuta K, Seino Y, Mizuno K. Neurohumoral factors and development of heart failure in hypertensive patients. *J Card Fail.* 2011;17(9):S129.
239. Setsuta K, Nishizawa A, Kitahara Y, et al. Clinical value of increased high-sensitivity cardiac troponin T in patients with essential hypertension. *Circulation.* 2012;126(21).
240. Sezer S, Karakan S, Acar NO. Increased cardiac troponin T levels are correlated with inflammatory markers and various indices of renal function in chronic renal disease patients. *NDT Plus.* 2010;3:iii138.
241. Shin ES, Park J, Chung HC, et al. Effect of remote ischemic preconditioning on myocardial injury during hemodialysis: A pilot study. *American Journal of Cardiology.* 2012;109(7):53S-4S.
242. Shroff G, Li S, Herzog CA. Survival of us dialysis patients after acute myocardial infarction: Is it finally getting better in the modern treatment era? *Circulation.* 2012;126(21).
243. Silva D, Cortez-Dias N, Jorge C, et al. Prognostic value of cystatin c in ST-segment elevation acute myocardial infarction.

European Heart Journal, Supplement. 2010;12:F9-F10.

244. Simoes Marques Assuncao Caetan AF, Barra S, Faustino C, et al. Cardiorenal syndrome in acute heart failure: An inevitable side effect? European Journal of Heart Failure, Supplement. 2010;9:S260.

245. Simoes Marques Assuncao Caetano AF, Barra S, Gomes P, et al. Cystatin-C and acute coronary syndromes: A better risk marker? Eur Heart J. 2010;31:650.

246. Sinkovic A, Svensek F. Predictors of in-hospital mortality in patients with acute ST-elevation myocardial infarction. Intensive Care Med. 2009;35:S285.

247. Smith SW, Pearce LA, Murakami MM, et al. Diagnosis of type i versus type ii myocardial infarction in emergency department patients with ischemic symptoms. Ann Emerg Med. 2011;58(4):S211-S2.

248. Solak Y, Yilmaz MI, Caglar K, et al. Red cell distribution width independently predicts cardiovascular events in patients with chronic kidney disease. Nephrology Dialysis Transplantation. 2012;27:ii385.

249. Solberg OG, Ueland T, Wergeland R, et al. The predictive value of troponin, C-reactive protein and brain natriuretic peptide in patients with symptomatic aortic stenosis. Eur Heart J. 2011;32:769.

250. Spasic-Obradovic G, Radakovic A, Obradovic S. High sensitive (HS) troponin t stat assay diagnostic value in patients with chest pain and underlying chronic disease. Clinical Chemistry and Laboratory Medicine. 2011;49:S362.

251. Taglieri N, Fernandez Berges DJ, Koenig W, et al. Plasma cystatin C for prediction of one year mortality in mediterranean patients with non ST elevation acute coronary syndrome. Eur Heart J. 2009;30:618.

252. Tagore R, Tai BC, Richards AM, et al. E/Em and plasma BNP predict adverse cardiovascular outcome in predialysis

chronic kidney disease: A prospective cohort study. Circulation. 2011;124(21).

253. Takashio S, Yamamuro M, Kojima S, et al. Cardiac troponin t release is correlated with diastolic load in patients with nonischemic heart failure. Circulation. 2011;124(21).

254. Tanaka A, Suzuki Y, Miki K, et al. Can BNP and Troponin T predict coronary artery disease and mortality in patients with chronic kidney disease at initiation of renal replacement therapy? Eur Heart J. 2009;30:187-8.

255. Teixeira R, Lourenco C, Baptista R, et al. Does diabetes matter in completely revascularized acute coronary syndrome patients? Eur Heart J. 2010;31:530.

256. Thirawuth V, Tangcharoen T, Vathesatogkit P, et al. A retrospective cohort of long term all-cause mortality and recurrent cardiovascular events in patients with acute coronary syndrome in Thailand. Eur Heart J. 2012;33:898.

257. Timoteo AT, Ramos R, Toste A, et al. Predictors of mortality in octogenarian patients with acute myocardial infarction. Eur Heart J. 2009;30:464-5.

258. Timoteo AT, Lousinha A, Miranda F, et al. Estimated glomerular filtration rate on admission and bleeding risk in the real world of acute coronary syndromes. Eur Heart J. 2010;31:52.

259. Tomaszuk-Kazberuk A, Kozuch M, Malyszko J, et al. Which method of glomerular filtration rate has the best prognostic value in STEMI treated with PCI: Cockcroft's index or MDRD equation or CKD-EPI index? A 6-year follow-up. Eur Heart J. 2011;32:1062-3.

260. Toutouzas K, Patsa CH, Tsiamis E, et al. Effectiveness and safety of drug eluting stents in patients with chronic renal failure. Eur Heart J. 2009;30:468.

261. Twerenbold R, Reichlin T, Reiter M, et al. Early diagnosis of acute myocardial infarction in patients with kidney disease

- using more sensitive cardiac troponin assays. *Eur Heart J*. 2012;33:910-1.
262. Van Berkel M, Vogels S, Geerse D, et al. Troponin i as a cardiac biomarker for cardiovascular mortality in patients on haemodialysis. *Nederlands Tijdschrift voor Klinische Chemie en Laboratoriumgeneeskunde*. 2011;36(2):91.
263. Vardhan A, Khattar R, Brenchley P, et al. The significance of minimally elevated cardiac troponin-T levels in predicting cardiovascular events & sudden death in clinically well patients with end-stage chronic kidney disease. *Eur Heart J*. 2010;31:804.
264. Vieira C, Rocha S, Ramos V, et al. In hospital deterioration of glomerular filtration rate - Prognostic predictor in acute coronary syndromes. *Eur Heart J*. 2011;32:98.
265. Vieira C, Nabais S, Ramos V, et al. Cystatin C in acute coronary syndromes: Predictor of prognosis independent of renal function? *Eur Heart J*. 2012;33:630.
266. Villarraga H, Adjei-Twum K, Cudjoe TKM, et al. Predictors of cardiac re-hospitalization in elderly adults presenting with decompensated heart failure. *European Journal of Echocardiography*. 2010;11:ii99.
267. Volz K, Sanchez L, Horowitz G, et al. CK-MB index should be eliminated in patients with indeterminate troponins in the emergency department. *Academic Emergency Medicine*. 2011;18(5):S200.
268. Wojakowski W, Tendera M, Tubaro M, et al. Impact of anemia and reduced left ventricular ejection fraction on in-hospital outcome of acute coronary syndromes. *Euro Heart Survey ACS III registry (2006-2008)*. *Eur Heart J*. 2009;30:171.
269. Wong PSC, Jones J, Ashrafi R, et al. Long term prognostic effect of cardiac troponin T in hospitalised patients. *Eur Heart J*. 2011;32:94.
270. Woo JS, Kim W, Kim CJ, et al. Triple versus dual antiplatelet therapy in acute myocardial infarction in relation to renal function. *American Journal of Cardiology*. 2012;109(7):10S.
271. Woudstra P, Damman P, Clayton T, et al. Routine invasive versus selective invasive strategy and long-term outcomes in patients with reduced renal function presenting with non-ST segment elevation acute coronary syndrome. *J Am Coll Cardiol*. 2012;59(13):E392.
272. Yim S, Bae EH, Kim SW, et al. Renal dysfunction and cardiovascular outcome after acute myocardial infarction: Results from Korea acute myocardial infarction registry. *Eur Heart J*. 2011;32:92.
273. Yoo BS, Lee JH, Lee JW, et al. A multi-marker approach for the prediction of adverse events in patients with acute myocardial infarction. *Circulation*. 2012;126(21).
274. Yoshimura Y, Toyama T, Hoshizaki H, et al. Chronic Kidney Disease can contribute to later major cardiac events in patients with initial acute myocardial infarction. *European Heart Journal, Supplement*. 2009;11:S5.
275. Yoshimura Y, Toyama T, Hoshizaki H, et al. The risk of chronic kidney disease for later major cardiac events in patients with initial acute myocardial infarction. *European Heart Journal, Supplement*. 2011;13:A65.
276. Yu J, Pinnelas R, Vlachojannis G, et al. Which glomerular filtration rate equation best predicts poor outcomes in patients with acute myocardial infarction undergoing primary PCI: Results from the horizonsami study. *J Am Coll Cardiol*. 2012;59(13):E64.
277. Zairis M, Patsourakos N, Panayiotinos J, et al. The prognostic value of comorbidities from extracardiac vascular beds in patients with acute coronary syndromes. *Eur Heart J*. 2010;31:353-4.
278. Zeymer U, Bauer T, Hochadel M, et al. The high event rate in patients with diabetes mellitus treated with PCI for acute coronary syndromes is observed in the subgroup of patients with impaired renal function.

Results of the Euro Heart Survey. *Eur Heart J*. 2011;32:1039-40.

279. Zhao Y, Li X, Wang D, et al. Glomerular filtration rate in the elderly with acute myocardial infarction as a prognostic factor of in-hospital events. *Circulation*. 2010;122(2):e138.

No Chronic Kidney Disease or End-Stage Renal Disease

280. Al-Aqeedi R, Sulaiman K, Al Suwaidi J, et al. Characteristics, management and outcomes of patients with acute coronary syndrome and prior coronary artery bypass surgery: findings from the second Gulf Registry of Acute Coronary Events. *Interact Cardiovasc Thorac Surg*. 2011 Dec;13(6):611-8. PMID: 21920933.

281. Apple FS, Maturen AJ, Mullins RE, et al. Multicenter clinical and analytical evaluation of the AxSYM troponin-I immunoassay to assist in the diagnosis of myocardial infarction. *Clin Chem*. 1999 Feb;45(2):206-12. PMID: 9931042.

282. Bakkouch AK, Graine H, Lavoigne A, et al. Myoglobin and troponin I immunoassay performances as evaluated on ACS 180(TM). *Immuno-Analyse et Biologie Specialisee*. 1999;14(5):348-53.

283. Barasch E, Kaushik V, Gupta R, et al. Elevated cardiac troponin levels do not predict adverse outcomes in hospitalized patients without clinical manifestations of acute coronary syndromes. *Cardiology*. 2000;93(1-2):1-6. PMID: 10894899.

284. Bennett AE, Bertholf RL. Discordant results of CK-MB and troponin I measurements: a review of 14 cases. *Ann Clin Lab Sci*. 2000 Apr;30(2):167-73. PMID: 10807160.

285. Carlson ER, Percy RF, Angiolillo DJ, et al. Prognostic significance of troponin T elevation in patients without chest pain. *Am J Cardiol*. 2008 Sep 15;102(6):668-71. PMID: 18773985.

286. Chance JJ, Segal JB, Wallerson G, et al. Cardiac troponin T and C-reactive protein as markers of acute cardiac allograft rejection. *Clin Chim Acta*. 2001 Oct;312(1-2):31-9. PMID: 11580907.

287. Chang CC, Ip MP, Hsu RM, et al. Evaluation of a proposed panel of cardiac markers for the diagnosis of acute myocardial infarction in patients with atraumatic chest pain. *Arch Pathol Lab Med*. 1998 Apr;122(4):320-4. PMID: 9648898.

288. Chen TH, Chang CH, Lin CY, et al. Acute kidney injury biomarkers for patients in a coronary care unit: a prospective cohort study. *PLoS One*. 2012;7(2):e32328. PMID: 22384218.

289. Chi Z, Mi SH, Zhang XX, et al. [Impact of anemia on long-term outcome in elderly patients with acute coronary syndrome undergoing percutaneous coronary interventions]. *Zhonghua Xin Xue Guan Bing Za Zhi*. 2012 Nov;40(11):920-3. PMID: 23363672.

290. Christenson RH, Apple FS, Morgan DL, et al. Cardiac troponin I measurement with the ACCESS immunoassay system: analytical and clinical performance characteristics. *Clin Chem*. 1998 Jan;44(1):52-60. PMID: 9550558.

291. Eigel P, van Ingen G, Wagenpfeil S. Predictive value of perioperative cardiac troponin I for adverse outcome in coronary artery bypass surgery. *Eur J Cardiothorac Surg*. 2001 Sep;20(3):544-9. PMID: 11509277.

292. Fiorina P, Astorri E, Albertini R, et al. Soluble antiapoptotic molecules and immune activation in chronic heart failure and unstable angina pectoris. *J Clin Immunol*. 2000 Mar;20(2):101-6. PMID: 10821461.

293. Hallen J, Johansen OE, Birkeland KI, et al. Determinants and prognostic implications of cardiac troponin T measured by a sensitive assay in type 2 diabetes mellitus.

- Cardiovasc Diabetol. 2010;9:52. PMID: 20843304.
294. Hsu HP, Jou YL, Lin SJ, et al. Comparison of in-hospital outcome of acute ST elevation myocardial infarction in patients with versus without diabetes mellitus. *Acta Cardiologica Sinica*. 2011;27(3):145-51.
295. Hwang SH, Jeong MH, Ahmed K, et al. Different clinical outcomes of acute kidney injury according to acute kidney injury network criteria in patients between ST elevation and non-ST elevation myocardial infarction. *Int J Cardiol*. 2011 Jul 1;150(1):99-101. PMID: 21481955.
296. Jug M, Rumenjak V, Alpeza I, et al. Clinical value of biochemical markers in the diagnosis of acute myocardial infarction. *Acta Med Croatica*. 2000;54(3):113-7. PMID: 11268788.
297. Khan IA, Tun A, Wattanasauwan N, et al. Elevation of serum cardiac troponin I in noncardiac and cardiac diseases other than acute coronary syndromes. *Am J Emerg Med*. 1999 May;17(3):225-9. PMID: 10337875.
298. Koszta G, Kacska Z, Szatmari K, et al. Lower whole blood selenium level is associated with higher operative risk and mortality following cardiac surgery. *J Anesth*. 2012 Dec;26(6):812-21. PMID: 22847607.
299. Kratz A, Lewandrowski KB, Januzzi JL, et al. Comparison of cardiac marker concentrations in healthy blood donors and hospital patients without acute coronary syndrome. *Am J Cardiol*; 2002. p. 177-8.
300. Krishnan E, Baker JF, Furst DE, et al. Gout and the risk of acute myocardial infarction. *Arthritis Rheum*. 2006 Aug;54(8):2688-96. PMID: 16871533.
301. Lafci B, Ozsoyler I, Kestelli M, et al. Predictors of mortality in elderly patients undergoing coronary revascularization. *Chirurgia*. 2008;21(3):139-42.
302. Landesberg G, Vesselov Y, Einav S, et al. Myocardial ischemia, cardiac troponin, and long-term survival of high-cardiac risk critically ill intensive care unit patients. *Crit Care Med*. 2005 Jun;33(6):1281-7. PMID: 15942345.
303. Lim P, Collet JP, Moutereau S, et al. Fetuin-A is an independent predictor of death after ST-elevation myocardial infarction. *Clin Chem*. 2007 Oct;53(10):1835-40. PMID: 17702860.
304. Mainet Gonzalez D, Sorell Gomez L, Pichardo Diaz D, et al. Evaluation of a rapid immunoassay for the quantification of cardiac troponin I in the diagnosis of acute myocardial infarction. *Quimica Clinica*. 2003;22(6):419-30.
305. Manzano-Fernandez S, Boronat-Garcia M, Albaladejo-Oton MD, et al. Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure. *Am J Cardiol*. 2009 Jun 15;103(12):1753-9. PMID: 19539088.
306. Morariu AM, Loef BG, Aarts LP, et al. Dexamethasone: benefit and prejudice for patients undergoing on-pump coronary artery bypass grafting: a study on myocardial, pulmonary, renal, intestinal, and hepatic injury. *Chest*. 2005 Oct;128(4):2677-87. PMID: 16236942.
307. Munzer T, Heim C, Riesen W. [Perioperative myocardial infarction and cardiac complications after noncardiac surgery in patients with prior myocardial infarction. III: Troponin T--a significant diagnostic alternative in perioperative myocardial infarction?]. *Anaesthesist*. 1996 Mar;45(3):225-30. PMID: 8919894.
308. Neeland IJ, Drazner MH, Berry JD, et al. Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population. *J Am Coll Cardiol*. 2013 Jan 15;61(2):187-95. PMID: 23219305.

309. O'Connor CM, Fiuzat M, Lombardi C, et al. Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study. *Circ Heart Fail*. 2011 Nov;4(6):724-32. PMID: 21900185.
310. Parenti N, Bartolacci S, Carle F, et al. Cardiac troponin I as prognostic marker in heart failure patients discharged from emergency department. *Intern Emerg Med*. 2008 Mar;3(1):43-7. PMID: 18273567.
311. Penttila K, Penttila I, Bonnell R, et al. Comparison of the troponin T and troponin I ELISA tests, as measured by microplate immunoassay techniques, in diagnosing acute myocardial infarction. *Eur J Clin Chem Clin Biochem*. 1997 Oct;35(10):767-74. PMID: 9368795.
312. Pervaiz S, Anderson FP, Lohmann TP, et al. Comparative analysis of cardiac troponin I and creatine kinase-MB as markers of acute myocardial infarction. *Clin Cardiol*. 1997 Mar;20(3):269-71. PMID: 9068915.
313. Rodriguez-Reyna TS, Arrieta O, Castillo-Martinez L, et al. Tumour Necrosis Factor alpha and Troponin T as predictors of poor prognosis in patients with stable heart failure. *Clin Invest Med*. 2005 Feb;28(1):23-9. PMID: 15770879.
314. Sabate S, Mases A, Guilera N, et al. Incidence and predictors of major perioperative adverse cardiac and cerebrovascular events in non-cardiac surgery. *Br J Anaesth*. 2011 Dec;107(6):879-90. PMID: 21890661.
315. Saiki A, Iwase M, Takeichi Y, et al. Diversity of the elevation of serum cardiac troponin I levels in patients during their first visit to the emergency room. *Circ J*. 2007 Sep;71(9):1458-62. PMID: 17721028.
316. Sathisha TG, Manjunatha GBK, Avinash SS, et al. Microalbuminuria in non-diabetic, non-hypertensive myocardial infarction in South Indian patients with relation to lipid profile and cardiac markers. *Journal of Clinical and Diagnostic Research*. 2012;5(6):1158-60.
317. Sato Y, Kataoka K, Matsumori A, et al. Measuring serum aminoterminal type III procollagen peptide, 7S domain of type IV collagen, and cardiac troponin T in patients with idiopathic dilated cardiomyopathy and secondary cardiomyopathy. *Heart*. 1997 Nov;78(5):505-8. PMID: 9415013.
318. Sato Y, Yamamoto E, Sawa T, et al. High-sensitivity cardiac troponin T in essential hypertension. *J Cardiol*. 2011 Nov;58(3):226-31. PMID: 21885250.
319. Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. *Circulation*. 2011 Apr 5;123(13):1367-76. PMID: 21422391.
320. Schuurin MJ, van Riel AC, Vis JC, et al. High-sensitivity Troponin T Is Associated with Poor Outcome in Adults with Pulmonary Arterial Hypertension due to Congenital Heart Disease. *Congenit Heart Dis*. 2012 Dec 14PMID: 23241414.
321. Setsuta K, Kitahara Y, Arae M, et al. Elevated cardiac troponin T predicts adverse outcomes in hypertensive patients. *Int Heart J*. 2011;52(3):164-9. PMID: 21646739.
322. Seyfert H, Bohlscheid V, Kaddatz J. Hyponatremia and acute myocardial infarction. *Pravention und Rehabilitation*. 2012;24(2):74-9.
323. Singh A, Uthappa S, Govindaraju V, et al. Serum markers for early diagnosis of non-'Q' wave and 'Q' wave myocardial infarction. *Indian J Clin Biochem*. 2002 Jan;17(1):25-8. PMID: 23105332.
324. Song D, de Zoysa JR, Ng A, et al. Troponins in acute kidney injury. *Ren Fail*. 2012;34(1):35-9. PMID: 22010639.
325. Urban P, Radovanovic D, Erne P, et al. Impact of changing definitions for myocardial infarction: a report from the

AMIS registry. *Am J Med.* 2008 Dec;121(12):1065-71. PMID: 19028202.

326. Wi J, Ko YG, Kim JS, et al. The impact of contrast-induced nephropathy on long-term outcomes in patients with acute myocardial infarction undergoing percutaneous coronary interventions. *J Am Coll Cardiol.* 2010;56(13):B97.

327. Windhausen F, Hirsch A, Fischer J, et al. Cystatin C for enhancement of risk stratification in non-ST elevation acute coronary syndrome patients with an increased troponin T. *Clin Chem.* 2009 Jun;55(6):1118-25. PMID: 19359536.

328. Young PJ, Dalley P, Garden A, et al. A pilot study investigating the effects of remote ischemic preconditioning in high-risk cardiac surgery using a randomised controlled double-blind protocol. *Basic Res Cardiol.* 2012;107(3):256. PMID: 22406977.

329. Zaninotto M, Altinier S, Lachin M, et al. Strategies for the early diagnosis of acute myocardial infarction using biochemical markers. *Am J Clin Pathol.* 1999 Mar;111(3):399-405. PMID: 10078116.

Troponin Not Evaluated

330. Abbott KC, Bucci JR, Cruess D, et al. Graft loss and acute coronary syndromes after renal transplantation in the United States. *J Am Soc Nephrol.* 2002 Oct;13(10):2560-9. PMID: 12239246.

331. Abbott JD, Ahmed HN, Vlachos HA, et al. Comparison of outcome in patients with ST-elevation versus non-ST-elevation acute myocardial infarction treated with percutaneous coronary intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). *Am J Cardiol.* 2007 Jul 15;100(2):190-5. PMID: 17631068.

332. Abu-Assi E, Lear P, Cabanas-Grandio P, et al. A comparison of the CKD-EPI, MDRD-4, and Cockcroft-Gault equations to assess renal function in predicting all-cause mortality in acute coronary syndrome

patients. *Int J Cardiol.* 2012 Dec 4 PMID: 23218581.

333. Afshinnia F, Ayazi P, Chadow HL. Glomerular filtration rate on admission independently predicts short-term in-hospital mortality after acute myocardial infarction. *Am J Nephrol.* 2006;26(4):408-14. PMID: 16926535.

334. Ahmed S, Cannon CP, Giugliano RP, et al. The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes. *Int J Cardiol.* 2008 Dec 17;131(1):105-12. PMID: 18187215.

335. Akerblom A, Wallentin L, Siegbahn A, et al. Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study. *Clin Chem.* 2012 Jan;58(1):190-9. PMID: 22126936.

336. Akkaya E, Ayhan E, Uyarel H, et al. [The impact of chronic kidney disease on in-hospital clinical outcomes in patients undergoing primary percutaneous angioplasty for ST-segment elevation myocardial infarction]. *Turk Kardiyol Dern Ars.* 2011 Jun;39(4):276-82. PMID: 21646828.

337. Al Faleh HF, AlSuwaida AO, Hersi AS, et al. In-hospital adverse clinical outcomes of ST elevation myocardial infarction patients with renal dysfunction. Insights from the Saudi Project for Assessment of Coronary Events. *Saudi Med J.* 2011 Aug;32(8):806-12. PMID: 21858389.

338. Al Suwaidi J, Reddan DN, Williams K, et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. *Circulation.* 2002 Aug 20;106(8):974-80. PMID: 12186803.

339. Alcock RF, Yong AS, Ng AC, et al. Acute coronary syndrome and stable

- coronary artery disease: Are they so different? Long-term outcomes in a contemporary PCI cohort. *Int J Cardiol.* 2012 Apr 23;PMID: 22534045.
340. Al-Hweish A, Sultan SS, Mogazi K, et al. Plasma myeloperoxidase, NT-proBNP, and troponin-I in patients on CAPD compared with those on regular hemodialysis. *Hemodial Int.* 2010 Jul;14(3):308-15. PMID: 20597992.
341. Ali M, Soaly E, Asim M, et al. Cardiovascular risk assessment among potential kidney transplant candidates and perioperative outcome: analysis of 75 consecutive Middle Eastern patients. *Transplant Proc.* 2011 Jun;43(5):1531-6. PMID: 21693230.
342. Amabile N, Guerin AP, Tedgui A, et al. Predictive value of circulating endothelial microparticles for cardiovascular mortality in end-stage renal failure: a pilot study. *Nephrol Dial Transplant.* 2012 May;27(5):1873-80. PMID: 22036944.
343. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. *N Engl J Med.* 2004 Sep 23;351(13):1285-95. PMID: 15385655.
344. Anavekar NS, Solomon SD, McMurray JJ, et al. Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus. *Am J Cardiol.* 2008 Apr 1;101(7):925-9. PMID: 18359309.
345. Arantes RL, Gowdak LHW, De Paula FJ, et al. Myocardial scintigraphy and clinical stratification as predictors of events in renal transplant candidates. *J Nephrol.* 2010;23(3):314-20.
346. Armstrong KA, Rakhit DJ, Case C, et al. Derivation and validation of a disease-specific risk score for cardiac risk stratification in chronic kidney disease. *Nephrol Dial Transplant.* 2005 Oct;20(10):2097-104. PMID: 16014347.
347. Aronson D, Hammerman H, Beyar R, et al. Serum blood urea nitrogen and long-term mortality in acute ST-elevation myocardial infarction. *Int J Cardiol.* 2008 Jul 21;127(3):380-5. PMID: 17765341.
348. Arribas-Leal JM, Pascual-Figal DA, Tornel-Osorio PL, et al. Prognostic role of a new biomarkers in off-pump coronary artery bypass surgery. *Rev Esp Cardiol.* 2006;59(3):280-3.
349. Asinger RW, Henry TD, Herzog CA, et al. Clinical outcomes of PTCA in chronic renal failure: a case-control study for comorbid features and evaluation of dialysis dependence. *J Invasive Cardiol.* 2001 Jan;13(1):21-8. PMID: 11146683.
350. Assali AR, Brosh D, Ben-Dor I, et al. The impact of renal insufficiency on patients' outcomes in emergent angioplasty for acute myocardial infarction. *Catheter Cardiovasc Interv.* 2007 Feb 15;69(3):395-400. PMID: 17195964.
351. Baber U, Kini AS, Sharma SK, et al. Thrombolysis In Myocardial Infarction (TIMI) risk score and mortality in patients with advanced chronic kidney disease and on dialysis. *Am J Cardiol.* 2009 Jun 1;103(11):1513-7. PMID: 19463508.
352. Baber U, Stone GW, Weisz G, et al. Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes. *JACC Cardiovasc Imaging.* 2012 Mar;5(3 Suppl):S53-61. PMID: 22421231.
353. Bacak-Kocman I, Basic-Jukic N, Lovcic V, et al. Renal replacement therapy in cardiology wards: changing trends in a transitional country. *Ther Apher Dial.* 2012 Apr;16(2):163-8. PMID: 22458396.
354. Baldovinos G, Petraglia A, Larre Borges P, et al. [Ischemic cardiopathy in patients undergoing chronic hemodialysis]. *Nefrologia.* 2002;22(1):60-5. PMID: 11987686.

355. Barthelemy O, Helft G, Silvain J, et al. One-year clinical outcomes in patients with chronic renal failure treated by percutaneous coronary intervention with drug-eluting stent. *Arch Cardiovasc Dis*. 2011 Dec;104(12):604-10. PMID: 22152512.
356. Bataille Y, Dery JP, Larose E, et al. Incidence and clinical impact of concurrent chronic total occlusion according to gender in ST- elevation myocardial infarction. *Catheter Cardiovasc Interv*. 2012 Oct 16; PMID: 23074092.
357. Beattie JN, Soman SS, Sandberg KR, et al. Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. *Am J Kidney Dis*. 2001 Jun;37(6):1191-200. PMID: 11382688.
358. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. *J Am Coll Cardiol*. 2003 Jul 16;42(2):201-8. PMID: 12875751.
359. Berger JS, Slater JN, Sherman W, et al. Impact of platelet glycoprotein IIb/IIIa inhibitor therapy on in-hospital outcomes and long-term survival following percutaneous coronary rotational atherectomy. *J Thromb Thrombolysis*. 2005 Feb;19(1):47-54. PMID: 15976967.
360. Bertomeu-Gonzalez V, Nunez J, Nunez E, et al. Prognostic effect of renal dysfunction after ST-segment elevation myocardial infarction with and without heart failure. *Int J Cardiol*. 2006 Sep 20;112(2):159-65. PMID: 16290104.
361. Bevc S, Penko M, Kanic V, et al. Mortality of patients with renal dysfunction after percutaneous coronary intervention. *Angiology*. 2010 Feb-Mar;61(1):24-30. PMID: 19525280.
362. Bittner HB, Savitt MA. Off-pump coronary artery bypass grafting decreases morbidity and mortality in a selected group of high-risk patients. *Ann Thorac Surg*. 2002 Jul;74(1):115-8. PMID: 12118740.
363. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. *Lancet*. 2000 Oct 7;356(9237):1213-8. PMID: 11072938.
364. Bonello L, De Labriolle A, Roy P, et al. Impact of optimal medical therapy and revascularization on outcome of patients with chronic kidney disease and on dialysis who presented with acute coronary syndrome. *Am J Cardiol*. 2008 Sep 1;102(5):535-40. PMID: 18721508.
365. Borentain M, Le Feuvre C, Helft G, et al. Long-term outcome after coronary angioplasty in renal transplant and hemodialysis patients. *J Interv Cardiol*. 2005;18(5):331-7.
366. Bruetto RG, Rodrigues FB, Torres US, et al. Renal function at hospital admission and mortality due to acute kidney injury after myocardial infarction. *PLoS One*. 2012;7(4):e35496. PMID: 22539974.
367. Brzosko S, Hryszko T, Lebkowska U, et al. Plasma tissue-type plasminogen activator, fibrinogen, and time on dialysis prior to transplantation are related to carotid intima media thickness in renal transplant recipients. *Transplant Proc*. 2003 Dec;35(8):2931-4. PMID: 14697941.
368. Buckley BS, Simpson CR, McLernon DJ, et al. Five year prognosis in patients with angina identified in primary care: incident cohort study. *BMJ*. 2009;339:b3058. PMID: 19661139.
369. Cabrerizo Garcia JL, Zalba Etayo B, Perez Calvo JI. [Prognostic value of glomerular filtrate in acute coronary syndrome: Cockcroft's index or MDRD equation?]. *Med Clin (Barc)*. 2010 May 15;134(14):624-9. PMID: 20202652.
370. Cai Q, Serrano R, Kalyanasundaram A, et al. A preoperative echocardiographic predictive model for assessment of

- cardiovascular outcome after renal transplantation. *J Am Soc Echocardiogr*. 2010 May;23(5):560-6. PMID: 20381999.
371. Campbell NG, Varagunam M, Sawhney V, et al. Mild chronic kidney disease is an independent predictor of long-term mortality after emergency angiography and primary percutaneous intervention in patients with ST-elevation myocardial infarction. *Heart*. 2012 Jan;98(1):42-7. PMID: 21880649.
372. Campbell LJ, Desai M, Hegazi A, et al. Renal impairment is associated with coronary heart disease in HIV-positive men. *HIV Clin Trials*. 2012 Nov-Dec;13(6):343-9. PMID: 23195672.
373. Cardarelli F, Bellasi A, Ou FS, et al. Combined impact of age and estimated glomerular filtration rate on in-hospital mortality after percutaneous coronary intervention for acute myocardial infarction (from the American College of Cardiology National Cardiovascular Data Registry). *Am J Cardiol*. 2009 Mar 15;103(6):766-71. PMID: 19268729.
374. Celik T, Iyisoy A, Yuksel CU, et al. Impact of admission glomerular filtration rate on the development of poor myocardial perfusion after primary percutaneous intervention in patients with acute myocardial infarction. *Coron Artery Dis*. 2008 Dec;19(8):543-9. PMID: 19005288.
375. Chan MY, Becker RC, Sim LL, et al. Reperfusion strategy and mortality in ST-elevation myocardial infarction among patients with and without impaired renal function. *Ann Acad Med Singapore*. 2010 Mar;39(3):179-84. PMID: 20372752.
376. Chan W, Stub D, Clark DJ, et al. Usefulness of transient and persistent no reflow to predict adverse clinical outcomes following percutaneous coronary intervention. *Am J Cardiol*. 2012 Feb 15;109(4):478-85. PMID: 22176999.
377. Chantrel F, Enache I, Bouiller M, et al. Abysmal prognosis of patients with type 2 diabetes entering dialysis. *Nephrol Dial Transplant*. 1999 Jan;14(1):129-36. PMID: 10052492.
378. Charytan D, Mauri L, Agarwal A, et al. The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients. *Am Heart J*. 2006 Sep;152(3):558-64. PMID: 16923431.
379. Chen HH, Wu CJ, Chen YC, et al. Metabolic syndrome is associated with severe coronary artery disease and poor cardiac outcome in end-stage renal disease patients with acute coronary syndrome. *Coron Artery Dis*. 2006 Nov;17(7):593-6. PMID: 17047442.
380. Chen SC, Chang JM, Liu WC, et al. Echocardiographic parameters are independently associated with increased cardiovascular events in patients with chronic kidney disease. *Nephrol Dial Transplant*. 2012 Mar;27(3):1064-70. PMID: 21813825.
381. Chen SC, Chang JM, Liu WC, et al. Decrease in ankle-brachial index over time and cardiovascular outcomes in patients with hemodialysis. *Am J Med Sci*. 2012 Dec;344(6):457-61. PMID: 23190561.
382. Chertow GM, Normand SL, Silva LR, et al. Survival after acute myocardial infarction in patients with end-stage renal disease: results from the cooperative cardiovascular project. *Am J Kidney Dis*. 2000 Jun;35(6):1044-51. PMID: 10845815.
383. Chertow GM, Block GA, Correa-Rotter R, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. *N Engl J Med*. 2012 Dec 27;367(26):2482-94. PMID: 23121374.
384. Cheung AK, Sarnak MJ, Yan G, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. *Kidney Int*. 2004 Jun;65(6):2380-9. PMID: 15149351.
385. Choi SG, Jeong MH, Ahn Y, et al. Relationship between obesity and N-terminal brain natriuretic Peptide level as a prognostic value after acute myocardial

- infarction. *Korean Circ J*. 2010 Nov;40(11):558-64. PMID: 21217932.
386. Choi YH, Suh SH, Choi JS, et al. Triple vs. dual antiplatelet therapy in patients with acute myocardial infarction and renal dysfunction. *Circ J*. 2012 Sep 25;76(10):2405-11. PMID: 22785460.
387. Chonchol MB, Aboyans V, Lacroix P, et al. Long-term outcomes after coronary artery bypass grafting: preoperative kidney function is prognostic. *J Thorac Cardiovasc Surg*. 2007 Sep;134(3):683-9. PMID: 17723818.
388. Chong E, Shen L, Tan HC, et al. A cohort study of risk factors and clinical outcome predictors for patients presenting with unstable angina and non ST segment elevation myocardial infarction undergoing coronary intervention. *Med J Malaysia*. 2011 Aug;66(3):249-52. PMID: 22111450.
389. Chou MT, Wang JJ, Sun YM, et al. Epidemiology and mortality among dialysis patients with acute coronary syndrome: Taiwan National Cohort Study. *Int J Cardiol*. 2012 Jul 12; PMID: 22795721.
390. Christenson JT, Schmuziger M, Simonet F. Reoperative coronary artery bypass procedures: risk factors for early mortality and late survival. *Eur J Cardiothorac Surg*. 1997 Jan;11(1):129-33. PMID: 9030801.
391. Chuang P, Gibney EM, Chan L, et al. Predictors of cardiovascular events and associated mortality within two years of kidney transplantation. *Transplant Proc*. 2004 Jun;36(5):1387-91. PMID: 15251339.
392. Coles AH, Fisher KA, Darling C, et al. Recent trends in post-discharge mortality among patients with an initial acute myocardial infarction. *Am J Cardiol*. 2012 Oct 15;110(8):1073-7. PMID: 22762720.
393. Cooper HA, Monge C, Panza JA. Patients with end-stage renal disease and acute myocardial infarction have poor short-term outcomes despite modern cardiac intensive care. *Coron Artery Dis*. 2008 Jun;19(4):231-5. PMID: 18480666.
394. Dalal D, de Jong JS, Tjong FV, et al. Mild-to-moderate kidney dysfunction and the risk of sudden cardiac death in the setting of acute myocardial infarction. *Heart Rhythm*. 2012 Apr;9(4):540-5. PMID: 22079886.
395. de la Torre-Hernandez JM, Alfonso F, Hernandez F, et al. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos). *J Am Coll Cardiol*. 2008 Mar 11;51(10):986-90. PMID: 18325436.
396. de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. *Circulation*. 2004 Aug 24;110(8):921-7. PMID: 15302780.
397. DeCarolis DD, Thorson JG, Clairmont MA, et al. Enoxaparin outcomes in patients with moderate renal impairment. *Arch Intern Med*. 2012;172(22):1713-8.
398. Dheir H, Ozkahya M, Kircelli F, et al. Glycosylated hemoglobin levels are associated with cardiovascular events in nondiabetic peritoneal dialysis patients. *J Nephrol*. 2012;25(1):107-12.
399. Dohi T, Miyauchi K, Okazaki S, et al. Long-term impact of mild chronic kidney disease in patients with acute coronary syndrome undergoing percutaneous coronary interventions. *Nephrol Dial Transplant*. 2011 Sep;26(9):2906-11. PMID: 21300704.
400. Dohi T, Kasai T, Miyauchi K, et al. Prognostic impact of chronic kidney disease on 10-year clinical outcomes among patients with acute coronary syndrome. *J Cardiol*. 2012 Dec;60(6):438-42. PMID: 23063662.
401. Dudek D, Chyrchel B, Siudak Z, et al. Renal insufficiency increases mortality in acute coronary syndromes regardless of TIMI risk score. *Kardiol Pol*. 2008 Jan;66(1):28-34; discussion 5-6. PMID: 18266185.

402. Dziewierz A, Siudak Z, Rakowski T, et al. More aggressive pharmacological treatment may improve clinical outcome in patients with non-ST-elevation acute coronary syndromes treated conservatively. *Coron Artery Dis.* 2007 Jun;18(4):299-303. PMID: 17496494.
403. El-Menyar A, Zubaid M, Sulaiman K, et al. In-hospital major clinical outcomes in patients with chronic renal insufficiency presenting with acute coronary syndrome: data from a Registry of 8176 patients. *Mayo Clin Proc.* 2010 Apr;85(4):332-40. PMID: 20360292.
404. Etter C, Straub Y, Hersberger M, et al. Pregnancy-associated plasma protein-A is an independent short-time predictor of mortality in patients on maintenance haemodialysis. *Eur Heart J.* 2010 Feb;31(3):354-9. PMID: 19850559.
405. Fabbian F, Pala M, De Giorgi A, et al. In-hospital mortality in patients with renal dysfunction admitted for myocardial infarction: the Emilia-Romagna region of Italy database of hospital admissions. *Int Urol Nephrol.* 2012 Jul 25 PMID: 22828743.
406. Fabbri A, Ottani F, Marchesini G, et al. Predicting unfavorable outcome in subjects with diagnosis of chest pain of undifferentiated origin. *Am J Emerg Med.* 2012 Jan;30(1):61-7. PMID: 21035982.
407. Facila L, Nunez J, Bodi V, et al. [Prognostic value of serum creatinine in non-ST-elevation acute coronary syndrome]. *Rev Esp Cardiol.* 2006 Mar;59(3):209-16. PMID: 16712744.
408. Fazelzadeh A, Mehdizadeh AR, Ostovan MA, et al. Predictors of cardiovascular events and associated mortality of kidney transplant recipients. *Transplant Proc.* 2006 Mar;38(2):509-11. PMID: 16549162.
409. Feldman DN, Minutello RM, Gade CL, et al. Outcomes following immediate (ad hoc) versus staged percutaneous coronary interventions (report from the 2000 to 2001 New York State Angioplasty Registry). *Am J Cardiol.* 2007 Feb 15;99(4):446-9. PMID: 17293181.
410. Ferguson ER, Hudson SL, Diethelm AG, et al. Outcome after myocardial revascularization and renal transplantation: a 25-year single-institution experience. *Ann Surg.* 1999 Aug;230(2):232-41. PMID: 10450738.
411. Ferrer-Hita JJ, Dominguez-Rodriguez A, Garcia-Gonzalez MJ, et al. Renal dysfunction is an independent predictor of in-hospital mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty. *Int J Cardiol.* 2007 May 31;118(2):243-5. PMID: 16997402.
412. Flu WJ, van Kuijk JP, Hoeks SE, et al. Intima media thickness of the common carotid artery in vascular surgery patients: a predictor of postoperative cardiovascular events. *Am Heart J.* 2009 Aug;158(2):202-8. PMID: 19619695.
413. Freeman RV, Mehta RH, Al Badr W, et al. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. *J Am Coll Cardiol.* 2003 Mar 5;41(5):718-24. PMID: 12628712.
414. Frilling B, Zahn R, Fraiture B, et al. Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab. *Am J Cardiol.* 2002 Feb 15;89(4):450-2. PMID: 11835927.
415. Fu SH, Zhu B, Zhang YX, et al. Chronic kidney disease: an independent risk factor of all-cause mortality for elderly Chinese patients with chronic heart failure. *J Geriatr Cardiol.* 2012 Dec;9(4):355-60. PMID: 23341840.
416. Funayama A, Shishido T, Miyashita T, et al. Renal tubulointerstitial damage is associated with short-term cardiovascular

- events in patients with myocardial infarction. *Circ J*. 2013 Jan 25;77(2):484-9. PMID: 23123554.
417. Furuhashi T, Moroi M, Joki N, et al. The predictive value of chronic kidney disease for assessing cardiovascular events under consideration of pretest probability for coronary artery disease in patients who underwent stress myocardial perfusion imaging. *Int J Cardiovasc Imaging*. 2013 Feb;29(2):513-9. PMID: 22806318.
418. Gai JJ, Gai LY, Liu HB, et al. [Correlation of heart and kidney biomarkers to the pathogenesis of cardiorenal syndrome]. *Nan Fang Yi Ke Da Xue Xue Bao*. 2010 May;30(5):1122-6. PMID: 20501410.
419. Garg P, Charytan DM, Novack L, et al. Impact of moderate renal insufficiency on restenosis and adverse clinical events after sirolimus-eluting and bare metal stent implantation (from the SIRIUS trials). *American Journal of Cardiology*. 2010;106(10):1436-42.
420. Garrido P, Bobadilla JF, Albertos J, et al. Cardiac surgery in patients under chronic hemodialysis. *Eur J Cardiothorac Surg*. 1995;9(1):36-9. PMID: 7727144.
421. Gibson CM, Pinto DS, Murphy SA, et al. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. *J Am Coll Cardiol*. 2003 Nov 5;42(9):1535-43. PMID: 14607434.
422. Gimeno-Orna JA, Lou-Arnal LM, Boned-Juliani B, et al. Mild renal insufficiency as a cardiovascular risk factor in non-proteinuric type II diabetes. *Diabetes Res Clin Pract*. 2004 Jun;64(3):191-9. PMID: 15126007.
423. Go J, Narmi A, Sype J, et al. Impact of renal dysfunction on the prognostic value of the TIMI risk score in patients with non-ST elevation acute coronary syndrome. *Coron Artery Dis*. 2011;22(6):411-5. PMID: 21691204.
424. Goldberg A, Hammerman H, Petcherski S, et al. Inhospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction. *Am Heart J*. 2005 Aug;150(2):330-7. PMID: 16086939.
425. Goldenberg I, Subirana I, Boyko V, et al. Relation between renal function and outcomes in patients with non-ST-segment elevation acute coronary syndrome: real-world data from the European Public Health Outcome Research and Indicators Collection Project. *Arch Intern Med*. 2010 May 24;170(10):888-95. PMID: 20498417.
426. Gurm HS, Gore JM, Anderson FA, Jr., et al. Comparison of acute coronary syndrome in patients receiving versus not receiving chronic dialysis (from the Global Registry of Acute Coronary Events [GRACE] Registry). *Am J Cardiol*. 2012 Jan 1;109(1):19-25. PMID: 21974963.
427. Hachinohe D, Jeong MH, Saito S, et al. Management of NonST-segment elevation acute myocardial infarction in patients with chronic kidney disease (from the Korea Acute Myocardial Infarction Registry). *American Journal of Cardiology*. 2011;108(2):206-13.
428. Hachinohe D, Jeong MH, Saito S, et al. Management of non-ST-segment elevation acute myocardial infarction in patients with chronic kidney disease (from the Korea Acute Myocardial Infarction Registry). *Am J Cardiol*. 2011 Jul 15;108(2):206-13. PMID: 21712106.
429. Halkin A, Singh M, Nikolsky E, et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. *J Am Coll Cardiol*. 2005 May 3;45(9):1397-405. PMID: 15862409.
430. Halkin A, Selzer F, Marroquin O, et al. Clinical outcomes following percutaneous coronary intervention with drug-eluting vs. bare-metal stents in dialysis patients. *Journal*

- of Invasive Cardiology. 2006;18(12):577-83.
431. Han JH, Chandra A, Mulgund J, et al. Chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. *Am J Med.* 2006 Mar;119(3):248-54. PMID: 16490471.
432. Harris S, Tepper D, Ip R. Comparison of hospital mortality with intra-aortic balloon counterpulsation insertion before vs after primary percutaneous coronary intervention for cardiogenic shock complicating acute myocardial infarction. *Congestive Heart Failure.* 2010;16(5):240-.
433. Hase H, Joki N, Ishikawa H, et al. Independent risk factors for progression of coronary atherosclerosis in hemodialysis patients. *Ther Apher Dial.* 2006 Aug;10(4):321-7. PMID: 16911184.
434. Hassani SE, Chu WW, Wolfram RM, et al. Clinical outcomes after percutaneous coronary intervention with drug-eluting stents in dialysis patients. *J Invasive Cardiol.* 2006 Jun;18(6):273-7. PMID: 16751681.
435. Herlitz J, Brandrup-Wognsen G, Karlsson T, et al. Predictors of death and other cardiac events within 2 years after coronary artery bypass grafting. *Cardiology.* 1998 Oct;90(2):110-4. PMID: 9778547.
436. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. *N Engl J Med.* 1998 Sep 17;339(12):799-805. PMID: 9738087.
437. Herzog CA. Acute myocardial infarction in patients with end-stage renal disease. *Kidney Int Suppl.* 1999 Jul;71:S130-3. PMID: 10412756.
438. Herzog CA, Ma JZ, Collins AJ. Long-term outcome of renal transplant recipients in the United States after coronary revascularization procedures. *Circulation.* 2004 Jun 15;109(23):2866-71. PMID: 15159290.
439. Holme I, Fayyad R, Faergeman O, et al. Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial. *J Intern Med;* 2010. p. 567-75.
440. Holzmam MJ, Janszky I, Al-Khalili F, et al. Renal dysfunction as a predictor of long-term mortality in middle-aged women following an acute coronary syndrome. *J Womens Health (Larchmt).* 2010 Aug;19(8):1487-91. PMID: 20626267.
441. Hsieh YC, Ting CT, Liu TJ, et al. Short- and long-term renal outcomes of immediate prophylactic hemodialysis after cardiovascular catheterizations in patients with severe renal insufficiency. *Int J Cardiol.* 2005 Jun 8;101(3):407-13. PMID: 15907408.
442. Hsieh TH, Wang JD, Tsai LM. Improving in-hospital mortality in elderly patients after acute coronary syndrome--a nationwide analysis of 97,220 patients in Taiwan during 2004-2008. *Int J Cardiol.* 2012 Feb 23;155(1):149-54. PMID: 22062897.
443. Huo Y, Ho W. [Renal insufficiency and clinical outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a multi-centre study]. *Beijing Da Xue Xue Bao.* 2007 Dec 18;39(6):624-9. PMID: 18087555.
444. Ifudu O, Miles AM, Friedman EA. Hemodialysis immediately after acute myocardial infarction. *Nephron.* 1996;74(1):104-9. PMID: 8883026.
445. Inoue T, Tokuyama K, Yoshi S, et al. Elevated resting heart rate is an independent predictor of all-cause death and cardiovascular events in Japanese ambulatory hemodialysis patients. *Clin Exp Nephrol.* 2012 Dec;16(6):938-44. PMID: 22588277.
446. Inrig JK, Patel UD, Briley LP, et al. Mortality, kidney disease and cardiac procedures following acute coronary syndrome. *Nephrol Dial Transplant.* 2008 Mar;23(3):934-40. PMID: 17984102.

447. Iseki K, Kinjo K, Kimura Y, et al. Evidence for high risk of cerebral hemorrhage in chronic dialysis patients. *Kidney Int.* 1993 Nov;44(5):1086-90. PMID: 8264139.
448. Iseki K, Fukiyama K. Long-term prognosis and incidence of acute myocardial infarction in patients on chronic hemodialysis. The Okinawa Dialysis Study Group. *Am J Kidney Dis.* 2000 Oct;36(4):820-5. PMID: 11007686.
449. Israni AK, Snyder JJ, Skeans MA, et al. Predicting coronary heart disease after kidney transplantation: Patient Outcomes in Renal Transplantation (PORT) Study. *Am J Transplant.* 2010 Feb;10(2):338-53. PMID: 20415903.
450. Itaya H, Shiba M, Joki N, et al. Combined assessment of chronic kidney disease and subclinical peripheral artery disease used to predict future cardiac events. *Nephrology (Carlton).* 2010 Mar;15(2):230-5. PMID: 20470284.
451. Januzzi JL, Cannon CP, DiBattiste PM, et al. Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). *Am J Cardiol.* 2002 Dec 1;90(11):1246-9. PMID: 12450608.
452. Jeong HC, Jeong JM, Jeong MH, et al. Effect of single or dual blockade of renin-angiotensin system in acute myocardial infarction patients according to renal function. *Int J Cardiol.* 2012 Jun 14;157(3):408-11. PMID: 22513185.
453. Jerbi B, Sahnoun M, Abid L, et al. [Chronic kidney disease and myocardial infarction: epidemiological, clinical, therapeutic and prognostic characteristics (about 231 cases)]. *Ann Cardiol Angeiol (Paris).* 2011 Jun;60(3):127-34. PMID: 21458774.
454. Joki N, Tanaka Y, Ishikawa H, et al. Optimum second screening point for detection of coronary artery disease in hemodialysis patients without advanced coronary artery disease. *Am J Nephrol.* 2009;29(5):420-5.
455. Kamimura MA, Carrero JJ, Canziani ME, et al. Visceral obesity assessed by computed tomography predicts cardiovascular events in chronic kidney disease patients. *Nutr Metab Cardiovasc Dis.* 2012 Jul 25 PMID: 22841184.
456. Kaya E, Cuneo A, Hochadel M, et al. Impact of chronic kidney disease on the prognosis of patients undergoing percutaneous coronary interventions using drug-eluting stents. *Clinical Research in Cardiology.* 2011;100(12):1103-9.
457. Keane WF, Tomassini JE, Neff DR. Lipid Abnormalities in Patients with Chronic Kidney Disease: Implications for the Pathophysiology of Atherosclerosis. *J Atheroscler Thromb.* 2012 Oct 25 PMID: 23095239.
458. Keeley EC, Kadakia R, Soman S, et al. Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes. *Am J Cardiol.* 2003 Sep 1;92(5):509-14. PMID: 12943868.
459. Kelly AM, Dabee P, Klim S, et al. External validation of the GRACE Freedom from Events score. *Heart Lung Circ.* 2012 Sep;21(9):582-5. PMID: 22710146.
460. Keltai M, Tonelli M, Mann JF, et al. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. *Eur J Cardiovasc Prev Rehabil.* 2007 Apr;14(2):312-8. PMID: 17446813.
461. Keough-Ryan TM, Kiberd BA, Dipchand CS, et al. Outcomes of acute coronary syndrome in a large Canadian cohort: impact of chronic renal insufficiency, cardiac interventions, and anemia. *Am J Kidney Dis.* 2005 Nov;46(5):845-55. PMID: 16253724.
462. Kessler M, Zannad F, Lehert P, et al. Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in dialysis

- study. *Nephrol Dial Transplant*. 2007 Dec;22(12):3573-9. PMID: 17611249.
463. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. *J Am Soc Nephrol*. 2005 Feb;16(2):520-8. PMID: 15615819.
464. Khambatta S, Farkouh ME, Wright RS, et al. Chronic kidney disease as a risk factor for acute coronary syndromes in patients presenting to the emergency room with chest pain. *Transl Res*. 2012 May;159(5):391-6. PMID: 22500512.
465. Kilickesmez KO, Kocas C, Abaci O, et al. Follow-up of aspirin-resistant patients with end-stage kidney disease. *Int Urol Nephrol*. 2012 Jun 20; PMID: 22714143.
466. Kim CS, Choi JS, Park JW, et al. Concomitant renal insufficiency and diabetes mellitus as prognostic factors for acute myocardial infarction. *Cardiovasc Diabetol*. 2011;10:95. PMID: 22035298.
467. Kim JY, Jeong MH, Ahn YK, et al. Decreased Glomerular Filtration Rate is an Independent Predictor of In-Hospital Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. *Korean Circ J*. 2011 Apr;41(4):184-90. PMID: 21607168.
468. Kim CS, Choi JS, Bae EH, et al. Association of metabolic syndrome and renal insufficiency with clinical outcome in acute myocardial infarction. *Metabolism*. 2012 Dec 5; PMID: 23218489.
469. Kinoshita N, Imai K, Kinjo K, et al. Longitudinal study of acute myocardial infarction in the southeast Osaka district from 1988 to 2002. *Circ J*. 2005 Oct;69(10):1170-5. PMID: 16195611.
470. Koganei H, Kasanuki H, Ogawa H, et al. Association of glomerular filtration rate with unsuccessful primary percutaneous coronary intervention and subsequent mortality in patients with acute myocardial infarction: from the HIJAMI registry. *Circ J*. 2008 Feb;72(2):179-85. PMID: 18219150.
471. Komukai K, Ogawa T, Yagi H, et al. Renal insufficiency is related to painless myocardial infarction. *Circ J*. 2007 Sep;71(9):1366-9. PMID: 17721012.
472. Kowalczyk J, Lenarczyk R, Kowalski O, et al. Different types of renal dysfunction in patients with acute myocardial infarction treated with percutaneous coronary intervention. *J Interv Cardiol*. 2007 Apr;20(2):143-52. PMID: 17391223.
473. Kowalczyk J, Lenarczyk R, Strojek K, et al. Prognosis in diabetic patients with acute myocardial infarction treated invasively is related to renal function. *Med Sci Monit*. 2010 Feb;16(2):CR67-74. PMID: 20110917.
474. Kowalczyk J, Francuz P, Swoboda R, et al. Prognostic significance of hyperuricemia in patients with different types of renal dysfunction and acute myocardial infarction treated with percutaneous coronary intervention. *Nephron Clin Pract*. 2010;116(2):c114-22. PMID: 20502047.
475. Krause MW, Massing M, Kshirsagar A, et al. Combination therapy improves survival after acute myocardial infarction in the elderly with chronic kidney disease. *Ren Fail*. 2004 Nov;26(6):715-25. PMID: 15600265.
476. Kumagai S, Ishii H, Amano T, et al. Impact of chronic kidney disease on the incidence of peri-procedural myocardial injury in patients undergoing elective stent implantation. *Nephrology Dialysis Transplantation*. 2012;27(3):1059-63.
477. Kuo PI, Severino R, Pashkow FJ. Mortality rates and hemorrhagic complications in asian-pacific islanders during treatment of acute myocardial infarction. *Am J Cardiol*. 2004 Sep 1;94(5):644-6, A9. PMID: 15342299.
478. Landray MJ, Emberson JR, Blackwell L, et al. Prediction of ESRD and death among people with CKD: the Chronic Renal

- Impairment in Birmingham (CRIB) prospective cohort study. *Am J Kidney Dis.* 2010 Dec;56(6):1082-94. PMID: 21035932.
479. Lansky AJ, Goto K, Cristea E, et al. Clinical and angiographic predictors of short- and long-term ischemic events in acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. *Circ Cardiovasc Interv.* 2010 Aug;3(4):308-16. PMID: 20647564.
480. Latchamsetty R, Fang J, Kline-Rogers E, et al. Prognostic value of transient and sustained increase in in-hospital creatinine on outcomes of patients admitted with acute coronary syndrome. *Am J Cardiol.* 2007 Apr 1;99(7):939-42. PMID: 17398188.
481. Lauzurica R, Pastor C, Bayes B, et al. Pretransplant pregnancy-associated plasma protein-a as a predictor of chronic allograft nephropathy and posttransplant cardiovascular events. *Transplantation.* 2005 Nov 27;80(10):1441-6. PMID: 16340789.
482. Lawesson SS, Todt T, Alfredsson J, et al. Gender difference in prevalence and prognostic impact of renal insufficiency in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. *Heart.* 2011;97(4):308-14.
483. Lee A, Lum JJ, Seto TB, et al. Severity of chronic kidney disease did not influence bleeding during treatment of acute coronary syndromes. *Hawaii Med J.* 2004 Nov;63(11):333-6. PMID: 15633659.
484. Lee SH, Kim YJ, Kim W, et al. Clinical outcomes and therapeutic strategy in patients with acute myocardial infarction according to renal function: data from the Korean Acute Myocardial Infarction Registry. *Circ J.* 2008 Sep;72(9):1410-8. PMID: 18724014.
485. Lee SH, Ha JW, Kim JS, et al. Plasma adiponectin and resistin levels as predictors of mortality in patients with acute myocardial infarction: data from infarction prognosis study registry. *Coron Artery Dis.* 2009 Jan;20(1):33-9. PMID: 18997620.
486. Lehmann R, Fichtlscherer S, Schachinger V, et al. Favorable long-term survival in patients undergoing multivessel-PCI compared to predicted prognosis of CABG estimated by EuroSCORE: procedural and clinical determinants of long-term outcome. *J Interv Cardiol.* 2009 Dec;22(6):511-9. PMID: 19732282.
487. Lewis EF, Velazquez EJ, Solomon SD, et al. Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. *Eur Heart J.* 2008 Mar;29(6):748-56. PMID: 18308687.
488. Limkakeng AT, Jr., Chandra A. Impact of renal dysfunction on acute coronary syndrome evaluation in observation unit patients. *Am J Emerg Med.* 2010 Jul;28(6):658-62. PMID: 20637379.
489. Lin Z, Gong Q, Zhou Z, et al. Increased plasma CXCL16 levels in patients with chronic kidney diseases. *Eur J Clin Invest.* 2011 Aug;41(8):836-45. PMID: 21299552.
490. Liu YW, Su CT, Chou CC, et al. Association of subtle left ventricular systolic dysfunction with elevated cardiac troponin T in asymptomatic hemodialysis patients with preserved left ventricular ejection fraction. *Acta Cardiologica Sinica.* 2012;28(2):95-102.
491. Lorusso R, Gelsomino S, De Ciccio G, et al. Mitral valve surgery in emergency for severe acute regurgitation: analysis of postoperative results from a multicentre study. *Eur J Cardiothorac Surg.* 2008 Apr;33(4):573-82. PMID: 18313322.
492. Lubos E, Messow CM, Schnabel R, et al. Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. *Atherosclerosis.* 2007 Jul;193(1):121-8. PMID: 16814296.

493. Lum JJ, Madison JR, Seto TB, et al. Management of patients with chronic kidney disease presenting with acute coronary syndrome. *Hawaii Med J.* 2004 Nov;63(11):330-2. PMID: 15633658.
494. Lum HD, Studenski SA, Degenholtz HB, et al. Early hospital readmission is a predictor of one-year mortality in community-dwelling older Medicare beneficiaries. *J Gen Intern Med.* 2012 Nov;27(11):1467-74. PMID: 22692634.
495. Luo Y, Lu L, Li GL, et al. [Analysis on correlative factors for occurrence of myocardial ischemia-reperfusion injury during primary percutaneous coronary intervention for acute myocardial infarction]. *Zhonghua Xin Xue Guan Bing Za Zhi.* 2005 Aug;33(8):691-4. PMID: 16188049.
496. Luo Y, Li GL, Pan YZ, et al. Determinants and prognostic implications of reperfusion injury during primary percutaneous coronary intervention in Chinese patients with acute myocardial infarction. *Clin Cardiol.* 2009 Mar;32(3):148-53. PMID: 19301290.
497. Ma C, Cao J, Lu XC, et al. Cardiovascular and cerebrovascular outcomes in elderly hypertensive patients treated with either ARB or ACEI. *J Geriatr Cardiol.* 2012 Sep;9(3):252-7. PMID: 23097655.
498. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. *J Am Coll Cardiol.* 2007 Mar 27;49(12):1362-8. PMID: 17394970.
499. Manzano-Fernandez S, Lopez-Cuenca A, Januzzi JL, et al. Usefulness of beta-trace protein and cystatin C for the prediction of mortality in non ST segment elevation acute coronary syndromes. *Am J Cardiol.* 2012 Nov 1;110(9):1240-8. PMID: 22818840.
500. Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. *J Am Coll Cardiol.* 2004 Nov 2;44(9):1780-5. PMID: 15519007.
501. Marenzi G, Moltrasio M, Assanelli E, et al. Impact of cardiac and renal dysfunction on in-hospital morbidity and mortality of patients with acute myocardial infarction undergoing primary angioplasty. *Am Heart J.* 2007 May;153(5):755-62. PMID: 17452149.
502. Marouf R, Zubaid M, Mojiminiyi OA, et al. Determinants of plasma homocysteine in relation to hematological and biochemical variables in patients with acute myocardial infarction. *South Med J.* 2006 Aug;99(8):811-6. PMID: 16929874.
503. Masoudi FA, Plomondon ME, Magid DJ, et al. Renal insufficiency and mortality from acute coronary syndromes. *Am Heart J.* 2004 Apr;147(4):623-9. PMID: 15077076.
504. Matsue Y, Matsumura A, Abe M, et al. Prognostic implications of chronic kidney disease and anemia after percutaneous coronary intervention in acute myocardial infarction patients. *Heart Vessels.* 2013 Jan;28(1):19-26. PMID: 22160439.
505. McClellan WM, Langston RD, Presley R. Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease. *J Am Soc Nephrol.* 2004 Jul;15(7):1912-9. PMID: 15213281.
506. McCullough PA, Nowak RM, Foreback C, et al. Emergency evaluation of chest pain in patients with advanced kidney disease. *Arch Intern Med.* 2002 Nov 25;162(21):2464-8. PMID: 12437406.
507. McCullough PA, Sandberg KR, Borzak S, et al. Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. *Am*

- Heart J. 2002 Aug;144(2):226-32. PMID: 12177638.
508. Medi C, Montalescot G, Budaj A, et al. Reperfusion in patients with renal dysfunction after presentation with ST-segment elevation or left bundle branch block: GRACE (Global Registry of Acute Coronary Events). *JACC Cardiovasc Interv.* 2009 Jan;2(1):26-33. PMID: 19463394.
509. Medi C, Chew DP, Amerena J, et al. An invasive management strategy is associated with improved outcomes in high-risk acute coronary syndromes in patients with chronic kidney disease. *Intern Med J.* 2011 Oct;41(10):743-50. PMID: 21040324.
510. Medina HM, Cannon CP, Fonarow GC, et al. Reperfusion strategies and quality of care in 5339 patients age 80 years or older presenting with ST-elevation myocardial infarction: analysis from get with the guidelines-coronary artery disease. *Clin Cardiol.* 2012 Oct;35(10):632-40. PMID: 22744844.
511. Mehran R, Nikolsky E, Lansky AJ, et al. Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUTY (Acute Catheterization and Urgent Intervention Triage strategy) substudy. *JACC Cardiovasc Interv.* 2009 Aug;2(8):748-57. PMID: 19695543.
512. Mehta RH, Chen AY, Pollack CV, Jr., et al. Challenges in predicting the need for coronary artery bypass grafting at presentation in patients with non-ST-segment elevation acute coronary syndromes. *Am J Cardiol.* 2006 Sep 1;98(5):624-7. PMID: 16923449.
513. Meizels A, Zeitoun DM, Bataille V, et al. Impact of polyvascular disease on baseline characteristics, management and mortality in acute myocardial infarction. The Alliance project. *Arch Cardiovasc Dis.* 2010 Apr;103(4):207-14. PMID: 20656631.
514. Mielniczuk LM, Pfeffer MA, Lewis EF, et al. Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome. *Am Heart J.* 2008 Apr;155(4):725-31. PMID: 18371483.
515. Mihalcea C, Pandeale GI. [Chronic myocardial infarction among patients with diabetes mellitus or impaired glucose tolerance]. *Rev Med Chir Soc Med Nat Iasi.* 2009 Jul-Sep;113(3):685-91. PMID: 20191816.
516. Mishkel GJ, Varghese JJ, Moore AL, et al. Short- and long-term clinical outcomes of coronary drug-eluting stent recipients presenting with chronic renal disease. *Journal of Invasive Cardiology.* 2007;19(8):331-7.
517. Moscucci M, Kline-Rogers E, Share D, et al. Simple bedside additive tool for prediction of in-hospital mortality after percutaneous coronary interventions. *Circulation.* 2001 Jul 17;104(3):263-8. PMID: 11457742.
518. Mota FM, Araujo J, Arruda JA, et al. Clinical outcome of renal transplant patients after coronary stenting. *Arq Bras Cardiol.* 2007 May;88(5):521-4. PMID: 17589625.
519. Nabais S, Rocha S, Joao C, et al. Prognostic impact of moderate renal dysfunction in acute coronary syndromes. *Rev Port Cardiol.* 2008 Mar;27(3):303-12; discussion 15-7. PMID: 18551917.
520. Nagashima M, Hagiwara N, Koyanagi R, et al. Chronic kidney disease and long-term outcomes of myocardial infarction. *Int J Cardiol.* 2012 May 6; PMID: 22569317.
521. Naiman N, Cheung AK, Goldfarb-Rumyantzev AS. Familiality of cardiovascular mortality in end-stage renal disease patients. *Am J Nephrol.* 2009;29(3):237-43. PMID: 18799871.
522. Naito K, Anzai T, Yoshikawa T, et al. Impact of chronic kidney disease on postinfarction inflammation, oxidative stress, and left ventricular remodeling. *J*

- Card Fail. 2008 Dec;14(10):831-8. PMID: 19041046.
523. Naruse Y, Makuuchi H, Kobayashi T, et al. Coronary artery bypass grafting in patients with dialysis-dependent renal failure. *Artif Organs*. 2001 Apr;25(4):260-2. PMID: 11318753.
524. Nayak AK, Kawamura A, Nesto RW, et al. Myocardial infarction as a presentation of clinical in-stent restenosis. *Circ J*. 2006 Aug;70(8):1026-9. PMID: 16864936.
525. Newsome BB, McClellan WM, Coffey CS, et al. Survival advantage of black patients with kidney disease after acute myocardial infarction. *Clin J Am Soc Nephrol*. 2006 Sep;1(5):993-9. PMID: 17699318.
526. Newsome BB, McClellan WM, Allison JJ, et al. Racial differences in the competing risks of mortality and ESRD after acute myocardial infarction. *Am J Kidney Dis*. 2008 Aug;52(2):251-61. PMID: 18468746.
527. Nishida H, Uchikawa S, Chikazawa G, et al. Coronary artery bypass grafting in 105 patients with hemodialysis-dependent renal failure. *Artif Organs*. 2001 Apr;25(4):268-72. PMID: 11318755.
528. Nishimura M, Tokoro T, Nishida M, et al. Oral nicorandil to reduce cardiac death after coronary revascularization in hemodialysis patients: a randomized trial. *Am J Kidney Dis*. 2009 Aug;54(2):307-17. PMID: 19535190.
529. Nishimura M, Sakoda C, Murakawa M, et al. Oral nicorandil for prevention of cardiac death in hemodialysis patients without obstructive coronary artery disease: a propensity-matched patient analysis. *Nephron Clin Pract*. 2011;119(4):c301-9. PMID: 21934329.
530. Nitta Y, Yamamoto R, Yamaguchi Y, et al. Impact of long-acting calcium channel blockers on the prognosis of patients with coronary artery disease with and without chronic kidney disease: A comparison of three drugs. *Journal of International Medical Research*. 2010;38(1):253-65.
531. Nurozler F, Kutlu T, Kucuk G. Off-pump CABG in diabetic patients: does insulin dependency matter? *Scand Cardiovasc J*. 2007 Jan;41(1):39-43. PMID: 17365976.
532. Oduncu V, Erkol A, Kurt M, et al. The prognostic value of very low admission LDL-cholesterol levels in ST-segment elevation myocardial infarction compared in statin-pretreated and statin-naive patients undergoing primary percutaneous coronary intervention. *Int J Cardiol*. 2012 Feb 1 PMID: 22305817.
533. Ogita M, Sakakura K, Nakamura T, et al. Association between deteriorated renal function and long-term clinical outcomes after percutaneous coronary intervention. *Heart Vessels*. 2012 Sep;27(5):460-7. PMID: 21822708.
534. Oishi K, Nagake Y, Yamasaki H, et al. The significance of atherogenic indices in patients on hemodialysis. *Am J Nephrol*. 2000 Mar-Apr;20(2):107-15. PMID: 10773610.
535. Okumura S, Sakakibara M, Hayashida R, et al. Accelerated decline in renal function after acute myocardial infarction in patients with high low-density lipoprotein-cholesterol to high-density lipoprotein-cholesterol ratio. *Heart Vessels*. 2013 Jan 29 PMID: 23358876.
536. Orii K, Hioki M, Iedokoro Y, et al. Prognostic factors affecting clinical outcomes after coronary artery bypass surgery: analysis of patients with chronic kidney disease after 5.9 years of follow-up. *J Nippon Med Sch*. 2011;78(3):156-65. PMID: 21720089.
537. Osaka S, Osawa H, Miyazawa M, et al. Immediate and long-term results of coronary artery bypass operation in hemodialysis patients. *Artif Organs*. 2001 Apr;25(4):252-5. PMID: 11318751.

538. Palmer SC, Yandle TG, Frampton CM, et al. Renal and cardiac function for long-term (10 year) risk stratification after myocardial infarction. *Eur Heart J*. 2009 Jun;30(12):1486-94. PMID: 19389787.
539. Palmerini T, Genereux P, Caixeta A, et al. A new score for risk stratification of patients with acute coronary syndromes undergoing percutaneous coronary intervention: the ACUITY-PCI (Acute Catheterization and Urgent Intervention Triage Strategy-Percutaneous Coronary Intervention) risk score. *JACC Cardiovasc Interv*. 2012 Nov;5(11):1108-16. PMID: 23174634.
540. Park JJ, Jang HJ, Oh IY, et al. Prognostic Value of Neutrophil to Lymphocyte Ratio in Patients Presenting With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. *Am J Cardiol*. 2012 Dec 27; PMID: 23273716.
541. Pendyala LK, Torguson R, Loh JP, et al. Comparison of Adverse Outcomes After Contemporary Percutaneous Coronary Intervention in Women Versus Men With Acute Coronary Syndrome. *Am J Cardiol*. 2013 Jan 23; PMID: 23352262.
542. Peterson PN, Ambardekar AV, Jones PG, et al. Increased mortality among survivors of myocardial infarction with kidney dysfunction: the contribution of gaps in the use of guideline-based therapies. *BMC Cardiovasc Disord*. 2009;9:29. PMID: 19586550.
543. Pfister R, Tan D, Thekkanal J, et al. NT-pro-BNP is associated with long-term outcome in a heterogeneous sample of cardiac inpatients. *Eur J Intern Med*. 2007 May;18(3):215-20. PMID: 17449394.
544. Pimenta E, Ramos RF, Gun C, et al. [Renal function outcome in acute myocardial infarction as a prognostic factor of in-hospital events and at one-year follow-up]. *Arq Bras Cardiol*. 2006 Mar;86(3):170-4. PMID: 16612442.
545. Pinto de Carvalho L, McCullough PA, Gao F, et al. Renal function and anaemia in acute myocardial infarction. *Int J Cardiol*. 2013 Jan 7; PMID: 23305857.
546. Pitsavos C, Kourlaba G, Panagiotakos DB, et al. Association of creatinine clearance and in-hospital mortality in patients with acute coronary syndromes: the GREECS study. *Circ J*. 2007 Jan;71(1):9-14. PMID: 17186971.
547. Pitsavos C, Kurlaba G, Panagiotakos DB, et al. Association of creatinine clearance and in-hospital mortality in patients with acute coronary syndromes - The GREECS study. *Circulation Journal*. 2007;71(1):9-14.
548. Podolecki TS, Lenarczyk RK, Kowalczyk JP, et al. The risk of stroke in patients with acute myocardial infarction treated invasively. *Coron Artery Dis*. 2012 Jan;23(1):9-15. PMID: 22064650.
549. Racki S, Zaputovic L, Vujicic B, et al. Cardiovascular risk factors and diseases strongly predict hemodialysis treatment outcome in maintenance hemodialysis patients. *Croat Med J*. 2005 Dec;46(6):936-41. PMID: 16342347.
550. Racki S, Zaputovic L, Vujicic B, et al. Comparison of survival between diabetic and non-diabetic patients on maintenance hemodialysis: a single-centre experience. *Diabetes Res Clin Pract*. 2007 Feb;75(2):169-75. PMID: 16824639.
551. Rakhit DJ, Armstrong KA, Beller E, et al. Risk stratification of patients with chronic kidney disease: results of screening strategies incorporating clinical risk scoring and dobutamine stress echocardiography. *Am Heart J*. 2006 Aug;152(2):363-70. PMID: 16875924.
552. Rakhit DJ, Marwick TH, Armstrong KA, et al. Effect of aggressive risk factor modification on cardiac events and myocardial ischaemia in patients with chronic kidney disease. *Heart*. 2006 Oct;92(10):1402-8. PMID: 16606867.

553. Rasty S, Borzak S, Tisdale JE. Bleeding associated with eptifibatid targeting higher risk patients with acute coronary syndromes: incidence and multivariate risk factors. *J Clin Pharmacol*. 2002 Dec;42(12):1366-73. PMID: 12463732.
554. Reddan DN, Szczech L, Bhapkar MV, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. *Nephrol Dial Transplant*. 2005 Oct;20(10):2105-12. PMID: 16030030.
555. Reibis R, Herbstleb J, Kamke W, et al. [Renal and cardiac functions as prognostic factors after revascularization for myocardial infarction]. *Dtsch Med Wochenschr*. 2007 Jun 8;132(23):1259-63. PMID: 17541867.
556. Rocha S, Nabais S, Magalhaes S, et al. Heart failure after acute coronary syndrome: identify to treat better! *Rev Port Cardiol*. 2007 Apr;26(4):349-59. PMID: 17695730.
557. Rutherford E, Leslie SJ, Soiza RL. Creatinine and eGFR are similarly predictive of outcome of acute coronary syndrome. *Int J Cardiol*. 2010 May 14;141(1):118-20. PMID: 19111358.
558. Rutten JHW, Korevaar JC, Boeschoten EW, et al. B-type natriuretic peptide and amino-terminal atrial natriuretic peptide predict survival in peritoneal dialysis. *Peritoneal Dialysis International*. 2006;26(5):598-602.
559. Sachdeva S, Singh NP, Saha R. Impact of renal dysfunction on the outcome of acute myocardial infarction. *Journal, Indian Academy of Clinical Medicine*. 2010;11(4):277-81.
560. Sadeghi HM, Stone GW, Grines CL, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. *Circulation*. 2003 Dec 2;108(22):2769-75. PMID: 14638545.
561. Sakai K, Nagayama S, Ihara K, et al. Primary percutaneous coronary intervention for acute myocardial infarction in the elderly aged ≥ 75 years. *Catheter Cardiovasc Interv*. 2012 Jan 1;79(1):50-6. PMID: 22215567.
562. Saltzman AJ, Stone GW, Claessen BE, et al. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. *JACC Cardiovasc Interv*. 2011 Sep;4(9):1011-9. PMID: 21939942.
563. Sanger S, Knorig J. Perioperative outcome and management of patients with dialysis-dependent renal insufficiency undergoing cardiac surgery. *Zeitschrift fur Herz-, Thorax- und Gefasschirurgie*. 2004;18(4):194-7.
564. Santolucito PA, Tighe DA, McManus DD, et al. Management and outcomes of renal disease and acute myocardial infarction. *Am J Med*. 2010 Sep;123(9):847-55. PMID: 20800154.
565. Santopinto JJ, Fox KA, Goldberg RJ, et al. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE). *Heart*. 2003 Sep;89(9):1003-8. PMID: 12923009.
566. Savic L, Mrdovic I, Perunicic J, et al. Impact of the combined left ventricular systolic and renal dysfunction on one-year outcomes after primary percutaneous coronary intervention. *J Interv Cardiol*. 2012 Apr;25(2):132-9. PMID: 22103669.
567. Schiele F, Seronde MF, Descotes-Genon V, et al. Impact of renal dysfunction and glucometabolic status on one month mortality after acute myocardial infarction. *Acute Card Care*. 2007;9(1):34-42. PMID: 17453537.
568. Schneider CA, Ferrannini E, Defronzo R, et al. Effect of pioglitazone on cardiovascular outcome in diabetes and

- chronic kidney disease. *J Am Soc Nephrol.* 2008 Jan;19(1):182-7. PMID: 18057215.
569. Schouten O, Hoeks SE, Goei D, et al. Plasma N-terminal pro-B-type natriuretic peptide as a predictor of perioperative and long-term outcome after vascular surgery. *J Vasc Surg.* 2009 Feb;49(2):435-41; discussion 41-2. PMID: 19028043.
570. Segev A, Matetzky S, Danenberg H, et al. Contemporary use and outcome of percutaneous coronary interventions in patients with acute coronary syndromes: insights from the 2010 ACSIS and ACSIS-PCI surveys. *EuroIntervention.* 2012 Aug;8(4):465-9. PMID: 22917730.
571. Selvarajah S, Fong AY, Selvaraj G, et al. An Asian validation of the TIMI risk score for ST-segment elevation myocardial infarction. *PLoS One.* 2012;7(7):e40249. PMID: 22815733.
572. Sendra JM, Sarria-Santamera A, Inigo J, et al. [Factors associated with acute myocardial infarction in-hospital mortality. Results of an observational study]. *Med Clin (Barc).* 2005 Nov 12;125(17):641-6. PMID: 16324492.
573. Serra A, Izzo A, Tomasi L, et al. [Mortality triplicates in acute myocardial infarction patients affected by chronic renal failure]. *G Ital Nefrol.* 2009 Mar-Apr;26 Suppl 45:S12-5. PMID: 19382088.
574. Seyfarth M, Kastrati A, Mann JF, et al. Prognostic value of kidney function in patients with ST-elevation and non-ST-elevation acute myocardial infarction treated with percutaneous coronary intervention. *Am J Kidney Dis.* 2009 Nov;54(5):830-9. PMID: 19592145.
575. Shao CL, Qiao SB, Zhu J, et al. [Impact of timing of intervention on prognosis of non-ST segment elevation acute coronary syndrome patients with renal dysfunction]. *Zhonghua Yi Xue Za Zhi.* 2010 Sep 14;90(34):2380-4. PMID: 21092504.
576. Shaw JA, Andrianopoulos N, Duffy S, et al. Renal impairment is an independent predictor of adverse events post coronary intervention in patients with and without drug-eluting stents. *Cardiovasc Revasc Med.* 2008 Oct-Dec;9(4):218-23. PMID: 18928945.
577. Shaya FT, Gu A, Yan X. Effect of Persistence with Drug Therapy On the Risk of Myocardial Re-infarction. *P T.* 2008 May;33(5):288-95. PMID: 19561792.
578. Shibui T, Nakagomi A, Kusama Y, et al. Impact of statin therapy on renal function and long-term prognosis in acute coronary syndrome patients with chronic kidney disease. *Int Heart J.* 2010;51(5):312-8. PMID: 20966602.
579. Shiga T, Kasanuki H, Hagiwara N, et al. Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients with coronary artery disease and impaired renal function. *Blood Press.* 2010 Dec;19(6):359-65. PMID: 20491606.
580. Shiraishi J, Kohno Y, Sawada T, et al. Prognostic impact of pulse pressure at admission on in-hospital outcome after primary percutaneous coronary intervention for acute myocardial infarction. *Heart Vessels.* 2012 Aug 28. PMID: 22926409.
581. Shiraishi J, Kohno Y, Sawada T, et al. Prognostic impact of systolic blood pressure at admission on in-hospital outcome after primary percutaneous coronary intervention for acute myocardial infarction. *J Cardiol.* 2012 Aug;60(2):139-44. PMID: 22521431.
582. Shlipak MG, Simon JA, Grady D, et al. Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. *J Am Coll Cardiol.* 2001 Sep;38(3):705-11. PMID: 11527621.
583. Simms AD, Reynolds S, Pieper K, et al. Evaluation of the NICE mini-GRACE risk scores for acute myocardial infarction using the Myocardial Ischaemia National Audit Project (MINAP) 2003-2009: National Institute for Cardiovascular Outcomes Research (NICOR). *Heart.* 2013 Jan;99(1):35-40. PMID: 23002253.

584. Skali H, Uno H, Levey AS, et al. Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation. *Am Heart J.* 2011 Sep;162(3):548-54. PMID: 21884875.
585. Smith GL, Masoudi FA, Shlipak MG, et al. Renal impairment predicts long-term mortality risk after acute myocardial infarction. *J Am Soc Nephrol.* 2008 Jan;19(1):141-50. PMID: 18003773.
586. Son J, Hur SH, Kim IC, et al. The impact of moderate to severe renal insufficiency on patients with acute myocardial infarction. *Korean Circ J.* 2011 Jun;41(6):308-12. PMID: 21779283.
587. Sooklim K, Srimahachota S, Boonyaratavej S, et al. Renal dysfunction as an independent predictor of total mortality after acute coronary syndrome: the Thai ACS Registry. *J Med Assoc Thai.* 2007 Oct;90 Suppl 1:32-40. PMID: 18431884.
588. Szczech LA, Reddan DN, Owen WF, et al. Differential survival after coronary revascularization procedures among patients with renal insufficiency. *Kidney Int.* 2001 Jul;60(1):292-9. PMID: 11422764.
589. Szummer K, Lundman P, Jacobson SH, et al. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). *Circulation.* 2009 Sep 8;120(10):851-8. PMID: 19704097.
590. Szummer K, Lundman P, Jacobson SH, et al. Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register. *J Intern Med.* 2010 Jul;268(1):40-9. PMID: 20210836.
591. Takahashi A, Takase H, Toriyama T, et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis—a randomized study. *Nephrol Dial Transplant.* 2006 Sep;21(9):2507-12. PMID: 16766543.
592. Takamura T, Takahashi N, Ishigami T, et al. Combining chronic kidney disease with 201thallium/123iodine beta methyl iodophenyl pentadecanoic acid dual myocardial single-photon emission computed tomography findings is useful for the evaluation of cardiac event risk. *Nucl Med Commun.* 2009 Jan;30(1):54-61. PMID: 19306514.
593. Takeuchi I, Moriguchi M, Imaki R, et al. Hemodialysis is an independent predictor of coronary in-stent restenosis after paclitaxel eluting stent implantation. *Internal Medicine.* 2010;49(22):2379-84.
594. Tanaka Y, Joki N, Hase H. History of acute coronary events during the predialysis phase of chronic kidney disease is a strong risk factor for major adverse cardiac events in patients initiating haemodialysis. *Nephrology Dialysis Transplantation.* 2007;22(10):2917-23.
595. Tang WH, Wu Y, Nicholls SJ, et al. Subclinical myocardial necrosis and cardiovascular risk in stable patients undergoing elective cardiac evaluation. *Arterioscler Thromb Vasc Biol.* 2010 Mar;30(3):634-40. PMID: 20032289.
596. Tay ELW, Chan M, Tan V, et al. Relation between combining evidence-based medications on mortality following myocardial infarction in patients with and without renal impairment. *Acta Cardiol.* 2010;65(2):211-6.
597. Teixeira R, Lourenco C, Baptista R, et al. Invasive versus conservative strategy in non-ST elevation acute coronary syndromes: data from a single Portuguese center. *Rev Port Cardiol.* 2009 Apr;28(4):355-73. PMID: 19634494.

598. Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. *N Engl J Med*. 2012 Oct 4;367(14):1287-96. PMID: 22920912.
599. Timoteo AT, Fiarresga A, Feliciano J, et al. The prognostic impact of renal failure in patients with ST-segment elevation acute myocardial infarction. *Kardiol Pol*. 2005 Oct;63(4):373-8; discussion 9-80. PMID: 16273475.
600. Tomaszuk-Kazberuk A, Kozuch M, Malyszko J, et al. Which method of GFR estimation has the best prognostic value in patients treated with primary PCI: Cockcroft-Gault formula, MDRD, or CKD-EPI equation?--A 6-year follow-up. *Ren Fail*. 2011;33(10):983-9. PMID: 22013931.
601. Tong PC, Kong AP, So WY, et al. Hematocrit, independent of chronic kidney disease, predicts adverse cardiovascular outcomes in chinese patients with type 2 diabetes. *Diabetes Care*. 2006 Nov;29(11):2439-44. PMID: 17065681.
602. Trespalacios FC, Taylor AJ, Agodoa LY, et al. Incident acute coronary syndromes in chronic dialysis patients in the United States. *Kidney Int*. 2002 Nov;62(5):1799-805. PMID: 12371982.
603. Tsagalis G, Akrivos T, Alevizaki M, et al. Renal dysfunction in acute stroke: an independent predictor of long-term all combined vascular events and overall mortality. *Nephrol Dial Transplant*. 2009 Jan;24(1):194-200. PMID: 18728156.
604. Vasaiwala S, Cannon CP, Fonarow GC, et al. Quality of care and outcomes among patients with acute myocardial infarction by level of kidney function at admission: report from the get with the guidelines coronary artery disease program. *Clin Cardiol*. 2012 Sep;35(9):541-7. PMID: 22744797.
605. Vasu S, Gruberg L, Brown DL. The impact of advanced chronic kidney disease on in-hospital mortality following percutaneous coronary intervention for acute myocardial infarction. *Catheter Cardiovasc Interv*. 2007 Nov 1;70(5):701-5. PMID: 17932900.
606. Vis MM, RJ VdS, Sjauw KD, et al. Creatinine clearance is independently associated with one year mortality in a primary PCI cohort with cardiogenic shock. *Acute Card Care*. 2009;11(2):107-12. PMID: 19449237.
607. Vis MM, Engstrom AE, Sjauw KD, et al. Plasma glucose and not hemoglobin or renal function predicts mortality in patients with STEMI complicated with cardiogenic shock. *J Cardiovasc Med (Hagerstown)*. 2010 Nov;11(11):827-31. PMID: 20686421.
608. Vogt A, Schoelmerich A, Pollner F, et al. Comparison of outcome in 1809 patients treated with drug-eluting stents or bare-metal stents in a real-world setting. *Vasc Health Risk Manag*. 2011;7:693-9. PMID: 22174579.
609. West AJ, Dixon SR, Kahn JK, et al. Effectiveness of primary angioplasty for acute myocardial infarction in patients on dialysis. *Am J Cardiol*. 2004 Feb 15;93(4):468-70. PMID: 14969626.
610. Wetmore JB, Sankaran S, Jones PG, et al. Association of decreased glomerular filtration rate with racial differences in survival after acute myocardial infarction. *Clin J Am Soc Nephrol*. 2011 Apr;6(4):733-40. PMID: 21310822.
611. Wison S, Foo K, Cunningham J, et al. Renal function and risk stratification in acute coronary syndromes. *Am J Cardiol*. 2003 May 1;91(9):1051-4. PMID: 12714145.
612. Wodzig KW, Kragten JA, Hermens WT, et al. Estimation of myocardial infarct size from plasma myoglobin or fatty acid-binding protein. Influence of renal function. *Eur J Clin Chem Clin Biochem*. 1997 Mar;35(3):191-8. PMID: 9127740.
613. Wohrle J, Nusser T, Mayer C, et al. Intracoronary application of abciximab in patients with ST-elevation myocardial

- infarction. *EuroIntervention*. 2008 Jan;3(4):465-9. PMID: 19736089.
614. Wong PN, Mak SK, Lo KY, et al. Adverse prognostic indicators in continuous ambulatory peritoneal dialysis patients without obvious vascular or nutritional comorbidities. *Perit Dial Int*. 2003 Dec;23 Suppl 2:S109-15. PMID: 17986527.
615. Wong JA, Goodman SG, Yan RT, et al. Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction. *Eur Heart J*. 2009 Mar;30(5):549-57. PMID: 19201761.
616. Woo J, Lacbawan FL, Sunheimer R, et al. Is myoglobin useful in the diagnosis of acute myocardial infarction in the emergency department setting? *Am J Clin Pathol*. 1995 Jun;103(6):725-9. PMID: 7785657.
617. Woo YM, McLean D, Kavanagh D, et al. The influence of pre-operative electrocardiographic abnormalities and cardiovascular risk factors on patient and graft survival following renal transplantation. *J Nephrol*. 2002 Jul-Aug;15(4):380-6. PMID: 12243367.
618. Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. *Ann Intern Med*. 2002 Oct 1;137(7):563-70. PMID: 12353943.
619. Yamaguchi J, Kasanuki H, Ishii Y, et al. Prognostic significance of serum creatinine concentration for in-hospital mortality in patients with acute myocardial infarction who underwent successful primary percutaneous coronary intervention (from the Heart Institute of Japan Acute Myocardial Infarction [HIJAMI] Registry). *Am J Cardiol*. 2004 Jun 15;93(12):1526-8. PMID: 15194026.
620. Yamaguchi J, Kasanuki H, Ishii Y, et al. Serum creatinine on admission predicts long-term mortality in acute myocardial infarction patients undergoing successful primary angioplasty: data from the Heart Institute of Japan Acute Myocardial Infarction (HIJAMI) Registry. *Circ J*. 2007 Sep;71(9):1354-9. PMID: 17721010.
621. Yan AT, Yan RT, Tan M, et al. Treatment and one-year outcome of patients with renal dysfunction across the broad spectrum of acute coronary syndromes. *Can J Cardiol*. 2006 Feb;22(2):115-20. PMID: 16485045.
622. Yan AT, Yan RT, Tan M, et al. Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome. *Am Heart J*. 2007 Dec;154(6):1108-15. PMID: 18035083.
623. Yoda S, Nakanishi K, Tano A, et al. Risk stratification of cardiovascular events in patients at all stages of chronic kidney disease using myocardial perfusion SPECT. *J Cardiol*. 2012 Nov;60(5):377-82. PMID: 22890072.
624. Young Altahan R, Goldenberg I, Kimron L, et al. Timing of coronary angiography and outcome in patients with non-ST elevation acute coronary syndromes and kidney disease: real-world data from the acute coronary syndromes Israeli survey. *Cardiology*. 2011;119(4):224-34. PMID: 22041637.
625. Zahn R, Hamm CW, Schneider S, et al. Predictors of death or myocardial infarction during follow-up after coronary stenting with the sirolimus-eluting stent. Results from the prospective multicenter German Cypher Stent Registry. *Am Heart J*. 2006 Dec;152(6):1146-52. PMID: 17161068.
626. Zdzienicka J, Siudak Z, Zawislak B, et al. Patients with non-ST-elevation myocardial infarction and without chest pain are treated less aggressively and experience higher in-hospital mortality. *Kardiol Pol*. 2007 Jul;65(7):769-75; discussion 76-7. PMID: 17694458.
627. Zhang Q, Shen WF, Zhang JS, et al. [Coronary stenting in patients with acute

coronary syndrome and renal dysfunction]. *Zhonghua Nei Ke Za Zhi*. 2004 Feb;43(2):106-8. PMID: 15059406.

628. Zhang Q, Zhang RY, Shen J, et al. Impact of admission creatinine level on clinical outcomes of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention with drug-eluting stent implantation. *Chin Med J (Engl)*. 2008 Dec 5;121(23):2379-83. PMID: 19102952.

629. Zhao FH, Chen YD, Song XT, et al. Predictive factors of recurrent angina after acute coronary syndrome: the global registry acute coronary events from China (Sino-GRACE). *Chin Med J (Engl)*. 2008 Jan 5;121(1):12-6. PMID: 18208658.

630. Zhao WS, Li KB, Zhang Y, et al. [The in-hospital mortality and its determinants for very elderly patients with acute myocardial infarction]. *Zhonghua Nei Ke Za Zhi*. 2011 Dec;50(12):1023-5. PMID: 22333170.

631. Zhu HN, Huo Y, Jiang J, et al. [Analysis of prognostic patients with non-ST-segment elevation acute myocardial infarction and clinical characteristics of those with renal dysfunction]. *Beijing Da Xue Xue Bao*. 2008 Oct 18;40(5):533-7. PMID: 18931720.

632. Zouaoui W, Ouldzein H, Boudou N, et al. Factors predictive for in-hospital mortality following percutaneous coronary intervention. *Arch Cardiovasc Dis*. 2008 Jul-Aug;101(7-8):443-8. PMID: 18848686.

Troponin Not Separate

633. Ahmed E, El-Menyar A, Singh R, et al. Effect of Age on Clinical Presentation and Outcome of Patients Hospitalized with Acute Coronary Syndrome: A 20-Year Registry in a Middle Eastern Country. *Open Cardiovasc Med J*. 2012;6:60-7. PMID: 22670161.

634. Alcock RF, Kouzios D, Naoum C, et al. Perioperative myocardial necrosis in patients at high cardiovascular risk undergoing

elective non-cardiac surgery. *Heart*. 2012 May;98(10):792-8. PMID: 22543837.

635. Alfaleh HF, Alsuwaida AO, Ullah A, et al. The prognostic impact of in-hospital worsening of renal function in patients with acute coronary syndrome. *Int J Cardiol*. 2012 Feb 18; PMID: 22349044.

636. Al-Rasadi K, Al-Zakwani I, Zubaid M, et al. Prevalence, Predictors, and Impact of Low High-Density Lipoprotein Cholesterol on in-Hospital Outcomes Among Acute Coronary Syndrome Patients in the Middle East. *Open Cardiovasc Med J*. 2011;5:203-9. PMID: 21966331.

637. Amin AP, Spertus JA, Reid KJ, et al. The prognostic importance of worsening renal function during an acute myocardial infarction on long-term mortality. *Am Heart J*. 2010 Dec;160(6):1065-71. PMID: 21146659.

638. Andrews N, Jenkins J, Andrews G, et al. Using postoperative cardiac Troponin-I (cTi) levels to detect myocardial ischaemia in patients undergoing vascular surgery. *Cardiovasc Surg*. 2001 Jun;9(3):254-65. PMID: 11336849.

639. Apple FS, Ler R, Chung AY, et al. Point-of-care i-STAT cardiac troponin I for assessment of patients with symptoms suggestive of acute coronary syndrome. *Clin Chem*. 2006 Feb;52(2):322-5. PMID: 16449217.

640. Apple FS, Pearce LA, Chung A, et al. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. *Clin Chem*. 2007 May;53(5):874-81. PMID: 17384009.

641. Audimoolam VK, McPhail MJ, Sherwood R, et al. Elevated troponin I and its prognostic significance in acute liver failure. *Crit Care*. 2012 Nov 28;16(6):R228. PMID: 23190744.

642. Azzazy HM, Duh SH, Fitzgerald RL, et al. Multisite study of a second generation whole blood rapid assay for cardiac troponin

- T. *Ann Clin Biochem.* 1999 Jul;36 (Pt 4):438-46. PMID: 10456205.
643. Barra S, Providencia R, Lourenco Gomes P, et al. [Prediction of cerebrovascular event risk following myocardial infarction]. *Rev Port Cardiol.* 2011 Jul;30(7-8):655-63. PMID: 22005309.
644. Biegus J, Zymlinski R, Szachniewicz J, et al. Clinical characteristics and predictors of in-hospital mortality in 270 consecutive patients hospitalised due to acute heart failure in a single cardiology centre during one year. *Kardiol Pol.* 2011;69(10):997-1005. PMID: 22006596.
645. Blasco L, Sanjuan R, Carbonell N, et al. Estimated Glomerular Filtration Rate in Short-Risk Stratification in Acute Myocardial Infarction. *Cardiorenal Med.* 2011;1(2):131-8. PMID: 22258400.
646. Bonnefoy E, Godon P, Kirkorian G, et al. Significance of serum troponin I elevation in patients with acute aortic dissection of the ascending aorta. *Acta Cardiol.* 2005 Apr;60(2):165-70. PMID: 15887472.
647. Brizuela Sanz JA, Gonzalez Fajardo JA, Fuentes LM, et al. Mortality in patients undergoing open aortoiliac surgery: prognostic value of troponin T in the immediate postoperative period. *Ann Vasc Surg.* 2010 Aug;24(6):747-51. PMID: 20472389.
648. Burton JO, Jefferies HJ, Selby NM, et al. Hemodialysis-induced cardiac injury: determinants and associated outcomes. *Clin J Am Soc Nephrol.* 2009 May;4(5):914-20. PMID: 19357245.
649. Cabrerizo Garcia JL, Zalba Etayo B, Perez Calvo JI. [Prognostic value of occult renal failure in the acute coronary syndrome]. *Rev Clin Esp.* 2010 Apr;210(4):204-6. PMID: 20304391.
650. Cakar MA, Gunduz H, Vatan MB, et al. The effect of admission creatinine levels on one-year mortality in acute myocardial infarction. *ScientificWorldJournal.* 2012;2012:186495. PMID: 22619619.
651. Calzavacca P, Licari E, Tee A, et al. Point-of-care testing during medical emergency team activations: a pilot study. *Resuscitation.* 2012 Sep;83(9):1119-23. PMID: 22353639.
652. Cauliez B, Hue G, Lavoigne A. [Assay of cardiac troponin T on Elecsys 2010: comparison with cardiac troponin I]. *Ann Biol Clin (Paris).* 1998 Nov-Dec;56(6):711-5. PMID: 9853030.
653. Chang SN, Hwang JJ, Chen YS, et al. Clinical experience with intra-aortic balloon counterpulsation over 10 years: a retrospective cohort study of 459 patients. *Resuscitation.* 2008 Jun;77(3):316-24. PMID: 18314247.
654. Chang AM, Edwards M, Matsuura AC, et al. Relationship between renal dysfunction and outcomes in emergency department patients with potential acute coronary syndromes. *Emerg Med J.* 2013 Feb;30(2):101-5. PMID: 22396383.
655. Chen RZ, Bu LP, Yu Y, et al. Relationship between serum cTnI/cTnT in patients with chronic heart failure and different cardiovascular diseases. *Fudan University Journal of Medical Sciences.* 2005;32(6):653-6.
656. Chiostrri M, Valente S, Crudeli E, et al. A new post-PCI scoring system for in-hospital mortality in STEMI patients. *J Cardiovasc Med (Hagerstown).* 2010 Oct;11(10):733-8. PMID: 20479658.
657. Choi SY, Lee JE, Jang EH, et al. Association between changes in N-terminal pro-brain natriuretic peptide levels and changes in left ventricular mass index in stable hemodialysis patients. *Nephron Clin Pract.* 2008;110(2):c93-100. PMID: 18815449.
658. Choi JS, Kim CS, Park JW, et al. Renal dysfunction as a risk factor for painless myocardial infarction: results from Korea Acute Myocardial Infarction Registry. *Clin*

- Res Cardiol. 2012 Oct;101(10):795-803. PMID: 22555520.
659. Chong C, Lam Q, Ryan J, et al. Impact of troponin I on long-term mortality after emergency orthopaedic surgery in older patients. *Intern Med J*. 2010 Nov;40(11):751-6. PMID: 19811558.
660. Chow GV, Hirsch GA, Spragg DD, et al. Prognostic significance of cardiac troponin I levels in hospitalized patients presenting with supraventricular tachycardia. *Medicine (Baltimore)*. 2010 May;89(3):141-8. PMID: 20453600.
661. Chrysohoou C, Pitsavos C, Aggelopoulos P, et al. Brain natriuretic peptide mediates the effect of creatinine clearance on development of left ventricular systolic dysfunction in patients with acute coronary syndrome. *Hellenic J Cardiol*. 2010 Sep-Oct;51(5):413-20. PMID: 20876054.
662. Clark GH, Kennon SR, Price CP. Evaluation of a new troponin I method on the Bayer Immuno 1 immunoassay analyser. *J Immunoassay*. 1999 Nov;20(4):253-73. PMID: 10595858.
663. Damman P, Kikkert WJ, Woudstra P, et al. Gender difference in the prognostic value of estimated glomerular filtration rate at admission in ST-segment elevation myocardial infarction: a prospective cohort study. *BMJ Open*. 2012;2(2):e000322. PMID: 22389358.
664. de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. *JAMA*. 2010 Dec 8;304(22):2503-12. PMID: 21139111.
665. De Mauri A, Bellomo G, Navino C, et al. Plasma B-type natriuretic peptide in dialyzed patients: marker of cardiovascular disease or link to plasma refilling. *J Nephrol*. 2011 Jul-Aug;24(4):507-14. PMID: 21240867.
666. DeFilippi CR, Fink JC, Nass CM, et al. N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. *Am J Kidney Dis*. 2005 Jul;46(1):35-44. PMID: 15983955.
667. deFilippi CR, Thorn EM, Aggarwal M, et al. Frequency and cause of cardiac troponin T elevation in chronic hemodialysis patients from study of cardiovascular magnetic resonance. *Am J Cardiol*. 2007 Sep 1;100(5):885-9. PMID: 17719339.
668. Dragu R, Behar S, Sandach A, et al. Should primary percutaneous coronary intervention be the preferred method of reperfusion therapy for patients with renal failure and ST-elevation acute myocardial infarction? *Am J Cardiol*. 2006 Apr 15;97(8):1142-5. PMID: 16616015.
669. Eggers KM, Dellborg M, Oldgren J, et al. Risk prediction in chest pain patients by biochemical markers including estimates of renal function. *Int J Cardiol*. 2008 Aug 18;128(2):207-13. PMID: 17662484.
670. Ekart R, Kanic V, Pecovnik Balon B, et al. Prognostic value of 48-hour ambulatory blood pressure measurement and cardiovascular mortality in hemodialysis patients. *Kidney Blood Press Res*. 2012;35(5):326-31. PMID: 22398387.
671. Everett BM, Cook NR, Magnone MC, et al. Sensitive cardiac troponin T assay and the risk of incident cardiovascular disease in women with and without diabetes mellitus: the Women's Health Study. *Circulation*. 2011 Jun 21;123(24):2811-8. PMID: 21632491.
672. Fernandez-Reyes MJ, Heras M, Sanchez R, et al. [Value of troponin T in patients with advanced chronic kidney failure. Clinical course after beginning hemodialysis]. *Nefrologia*. 2005;25(5):574-5. PMID: 16392311.
673. Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-

- term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. *Circulation*. 2010 Jan 26;121(3):357-65. PMID: 20065168.
674. Furuhashi M, Ura N, Hasegawa K, et al. Serum ratio of heart-type fatty acid-binding protein to myoglobin. A novel marker of cardiac damage and volume overload in hemodialysis patients. *Nephron Clin Pract*. 2003;93(2):C69-74. PMID: 12616033.
675. Garcia Acuna JM, Gonzalez-Babarro E, Grigorian Shamagian L, et al. Cystatin C provides more information than other renal function parameters for stratifying risk in patients with acute coronary syndrome. *Rev Esp Cardiol*. 2009 May;62(5):510-9. PMID: 19406065.
676. Goicoechea M, de Vinuesa SG, Gomez-Campdera F, et al. Predictive cardiovascular risk factors in patients with chronic kidney disease (CKD). *Kidney Int Suppl*. 2005 Jan(93):S35-8. PMID: 15613066.
677. Greenberg G, Assali A, Assa-Vaknin H, et al. Outcome of patients presenting with ST elevation myocardial infarct and cardiogenic shock: a contemporary single center's experience. *Cardiology*. 2012;122(2):83-8. PMID: 22739496.
678. Hafner G, Peetz D, Dati F, et al. Analytical and clinical evaluation of troponin I determination on dimension RXL-HM. *Clin Chem Lab Med*. 2000 Apr;38(4):355-61. PMID: 10928657.
679. Hanna EB, Chen AY, Roe MT, et al. Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention. *JACC Cardiovasc Interv*. 2011 Sep;4(9):1002-8. PMID: 21939940.
680. Hanna EB, Chen AY, Roe MT, et al. Characteristics and in-hospital outcomes of patients presenting with non-ST-segment elevation myocardial infarction found to have significant coronary artery disease on coronary angiography and managed medically: stratification according to renal function. *Am Heart J*. 2012 Jul;164(1):52-7 e1. PMID: 22795282.
681. Harada RK, Eagle KA, Kline-Rogers EM, et al. Low utilization of secondary preventive medications and its potential impact in patients with chronic kidney disease and acute coronary syndromes. *Indian Heart J*. 2006 May-Jun;58(3):222-9. PMID: 19033620.
682. Heitner JF, Curtis JP, Haq SA, et al. The significance of elevated troponin T in patients with nondialysis-dependent renal insufficiency: a validation with coronary angiography. *Clin Cardiol*. 2005 Jul;28(7):333-6. PMID: 16075826.
683. Hoiseith A, Neukamm A, Brekke PH, et al. Prognostic value of troponin T in COPD exacerbation. *Am J Respir Crit Care Med*. 2010;181(1).
684. Hollander JE, Levitt MA, Young GP, et al. Effect of recent cocaine use on the specificity of cardiac markers for diagnosis of acute myocardial infarction. *Am Heart J*. 1998 Feb;135(2 Pt 1):245-52. PMID: 9489972.
685. Hossein-Nia M, Anderson JR, Corbishley C, et al. Cardiac troponin T release following cardiac transplantation. *European Journal of Laboratory Medicine*. 1995;3(3):239-43.
686. Hudson MP, O'Connor CM, Gattis WA, et al. Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis. *Am Heart J*. 2004 Mar;147(3):546-52. PMID: 14999208.
687. Hur SJ, Kim DM, Lim KH, et al. Vitamin D levels and their relationship with cardiac biomarkers in chronic hemodialysis

- patients. *J Korean Med Sci.* 2009 Jan;24 Suppl:S109-14. PMID: 19194538.
688. Ilva TJ, Eskola MJ, Nikus KC, et al. The etiology and prognostic significance of cardiac troponin I elevation in unselected emergency department patients. *J Emerg Med.* 2010 Jan;38(1):1-5. PMID: 18687565.
689. Jacob J, Martin-Sanchez FJ, Herrero P, et al. [Prognostic value of troponin in patients with acute heart failure attended in Spanish Emergency Departments: TROPICA study (TROPOnin in acute heart failure).]. *Med Clin (Barc).* 2012 Oct 30; PMID: 23122607.
690. James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. *Circulation.* 2003 Jul 22;108(3):275-81. PMID: 12847065.
691. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. *Circulation.* 2010 Sep 14;122(11):1056-67. PMID: 20805430.
692. Januzzi Jr JL, Rehman S, Mueller T, et al. Importance of biomarkers for long-term mortality prediction in acutely dyspneic patients. *Clin Chem.* 2010;56(12):1814-21.
693. Jensen JK, Kristensen SR, Bak S, et al. Frequency and significance of troponin T elevation in acute ischemic stroke. *Am J Cardiol.* 2007 Jan 1;99(1):108-12. PMID: 17196472.
694. Jensen JK, Ueland T, Aukrust P, et al. Highly sensitive troponin T in patients with acute ischemic stroke. *Eur Neurol.* 2012;68(5):287-93. PMID: 23051820.
695. Kalla C, Raveh D, Algur N, et al. Incidence and significance of a positive troponin test in bacteremic patients without acute coronary syndrome. *Am J Med.* 2008 Oct;121(10):909-15. PMID: 18823863.
696. Kang YU, Jeong MH, Kim SW. Impact of renal dysfunction on clinical outcomes of acute coronary syndrome. *Yonsei Med J.* 2009 Aug 31;50(4):537-45. PMID: 19718403.
697. Kiatchoosakun S, Sahasthas D, Wongvipaporn C, et al. Cardiac troponin-T in pre-end stage kidney disease. *J Med Assoc Thai.* 2008 Dec;91(12):1806-11. PMID: 19133513.
698. Kilic T, Oner G, Ural E, et al. Comparison of the long-term prognostic value of cystatin C to other indicators of renal function, markers of inflammation and systolic dysfunction among patients with acute coronary syndrome. *Atherosclerosis.* 2009 Dec;207(2):552-8. PMID: 19523634.
699. Kim BS, Jeon DS, Shin MJ, et al. Persistent elevation of C-reactive protein may predict cardiac hypertrophy and dysfunction in patients maintained on hemodialysis. *Am J Nephrol.* 2005 May-Jun;25(3):189-95. PMID: 15863980.
700. Kirtane AJ, Leder DM, Waikar SS, et al. Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates. *J Am Coll Cardiol.* 2005 Jun 7;45(11):1781-6. PMID: 15936606.
701. Knafelj R, Radsel P, Ploj T, et al. Primary percutaneous coronary intervention and mild induced hypothermia in comatose survivors of ventricular fibrillation with ST-elevation acute myocardial infarction. *Resuscitation.* 2007 Aug;74(2):227-34. PMID: 17383070.
702. Kontos MC, Jamal S, Tatum JL, et al. Predictive power of systolic function and congestive heart failure in patients with patients admitted for chest pain without ST elevation in the troponin era. *Am Heart J.* 2008 Aug;156(2):329-35. PMID: 18657664.

703. Kratz A, Januzzi JL, Lewandrowski KB, et al. Positive predictive value of a point-of-care testing strategy on first-draw specimens for the emergency department-based detection of acute coronary syndromes. *Arch Pathol Lab Med.* 2002 Dec;126(12):1487-93. PMID: 12456209.
704. Kristen AV, Giannitsis E, Lehrke S, et al. Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. *Blood.* 2010 Oct 7;116(14):2455-61. PMID: 20581312.
705. Lambert ND, Sacrinty MT, Ketch TR, et al. Chronic kidney disease and dipstick proteinuria are risk factors for stent thrombosis in patients with myocardial infarction. *Am Heart J.* 2009 Apr;157(4):688-94. PMID: 19332197.
706. Landesberg G, Shatz V, Akopnik I, et al. Association of cardiac troponin, CK-MB, and postoperative myocardial ischemia with long-term survival after major vascular surgery. *J Am Coll Cardiol.* 2003 Nov 5;42(9):1547-54. PMID: 14607436.
707. Lankeit M, Jimenez D, Kostrubiec M, et al. Predictive value of the high-sensitivity troponin T assay and the simplified Pulmonary Embolism Severity Index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. *Circulation.* 2011 Dec 13;124(24):2716-24. PMID: 22082681.
708. Lasocki S, Provenchere S, Benessiano J, et al. Cardiac troponin I is an independent predictor of in-hospital death after adult cardiac surgery. *Anesthesiology.* 2002 Aug;97(2):405-11. PMID: 12151931.
709. Lavoigne A, Cauliez B, Eltchaninoff H, et al. Analytical and clinical performance of the Immulite cardiac troponin I assay. *Clin Chem.* 2000 Dec;46(12):1989-90. PMID: 11106332.
710. Lazzeri C, Valente S, Chiostrì M, et al. Microalbuminuria in non-diabetic stemi: an independent predictor for acute kidney injury. *Scand Cardiovasc J.* 2012 Dec;46(6):324-9. PMID: 22694718.
711. Lazzeri C, Valente S, Chiostrì M, et al. Uric acid in the early risk stratification of ST-elevation myocardial infarction. *Intern Emerg Med.* 2012 Feb;7(1):33-9. PMID: 21234713.
712. Li JP, Momin M, Huo Y, et al. Renal insufficiency is an independent predictor of in-hospital mortality for patients with acute myocardial infarction receiving primary percutaneous coronary intervention. *J Zhejiang Univ Sci B.* 2012 Aug;13(8):638-44. PMID: 22843184.
713. Lim W, Whitlock R, Khera V, et al. Etiology of troponin elevation in critically ill patients. *J Crit Care.* 2010 Jun;25(2):322-8. PMID: 19781898.
714. Lim SY, Bae EH, Choi JS, et al. Effect on short- and long-term major adverse cardiac events of statin treatment in patients with acute myocardial infarction and renal dysfunction. *Am J Cardiol.* 2012 May 15;109(10):1425-30. PMID: 22356794.
715. Loeb HS, Liu JC. Frequency, risk factors, and effect on long-term survival of increased troponin I following uncomplicated elective percutaneous coronary intervention. *Clin Cardiol.* 2010 Dec;33(12):E40-4. PMID: 21184543.
716. Lowbeer C, Gustafsson SA, Seeberger A, et al. Serum cardiac troponin T in patients hospitalized with heart failure is associated with left ventricular hypertrophy and systolic dysfunction. *Scand J Clin Lab Invest.* 2004;64(7):667-76. PMID: 15513324.
717. Manzano-Fernandez S, Januzzi Jr JL, Boronat-Garcia M, et al. (beta)-trace protein and cystatin C as predictors of long-term outcomes in patients with acute heart failure. *J Am Coll Cardiol.* 2011;57(7):849-58.
718. Masson S, Anand I, Favero C, et al. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large

- randomized clinical trials. *Circulation*. 2012 Jan 17;125(2):280-8. PMID: 22139751.
719. Matsumori R, Shimada K, Kiyanagi T, et al. Clinical significance of the measurements of urinary liver-type fatty acid binding protein levels in patients with acute coronary syndrome. *J Cardiol*. 2012 Sep;60(3):168-73. PMID: 22658694.
720. McCann CJ, Glover BM, Menown IB, et al. Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T. *Eur Heart J*. 2008 Dec;29(23):2843-50. PMID: 18682444.
721. Metra M, Bettari L, Pagani F, et al. Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation. *Clin Res Cardiol*. 2012 Aug;101(8):663-72. PMID: 22407461.
722. Metra M, Cotter G, Davison BA, et al. Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program: Correlation With Outcomes. *J Am Coll Cardiol*. 2013 Jan 15;61(2):196-206. PMID: 23273292.
723. Meune C, Balmelli C, Twerenbold R, et al. Patients with acute coronary syndrome and normal high-sensitivity troponin. *Am J Med*. 2011 Dec;124(12):1151-7. PMID: 22014790.
724. Mueller C, Neumann FJ, Perruchoud AP, et al. Renal function and long term mortality after unstable angina/non-ST segment elevation myocardial infarction treated very early and predominantly with percutaneous coronary intervention. *Heart*. 2004 Aug;90(8):902-7. PMID: 15253964.
725. Muller-Bardorff M, Hallermayer K, Schroder A, et al. Improved troponin T ELISA specific for cardiac troponin T isoform: Assay development and analytical and clinical validation. *Clin Chem*. 1997;43(3):458-66.
726. Nanda N, Sen SK, Arokiaraj MC. Ejection fraction at the first attack of myocardial infarction and postinfarction survival in South Indian population. *Indian J Physiol Pharmacol*. 2012 Jan-Mar;56(1):21-7. PMID: 23029960.
727. Nunes JP, Faria Mdo S, Garcia JM, et al. Glomerular filtration rate and coronary artery disease burden in patients with acute coronary syndrome. *Clin Cardiol*. 2007 Sep;30(9):464-8. PMID: 17803203.
728. Nunes JPL, Faria MDS, Garcia JMM, et al. Glomerular filtration rate and coronary artery disease burden in patients with acute coronary syndrome. *Clin Cardiol*. 2007;30(9):464-8.
729. Osherov AB, Roguin A, Aronson D, et al. Impact of platelet glycoprotein IIb/IIIa receptor inhibitors on renal function in patients with ST-segment elevation myocardial infarction treated with primary or rescue percutaneous coronary intervention. *EuroIntervention*. 2009 Nov;5(5):604-9. PMID: 20142182.
730. Paparella D, Scrascia G, Paramythiotis A, et al. Preoperative cardiac troponin I to assess midterm risks of coronary bypass grafting operations in patients with recent myocardial infarction. *Ann Thorac Surg*. 2010 Mar;89(3):696-702. PMID: 20172112.
731. Patil A, Aronow WS, Alexa M, et al. Causes of increased cardiac troponin I levels in hospitalized patients without coronary artery disease. *Open Journal of Cardiology*. 2012;2(1).
732. Patti G, Pasceri V, D'Antonio L, et al. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study). *Am J Cardiol*. 2012 Aug 15;110(4):478-84. PMID: 22583760.
733. Pervae S, Anderson FP, Lohmann TP, et al. Comparative analysis of cardiac troponin I and creatine kinase-MB as markers of

- acute myocardial infarction. *Clin Cardiol.* 1997;20(3):269-71.
734. Pitsavos C, Kourlaba G, Panagiotakos DB, et al. Characteristics and in-hospital mortality of diabetics and nondiabetics with an acute coronary syndrome; the GREECS study. *Clin Cardiol.* 2007 May;30(5):239-44. PMID: 17492678.
735. Prellwitz W, Hafner G, Rupprecht HJ, et al. [Diagnostic and differential diagnostic value of troponins]. *Med Klin (Munich).* 1996 Jun 15;91(6):336-42. PMID: 8767305.
736. Rittger H, Schnupp S, Sinha AM, et al. Predictors of treatment in acute coronary syndromes in the elderly: impact on decision making and clinical outcome after interventional versus conservative treatment. *Catheter Cardiovasc Interv.* 2012 Nov 1;80(5):735-43. PMID: 22121113.
737. Roe MT, Peterson ED, Li Y, et al. Relationship between risk stratification by cardiac troponin level and adherence to guidelines for non-ST-segment elevation acute coronary syndromes. *Arch Intern Med.* 2005 Sep 12;165(16):1870-6. PMID: 16157831.
738. Sanchez Hidalgo A, Pou M, Leiro R, et al. [Renal failure stages as predictors of mortality following acute coronary syndrome]. *Nefrologia.* 2009;29(1):53-60. PMID: 19240772.
739. Sanchez-Diaz CJ, Garcia-Badillo E, Sanchez-Ramirez CJ, et al. Clinical characteristics, process of care and outcomes among Mexican, Hispanic and non-Hispanic white patients presenting with non-ST elevation acute coronary syndromes: Data from RENASICA and CRUSADE registries. *Arch Cardiol Mex.* 2012 Jan;82(1):14-21. PMID: 22452861.
740. Sandhu KS, Singh A, Nadar SK. Management of elderly patients with troponin positive chest pain in a district general hospital. *Cardiol J.* 2012;19(4):395-401. PMID: 22825901.
741. Scheitz JF, Endres M, Mochmann HC, et al. Frequency, determinants and outcome of elevated troponin in acute ischemic stroke patients. *Int J Cardiol.* 2012 May 31;157(2):239-42. PMID: 22326514.
742. Sciahbasi A, Rizzello V, Gonzini L, et al. Chronic aspirin and statin therapy in patients with impaired renal function and acute coronary syndromes: results from the IN-ACS Outcome Registry. *Eur J Prev Cardiol.* 2012 Sep 5; PMID: 22952286.
743. Sharma R, Pellerin D, Gaze DC, et al. Mitral annular calcification predicts mortality and coronary artery disease in end stage renal disease. *Atherosclerosis.* 2007 Apr;191(2):348-54. PMID: 16647710.
744. Skelding KA, Boga G, Sartorius J, et al. Frequency of Coronary Angiography and Revascularization among Men and Women with Myocardial Infarction and Their Relationship to Mortality at One Year: An Analysis of the Geisinger Myocardial Infarction Cohort. *J Interv Cardiol.* 2013.
745. Stromme JH, Halvorsen S, Frederichsen P. [Diagnoses and increased levels of troponin T among discharged patients]. *Tidsskr Nor Laegeforen.* 2001 Oct 30;121(26):3041-5. PMID: 11757436.
746. Szummer K, Lindahl B, Sylven C, et al. Relationship of plasma erythropoietin to long-term outcome in acute coronary syndrome. *Int J Cardiol.* 2010 Aug 20;143(2):165-70. PMID: 19269703.
747. Urso S, Garozzo M, Milone F, et al. Cardiovascular risk markers in hemodialysis patients. *Int J Artif Organs.* 2004 Dec;27(12):1083-90. PMID: 15645620.
748. Verouden NJ, Haecck JD, Kuijt WJ, et al. Comparison of the usefulness of N-terminal pro-brain natriuretic peptide to other serum biomarkers as an early predictor of ST-segment recovery after primary percutaneous coronary intervention. *Am J Cardiol.* 2010 Apr 15;105(8):1047-52. PMID: 20381651.

749. Wallace TW, Abdullah SM, Drazner MH, et al. Prevalence and determinants of troponin T elevation in the general population. *Circulation*. 2006 Apr 25;113(16):1958-65. PMID: 16618821.
750. Wang CP, Lu LF, Tsai IT, et al. Roles of serum total P-cresylsulfate and chronic kidney disease in coronary atherosclerotic burden in acute coronary syndrome patients. *Acta Cardiologica Sinica*. 2012;28(4):297-305.
751. Waxman DA, Hecht S, Schappert J, et al. A model for troponin I as a quantitative predictor of in-hospital mortality. *J Am Coll Cardiol*. 2006 Nov 7;48(9):1755-62. PMID: 17084245.
752. Wong PS, Jones JD, Ashrafi R, et al. Early and late mortality in hospitalised patients with raised cardiac troponin T. *Postgrad Med J*. 2012 Aug;88(1042):437-42. PMID: 22543243.
753. Wood FO, Leonowicz NA, Vanhecke TE, et al. Mortality in patients with ST-segment elevation myocardial infarction who do not undergo reperfusion. *Am J Cardiol*. 2012 Aug 15;110(4):509-14. PMID: 22633204.
754. Zahid M, Good CB, Singla I, et al. Clinical significance of borderline elevated troponin I levels across different assays in patients with suspected acute coronary syndrome. *Am J Cardiol*. 2009 Jul 15;104(2):164-8. PMID: 19576340.
755. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. *N Engl J Med*. 2008 May 15;358(20):2107-16. PMID: 18480203.
756. Badero OJ, Salifu MO. Prediction of hemodynamically significant coronary artery disease using troponin I in hemodialysis patients presenting with chest pain: A case-control study. *Cardiology*. 2009;114(4):292-7. PMID: 19696481.
757. Barthelemy O, Helft G, Berman E, et al. Primary PCI in patients with impaired renal function. *Eur Heart J*. 2012;33:387.
758. Christenson RH, Fitzgerald RL, Ochs L, et al. Characteristics of a 20-minute whole blood rapid assay for cardiac troponin T. *Clin Biochem*. 1997 Feb;30(1):27-33. PMID: 9056106.
759. Davis GK, Labugger R, Van Eyk JE, et al. Cardiac troponin T is not detected in Western blots of diseased renal tissue. *Clin Chem*. 2001 Apr;47(4):782-3. PMID: 11274043.
760. Escalon JC, Wong SS. False-positive cardiac troponin T levels in chronic hemodialysis patients. *Cardiology*. 1996 May-Jun;87(3):268-9. PMID: 8725327.
761. Finsterer J, Stollberger C, Krugluger W. Positive troponin-T in noncompaction is associated with neuromuscular disorders and poor outcome. *Clin Res Cardiol*. 2007 Feb;96(2):109-13. PMID: 17146603.
762. Heeschen C, Goldmann BU, Moeller RH, et al. Analytical performance and clinical application of a new rapid bedside assay for the detection of serum cardiac troponin I. *Clin Chem*. 1998 Sep;44(9):1925-30. PMID: 9732978.
763. Jernberg T, Lindahl B, James S, et al. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. *Circulation*. 2004 Oct 19;110(16):2342-8. PMID: 15477399.
764. Karwowski D, Kalinaczk L, Majewski K, et al. Impaired renal function in patients with myocardial infarction treated with primary angioplasty and the risk for failed myocardial tissue reperfusion and thus worse long-term outcomes. *Postepy w Kardiologii Interwencyjnej*. 2012;8(1):18-24.
765. Lazaros G, Tsiachris D, Tousoulis D, et al. In-hospital worsening renal function is an independent predictor of one-year mortality

in patients with acute myocardial infarction. *Int J Cardiol.* 2012 Feb 23;155(1):97-101. PMID: 21078526.

766. Lee MG, Jeong MH, Lee KH, et al. Comparison of chronic kidney disease and risk for presenting with painless versus nonpainless acute myocardial infarction. *Am J Cardiol.* 2012 Sep 15;110(6):790-4. PMID: 22657394.

767. Lourenco C, Teixeira R, Antonio N, et al. Impact of renal function on mortality and incidence of major adverse cardiovascular events following acute coronary syndromes. *Rev Port Cardiol.* 2010 Sep;29(9):1331-52. PMID: 21179976.

768. McLaurin MD, Apple FS, Voss EM, et al. Cardiac troponin I, cardiac troponin T, and creatine kinase MB in dialysis patients without ischemic heart disease: evidence of cardiac troponin T expression in skeletal muscle. *Clin Chem.* 1997 Jun;43(6 Pt 1):976-82. PMID: 9191549.

769. Panteghini M, Bonora R, Pagani F. Rapid and specific immunoassay for cardiac troponin I in the diagnosis of myocardial damage. *Int J Clin Lab Res.* 1997;27(1):60-4. PMID: 9144029.

770. Park SH, Lee SW, Lee SJ, et al. The association between left ventricular hypertrophy and biomarkers in patients on continuous ambulatory peritoneal dialysis. *Korean Circ J.* 2009 Nov;39(11):488-93. PMID: 19997545.

771. Petrovic D, Stojimirovic B. Cardiovascular morbidity and mortality in patients treated with hemodialysis--epidemiological analysis. *Vojnosanit Pregl.* 2008 Dec;65(12):893-900. PMID: 19160983.

772. Sahinarslan A, Guz G, Mutluay R, et al. The impact of dialysis type on biomarkers for cardiovascular diseases. *Turk Kardiyol Dern Ars.* 2011 Sep;39(6):456-62. PMID: 21918314.

773. Steen H, Madadi-Schroeder M, Lehrke S, et al. Staged cardiovascular magnetic

resonance for differential diagnosis of troponin T positive patients with low likelihood for acute coronary syndrome. *J Cardiovasc Magn Reson.* 2010;12:51. PMID: 20840783.

774. Wu AHB. Interpretation of high sensitivity cardiac troponin I results: Reference to biological variability in patients who present to the emergency room with chest pain: Case report series. *Clinica Chimica Acta.* 2009;401(1-2):170-4.

775. Ziebig R, Lun A, Hocher B, et al. Renal elimination of troponin T and troponin I. *Clin Chem.* 2003 Jul;49(7):1191-3. PMID: 12816921.

No Outcome of Interest

776. Adams JE, 3rd, Bodor GS, Davila-Roman VG, et al. Cardiac troponin I. A marker with high specificity for cardiac injury. *Circulation.* 1993 Jul;88(1):101-6. PMID: 8319322.

777. Adhyapak SM, Iyengar SS. Characteristics of a subset of patients with reversible systolic dysfunction in chronic kidney disease. *Congest Heart Fail.* 2011 May-Jun;17(3):120-6. PMID: 21609385.

778. Afsar B, Elsurer R, Akgul A, et al. Factors related to silent myocardial damage in hemodialysis patients. *Ren Fail.* 2009;31(10):933-41. PMID: 20030529.

779. Akagi M, Nagake Y, Makino H, et al. A comparative study of myocardial troponin T levels in patients undergoing hemodialysis. *Nihon Jinzo Gakkai Shi.* 1995 Nov;37(11):639-43. PMID: 8583700.

780. Akagi M, Nagake Y, Ichikawa H, et al. Myocardial troponin T levels in patients with diabetic nephropathy. *Nihon Jinzo Gakkai Shi.* 1996 Mar;38(3):136-40. PMID: 8721335.

781. Aksoy N, Ozer O, Sari I, et al. Contribution of renal function impairment to unexplained troponin T elevations in

- congestive heart failure. *Ren Fail.* 2009;31(4):272-7. PMID: 19462275.
782. Al Badr W, Mukherjee D, Kline-Rogers E, et al. Clinical association between renal insufficiency and positive troponin I in patients with acute coronary syndrome. *Cardiology.* 2004;102(4):215-9. PMID: 15452394.
783. Al-Hadi HA, William B, Fox KA. Serum level of heart-type Fatty Acid-binding protein in patients with chronic renal failure. *Sultan Qaboos Univ Med J.* 2009 Dec;9(3):311-4. PMID: 21509315.
784. Apple FS, Ricchiuti V, Voss EM, et al. Expression of cardiac troponin T isoforms in skeletal muscle of renal disease patients will not cause false-positive serum results by the second generation cardiac troponin T assay. *Eur Heart J.* 1998 Nov;19 Suppl N:N30-3. PMID: 9857936.
785. Arroyo D, Quiroga B, Panizo N, et al. High-sensitivity troponin T levels in kidney transplant recipients. *Transplant Proc.* 2012 Nov;44(9):2545-7. PMID: 23146449.
786. Balamuthusamy S, Khosla S, Meka S, et al. Clinical utility of cardiac troponin I in the diagnosis of acute coronary syndrome in patients with renal failure. *Am J Ther.* 2007 Jul-Aug;14(4):356-60. PMID: 17667211.
787. Bolasco P, Ghezzi PM, Serra A, et al. Effects of acetate-free haemodiafiltration (HDF) with endogenous reinfusion (HFR) on cardiac troponin levels. *Nephrol Dial Transplant.* 2011 Jan;26(1):258-63. PMID: 20601367.
788. Boulier A, Bosc JY, Boularan AM, et al. So the reference values for cTroponin I must be modified in end stage renal disease? *Immuno-Analyse et Biologie Specialisee.* 2004;19(2):101-4.
789. Braun SL, Baum H, Neumeier D, et al. Troponin T and troponin I after coronary artery bypass grafting: discordant results in patients with renal failure. *Clin Chem.* 1996 May;42(5):781-3. PMID: 8653914.
790. Breidthardt T, Burton JO, Odudu A, et al. Troponin T for the detection of dialysis-induced myocardial stunning in hemodialysis patients. *Clin J Am Soc Nephrol.* 2012 Aug;7(8):1285-92. PMID: 22822013.
791. Caliskan Y, Ozkok A, Akagun T, et al. Cardiac biomarkers and noninvasive predictors of atherosclerosis in chronic peritoneal dialysis patients. *Kidney Blood Press Res.* 2012;35(5):340-8. PMID: 22473007.
792. Cauliez B, Hue G, Lavoigne A. Cardiac troponin T on Elecsys 2010: Comparison with cardiac troponin I. *Ann Biol Clin (Paris).* 1998;56(6):711-5,23.
793. Charytan DM, Setoguchi S, Solomon DH, et al. Clinical presentation of myocardial infarction contributes to lower use of coronary angiography in patients with chronic kidney disease. *Kidney Int.* 2007 May;71(9):938-45. PMID: 17342183.
794. Collado S, Coll E, Deulofeu R, et al. [Prevalence of cardiovascular disease in uraemia and relevance of cardiovascular risk factors]. *Nefrologia.* 2010;30(3):342-8. PMID: 20514101.
795. Collinson PO, Hadcocks L, Foo Y, et al. Cardiac troponins in patients with renal dysfunction. *Ann Clin Biochem.* 1998 May;35 (Pt 3):380-6. PMID: 9635103.
796. Coritsidis G, Sutariya D, Stern A, et al. Does timing of dialysis in patients with ESRD and acute myocardial infarcts affect morbidity or mortality? *Clin J Am Soc Nephrol.* 2009 Aug;4(8):1324-30. PMID: 19590061.
797. Correia LC, Barbosa CE, Cerqueira T, et al. Moderate renal dysfunction is not associated with elevated Troponin T in acute coronary syndromes. *Arq Bras Cardiol.* 2010 Oct;95(5):600-5. PMID: 21225113.
798. Desai AS, Toto R, Jarolim P, et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD.

- Am J Kidney Dis. 2011 Nov;58(5):717-28. PMID: 21820220.
799. Diris JH, Hackeng CM, Kooman JP, et al. Impaired renal clearance explains elevated troponin T fragments in hemodialysis patients. *Circulation*. 2004 Jan 6;109(1):23-5. PMID: 14691043.
800. Donnino MW, Karriem-Norwood V, Rivers EP, et al. Prevalence of elevated troponin I in end-stage renal disease patients receiving hemodialysis. *Acad Emerg Med*. 2004 Sep;11(9):979-81. PMID: 15347551.
801. Fahie-Wilson MN, Carmichael DJ, Delaney MP, et al. Cardiac troponin T circulates in the free, intact form in patients with kidney failure. *Clin Chem*. 2006 Mar;52(3):414-20. PMID: 16410339.
802. Falaknazi K, Bagheri N, Taziki O. Assessment of inflammatory factors and cardiac troponin T in hemodialysis patients. *Saudi J Kidney Dis Transpl*. 2009 Mar;20(2):219-22. PMID: 19237807.
803. Flisinski M, Strozecki P, Stefanska A, et al. Cardiac troponin I in patients with chronic kidney disease treated conservatively or undergoing long-term haemodialysis. *Kardiol Pol*. 2007 Sep;65(9):1068-75; discussion 76-8. PMID: 17975754.
804. Ford ML, Smith ER, Tomlinson LA, et al. FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart. *Nephrol Dial Transplant*. 2012 Feb;27(2):727-33. PMID: 21750158.
805. Fredericks S, Chang R, Gregson H, et al. Circulating cardiac troponin-T in patients before and after renal transplantation. *Clin Chim Acta*. 2001 Aug 20;310(2):199-203. PMID: 11498086.
806. Gabr AE, Ibrahim IA, Aloulou SM, et al. Cardiac troponin T and end stage renal disease. *Saudi Med J*. 2004 Aug;25(8):1015-9. PMID: 15322590.
807. Guz G, Sahinarslan A, Dhondt AW, et al. Elevated cardiac troponin T in hemodialysis patients receiving more intravenous iron sucrose. *Ren Fail*. 2004 Nov;26(6):663-72. PMID: 15600258.
808. Hafner G, Thome-Kromer B, Schaube J, et al. Cardiac troponins in serum in chronic renal failure. *Clin Chem*. 1994 Sep;40(9):1790-1. PMID: 8070099.
809. Haller C, Zehelein J, Remppis A, et al. Cardiac troponin T in patients with end-stage renal disease: absence of expression in truncal skeletal muscle. *Clin Chem*. 1998 May;44(5):930-8. PMID: 9590364.
810. Hausken J, Klingenberg O, Morkrid L, et al. Elevated troponin I and NT-proBNP at the time of transplantation may predict a major adverse cardiac event in the early postoperative period after renal transplantation. *Transplantation*. 2012 Jul 27;94(2):e15-6. PMID: 22820562.
811. Hayashi T, Obi Y, Kimura T, et al. Cardiac troponin T predicts occult coronary artery stenosis in patients with chronic kidney disease at the start of renal replacement therapy. *Nephrol Dial Transplant*. 2008 Sep;23(9):2936-42. PMID: 18403432.
812. Iliou MC, Fumeron C, Benoit MO, et al. Factors associated with increased serum levels of cardiac troponins T and I in chronic haemodialysis patients: Chronic Haemodialysis And New Cardiac Markers Evaluation (CHANCE) study. *Nephrol Dial Transplant*. 2001 Jul;16(7):1452-8. PMID: 11427640.
813. Ishii J, Ishikawa T, Yukitake J, et al. Clinical specificity of a second-generation cardiac troponin T assay in patients with chronic renal failure. *Clin Chim Acta*. 1998 Feb 23;270(2):183-8. PMID: 9544455.
814. Jacobs LH, van de Kerkhof JJ, Mingels AM, et al. Inflammation, overhydration and cardiac biomarkers in haemodialysis patients: a longitudinal study. *Nephrol Dial*

- Transplant. 2010 Jan;25(1):243-8. PMID: 19692417.
815. Jaroszynski A, Czekajska-Chechab E, Drelich-Zbroja A, et al. Spatial QRS-T angle in peritoneal dialysis patients: association with carotid artery atherosclerosis, coronary artery calcification and troponin T. *Nephrol Dial Transplant*. 2009 Mar;24(3):1003-8. PMID: 18978067.
816. Jefferies HJ, Virk B, Schiller B, et al. Frequent hemodialysis schedules are associated with reduced levels of dialysis-induced cardiac injury (myocardial stunning). *Clin J Am Soc Nephrol*. 2011 Jun;6(6):1326-32. PMID: 21597028.
817. Jung HH, Ma KR, Han H. Elevated concentrations of cardiac troponins are associated with severe coronary artery calcification in asymptomatic haemodialysis patients. *Nephrol Dial Transplant*. 2004 Dec;19(12):3117-23. PMID: 15546893.
818. Kandil ME, Hussein G, Bazaraa HM, et al. Left ventricular hypertrophy and cardiac troponin I in pediatric hemodialysis. *Journal of Clinical and Basic Cardiology*. 2009;12(1-4):5-10.
819. Koehnlein T, Schmidt A, Moesenthin M, et al. Increased cardiac troponin T and C-reactive protein levels in end-stage renal disease are associated with obstructive sleep apnea. *Clin Nephrol*. 2009 Jan;71(1):50-8. PMID: 19203550.
820. Korkmaz H, Sasak G, Celik A, et al. The comparison of cardiac biomarkers positivities in hemodialysis patients without acute coronary syndrome. *Ren Fail*. 2011;33(6):578-81. PMID: 21663388.
821. Kostrubiec M, Labyk A, Pedowska-Wloszek J, et al. Impaired renal function predicts short term prognosis in patients with acute pulmonary embolism. *Eur Heart J*. 2010;31:915.
822. Lazzeri C, Valente S, Chiostrri M, et al. ST-elevation myocardial infarction with preserved ejection fraction: the impact of worsening renal failure. *Int J Cardiol*. 2012 Feb 23;155(1):170-2. PMID: 22188989.
823. Leowattana W, Ong-Ajyooth L, Taruangsri P, et al. Circulating N-terminal pro-brain natriuretic peptide and cardiac troponin T in chronic dialysis patients. *J Med Assoc Thai*. 2003 May;86 Suppl 1:S52-8. PMID: 12866769.
824. Linnemann B, Sutter T, Sixt S, et al. Elevated cardiac troponin T contributes to prediction of worse in-hospital outcomes after endovascular therapy for acute limb ischemia. *J Vasc Surg*. 2012 Mar;55(3):721-9. PMID: 22277685.
825. Lippi G, Tessitore N, Montagnana M, et al. Influence of sampling time and ultrafiltration coefficient of the dialysis membrane on cardiac troponin I and T. *Arch Pathol Lab Med*. 2008 Jan;132(1):72-6. PMID: 18181677.
826. Liu YW, Su CT, Wang SP, et al. Application of speckle-tracking echocardiography in detecting coronary artery disease in patients with maintenance hemodialysis. *Blood Purif*. 2011;32(1):38-42. PMID: 21293120.
827. Lowbeer C, Ottosson-Seeberger A, Gustafsson SA, et al. Increased cardiac troponin T and endothelin-1 concentrations in dialysis patients may indicate heart disease. *Nephrol Dial Transplant*. 1999 Aug;14(8):1948-55. PMID: 10462276.
828. Mallamaci F, Zoccali C, Parlongo S, et al. Diagnostic value of troponin T for alterations in left ventricular mass and function in dialysis patients. *Kidney Int*. 2002 Nov;62(5):1884-90. PMID: 12371993.
829. Marjani A, Moradi A, Veghari G. Comparison of plasma cardiac Troponin I and cardiac enzymes in haemodialysis patients of Gorgan (south east of Iran). *Pak J Biol Sci*. 2007 Nov 1;10(21):3915-8. PMID: 19090253.
830. Mekontso Dessap A, Lellouche N, Audard V, et al. Effect of renal failure on peak troponin Ic level in patients with acute

- myocardial infarction. *Cardiology*. 2008;109(4):217-21. PMID: 17873484.
831. Melanson SE, Conrad MJ, Mosammaparast N, et al. Implementation of a highly sensitive cardiac troponin I assay: test volumes, positivity rates and interpretation of results. *Clin Chim Acta*. 2008 Sep;395(1-2):57-61. PMID: 18515084.
832. Mielniczuk LM, Pfeffer MA, Lewis EF, et al. Acute decline in renal function, inflammation, and cardiovascular risk after an acute coronary syndrome. *Clin J Am Soc Nephrol*. 2009 Nov;4(11):1811-7. PMID: 19820133.
833. Mishra RK, Li Y, Defilippi C, et al. Association of Cardiac Troponin T With Left Ventricular Structure and Function in CKD. *Am J Kidney Dis*. 2013 Jan 3 PMID: 23291148.
834. Mnif O, Belhadj R, Zerelli L, et al. Variation of C troponin T in chronic hemodialysis patients: Study about 52 cases. *Tunisie Medicale*. 2009;87(4):285-8.
835. Mongeon FP, Dorais M, Lorier JL, et al. Effect of hemodialysis, coronary artery disease and diabetes on cardiac troponin T: a prospective survey over one year. *Open Cardiovasc Med J*. 2009;3:69-77. PMID: 19590593.
836. Montagnana M, Lippi G, Tessitore N, et al. Effect of hemodialysis on traditional and innovative cardiac markers. *J Clin Lab Anal*. 2008;22(1):59-65. PMID: 18200568.
837. Mutluay R, Konca C, Erten Y, et al. Predictive markers of asymptomatic atherosclerosis in end-stage renal disease patients. *Ren Fail*. 2010 May;32(4):448-54. PMID: 20446782.
838. Nakai K, Nagane Y, Obara W, et al. Serum levels of cardiac troponin I and other marker proteins in patients with chronic renal failure. *Clin Exp Nephrol*. 2004 Mar;8(1):43-7. PMID: 15067515.
839. Negishi K, Kobayashi M, Ochiai I, et al. Association between fibroblast growth factor 23 and left ventricular hypertrophy in maintenance hemodialysis patients. Comparison with B-type natriuretic peptide and cardiac troponin T. *Circ J*. 2010 Nov;74(12):2734-40. PMID: 21041973.
840. Ninan VT, Hilali N, Ali JH, et al. Baseline cardiac troponin I in patients on maintenance dialysis. *Transplant Proc*. 2004 Jul-Aug;36(6):1829-30. PMID: 15350489.
841. Obialo CI, Sharda S, Goyal S, et al. Ability of troponin T to predict angiographic coronary artery disease in patients with chronic kidney disease. *Am J Cardiol*. 2004 Sep 15;94(6):834-6. PMID: 15374805.
842. Ooi DS, House AA. Cardiac troponin T in hemodialyzed patients. *Clin Chem*. 1998 Jul;44(7):1410-6. PMID: 9665417.
843. Ortega O, Rodriguez I, Gracia C, et al. Strict volume control and longitudinal changes in cardiac biomarker levels in hemodialysis patients. *Nephron Clin Pract*. 2009;113(2):c96-103. PMID: 19602905.
844. Popowska-Drojecka J, Muszytowski M, Sobilo-Jarek L, et al. Increased serum levels of troponin I and lesions in coronary angiography in hemodialysed patients. *Rocz Akad Med Bialymst*. 2005;50:311-3. PMID: 16358990.
845. Porter GA, Norton TL, Lindsley J, et al. Relationship between elevated serum troponin values in end-stage renal disease patients and abnormal isotopic cardiac scans following stress. *Ren Fail*. 2003 Jan;25(1):55-65. PMID: 12617333.
846. Quiroga B, Goicoechea M, Garcia de Vinuesa S, et al. [Cardiac markers in different degrees of chronic kidney disease: influence of inflammation and previous heart disease]. *Med Clin (Barc)*. 2012 Jun 30;139(3):98-102. PMID: 21807382.
847. Roberts MA, MacMillan N, Hare DL, et al. Cardiac troponin levels in asymptomatic patients on the renal transplant waiting list. *Nephrology (Carlton)*. 2006 Oct;11(5):471-6. PMID: 17014564.
848. Ryu DR, Park JT, Chung JH, et al. A more appropriate cardiac troponin T level

- that can predict outcomes in end-stage renal disease patients with acute coronary syndrome. *Yonsei Med J.* 2011 Jul;52(4):595-602. PMID: 21623601.
849. Sahinarslan A, Guz G, Okyay K, et al. Brain natriuretic peptide correlates with troponin T in patients with renal failure. *Acta Cardiol.* 2007 Apr;62(2):171-6. PMID: 17536606.
850. Seco Garcia ML, Borque de Larrea L, Rus Martinez A, et al. Cardiac troponins and other myocardial markers in patients with renal disease. *Quimica Clinica.* 2000;19(5):390-4.
851. Seino Y, Hori M, Sonoda T. Multicenter prospective investigation on cardiovascular adverse effects of tacrolimus in kidney transplantations. *Cardiovasc Drugs Ther.* 2003 Mar;17(2):141-9. PMID: 12975596.
852. Sezer S, Karakan S, Ozdemir N. Increased cardiac troponin T levels are related to inflammatory markers and various indices of renal function in chronic renal disease patients. *Ren Fail.* 2012;34(4):454-9. PMID: 22320145.
853. Shroff GR, Frederick PD, Herzog CA. Renal failure and acute myocardial infarction: clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry of Myocardial Infarction. *Am Heart J.* 2012 Mar;163(3):399-406. PMID: 22424010.
854. Sommerer C, Hecke S, Schwenger V, et al. Cardiac biomarkers are influenced by dialysis characteristics. *Clin Nephrol.* 2007 Dec;68(6):392-400. PMID: 18184522.
855. Su CT, Liu YW, Lin JW, et al. Increased procollagen type I C-terminal peptide levels indicate diastolic dysfunction in end-stage renal disease patients undergoing maintenance dialysis therapy. *J Am Soc Echocardiogr.* 2012 Aug;25(8):895-901. PMID: 22658561.
856. Sutidze M, Sulakvelidze M, Kochiashvili D, et al. Creatine kinase mb, cardiac troponin T and cardiac troponin I as the markers of rhabdomyolysis in chronic hemodialysis patients. *Georgian Med News.* 2006 Mar(132):68-71. PMID: 16636385.
857. Sutidze M, Kajrishvili M, Tsimakuridze M, et al. Factors associated with increased serum levels of specific markers of myocardial injury--cardiac troponins T and I in chronic haemodialysis patients. *Georgian Med News.* 2009 Apr(169):39-43. PMID: 19430042.
858. Taki K, Tsuruta Y, Niwa T. Cardiac troponin T and advanced glycation end-products in hemodialysis patients. *Am J Nephrol.* 2008;28(5):701-6. PMID: 18431051.
859. Taskapan MC, Taskapan H, Ulutas O, et al. Relationships between brain natriuretic peptide, troponin I and QT dispersion in asymptomatic dialysis patients. *Ren Fail.* 2007;29(2):221-5. PMID: 17365940.
860. Trimarchi H, Muryan A, Campolo-Girard V, et al. Elevated pro-brain natriuretic peptide, troponin T and malnutrition inflammatory score in chronic hemodialysis patients with overt cardiovascular disease. *Nephron Clin Pract.* 2011;117(3):c198-205. PMID: 20805692.
861. Trimarchi H, Muryan A, Dicugno M, et al. Proteinuria: an ignored marker of inflammation and cardiovascular disease in chronic hemodialysis. *Int J Nephrol Renovasc Dis.* 2012;5:1-7. PMID: 22334794.
862. Trinquier S, Flecheux O, Bullenger M, et al. Highly specific immunoassay for cardiac troponin I assessed in noninfarct patients with chronic renal failure or severe polytrauma. *Clin Chem.* 1995 Nov;41(11):1675-6. PMID: 7586570.
863. Tsutamoto T, Kawahara C, Yamaji M, et al. Relationship between renal function and serum cardiac troponin T in patients

- with chronic heart failure. *Eur J Heart Fail*. 2009 Jul;11(7):653-8. PMID: 19502379.
864. Tun A, Khan IA, Win MT, et al. Specificity of cardiac troponin I and creatine kinase-MB isoenzyme in asymptomatic long-term hemodialysis patients and effect of hemodialysis on these cardiac markers. *Cardiology*. 1998;90(4):280-5. PMID: 10085490.
865. Urso S, Milone F, Garozzo M, et al. [Cardiovascular risk markers in hemodialysis]. *G Ital Nefrol*. 2004 Nov-Dec;21 Suppl 30:S212-6. PMID: 15750988.
866. Wang AY, Lam CW, Wang M, et al. Diagnostic potential of serum biomarkers for left ventricular abnormalities in chronic peritoneal dialysis patients. *Nephrol Dial Transplant*. 2009 Jun;24(6):1962-9. PMID: 19237403.
867. Wang F, Ye P, Luo L, et al. Association of glomerular filtration rate with high-sensitivity cardiac troponin T in a community-based population study in Beijing. *PLoS One*. 2012;7(5):e38218. PMID: 22675450.
868. Wiessner R, Hannemann-Pohl K, Ziebig R, et al. Impact of kidney function on plasma troponin concentrations after coronary artery bypass grafting. *Nephrol Dial Transplant*. 2008 Jan;23(1):231-8. PMID: 17898023.
869. Willging S, Keller F, Steinbach G. Specificity of cardiac troponins I and T in renal disease. *Clin Chem Lab Med*. 1998 Feb;36(2):87-92. PMID: 9594044.
870. Wong CK, Szeto CC, Chan MH, et al. Elevation of pro-inflammatory cytokines, C-reactive protein and cardiac troponin T in chronic renal failure patients on dialysis. *Immunol Invest*. 2007;36(1):47-57. PMID: 17190649.
871. Wrenn K, Blair R, Parl FF, et al. Calcium-phosphorus product and troponin-T values in renal failure. *Am J Emerg Med*. 2006 Nov;24(7):836-8. PMID: 17098107.
872. Wu AH, Feng YJ, Roper L, et al. Cardiac troponins T and I before and after renal transplantation. *Clin Chem*. 1997 Feb;43(2):411-2. PMID: 9023153.
873. Yamashita T, Seino Y, Ogawa A, et al. N-terminal pro-BNP is a novel biomarker for integrated cardio-renal burden and early risk stratification in patients admitted for cardiac emergency. *J Cardiol*. 2010 May;55(3):377-83. PMID: 20350516.
874. Zaman Z, De Spiegeleer S, Gerits M, et al. Analytical and clinical performance of two cardiac troponin I immunoassays. *Clin Chem Lab Med*. 1999 Sep;37(9):889-97. PMID: 10596955.
875. Zand Parsa AF, Abdolahi A, Mahdavi-mazdeh M. Is cardiac biomarkers and left ventricular function affected by chronic kidney disease? *Indian Heart J*. 2012 Sep-Oct;64(5):479-83. PMID: 23102386.
876. Zaninotto M, Altinier S, Lachin M, et al. Fluoroenzymometric method to measure cardiac troponin I in sera of patients with myocardial infarction. *Clin Chem*. 1996 Sep;42(9):1460-6. PMID: 8787705.
877. Zumrutdal A, Baltali M, Micozkadioglu H, et al. Determinants of coronary artery disease in nondiabetic hemodialysis patients: a matched case-control study. *Ren Fail*. 2007;29(1):67-71. PMID: 17365912.

No Key Question Addressed

878. Abeygunasekara SC, Horner CW. High prevalence of undiagnosed kidney disease in those presenting with troponin positive acute coronary syndrome. *Ren Fail*. 2012;34(7):845-8. PMID: 22680915.
879. Ahmed K, Jeong MH, Chakraborty R, et al. Coronary Stents in Patients with ST-Elevation Myocardial Infarction and Chronic Kidney Disease Undergoing Primary Percutaneous Coronary Intervention. *Korean Circ J*. 2012 Dec;42(12):830-8. PMID: 23323121.

880. Bae EH, Lim SY, Cho KH, et al. GFR and cardiovascular outcomes after acute myocardial infarction: results from the Korea Acute Myocardial Infarction Registry. *Am J Kidney Dis.* 2012 Jun;59(6):795-802. PMID: 22445708.
881. Birnbaum Y, Strasberg B, Rechavia E, et al. Acute renal failure following intravenous streptokinase infusion for acute myocardial infarction. *Western Journal of Medicine.* 1993;158(4):406-7.
882. Chapelle JP, Dubois B, Bovy C, et al. Comparison of plasma cardiac troponins T and I in chronically hemodialyzed patients in relation to cardiac status and age. *Clin Chem Lab Med.* 2002 Mar;40(3):240-5. PMID: 12005213.
883. Ellis K, Dreisbach AW, Lertora JL. Plasma elimination of cardiac troponin I in end-stage renal disease. *South Med J.* 2001 Oct;94(10):993-6. PMID: 11702827.
884. Fredericks S, Murray JF, Bewick M, et al. Cardiac troponin T and creatine kinase MB are not increased in exterior oblique muscle of patients with renal failure. *Clin Chem.* 2001 Jun;47(6):1023-30. PMID: 11375287.
885. Fredericks S, Bainbridge K, Fenske CD, et al. Cardiac troponin-I content of skeletal muscle in patients with renal failure. *Clin Biochem.* 2002 Jul;35(5):421-3. PMID: 12270775.
886. Gagliardi GM, Rossi S, Manes MT, et al. [Impact of left ventricular patterns and diastolic dysfunction on hemodialysis patients]. *G Ital Nefrol.* 2004 Jan-Feb;21(1):45-50. PMID: 15356847.
887. Hill SA, Cleve R, Carlisle E, et al. Intra-individual variability in troponin T concentration in dialysis patients. *Clin Biochem.* 2009 Jul;42(10-11):991-5. PMID: 19362083.
888. Hussein MM, Mooij JM, Al Malki N, et al. Troponin-I is not falsely elevated in asymptomatic dialysis patients. *Saudi J Kidney Dis Transpl.* 2013 Jan;24(1):48-53. PMID: 23354191.
889. Irfan A, Twerenbold R, Reiter M, et al. Determinants of high-sensitivity troponin T among patients with a noncardiac cause of chest pain. *Am J Med.* 2012 May;125(5):491-8 e1. PMID: 22482847.
890. Jacobs L, Van De Kerkhof J, Mingels A, et al. Cardiac biomarkers in dialysis patients: Variations during a six month follow up. *Nederlands Tijdschrift voor Klinische Chemie en Laboratoriumgeneeskunde.* 2008;33(3):176-8.
891. Jeon DS, Lee MY, Kim CJ, et al. Clinical findings in patients with cardiac troponin T elevation and end-stage renal disease without acute coronary syndrome. *Am J Cardiol.* 2004 Sep 15;94(6):831-4. PMID: 15374804.
892. Keddis MT, El-Zoghby ZM, El Ters M, et al. Cardiac troponin T before and after kidney transplantation: determinants and implications for posttransplant survival. *Am J Transplant.* 2013 Feb;13(2):406-14. PMID: 23137067.
893. Kim SB, Lee SK, Min WK, et al. Lack of effects of low-dose aspirin on high-sensitivity C-reactive protein, hemostatic factors, and troponin T in CAPD patients. *Perit Dial Int.* 2002 Nov-Dec;22(6):721-3. PMID: 12556076.
894. Li D, Jialal I, Keffer J. Greater frequency of increased cardiac troponin T than increased cardiac troponin I in patients with chronic renal failure. *Clin Chem.* 1996 Jan;42(1):114-5. PMID: 8565211.
895. Nakamura T, Ushiyama C, Osada S, et al. Effect of dilazep dihydrochloride on serum cardiac troponin T levels in hemodialysis patients. *Kidney Blood Press Res.* 2002;25(1):50-4. PMID: 11834877.
896. Nakamura T, Ushiyama C, Shoji H, et al. Effects of hemoperfusion on serum cardiac troponin T concentrations using polymyxin B-immobilized fibers in septic

patients undergoing hemodialysis. *ASAIO J.* 2002 Jan-Feb;48(1):41-4. PMID: 11814097.

897. Resic H, Ajanovic S, Kukavica N, et al. Plasma levels of brain natriuretic peptides and cardiac troponin in hemodialysis patients. *Bosn J Basic Med Sci.* 2009 May;9(2):137-41. PMID: 19485946.

898. Selby NM, Fluck RJ, Taal MW, et al. Effects of acetate-free double-chamber hemodiafiltration and standard dialysis on systemic hemodynamics and troponin T levels. *ASAIO J.* 2006 Jan-Feb;52(1):62-9. PMID: 16436892.

899. van der Putten RF, te Velthuis HT, de Zwaan C, et al. State and diagnostic value of plasma tissue factor in early-hospitalised patients with chest pain. *Br J Haematol.* 2005 Oct;131(1):91-9. PMID: 16173968.

900. Zumrutdal A, Bakinen O, Ucan H, et al. Relationship between uremic myopathy and false-positive cardiac troponin T test. *Nephron.* 2000 Dec;86(4):522-3. PMID: 11124612.

Other reason for exclusion

901. McNeil AR. Implications of a rapid decrease in serum Troponin T levels after renal transplantation. *Australian and New Zealand Journal of Medicine.* 2000;30(5):638-9.

902. Rinat C, Becker-Cohen R, Nir A, et al. B-type natriuretic peptides are reliable markers of cardiac strain in CKD pediatric patients. *Pediatr Nephrol.* 2012 Apr;27(4):617-25. PMID: 22038201.

Appendix D: Evidence Tables

Table 1. Study Design Characteristics of included articles

Author, year	Design	Location Setting	Enrollment Followup	Sample Size	ACS information (if applicable)	CKD stages GFR Definition	Exclusion criteria
Abaci, 2004 ¹	Prospective	Turkey hospital	Study date NR Mean followup: 2 years	129	no ACS	Dialysis, ESRD, GFR equation NR	Angiographically proven stenosis, ACS, history of MI, ECG changes suggestive of ischemia, Chronic stable angina pectoris, previous coronary revascularization, regional wall motion abnormalities in ECG
Abbas, 2005 ²	Prospective	Europe outpatient	Start: 2003 End: 2004 Mean followup: 19 months	Total: 227 CKD: 222	no ACS	Stage 3, stage 4, stage 5, dialysis, MDRD	Age < 18, acute renal failure, functioning renal transplant, patients on dialysis, recent cardiac event
Acharji, 2012 ³	Post hoc	US hospital	Study date NR Mean followup: 1 years	2179	Patients with ACS included Cardiologist adjudication NR panel Definition: Adjudication definition NR	Stage 3, stage 4, dialysis, Cockcroft-Gault formula	Other exclusions NR
Alcalai, 2007 ⁴	Prospective	Israel hospital	Start: 2003 End: 2003 Maximum followup: 2.5 years	615	Patients with ACS included Adjudicated Cardiologist adjudicated panel adjudicator panel: 2 people Definition: ESC/ACC	Dialysis, creatinine > 2.26 mg/dL, GFR equation NR	Age < 16, out-of hospital cardiac arrest who died within 48 hours of admission

Author, year	Design	Location Setting	Enrollment Followup	Sample Size	ACS information (if applicable)	CKD stages GFR Definition	Exclusion criteria
Apple, 1997 ⁵	Retrospective	US outpatient	Start: 1994 End: 1994 Mean followup: 12 months	16	no ACS	Dialysis GFR equation NR	Other exclusions NR
Apple, 1999 ⁶	Retrospective	US hospital	Study date NR Followup NR	1601	Patients with ACS included Adjudicated Cardiologist adjudication NR panel adjudicator Definition: 2 of 3: chest pain, ECG changes, biomarkers	Dialysis, stage NR GFR equation NR	Other exclusions NR
Apple, 2002 ⁷	Prospective	US outpatient; Dialysis centers	Start: 1998 End: 1999 Median followup: 1.6 years	733	ACS NR	Stage 5, dialysis, ESRD, GFR equation NR	Other exclusions NR
Apple, 2004 ⁸	Prospective	US outpatient	Start: 1998 End: 1999 Median followup: 1.7 years	399	ACS NR	dialysis, ESRD, GFR equation NR	Other exclusions NR

Author, year	Design	Location Setting	Enrollment Followup	Sample Size	ACS information (if applicable)	CKD stages GFR Definition	Exclusion criteria
Apple, 2007 ⁹	Prospective	US emergency dept	Study date NR Mean followup: 6 months	Total: 510 CKD: not stated	Patients with ACS included Definition: clinical features considered indicative of ACS Cardiologist adjudication NR Adjudicator NS Definition: Adjudication definition NR	Stage 1, stage 2, stage 3, stage 4, dialysis, MDRD	Other exclusions NR
Artunc, 2012 ¹⁰	Prospective	Europe outpatient; 4 hemodialysis centers	Start: 2009 End: 2011 Mean followup: 2 years	239	no ACS Cardiologist adjudication NR Adjudicator NS Definition: Adjudication definition NR	Dialysis, GFR equation NR	Patients with cardiac diseases that elevated serum troponin., evidence of an acute illness and

Author, year	Design	Location Setting	Enrollment Followup	Sample Size	ACS information (if applicable)	CKD stages GFR Definition	Exclusion criteria
Aviles, 2002 ¹¹	Post hoc	Worldwide hospital	Start: 1998 End: 2000 Maximum followup: 30 days	Total: 7033 CKD: 1733	Patients with ACS included other dx: one or more episodes of angina while at rest that lasted at least five minutes and new ST-segment depression of at least 0.5 mm; or an abnormal result on a cardiac troponin Cardiologist adjudication NR Adjudicator NS Definition: Adjudication definition NR	Stage 1, stage 2, stage 3, stage 4, stage 5, dialysis, Cockcroft-Gault formula	Underwent early revascularization
Bagheri, 2009 ¹²	Prospective	Iran Hospital; dialysis center	Start: 2005 End: 2007 Mean followup: 30 months	138	ACS NR	Dialysis, GFR equation NR	Systemic inflammation, Ongoing ischemia or any revascularization procedure within past 8 weeks

Author, year	Design	Location Setting	Enrollment Followup	Sample Size	ACS information (if applicable)	CKD stages GFR Definition	Exclusion criteria
Barthelemy, 2012 ¹³		Europe hospital	Start: 2006 End: 2008 Mean followup: 1 months	Total: 345 CKD: 75	Patients with ACS included other dx: 2 out of 3: 1. symptoms of myocardial ischemia 2. ST segment abnormalities 3. elevated cTnl Cardiologist adjudication NR Adjudicator NS Definition: Adjudication definition NR	Stage 3, stage 4, dialysis, Cockcroft-Gault formula	Age < 18, refractory ischemia, major arrhythmias, or hemodynamic instability requiring immediate catheterization, Ongoing treatment with warfarin, fibrinolysis or GPIIb/IIIa inhibitors, Contraindications to abciximab
Beciani, 2003 ¹⁴	Prospective	Europe hospital	Study date NR Mean followup: 1 years	101	no ACS	Dialysis GFR equation NR	Recent (3 month) acute CAD, recent chest pain, recent major cardiovascular surgery
Bhagavan, 1998 ¹⁵	Retrospective	US hospital	Study date NR Followup NR	Total: 155 CKD: 31	ACS NR	Dialysis GFR equation NR	Other exclusions NR
Boulier, 2004 ¹⁶	Prospective	Europe outpatient; hospital	Start: 2001 End: 2001 Median followup: 418 days	191	no ACS	Dialysis GFR equation NR	Other exclusions NR
Bozbas, 2004 ¹⁷	Prospective	Turkey hospital	Start: 2001 End: 2002 Mean followup: 30 days	34	ACS NR	Dialysis, kidney transplant GFR equation NR	Other exclusions NR
Brunet, 2008 ¹⁸	Prospective	Europe outpatient dialysis unit	Start: 2003 End: 2003 Mean followup: 2.5 years	105	no ACS	dialysis, GFR equation NR	No ACS within 3 months, treated with different HD parameters

Author, year	Design	Location Setting	Enrollment Followup	Sample Size	ACS information (if applicable)	CKD stages GFR Definition	Exclusion criteria
Bueti, 2006 ¹⁹	Prospective	Canada emergency dept	Start: 2001 End: 2002 Mean followup: 30 days	149	Patients with ACS included other dx: not defined No cardiologist adjudication Adjudicator NS Definition: Adjudication definition NR	Dialysis GFR equation NR	Other exclusions NR
Chew, 2008 ²⁰	Retrospective	Singapore hospital	Start: 2002 End: 2005 Followup NR	227	Patients with ACS included Adjudicated Cardiologist adjudicated panel adjudicator panel: 2 Definition: Based on the clinical picture, serial ECG, cardiac enzymes, and cardiac catheter or noninvasive cardiac imaging	Stage 4, dialysis GFR equation NR	Other exclusions NR
Choy, 2003 ²¹	Prospective	Canada outpatient	Study date NR Mean followup: 6 months	113	ACS NR	Stage 5, dialysis GFR equation NR	Patients refusing to give consent

Author, year	Design	Location Setting	Enrollment Followup	Sample Size	ACS information (if applicable)	CKD stages GFR Definition	Exclusion criteria
Chrysochou, 2009 ²²	Prospective	Europe Dialysis Center	Study date NR Mean followup: 40.2 months	82	no ACS	Combined CKD, stage 1, stage 2, stage 3, stage 4, dialysis, kidney transplant Cockcroft-Gault formula	Atrial Fibrillation, Poor ECG Images
Claes, 2010 ²³	Prospective	Europe hospital	Start: 2005 End: 2008 Mean followup: 2 weeks	331	ACS NR	Dialysis, kidney transplant GFR equation NR	Combined transplant other than renal/pancreatic.
Codognotto, 2010 ²⁴	Prospective	Europe hospital	Study date NR Maximum followup: 3	50	ACS NR	Dialysis GFR equation NR	Atrial fibrillation, pacemakers, previous surgical heart procedures, valvular and congenital heart disorders
Connolly, 2008 ²⁵	Prospective	Europe hospital	Start: 2000 End: 2002 Mean followup: 1626 days Median followup: 1739 days	372	no ACS	dialysis, kidney transplant MDRD	Chest pain - deferred until re-assessment, Signs of sepsis - deferred until re-assessment
Conway, 2005 ²⁶	Prospective	Europe outpatient; hospital	Start: 2003 End: 2003 Mean followup: 18 months	75	no ACS Definition: hospital admission with diagnostic code of ACS	Dialysis GFR equation NR	Other exclusions NR
Deegan, 2001 ²⁷	Prospective	Europe hospital; hospital hemodialysis	Study date NR Mean followup: 15 months	73	ACS NR	Dialysis GFR equation NR	Other exclusions NR
deFilippi, 2003 ²⁸	Prospective	US outpatient; Dialysis	Start: 1998 End: 1998 Mean followup: 827 days	224	no ACS	Dialysis GFR equation NR	Age < 18, On hemodialysis less than 30 days, Acute coronary event less than 4 weeks

Author, year	Design	Location Setting	Enrollment Followup	Sample Size	ACS information (if applicable)	CKD stages GFR Definition	Exclusion criteria
deFilippi, 2012 ²⁹	Prospective	US outpatient	Start: 2006 End: 2007 Median followup: 4.8 years	148	no ACS	Combined CKD, dialysis MDRD	Age < 30, Stage V CKD, Renal Replacement therapy, History of MI or CABG within 90 days of enrollment, Patients with symptoms greater than NY Heart Association Class I HF, Patients with symptoms greater than Canadian CV Society Class I Angina
Dierkes, 2000 ³⁰	Prospective	Europe Dialysis center	Study date NR Mean followup: 2 years	102	no ACS	Dialysis, ESRD GFR equation NR	Age > 85, Unstable clinical status, No ACS within 4 weeks
Duman, 2005 ³¹	Prospective	Turkey outpatient	Study date NR Mean followup: 48 months	65	no ACS	Dialysis GFR equation NR	Patients with CV disease within 4 weeks of study onset.
Farkouh, 2003 ³²	Prospective	US outpatient; dialysis centers	Study date NR Mean followup: 15 months	137	no ACS	Stage 5, dialysis GFR equation NR	Refusal to participate, ACS within preceding 30 days
Fehr, 2003 ³³	Retrospective	Europe NR	Study date NR Mean followup: 12 months	31	Patients with ACS included other dx: NR Cardiologist adjudication NR Adjudicator NS Definition: Adjudication definition NR	Dialysis GFR equation NR	Other exclusions NR
Feringa, 2006 ³⁴	Prospective	Europe hospital	Start: 2000 End: 2006 Mean followup: 3.5 years	Total: 558 CKD: 240	no ACS	Combined CKD, stage 1, stage 2, stage 3, stage 4, dialysis MDRD	Patients who died during surgery, patients who died before hospital discharge
Fernandez-Reyes, 2004 ³⁵	Prospective	Europe hospital	Start: 2000 End: 2002 Mean followup: 2.5 years	58	ACS NR	Dialysis GFR equation NR	Clinical signs of HF or Ischemic Heart Disease during previous month

Author, year	Design	Location Setting	Enrollment Followup	Sample Size	ACS information (if applicable)	CKD stages GFR Definition	Exclusion criteria
Flores, 2006 ³⁶	Retrospective	Europe, Spain ED (64%) ICU(10%) and IM-Cardiology and Nephrology services	Start: 2004 End: 2004 Followup NR	467	Patients with ACS included Cardiologist adjudication NR Adjudicator NS Definition: Adjudication definition NR	Combined CKD, dialysis MDRD	
Flores-Solis, 2012 ³⁷	Prospective	Europe hospital	Start: 2009 End: 2010 Mean followup: 6 months	484	Patients with ACS included other dx: European Society of Cardiology AMI definition Cardiologist adjudication NR Adjudicator NS Definition: Adjudication definition NR	Stage 3, stage 4, dialysis, MDRD	Patients transferred to another hospital, Psychiatric patients, Patients who refused to sign an informed consent, Patients diagnosed with multiple conditions who could not be assigned to a group.
Gaiki, 2012 ³⁸	Prospective	US hospital	Study date NR Mean followup: 2 years	51	no ACS	Dialysis GFR equation NR	Other exclusions NR
Geerse, 2012 ³⁹	Prospective	Europe hospital	Start: 2007 End: 2009 Median followup: 28 months	206	ACS NR	Dialysis GFR equation NR	Age < 18
Goicoechea, 2004 ⁴⁰	Prospective	Europe outpatient	Start: 2002 End: 2002 Mean followup: 12.9 months	176	no ACS Definition: Joint European Society of cardiology/ACC	Combined CKD, dialysis Cockcroft-Gault formula	Other exclusions NR

Author, year	Design	Location Setting	Enrollment Followup	Sample Size	ACS information (if applicable)	CKD stages GFR Definition	Exclusion criteria
Gruberg, 2002 ⁴¹	Prospective	US hospital	Start: 1994 End: 1999 Mean followup: 12 months	116	Patients with ACS included Cardiologist adjudication NR Adjudicator NS Definition: Adjudication definition NR	Dialysis, creatinine > , Chronic Renal Insufficiency, Cockcroft-Gault formula	Patients on dialysis, Patients with baseline increased cTnl >0.15 ng/mL, Patients with AMI within previous 72 hrs
Hallen, 2011 ⁴²	Retrospective	Europe Hospital, dialysis	Start: 2002 End: 2003 Mean followup: 926 days	107	ACS NR	Dialysis, ESRD GFR equation NR	Age < 18, Failure to cooperate, Hepatic disease, Malignant disease, Rhabdomyolysis, Dermatomyositis, polymyositis, History of epilepsy or convulsions
Han, 2005 ⁴³	Retrospective	US emergency dept	Start: 1999 End: 2003 Mean followup: 6 months	90	Patients with ACS included other dx: medical record and social security death index Cardiologist adjudication NR	Combined CKD, dialysis, creatinine < , Clearance <30 ml/min GFR equation NR	Kidney transplant, died secondary to trauma, terminal cancer, trauma, terminal cancer
Han, 2009 ⁴⁴	Prospective	South Korea hospital	Study date NR Mean followup: 3 years	107	ACS NR	Dialysis GFR equation NR	CVD - AMI, PVD, Cerebrovascular, angina, Infection within past 3 months, History of malignancy, chronic inflammatory disease
Hasegawa, 2012 ⁴⁵	Prospective	Japan outpatient	Start: 2009 End: 2010 Median followup: 22 months	442	ACS NR	Stage 3, stage 4, dialysis, stage 5, MDRD	CKD patients on dialysis.
Havekes, 2006 ⁴⁶	Prospective	Netherlands outpatient	Start: 1997 End: 2001 Followup NR	847	no ACS	Dialysis, mean creatinine and urea clearances adjusted for body surface area	Age < 18

Author, year	Design	Location Setting	Enrollment Followup	Sample Size	ACS information (if applicable)	CKD stages GFR Definition	Exclusion criteria
Heeschen, 2000 ⁴⁷	Prospective	Europe outpatient	Start: 1994 End: 1998 Maximum followup: 30 days	26	no ACS	Dialysis GFR equation NR	
Helleskov Madsen, 2008 ⁴⁸	Prospective	Europe Hemodialysis in hospital	Start: 2002 End: 2003 Mean followup: 712 days	109	no ACS	Dialysis GFR equation NR	Age < 18, conditions giving falsely elevated troponins (liver disease, malignancy, rhabdo, dermato/polymyos, epilepsy), patients unable to cooperate
Hickman, 2009 ⁴⁹	Prospective	Australia outpatient	Study date NR Median followup: 30 months	143	no ACS	Dialysis GFR equation NR	Other exclusions NR
Hickson, 2008 ⁵⁰	Prospective	US outpatient	Start: 2004 End: 2006 Mean followup: 11.5 months Median followup: 6.2 months	644	no ACS	Dialysis, kidney transplant candidates, GFR equation NR	Patients on kidney transplant waiting list
Hickson, 2009 ⁵¹	Prospective	US outpatient	Start: 2004 End: 2007 Mean followup: 28.4 months	603	no ACS	Dialysis, kidney transplant GFR equation NR	Kidney transplant recipients
Hoher, 2003 ⁵²	Prospective	Europe hospitalDialysis Center	Start: 2000 Mean followup: 775 days	245	no ACS	Dialysis GFR equation NR	Malignancies, Chronic infections, conditions that affect serum parameters
Hoher, 2004 ⁵³	Prospective	Europe outpatient; Dialysis Center	Start: 2000 Mean followup: 1140 days	245	no ACS	Dialysis, ESRD, GFR equation NR	Other exclusions NR
Hoher, 2008 ⁵⁴	Prospective	Europe outpatient	Start: 2000 End: 2000 Mean followup: 52 months	230	no ACS	Dialysis GFR equation NR	Acute disease including unstable angina, acute MI, arterial embolism, acute neurological disorder, malignancy, chronic infection, other conditions that might affect the serum parameters
Hojs, 2005 ⁵⁵	Prospective	Europe outpatient	Study date NR Mean followup: 21 months	90	no ACS	Dialysis GFR equation NR	Other exclusions NR

Author, year	Design	Location Setting	Enrollment Followup	Sample Size	ACS information (if applicable)	CKD stages GFR Definition	Exclusion criteria
Holden, 2012 ⁵⁶	Prospective	Canada Dialysis Center	Start: 2002 Mean followup: 3.5 years	103	ACS NR	Dialysis GFR equation NR	Other exclusions NR
Hung, 2004 ⁵⁷	Prospective	Taiwan outpatient	Study date NR Mean followup: 12 months	70	no ACS	Dialysis GFR equation NR	Age < 20, receiving HD for <6months, MI within 3 months, major vascular surgery within 3 months, acute chest pain, intramuscular injection/trauma, history of autoimmune disease
Hussein, 2004 ⁵⁸	Prospective	Saudi Arabia outpatient	Study date NR Mean followup: 1 years	93	no ACS	Dialysis GFR equation NR	Other exclusions NR
Ile, 2004 ⁵⁹	Prospective	Europe dialysis center	Study date NR Mean followup: 2 years	49	no ACS	Dialysis GFR equation NR	Other exclusions NR
Iliou, 2003 ⁶⁰	Prospective	Europe outpatient; hospital; hemodialysis centers	Start: 1999 End: 1999 Mean followup: 2 years	258	no ACS	Dialysis GFR equation NR	MI, revascularization, angina within 3 weeks of study, sever infection 8 days before study, hemoglobin <8 g/dl
Ilva, 2008 ⁶¹	Prospective	Europe hospital	Start: 2004 End: 2004 Mean followup: 6 months	Total: 364 CKD: 163	no ACS	Dialysis, renal failure defined as CysC above 1.2 for age <50 and 1.4 for age >50	ACS, patients with missing troponin values
Ishii, 2001 ⁶²	Prospective	Japan outpatient; at dialysis center	Start: 1997 End: 1997 Mean followup: 2 years	100	no ACS	Dialysis GFR equation NR	Dialysis for <12months, acute coronary syndrome <3months
Jensen, 2012 ⁶³		Europe hospital	Start: 2003 End: 2004 Median followup: 4.4 years	193	no ACS	Dialysis GFR equation NR	Unwillingness to participate, Prior MI, symptoms of acute MI, Unstable Angina, Pathological Q Waves upon admission, Previous Coronary Angioplasty, Atrial Fibrillation, Stroke-like symptoms >7 d prior to admission

Author, year	Design	Location Setting	Enrollment Followup	Sample Size	ACS information (if applicable)	CKD stages GFR Definition	Exclusion criteria
Kalaji, 2012 ⁶⁴	Prospective	Syria hospital	Start: 2008 End: 2008 Median followup: 551 days	145	no ACS	Dialysis, Stage V CKD GFR equation NR	Age < 18, Acute coronary event within 1 month, Undergoing dialysis for less than 1 month., Refusal to participate in the study.
Kang, 2009 ⁶⁵	Prospective	South Korea hospital	Start: 2003 End: 2005 Mean followup: 90 days	121	no ACS	Dialysis GFR equation NR	Age < 18, dialysis <3 months
Kanwar, 2006 ⁶⁶	Prospective	US Dialysis center	Start: 2001 End: 2002 Mean followup: 27 months	173	no ACS	Dialysis GFR equation NR	Any evidence of ongoing ischemia, PCI or revascularization 6 weeks before evaluation, Systemic inflammatory disorders
Katerinis, 2008 ⁶⁷	Prospective	Switzerland dialysis center	Study date NR Mean followup: 12 months	50	no ACS	Dialysis GFR equation NR	ACS within four weeks
Kertai, 2004 ⁶⁸	Prospective	Europe outpatient; hospital	Start: 1996 End: 2000 Median followup: 4 years	Total: 393 CKD: 58	no ACS	Dialysis GFR equation NR	Mortality or MI within 30 days of their vascular surgery
Khan, 2001 ⁶⁹	Prospective	US hospital	Study date NR Mean followup: 2 years	128	no ACS	Dialysis, CRF GFR equation NR	ACS within 3 months, Chronic stable angina pectoris, Chest pain in peridialysis period, Recent major CV surgery, ECG changes suggesting MI / EKG changes- ishcemia
Kontos, 2005 ⁷⁰	Prospective	US hospital	Start: 1996 End: 2000 Mean followup: 1 years	3774	Patients with ACS included other dx: Not reported Cardiologist adjudication NR Adjudicator NS Definition: Adjudication definition NR	Stage 2, stage 3, stage 4, dialysis Cockcroft-Gault formula	ST-segment elevation that met criteria for fibrinolytic therapy, Did not have 8-hour cTnI determined

Author, year	Design	Location Setting	Enrollment Followup	Sample Size	ACS information (if applicable)	CKD stages GFR Definition	Exclusion criteria
Kontos, 2005 ⁷¹	Prospective	US emergency dept	Start: 1996 End: 2000 Followup NR	3074	Patients with ACS included other dx: ECG changes, known coronary disease w/ typical symptoms, or MPI with positive results Cardiologist adjudication NR Adjudicator NS Definition: Adjudication definition NR	Stage 1, stage 2, stage 3, stage 4, dialysis Cockcroft-Gault formula	ST-segment elevation, No 8-house cardiac isoform of cTnl obtained, No EF obtained
Kontos, 2008 ⁷²	Retrospective	US hospital	Start: 1996 End: 2000 Mean followup: 1 years	Total: 4343 CKD: not stated	Patients with ACS included other dx: not specified Cardiologist adjudication NR Adjudicator NS Definition: Adjudication definition NR	Stage 1, stage 2, stage 3, stage 4, dialysis, no kidney disease MDRD; Cockcroft-Gault formula	STEMI, Did not have 8-hour Troponin measured, Did not have weight measurement available
Kostrubiec, 2010 ⁷³	Prospective	Europe hospital	Start: 2006 End: 2009 Mean followup: 30 days	220	ACS NR	Combined CKD, dialysis, Acute Pulmonary Embolism, MDRD	Other exclusions NR

Author, year	Design	Location Setting	Enrollment Followup	Sample Size	ACS information (if applicable)	CKD stages GFR Definition	Exclusion criteria
Lamb, 2007 ⁷⁴	Prospective	England outpatient	Start: 2003 End: 2004 Maximum followup: 32 months	227	no ACS	Stage 3, stage 4, stage 5, dialysis MDRD	Age < 18, functioning renal transplant, receiving dialysis; recent (< 1 month) cardiac event, acute renal failure, cardiac event <1 month
Lang, 2001 ⁷⁵	Prospective	Europe hospital	Study date NR Mean followup: 2 years	100	no ACS	Dialysis, ESRD, GFR equation NR	History of angina pectoris within 3 mos., MI within 2 years, malignancies, systemic autoimmune disease, inflammatory or hereditary muscle disease, trauma in previous 6 mos., known myocarditis, idiopathic dilated cardiomyopathy, hypertrophic or restrictive cardiomyopathy
Le Goff, 2007 ⁷⁶	Prospective	Europe outpatient;	Study date NR Mean followup: 3 years	86	ACS NR	Dialysis GFR equation NR	Other exclusions NR
Lowbeer, 2002 ⁷⁷	Prospective	Europe outpatient; Dialysis center	Study date NR Mean followup: 48 months	26	no ACS	Dialysis, Chronic Ambulator Peritoneal Dialysis GFR equation NR	AMI 3 weeks prior to study enrollment, Clinical symptoms of inflammation
Lowbeer, 2003 ⁷⁸	Prospective	Europe outpatient	Study date NR Mean followup: 2.7 months	115	ACS NR	Dialysis, ESRD GFR equation NR	Age > 70, Unwillingness to participate
Mallamaci, 2002 ⁷⁹	Prospective	Europe outpatient	Study date NR Mean followup: 35 months	199	no ACS	Dialysis, ESRD GFR equation NR	Other exclusions NR
Martin, 1998 ⁸⁰	Prospective case-series	US hospital	Study date NR Mean followup: 6 months	56	ACS NR	Dialysis, ESRD, Chronic renal failure, or acute renal failure, GFR equation NR	Other exclusions NR

Author, year	Design	Location Setting	Enrollment Followup	Sample Size	ACS information (if applicable)	CKD stages GFR Definition	Exclusion criteria
McCullough, 2002 ⁸¹	Prospective	US hospital	Start: 1999 End: 1999 Mean followup: 30 days	1024	Patients with ACS included Adjudicated Cardiologist adjudicated panel adjudicator panel: 2 people Definition: Thrombolysis in Myocardial Infarction Study Group	Dialysis, Corrected Creatinine Clearance, GFR equation NR	Patients with ST-elevation AMI receiving thrombolytic therapy or immediate angioplasty
McGill, 2010 ⁸²	Retrospective	Australia hospital	Study date NR Mean followup: 3.9 years	143	ACS NR	Dialysis GFR equation NR	Other exclusions NR
McMurray, 2011 ⁸³	Post hoc	Worldwide hospital	Start: 2004 End: 2007 Median followup: 2.4 years	955	no ACS	Dialysis, eGFR 20 - 60 mL/min MDRD	Uncontrolled hypertension, previous kidney transplant or scheduled transplant, use of antibiotics, Use of chemotherapy or radiation therapy, Cancer (excl basal- or squamous-cell carcinoma of skin), Active bleeding, Hematologic disease or pregnancy
Melloni, 2008 ⁸⁴	Post hoc	US hospital	Start: 2003 End: 2005 Followup NR	31586	Patients with ACS included Cardiologist adjudication NR Adjudicator NS Definition: Adjudication definition NR	Stage 1, stage 2, stage 3, stage 4, stage 5, dialysis MDRD	Patients transferring in or out of the hospital, Inadequate troponin data, Missing data for age, sex, creatinine, etc needed for MDRD to calculate eGFR
Mockel, 1999 ⁸⁵	Prospective	Europe Dialysis Center	Study date NR Median followup: 9 months	40	no ACS	Stage 4, stage 5, dialysis GFR equation NR	Age > 80, neoplasia, ARF, ACS in the last 4 weeks

Author, year	Design	Location Setting	Enrollment Followup	Sample Size	ACS information (if applicable)	CKD stages GFR Definition	Exclusion criteria
Morton, 1998 ⁸⁶	Prospective	Canada Hospital dialysis center	Study date NR Mean followup: 1 years	112	no ACS	Dialysis GFR equation NR	Other exclusions NR
Musso, 1999 ⁸⁷	Prospective	Europe outpatient	Study date NR Maximum followup: 18 months	Total: 166 CKD: 49	ACS NR	Stage 5, dialysis GFR equation NR	History of CAD or angina symptoms, ischemic changes or segmental wall abnormality on ECG, cardiomegaly on CXR, diabetes, muscular disease
Noeller, 2003 ⁸⁸	Prospective	US hospital	Study date NR Mean followup: 14 months	695	Patients with ACS included other dx: STEMI: ECG changes plus chest pain or CK-MB increase; NSTEMI: EKG changes and either CP or EkG changes; UA: angina change/at rest/EKG changes Cardiologist adjudication NR Adjudicator NS Definition: definition as above	Dialysis GFR equation NR	cardiopulmonary resuscitation within 7 days of presentation, PCI or thrombolytic therapy within 3 weeks before presentation, vasopressors before enrollment, Major abdominal/thoracic/orthopedic surgery within 7 days of presentation
Ooi, 1999 ⁸⁹	Prospective	Canada hospital	Start: 1997 End: 1997 Maximum followup: 1 year	172	no ACS	Dialysis GFR equation NR	Other exclusions NR

Author, year	Design	Location Setting	Enrollment Followup	Sample Size	ACS information (if applicable)	CKD stages GFR Definition	Exclusion criteria
Ooi, 2001 ⁹⁰	Prospective	Canada Dialysis center	Start: 1997 End: 1999 Mean followup: 34 months	244	no ACS	Dialysis GFR equation NR	Increased cTnT values that were collected during an acute coronary event were excluded
Orea-Tejeda, 2010 ⁹¹	Prospective	Mexico hospital	Study date NR Mean followup: 42 months	152	ACS NR	Dialysis, Patients with eGFR <60 mL/min were included, but it did not specify ranges Cockcroft-Gault formula	Age < 18, Myopericarditis, Cardiac trauma, Neoplastic and infiltrative processes, Chemotherapy, Pulmonary Embolism, End stage Kidney failure, terminal liver failure
Peetz, 2003 ⁹²	Prospective	Europe outpatient; hospital	Study date NR Mean followup: 6 months	104	ACS NR	Dialysis GFR equation NR	Patients with acute myocardial infarction within 3 months, Patients with acute symptoms of angina pectoris within 3 months, on dialysis less than one year, on dialysis less than three times a week
Petrovic, 2009 ⁹³	Prospective	Europe hospital	Study date NR Mean followup: 2 years	115	no ACS	Dialysis GFR equation NR	Other exclusions NR
Porter, 1998 ⁹⁴	Prospective	US Hospital; Dialysis center	Study date NR Mean followup: 12 months	30	ACS NR	Dialysis GFR equation NR	Other exclusions NR
Porter, 2000 ⁹⁵	Prospective	US outpatient; dialysis center	Start: 1996 End: 1996 Maximum followup: 24 months	30	no ACS	Dialysis GFR equation NR	Other exclusions NR
Roberts, 2004 ⁹⁶	Prospective	Australia outpatient; hospital	Study date NR Mean followup: 9 months Maximum followup: 9 months	88	ACS NR	Dialysis GFR equation NR	Poor life expectancy (<6 months)
Roberts, 2009 ⁹⁷	Prospective	Australia hospital	Start: 2003 End: 2004 Mean followup: 1.8 years	81	ACS NR	Combined CKD, dialysis GFR equation NR	Began dialysis in past 6 months, Had CV event in past 3 months, Expected to survive less than 3 months

Author, year	Design	Location Setting	Enrollment Followup	Sample Size	ACS information (if applicable)	CKD stages GFR Definition	Exclusion criteria
Roppolo, 1999 ⁹⁸	Prospective	US hospital	Study date NR Maximum followup: 6	134	ACS NR	Dialysis, chronic renal failure, but not on dialysis GFR equation NR	Other exclusions NR
Sahinarslan, 2008 ⁹⁹	Prospective	Europe hospital	Study date NR Mean followup: 5 years	78	no ACS	Dialysis GFR equation NR	CVD - CAD, Revascularization, HF, Stroke, Malignancy, any systemic disease other than RF
Satyan, 2007 ¹⁰⁰	Prospective	US hospital	Start: 2003 End: 2005 Median followup: 24 months	150	ACS NR	Dialysis GFR equation NR	Age < 18, Active drug abuse, Chronic atrial fibrillation, BMI \geq 40 kg/m ² , expected survival <6 mos, active cancer or known HIV, recent change in antihypertensive drugs, Inability to learn/perform BP monitoring
Scheven, 2012 ¹⁰¹	Prospective	Europe hospital	Start: 1997 Followup NR	Total: 8121 CKD: 1805	ACS NR	Combined CKD, stage 1, stage 2, stage 3, stage 4, dialysis CKD epi formula	Type I Diabetics, Pregnancy, Failure to sign consent form, no baseline troponin information.
Scott, 2003 ¹⁰²	Prospective	Europe Dialysis centers	Study date NR Mean followup: 1 years	71	ACS NR	Dialysis GFR equation NR	Other exclusions NR
Sharma, 2005 ¹⁰³	Prospective	Europe outpatient; hospital	Study date NR Mean followup: 1.32 years	118	no ACS	Dialysis, stage 5, pre-dialysis GFR equation NR	Age < 18, severe aortic stenosis, unstable angina, inability to consent
Sharma, 2006 ¹⁰⁴	Prospective	Europe hospital	Start: 2002 End: 2003 Mean followup: 2.25 years	114	no ACS	Dialysis, Renal Transplant Candidates Cockcroft-Gault formula	Age < 18, Severe aortic stenosis, Unstable angina, Inability to consent, unstable angina
Sharma, 2006 ¹⁰⁵	Prospective	Europe outpatient; hospital	Study date NR Followup NR	126	no ACS	Dialysis, stage 5, pre-dialysis, Cockcroft-Gault formula	Age < 18, severe aortic stenosis, unstable angina

Author, year	Design	Location Setting	Enrollment Followup	Sample Size	ACS information (if applicable)	CKD stages GFR Definition	Exclusion criteria
Shroff, 2012 ¹⁰⁶	Retrospective	US hospital	Start: 2005 End: 2007 Mean followup: 1 years	376	ACS NR	Dialysis, kidney transplant GFR equation NR	Other exclusions NR
Sommerer, 2007 ¹⁰⁷	Prospective	Germany outpatient; chronic dialysis center	Start: 2001 End: 2003 Maximum followup: 36	134	no ACS	Dialysis GFR equation NR	Age < 18, on hemodialysis < 6 months, < 3 hemodialysis sessions for four hours per week, acute infections, malignancy, acute myocardial ischemia, cardiomyopathy, and amyloidosis
Stolear, 1999 ¹⁰⁸	Prospective	Europe in-hospital dialysis unit	Study date NR Mean followup: 12 months	94	no ACS	Dialysis GFR equation NR	Other exclusions NR
Sukonthasarn, 2007 ¹⁰⁹	Cross-sectional	Thailand hospital	Start: 2005 End: 2006 Mean followup: years Maximum followup: 1	53	Patients with ACS included other dx: European Society of Cardiology AMI definition Cardiologist adjudication NR Adjudicator NS Definition: Adjudication definition NR	Dialysis GFR equation NR	Patients with suspected ACS do not match symptoms of AMI, pulmonary embolism, muscle diseases, acute stroke, renal dysfunction less than 3 months, recent ACS other than at admission
Svensson, 2009 ¹¹⁰	Post hoc	Europe dialysis	Study date NR Mean followup: 2 years	206	ACS NR	Dialysis GFR equation NR	Other exclusions NR
Trape, 2008 ¹¹¹	Prospective	Europe hospital	Start: 2002 End: 2004 Mean followup: 3 years	52	ACS NR	Dialysis, ESRD GFR equation NR	Dialysis less than three months.

Author, year	Design	Location Setting	Enrollment Followup	Sample Size	ACS information (if applicable)	CKD stages GFR Definition	Exclusion criteria
Troyanov, 2005 ¹¹²	Prospective	Canada hospital	Start: 2001 End: 2001 Mean followup: 3 years	101	no ACS	Dialysis GFR equation NR	Patients w angina within previous 14 days of admission or dx of ACS within previous 4 weeks, Pericarditis, documented left ventricular ejection fraction <25%, Pulmonary embolism 14 days prior
Van Lente, 1999 ¹¹³	Prospective	US emergency dept	Start: 1995 End: 1997 Maximum followup: 6 months	Total: 153 CKD: 51	Patients with ACS included other dx: not specified Cardiologist adjudication NR single adjudicator Definition: WHO criteria of at least 2 of the following: chest pain c/w cardiac origin, ECG changes or changes in CK and CK-MB	Dialysis	cardiopulmonary resuscitation within 7 days of presentation, angiography or thrombolytic therapy within 3 weeks of presentation, those given vasopressors
Vichairuangthum, 2006 ¹¹⁴	Prospective	Thailand Hospital; Dialysis Center	Study date NR Mean followup: 18 months	63	no ACS	Dialysis GFR equation NR	ACS within 3 mos., chronic stable angina pectoris, chest pain in peridialysis period or 4 weeks before enrollment, recent major CV surgery, significant EEG changes suggestive of myocardial ischemia, refusal to participate
Wang, 2006 ¹¹⁵	Prospective	Hong Kong outpatient;	Study date NR Mean followup: 3 years	222	no ACS	Dialysis GFR equation NR	acute heart failure, underlying malignancy, chronic liver disease, SLE, rheumatic HD, congenital HD, those on automated PD, those with incomplete data

Author, year	Design	Location Setting	Enrollment Followup	Sample Size	ACS information (if applicable)	CKD stages GFR Definition	Exclusion criteria
Wang, 2007 ¹¹⁶	Prospective	China Hospital; Dialysis Center	Start: 1999 End: 2000 Mean followup: 3 years	238	no ACS	Dialysis, ESRD GFR equation NR	ACS, Malignancy, Chronic liver disease, Systemic lupus erthematosus, chronic rheumatic heart disease, congenital heart disease, refusal to give consent
Wang, 2010 ¹¹⁷	Prospective	Hong Kong outpatient; outpatient dialysis center	Start: 1999 End: 2005 Maximum followup: 5	230	no ACS	Dialysis Residual GFR calculated as average of 24 hour urine area and creatinine clearances	Underlying malignancy, COPD, Chronic rheumatic heart disease, congenital heart disease
Wang, 2010 ¹¹⁸	Prospective	China Dialysis Center	Start: 1999 End: 2005 Mean followup: 5 years	230	ACS NR	Dialysis, ESRD GFR equation NR	Underlying malignancy, COPD, Chronic rheumatic heart disease, Congenital heart disease, Refusal to provide consent
Wayand, 2000 ¹¹⁹	Prospective	Europe Dialysis center	Study date NR Mean followup: 2 years	59	Patients with ACS included Cardiologist adjudication NR Adjudicator NS Definition: Adjudication definition NR	Dialysis, ESRD GFR equation NR	Other exclusions NR
Wood, 2003 ¹²⁰	Prospective	Europe outpatient	Study date NR Mean followup: 2 years	96	ACS NR	Stage 5, dialysis, Advanced Renal Impairment, planning to receive dialysis GFR equation NR	Acute Renal Failure, Acute on CRF
Yakupoglu, 2002 ¹²¹	Prospective	Turkey outpatient; Dialysis Center	Study date NR Mean followup: 48 months	38	ACS NR	Dialysis GFR equation NR	Other exclusions NR

References

1. Abaci A, Ekici E, Oguzhan A, et al. Cardiac troponins T and I in patients with end-stage renal disease: the relation with left ventricular mass and their prognostic value. *Clin Cardiol.* 2004 Dec;27(12):704-9. PMID: 15628116.
2. Abbas NA, John RI, Webb MC, et al. Cardiac troponins and renal function in nondialysis patients with chronic kidney disease. *Clin Chem.* 2005 Nov;51(11):2059-66. PMID: 16166165.
3. Acharji S, Baber U, Mehran R, et al. Prognostic significance of elevated baseline troponin in patients with acute coronary syndromes and chronic kidney disease treated with different antithrombotic regimens: a substudy from the ACUITY trial. *Circ Cardiovasc Interv.* 2012 Apr;5(2):157-65. PMID: 22354934.
4. Alcalai R, Planer D, Culhaoglu A, et al. Acute coronary syndrome vs nonspecific troponin elevation: clinical predictors and survival analysis. *Arch Intern Med.* 2007 Feb 12;167(3):276-81. PMID: 17296884.
5. Apple FS, Sharkey SW, Hoefft P, et al. Prognostic value of serum cardiac troponin I and T in chronic dialysis patients: a 1-year outcomes analysis. *Am J Kidney Dis.* 1997 Mar;29(3):399-403. PMID: 9041216.
6. Apple FS, Christenson RH, Valdes R, Jr., et al. Simultaneous rapid measurement of whole blood myoglobin, creatine kinase MB, and cardiac troponin I by the triage cardiac panel for detection of myocardial infarction. *Clin Chem.* 1999 Feb;45(2):199-205. PMID: 9931041.
7. Apple FS, Murakami MM, Pearce LA, et al. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. *Circulation.* 2002 Dec 3;106(23):2941-5. PMID: 12460876.
8. Apple FS, Murakami MM, Pearce LA, et al. Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. *Clin Chem.* 2004 Dec;50(12):2279-85. PMID: 15364888.
9. Apple FS, Pearce LA, Doyle PJ, et al. Cardiac troponin risk stratification based on 99th percentile reference cutoffs in patients with ischemic symptoms suggestive of acute coronary syndrome: influence of estimated glomerular filtration rates. *Am J Clin Pathol.* 2007 Apr;127(4):598-603. PMID: 17369136.
10. Artunc F, Mueller C, Breidhardt T, et al. Sensitive troponins--which suits better for hemodialysis patients? Associated factors and prediction of mortality. *PLoS One.* 2012;7(10):e47610. PMID: 23077650.
11. Aviles RJ, Askari AT, Lindahl B, et al. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. *N Engl J Med.* 2002 Jun 27;346(26):2047-52. PMID: 12087140.
12. Bagheri N, Taziki O, Falaknazi K. C- Reactive protein, cardiac troponin T and low albumin are predictors of mortality in hemodialysis patients. *Saudi J Kidney Dis Transpl.* 2009 Sep;20(5):789-93. PMID: 19736474.
13. Barthelemy O, Cayla G, Silvain J, et al. Optimal time for catheterization in NSTEMI-ACS patients with impaired renal function: Insights from the ABOARD Study. *Int J Cardiol.* 2012 Jul 12 PMID: 22795712.

14. Beciani M, Tedesco A, Violante A, et al. Cardiac troponin I (2nd generation assay) in chronic haemodialysis patients: prevalence and prognostic value. *Nephrol Dial Transplant*. 2003 May;18(5):942-6. PMID: 12686669.
15. Bhagavan NV, Goldstein AP, Honda SA, et al. Role of cardiac troponin I in the evaluation of myocardial injury. *J Clin Lab Anal*. 1998;12(5):276-9. PMID: 9773957.
16. Boulier A, Jaussent I, Terrier N, et al. Measurement of circulating troponin Ic enhances the prognostic value of C-reactive protein in haemodialysis patients. *Nephrol Dial Transplant*. 2004 Sep;19(9):2313-8. PMID: 15252159.
17. Bozbas H, Korkmaz ME, Atar I, et al. Serum levels of cardiac enzymes before and after renal transplantation. *Clin Cardiol*. 2004 Oct;27(10):559-62. PMID: 15553307.
18. Brunet P, Oddoze C, Paganelli F, et al. Cardiac troponins I and T in hemodialysis patients without acute coronary syndrome. *Int J Cardiol*. 2008 Sep 26;129(2):205-9. PMID: 17662483.
19. Buetti J, Krahn J, Karpinski M, et al. Troponin I testing in dialysis patients presenting to the emergency room: does troponin I predict the 30-day outcome? *Nephron Clin Pract*. 2006;103(4):c129-36. PMID: 16636580.
20. Chew HC. Cardiac troponin T in acute coronary syndrome with renal insufficiency. *Asian Cardiovasc Thorac Ann*. 2008 Aug;16(4):284-7. PMID: 18670019.
21. Choy JB, Armstrong PW, Ulan RA, et al. Do cardiac troponins provide prognostic insight in hemodialysis patients? *Can J Cardiol*. 2003 Jul;19(8):907-11. PMID: 12876611.
22. Chrysochou C, Manzoor S, Wright J, et al. Role of renal function and cardiac biomarkers (NT-proBNP and Troponin) in determining mortality and cardiac outcome in atheromatous renovascular disease. *Kidney Blood Press Res*. 2009;32(5):373-9. PMID: 19887825.
23. Claes K, Bammens B, Evenepoel P, et al. Troponin I is a predictor of acute cardiac events in the immediate postoperative renal transplant period. *Transplantation*. 2010 Feb 15;89(3):341-6. PMID: 20145526.
24. Codognotto M, Piccoli A, Zaninotto M, et al. Effect of a dialysis session on the prognostic values of NT-proBNP, troponins, endothelial damage and inflammation biomarkers. *J Nephrol*. 2010 Jul-Aug;23(4):465-71. PMID: 20540041.
25. Connolly GM, Cunningham R, McNamee PT, et al. Troponin T is an independent predictor of mortality in renal transplant recipients. *Nephrol Dial Transplant*. 2008 Mar;23(3):1019-25. PMID: 18065785.
26. Conway B, McLaughlin M, Sharpe P, et al. Use of cardiac troponin T in diagnosis and prognosis of cardiac events in patients on chronic haemodialysis. *Nephrol Dial Transplant*. 2005 Dec;20(12):2759-64. PMID: 16188899.
27. Deegan PB, Lafferty ME, Blumsohn A, et al. Prognostic value of troponin T in hemodialysis patients is independent of comorbidity. *Kidney Int*. 2001 Dec;60(6):2399-405. PMID: 11737616.
28. deFilippi C, Wasserman S, Rosanio S, et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. *JAMA*. 2003 Jul 16;290(3):353-9. PMID: 12865376.

29. deFilippi C, Seliger SL, Kelley W, et al. Interpreting cardiac troponin results from high-sensitivity assays in chronic kidney disease without acute coronary syndrome. *Clin Chem*. 2012 Sep;58(9):1342-51. PMID: 22791885.
30. Dierkes J, Domrose U, Westphal S, et al. Cardiac troponin T predicts mortality in patients with end-stage renal disease. *Circulation*. 2000 Oct 17;102(16):1964-9. PMID: 11034946.
31. Duman D, Tokay S, Toprak A, et al. Elevated cardiac troponin T is associated with increased left ventricular mass index and predicts mortality in continuous ambulatory peritoneal dialysis patients. *Nephrol Dial Transplant*. 2005 May;20(5):962-7. PMID: 15741207.
32. Farkouh ME, Robbins MJ, Zafar MU, et al. Association between troponin I levels and mortality in stable hemodialysis patients. *Am J Med*. 2003 Feb 15;114(3):224-6. PMID: 12637137.
33. Fehr T, Knoflach A, Ammann P, et al. Differential use of cardiac troponin T versus I in hemodialysis patients. *Clin Nephrol*. 2003 Jan;59(1):35-9. PMID: 12572929.
34. Feringa HH, Bax JJ, de Jonge R, et al. Impact of glomerular filtration rate on minor troponin T elevations for risk assessment in patients undergoing operation for abdominal aortic aneurysm or lower extremity arterial obstruction. *Am J Cardiol*. 2006 Dec 1;98(11):1515-8. PMID: 17126662.
35. Fernandez-Reyes MJ, Mon C, Heras M, et al. Predictive value of troponin T levels for ischemic heart disease and mortality in patients on hemodialysis. *J Nephrol*. 2004 Sep-Oct;17(5):721-7. PMID: 15593041.
36. Flores LM, Hernandez Dominguez JL, Otero A, et al. [Cardiac troponin I determination in patients with chronic renal failure]. *Nefrologia*. 2006;26(1):107-12. PMID: 16649431.
37. Flores-Solis LM, Hernandez-Dominguez JL, Otero-Gonzalez A, et al. Cardiac troponin I and creatine kinase MB isoenzyme in patients with chronic renal failure. *Nefrologia*. 2012;32(6):809-18. PMID: 23169364.
38. Gaiki MR, DeVita MV, Michelis MF, et al. Troponin I as a prognostic marker of cardiac events in asymptomatic hemodialysis patients using a sensitive troponin I assay. *Int Urol Nephrol*. 2012 Dec;44(6):1841-5. PMID: 22311387.
39. Geerse DA, van Berkel M, Vogels S, et al. Moderate elevations of high-sensitivity cardiac troponin I and B-type natriuretic peptide in chronic hemodialysis patients are associated with mortality. *Clin Chem Lab Med*. 2012 Dec 10:1-8. PMID: 23241607.
40. Goicoechea M, Garca de Vinuesa S, Gomez-Campdera F, et al. Clinical significance of cardiac troponin T levels in chronic kidney disease patients: predictive value for cardiovascular risk. *Am J Kidney Dis*. 2004 May;43(5):846-53. PMID: 15112175.
41. Gruberg L, Fuchs S, Waksman R, et al. Prognostic value of cardiac troponin I elevation after percutaneous coronary intervention in patients with chronic renal insufficiency: a 12-month outcome analysis. *Catheter Cardiovasc Interv*. 2002 Feb;55(2):174-9. PMID: 11835642.
42. Hallen J, Madsen L, Ladefoged S, et al. Incremental value of a combination of cardiac troponin T, N-terminal pro-brain natriuretic peptide and C-reactive protein for prediction of mortality in end-stage renal disease. *Scand J Urol Nephrol*. 2011 Mar;45(2):151-8. PMID: 21091090.

43. Han JH, Lindsell CJ, Ryan RJ, et al. Changes in cardiac troponin T measurements are associated with adverse cardiac events in patients with chronic kidney disease. *Am J Emerg Med.* 2005 Jul;23(4):468-73. PMID: 16032613.
44. Han SH, Choi HY, Kim DK, et al. Elevated cardiac troponin T predicts cardiovascular events in asymptomatic continuous ambulatory peritoneal dialysis patients without a history of cardiovascular disease. *Am J Nephrol.* 2009;29(2):129-35. PMID: 18719346.
45. Hasegawa M, Ishii J, Kitagawa F, et al. Prognostic value of highly sensitive troponin T on cardiac events in patients with chronic kidney disease not on dialysis. *Heart Vessels.* 2012 Aug 23; PMID: 22914904.
46. Havekes B, van Manen JG, Krediet RT, et al. Serum troponin T concentration as a predictor of mortality in hemodialysis and peritoneal dialysis patients. *Am J Kidney Dis.* 2006 May;47(5):823-9. PMID: 16632021.
47. Heesch C, Deu A, Langenbrink L, et al. Analytical and diagnostic performance of troponin assays in patients suspicious for acute coronary syndromes. *Clin Biochem.* 2000 Jul;33(5):359-68. PMID: 11018687.
48. Helleskov Madsen L, Ladefoged S, Hildebrandt P, et al. Comparison of four different cardiac troponin assays in patients with end-stage renal disease on chronic haemodialysis. *Acute Card Care.* 2008;10(3):173-80. PMID: 18608043.
49. Hickman PE, McGill DA, Talaulikar G, et al. Prognostic efficacy of cardiac biomarkers for mortality in dialysis patients. *Intern Med J.* 2009 Dec;39(12):812-8. PMID: 20233242.
50. Hickson LJ, Cosio FG, El-Zoghby ZM, et al. Survival of patients on the kidney transplant wait list: relationship to cardiac troponin T. *Am J Transplant.* 2008 Nov;8(11):2352-9. PMID: 18785956.
51. Hickson LT, El-Zoghby ZM, Lorenz EC, et al. Patient survival after kidney transplantation: relationship to pretransplant cardiac troponin T levels. *Am J Transplant.* 2009 Jun;9(6):1354-61. PMID: 19459818.
52. Hocher B, Ziebig R, Altermann C, et al. Different impact of biomarkers as mortality predictors among diabetic and nondiabetic patients undergoing hemodialysis. *J Am Soc Nephrol.* 2003 Sep;14(9):2329-37. PMID: 12937310.
53. Hocher B, Ziebig R, Krause R, et al. Relaxin is an independent risk factor predicting death in male patients with end-stage kidney disease. *Circulation.* 2004 May 18;109(19):2266-8. PMID: 15136497.
54. Hocher B, Kalk P, Godes M, et al. Gender-dependent impact of risk factors for cardiovascular and non-cardiovascular mortality in end-stage renal disease patients on haemodialysis. *Kidney Blood Press Res.* 2008;31(5):360-6. PMID: 19023219.
55. Hojs R, Ekart R, Hojs Fabjan T, et al. Cardiac troponin T (cTnT) in hemodialysis patients with asymptomatic and symptomatic atherosclerosis. *Arch Med Res.* 2005 Jul-Aug;36(4):367-71. PMID: 15950076.
56. Holden RM, Beseau D, Booth SL, et al. FGF-23 is associated with cardiac troponin T and mortality in hemodialysis patients. *Hemodial Int.* 2012 Jan;16(1):53-8. PMID: 22099949.
57. Hung SY, Hung YM, Fang HC, et al. Cardiac troponin I and creatine kinase isoenzyme MB in patients with intradialytic hypotension. *Blood Purif.* 2004;22(4):338-43. PMID: 15218282.
58. Hussein M, Mooij J, Roujouleh H, et al. Cardiac troponin-I and its prognostic significance in a dialysis population. *Hemodial Int.* 2004 Oct 1;8(4):332-7. PMID: 19379438.

59. Ie EH, Klootwijk PJ, Weimar W, et al. Significance of acute versus chronic troponin T elevation in dialysis patients. *Nephron Clin Pract.* 2004;98(3):c87-92. PMID: 15528943.
60. Iliou MC, Fumeron C, Benoit MO, et al. Prognostic value of cardiac markers in ESRD: Chronic Hemodialysis and New Cardiac Markers Evaluation (CHANCE) study. *Am J Kidney Dis.* 2003 Sep;42(3):513-23. PMID: 12955679.
61. Ilva T, Lassus J, Siirila-Waris K, et al. Clinical significance of cardiac troponins I and T in acute heart failure. *Eur J Heart Fail.* 2008;10(8):772-9.
62. Ishii J, Nomura M, Okuma T, et al. Risk stratification using serum concentrations of cardiac troponin T in patients with end-stage renal disease on chronic maintenance dialysis. *Clin Chim Acta.* 2001 Oct;312(1-2):69-79. PMID: 11580911.
63. Jensen JK, Ueland T, Aukrust P, et al. Highly sensitive troponin T in patients with acute ischemic stroke. *Eur Neurol.* 2012;68(5):287-93. PMID: 23051820.
64. Kalaji FR, Albitar S. Predictive value of cardiac troponin T and I in hemodialysis patients. *Saudi J Kidney Dis Transpl.* 2012 Sep;23(5):939-45. PMID: 22982904.
65. Kang EW, Na HJ, Hong SM, et al. Prognostic value of elevated cardiac troponin I in ESRD patients with sepsis. *Nephrol Dial Transplant.* 2009 May;24(5):1568-73. PMID: 19145004.
66. Kanwar M, Hashem M, Rosman H, et al. Usefulness of clinical evaluation, troponins, and C-reactive protein in predicting mortality among stable hemodialysis patients. *Am J Cardiol.* 2006 Nov 1;98(9):1283-7. PMID: 17056347.
67. Katerinis I, Nguyen QV, Magnin JL, et al. Cardiac findings in asymptomatic chronic hemodialysis patients with persistently elevated cardiac troponin I levels. *Ren Fail.* 2008;30(4):357-62. PMID: 18569907.
68. Kertai MD, Boersma E, Klein J, et al. Long-term prognostic value of asymptomatic cardiac troponin T elevations in patients after major vascular surgery. *Eur J Vasc Endovasc Surg.* 2004 Jul;28(1):59-66. PMID: 15177233.
69. Khan IA, Wattanasuwan N, Mehta NJ, et al. Prognostic value of serum cardiac troponin I in ambulatory patients with chronic renal failure undergoing long-term hemodialysis: a two-year outcome analysis. *J Am Coll Cardiol.* 2001 Oct;38(4):991-8. PMID: 11583870.
70. Kontos MC, Garg R, Anderson FP, et al. Outcomes in patients admitted for chest pain with renal failure and troponin I elevations. *Am Heart J.* 2005 Oct;150(4):674-80. PMID: 16209963.
71. Kontos MC, Garg R, Anderson FP, et al. Predictive power of ejection fraction and renal failure in patients admitted for chest pain without ST elevation in the troponin era. *Am Heart J.* 2005 Oct;150(4):666-73. PMID: 16209962.
72. Kontos MC, Jamal SM, Ornato JP, et al. Comparison of the modification of diet in renal disease and the Cockcroft-Gault equations for predicting mortality in patients admitted for exclusion of myocardial ischemia. *Am J Cardiol.* 2008 Jul 15;102(2):140-5. PMID: 18602510.
73. Kostrubiec M, Labyk A, Pedowska-Wloszek J, et al. Assessment of renal dysfunction improves troponin-based short-term prognosis in patients with acute symptomatic pulmonary embolism. *J Thromb Haemost.* 2010 Apr;8(4):651-8. PMID: 20088923.

74. Lamb EJ, Kenny C, Abbas NA, et al. Cardiac troponin I concentration is commonly increased in nondialysis patients with CKD: experience with a sensitive assay. *Am J Kidney Dis.* 2007 Apr;49(4):507-16. PMID: 17386318.
75. Lang K, Schindler S, Forberger C, et al. Cardiac troponins have no prognostic value for acute and chronic cardiac events in asymptomatic patients with end-stage renal failure. *Clin Nephrol.* 2001 Jul;56(1):44-51. PMID: 11499658.
76. Le Goff C, Bovy C, Aldenhoff MC, et al. Three-year prognostic interest of cardiac troponin T (cTnT) and amino-terminal pro-B-natriuretic peptide (NT-proBNP) in hemodialyzed patients. *Immuno-Analyse et Biologie Specialisee.* 2007;22(6):377-83.
77. Lowbeer C, Gutierrez A, Gustafsson SA, et al. Elevated cardiac troponin T in peritoneal dialysis patients is associated with CRP and predicts all-cause mortality and cardiac death. *Nephrol Dial Transplant.* 2002 Dec;17(12):2178-83. PMID: 12454230.
78. Lowbeer C, Stenvinkel P, Pecoits-Filho R, et al. Elevated cardiac troponin T in predialysis patients is associated with inflammation and predicts mortality. *J Intern Med.* 2003 Feb;253(2):153-60. PMID: 12542555.
79. Mallamaci F, Zoccali C, Parlongo S, et al. Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. *Am J Kidney Dis.* 2002 Jul;40(1):68-75. PMID: 12087563.
80. Martin GS, Becker BN, Schulman G. Cardiac troponin-I accurately predicts myocardial injury in renal failure. *Nephrol Dial Transplant.* 1998 Jul;13(7):1709-12. PMID: 9681716.
81. McCullough PA, Nowak RM, Foreback C, et al. Performance of multiple cardiac biomarkers measured in the emergency department in patients with chronic kidney disease and chest pain. *Acad Emerg Med.* 2002 Dec;9(12):1389-96. PMID: 12460842.
82. McGill D, Talaulikar G, Potter JM, et al. Over time, high-sensitivity TnT replaces NT-proBNP as the most powerful predictor of death in patients with dialysis-dependent chronic renal failure. *Clin Chim Acta.* 2010 Jul 4;411(13-14):936-9. PMID: 20298685.
83. McMurray JJ, Uno H, Jarolim P, et al. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). *Am Heart J.* 2011 Oct;162(4):748-55 e3. PMID: 21982669.
84. Melloni C, Alexander KP, Milford-Beland S, et al. Prognostic value of troponins in patients with non-ST-segment elevation acute coronary syndromes and chronic kidney disease. *Clin Cardiol.* 2008 Mar;31(3):125-9. PMID: 18383049.
85. Mockel M, Schindler R, Knorr L, et al. Prognostic value of cardiac troponin T and I elevations in renal disease patients without acute coronary syndromes: a 9-month outcome analysis. *Nephrol Dial Transplant.* 1999 Jun;14(6):1489-95. PMID: 10383013.
86. Morton AR, Collier CP, Ali N, et al. Cardiac troponin I in patients receiving renal replacement therapy. *ASAIO J.* 1998 Sep-Oct;44(5):M433-5. PMID: 9804466.
87. Musso P, Cox I, Vidano E, et al. Cardiac troponin elevations in chronic renal failure: prevalence and clinical significance. *Clin Biochem.* 1999 Mar;32(2):125-30. PMID: 10211629.
88. Noeller TP, Meldon SW, Peacock WF, et al. Troponin T in elders with suspected acute coronary syndromes. *Am J Emerg Med.* 2003 Jul;21(4):293-7. PMID: 12898485.

89. Ooi DS, Veinot JP, Wells GA, et al. Increased mortality in hemodialyzed patients with elevated serum troponin T: a one-year outcome study. *Clin Biochem*. 1999 Nov;32(8):647-52. PMID: 10638948.
90. Ooi DS, Zimmerman D, Graham J, et al. Cardiac troponin T predicts long-term outcomes in hemodialysis patients. *Clin Chem*. 2001 Mar;47(3):412-7. PMID: 11238290.
91. Orea-Tejeda A, Sanchez-Gonzalez LR, Castillo-Martinez L, et al. Prognostic value of cardiac troponin T elevation is independent of renal function and clinical findings in heart failure patients. *Cardiol J*. 2010;17(1):42-8. PMID: 20104456.
92. Peetz D, Schutt S, Sucke B, et al. Prognostic value of troponin T, troponin I, and CK-MBmass in patients with chronic renal failure. *Med Klin (Munich)*. 2003 Apr 15;98(4):188-92. PMID: 12715142.
93. Petrovic D, Stojimirovic BB. Cardiac troponins: outcome predictors in hemodialysis patients. *J Artif Organs*. 2009;12(4):258-63. PMID: 20035399.
94. Porter GA, Norton T, Bennett WB. Troponin T, a predictor of death in chronic haemodialysis patients. *Eur Heart J*. 1998 Nov;19 Suppl N:N34-7. PMID: 9857937.
95. Porter GA, Norton T, Bennett WM. Long term follow up of the utility of troponin T to assess cardiac risk in stable chronic hemodialysis patients. *Clin Lab*. 2000;46(9-10):469-76. PMID: 11034532.
96. Roberts MA, Fernando D, Macmillan N, et al. Single and serial measurements of cardiac troponin I in asymptomatic patients on chronic hemodialysis. *Clin Nephrol*. 2004 Jan;61(1):40-6. PMID: 14964456.
97. Roberts MA, Hare DL, Macmillan N, et al. Serial increased cardiac troponin T predicts mortality in asymptomatic patients treated with chronic haemodialysis. *Ann Clin Biochem*. 2009 Jul;46(Pt 4):291-5. PMID: 19454539.
98. Roppolo LP, Fitzgerald R, Dillow J, et al. A comparison of troponin T and troponin I as predictors of cardiac events in patients undergoing chronic dialysis at a Veteran's Hospital: a pilot study. *J Am Coll Cardiol*. 1999 Aug;34(2):448-54. PMID: 10440158.
99. Sahinarslan A, Guz G, Okyay K, et al. Prognostic value of troponin T and homocysteine in patients with end-stage renal disease. *Turk Kardiyol Dern Ars*. 2008 Sep;36(6):382-7. PMID: 19155641.
100. Satyan S, Light RP, Agarwal R. Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. *Am J Kidney Dis*. 2007 Dec;50(6):1009-19. PMID: 18037101.
101. Scheven L, de Jong PE, Hillege HL, et al. High-sensitive troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate. *Eur Heart J*. 2012 Sep;33(18):2272-81. PMID: 22740385.
102. Scott B, Deman A, Peeters P, et al. Cardiac troponin T and malondialdehyde modified plasma lipids in haemodialysis patients. *Nephrol Dial Transplant*. 2003 Apr;18(4):737-42. PMID: 12637643.

103. Sharma R, Pellerin D, Gaze DC, et al. Dobutamine stress echocardiography and cardiac troponin T for the detection of significant coronary artery disease and predicting outcome in renal transplant candidates. *Eur J Echocardiogr.* 2005 Oct;6(5):327-35. PMID: 15985387.
104. Sharma R, Gaze DC, Pellerin D, et al. Ischemia-modified albumin predicts mortality in ESRD. *Am J Kidney Dis.* 2006 Mar;47(3):493-502. PMID: 16490629.
105. Sharma R, Gaze DC, Pellerin D, et al. Cardiac structural and functional abnormalities in end stage renal disease patients with elevated cardiac troponin T. *Heart.* 2006 Jun;92(6):804-9. PMID: 16216854.
106. Shroff GR, Akkina SK, Miedema MD, et al. Troponin I levels and postoperative myocardial infarction following renal transplantation. *Am J Nephrol.* 2012;35(2):175-80. PMID: 22286592.
107. Sommerer C, Beimler J, Schwenger V, et al. Cardiac biomarkers and survival in haemodialysis patients. *Eur J Clin Invest.* 2007 May;37(5):350-6. PMID: 17461980.
108. Stolear JC, Georges B, Shita A, et al. The predictive value of cardiac troponin T measurements in subjects on regular haemodialysis. *Nephrol Dial Transplant.* 1999 Aug;14(8):1961-7. PMID: 10462278.
109. Sukonthasarn A, Ponglopisit S. Diagnostic level of cardiac troponin T in patients with chronic renal dysfunction, a pilot study. *J Med Assoc Thai.* 2007 Sep;90(9):1749-58. PMID: 17957915.
110. Svensson M, Gorst-Rasmussen A, Schmidt EB, et al. NT-pro-BNP is an independent predictor of mortality in patients with end-stage renal disease. *Clin Nephrol.* 2009;71(4):380-6.
111. Trape J, Perez A, Naval I, et al. Nt-proBNP in haemodialysis patients: a preliminary study. *Scand J Clin Lab Invest.* 2008;68(5):415-20. PMID: 19172698.
112. Troyanov S, Ly QH, Schampaert E, et al. Diagnostic specificity and prognostic value of cardiac troponins in asymptomatic chronic haemodialysis patients: a three year prospective study. *Heart.* 2005 Sep;91(9):1227-8. PMID: 16103574.
113. Van Lente F, McErlean ES, DeLuca SA, et al. Ability of troponins to predict adverse outcomes in patients with renal insufficiency and suspected acute coronary syndromes: a case-matched study. *J Am Coll Cardiol.* 1999 Feb;33(2):471-8. PMID: 9973028.
114. Vichairuangthum K, Leowattana W, Ong-Ajyooth L, et al. The relationship between serum concentration of cardiac troponin I in chronic renal failure patients and cardiovascular events. *J Med Assoc Thai.* 2006 May;89(5):714-20. PMID: 16756060.
115. Wang AY, Lam CW, Yu CM, et al. Troponin T, left ventricular mass, and function are excellent predictors of cardiovascular congestion in peritoneal dialysis. *Kidney Int.* 2006 Aug;70(3):444-52. PMID: 16871255.
116. Wang AY, Lam CW, Wang M, et al. Prognostic value of cardiac troponin T is independent of inflammation, residual renal function, and cardiac hypertrophy and dysfunction in peritoneal dialysis patients. *Clin Chem.* 2007 May;53(5):882-9. PMID: 17395709.
117. Wang AYM, Lam CW, Chan IH, et al. Sudden cardiac death in end-stage renal disease patients: A 5-year prospective analysis. *NDT Plus.* 2010;3:iii291.

118. Wang AY, Lam CW, Chan IH, et al. Sudden cardiac death in end-stage renal disease patients: a 5-year prospective analysis. *Hypertension*. 2010 Aug;56(2):210-6. PMID: 20606110.
119. Wayand D, Baum H, Schatzle G, et al. Cardiac troponin T and I in end-stage renal failure. *Clin Chem*. 2000 Sep;46(9):1345-50. PMID: 10973864.
120. Wood GN, Keevil B, Gupta J, et al. Serum troponin T measurement in patients with chronic renal impairment predicts survival and vascular disease: a 2 year prospective study. *Nephrol Dial Transplant*. 2003 Aug;18(8):1610-5. PMID: 12897102.
121. Yakupoglu U, Ozdemir FN, Arat Z, et al. Can troponin-I predict cardiovascular mortality due to myocardial injury in hemodialysis patients? *Transplant Proc*. 2002 Sep;34(6):2033-4. PMID: 12270303.

Table 2. Study population characteristics of studies included in Troponin report

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Abaci, 2004 ¹	Total sample, 129	44	55	On dialysis: 76	NR	NR	NR
Abaci, 2004 ¹	cTnT >0.1 ng/mL, 27	50	70	NR	NR	NR	NR
Abaci, 2004 ¹	cTnT 0.03-0.1 ng/mL, 27	46	59	NR	NR	NR	NR
Abaci, 2004 ¹	cTnT <0.03 ng/mL, 75	42	48	NR	NR	NR	NR
Abbas, 2005 ²	Total sample, 222	67	65	NR	NR	Stage 3 kidney disease, percent: 25, Stage 4 kidney disease, percent: 31, Stage 5 kidney disease, percent: 43	NR
Abbas, 2005 ²	Stage 3, 56	68	77	NR	NR	NR	NR
Abbas, 2005 ²	Stage 4, 70	71	70	NR	NR	NR	NR
Abbas, 2005 ²	Stage 5, 96	64	55	NR	NR	NR	NR

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Acharji, 2012 ³	Troponin Positive, 1291	Median: 76	53.3	NR	NR	NR	NR
Acharji, 2012 ³	Troponin Negative, 888	Median: 75	53.7	NR	NR	NR	NR
Alcalai, 2007 ⁴	NTTE (Nonthrombotic troponin elevation), 254	71.4	61	NR	NR	NR	NR
Alcalai, 2007 ⁴	ACS, 326	65	69	NR	NR	NR	NR
Alcalai, 2007 ⁴	unknown, 35	72.2	51	NR	NR	NR	NR
Alcalai, 2007 ⁴	Total sample, 615	68	65	NR	NR	NR	NR
Apple, 1997 ⁵	Total sample, 16	46	44	On dialysis: 100	Known CAD: 56	Stage 5 kidney disease, percent: 100	NR
Apple, 1999 ⁶	Total sample, 1601	NR	NR	NR	NR	NR	NR
Apple, 2002 ⁷	Total sample, 733	62	56	On dialysis: 100	Known CAD: 29	Stage 5 kidney disease, percent: 100	White: 60, African American: 23, Hispanic: 3,

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Apple, 2004 ⁸	Total sample, 399	61	58	On dialysis: 100	Known CAD: 30	Stage 5 kidney disease, percent: 100	White: 59, African American: 26, Hispanic: 2, Other race/ethnicity: 12,
Apple, 2007 ⁹	Tosoh cTnl	57	NR	NR	NR	NR	
Apple, 2007 ⁹	Roche cTnT, 420	58	13	NR	NR	NR	White: 11, African American: 8, Other race/ethnicity: 4,
Apple, 2007 ⁹	Beckman cTnl, 421	58	14	NR	NR	NR	White: 11, African American: 9, Other race/ethnicity: 4,
Apple, 2007 ⁹	Dade cTnl, 490	58	12	NR	NR	NR	White: 10, African American: 7, Other race/ethnicity: 4,
Artunc, 2012 ¹⁰	Total sample, 239	Median: 70	64	On dialysis: 100	Known CAD: 74	Stage 5 kidney disease, percent: 100,	NR
Aviles, 2002 ¹¹	CrCl and Trop T both Normal, 2605	NR	59	NR	NR	NR	NR
Aviles, 2002 ¹¹	Trop T abnormal and CrCl normal, 2695	NR	75	NR	NR	NR	NR
Aviles, 2002 ¹¹	Total sample, 7033	NR	NR	NR	NR	NR	NR

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Aviles, 2002 ¹¹	CrCl abnormal and Trop T normal, 783	NR	41	NR	NR	NR	NR
Aviles, 2002 ¹¹	CrCl and Trop T both abnormal, 950	NR	51	NR	NR	NR	NR
Bagheri, 2009 ¹²	CAD-, cTnT >0.05 mg/L, 10	NR	NR	NR	NR	NR	NR
Bagheri, 2009 ¹²	Total sample, 138	65	52	On dialysis: 100	NR	NR	NR
Bagheri, 2009 ¹²	CAD+, cTnT <0.05 mg/L, 20	NR	NR	NR	NR	NR	NR
Bagheri, 2009 ¹²	CAD+, cTnT >0.05 mg/L, 46	NR	NR	NR	NR	NR	NR
Bagheri, 2009 ¹²	CAD-, cTnT <0.05 mg/L, 62	NR	NR	NR	NR	NR	NR
Barthelemy, 2012 ¹³	Creatinine Clearance \geq to GmL/min, 270	62	NR	NR	NR	NR	NR
Barthelemy, 2012 ¹³	Renal Failure - Creatinine Clearance < 60 mL/min, 75	76	NR	NR	NR	NR	NR

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Beciani, 2003 ¹⁴	Group 3: >0.15ng/ml cTNI, 14	67	NR	On dialysis: 100	NR	NR	NR
Beciani, 2003 ¹⁴	Group 2: </>0.15ng/ml cTNI, 15	64	NR	On dialysis: 100	NR	NR	NR
Beciani, 2003 ¹⁴	Group 1: <0.15ng/ml cTNI, 72	60	NR	On dialysis: 100	NR	NR	NR
Bhagavan, 1998 ¹⁵	Total sample, 155	NR	NR	NR	NR	NR	NR
Boulier, 2004 ¹⁶	Total sample, 191	Median: 66.7	50.8	On dialysis: 100	Known CAD: 32.5	Stage 5 kidney disease, percent: 100	NR
Bozbas, 2004 ¹⁷	Total sample, 34	31.8	68	On dialysis: 100	Known CAD: 12	Stage 5 kidney disease, percent: 294	NR
Brunet, 2008 ¹⁸	Total sample, 105	65.5	59	On dialysis: 100	Known CAD: 31	Stage 5 kidney disease, percent: 100	NR
Bueti, 2006 ¹⁹	Total sample, 149	Median: 63	49	On dialysis: 100	Known CAD: 43	Stage 5 kidney disease, percent: 100	NR
Chew, 2008 ²⁰	Total sample, 227	66.26	54	On dialysis: 48NR	Known CAD: 63NR	NR	Other race/ethnicity: 100

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Choy, 2003 ²¹	Total sample, 113	Median: 63	NR	On dialysis: 100	NR	Stage 5 kidney disease, percent: 100	NR
Choy, 2003 ²¹	cTnl>0.5, 17	NR	NR	On dialysis: 100	NR	Stage 5 kidney disease, percent: 100	NR
Choy, 2003 ²¹	cTnT >0.1 ug/L, 48	NR	NR	On dialysis: 100	NR	Stage 5 kidney disease, percent: 100	NR
Choy, 2003 ²¹	cTnT <0.1 ug/L, 65	NR	NR	On dialysis: 100	NR	Stage 5 kidney disease, percent: 100	NR
Choy, 2003 ²¹	cTnl<0.5, 96	NR	NR	On dialysis: 100	NR	Stage 5 kidney disease, percent: 100	NR
Chrysochou, 2009 ²²	cTnT >0.03 ng/mL, 11	74	55	NR	Known CAD: 55	NR	NR
Chrysochou, 2009 ²²	cTnT <0.03 ng/mL, 71	72	63	NR	Known CAD: 62	NR	NR
Claes, 2010 ²³	Total sample	Median: 53	NR	NR	Known CAD: 23.6NR	NR	

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Codognotto, 2010 ²⁴	Total sample, 50	68	72	On dialysis: 100	NR	NR	NR
Connolly, 2008 ²⁵	cTnT >0.03 ug/L, 21	56.5	76	NR	NR	NR	
Connolly, 2008 ²⁵	cTnT <0.03 ug/L, 351	46.7	64	NR	NR	NR	
Conway, 2005 ²⁶	Total sample, 75	Median: 64	60	On dialysis: 100	Known CAD: 33	Stage 5 kidney disease, percent: 100	NR
Deegan, 2001 ²⁷	Total sample, 73	Median: 64	58	On dialysis: 100	Known CAD: 25	Stage 5 kidney disease, percent: 100	NR
deFilippi, 2003 ²⁸	Total sample, 224	Median: 62	54	On dialysis: 100	Known CAD: 36	Stage 5 kidney disease, percent: 100	White: 38, African American: 38, Hispanic: 21,
deFilippi, 2012 ²⁹	Total sample, 148	63.2	68.9	NR	Known CAD: 16.9	NR	White: 59.5,
Dierkes, 2000 ³⁰	Total sample, 102	64	49	On dialysis: 100	Known CAD: 28	Stage 5 kidney disease, percent: 100	NR
Dierkes, 2000 ³⁰	cTnT >0.04 ng/mL, 40	NR	NR	NR	NR	NR	NR

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Dierkes, 2000 ³⁰	cTnT <0.04 ng/mL, 62	NR	NR	NR	NR	NR	NR
Duman, 2005 ³¹	cTnT >0.035 ng/mL, 29	NR	NR	NR	Known CAD: 24	NR	NR
Duman, 2005 ³¹	cTnT <0.035 ng/mL, 36	NR	NR	NR	Known CAD: 8	NR	NR
Duman, 2005 ³¹	Total sample, 65	56	55	On dialysis: 100	Known CAD: 15	NR	NR
Facila, 2006 ³²	creatinine >1.3, 217	73.8	71.4	NR	Known CAD: 53	NR	NR
Facila, 2006 ³²	Creatinine <=1.3, 812	67.1	64	NR	Known CAD: 46	NR	NR
Farkouh, 2003 ³³	Total sample,	58	NR	On dialysis: 100	NR	NR	NR
Farkouh, 2003 ³³	cTnI >1.0 ng/mL, 10	66	50	On dialysis: 100	Known CAD: 60	NR	NR
Farkouh, 2003 ³³	cTnI <1.0 ng/ml, 127	58	58	On dialysis: 100	Known CAD: 36	NR	NR

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Fehr, 2003 ³⁴	Total sample, 31	55	65	On dialysis: 100	NR	NR	NR
Feringa, 2006 ³⁵	Trop T >=0.10,	70.7	78.3	NR	Known CAD: 58.7	NR	NR
Feringa, 2006 ³⁵	Trop T 0.03-0.09, 25	68.6	76	NR	Known CAD: 60	NR	NR
Feringa, 2006 ³⁵	Trop T <0.03, 487	66.6	76.6	NR	Known CAD: 40.5	NR	NR
Feringa, 2006 ³⁵	Total sample, 558	66.6	76.7	NR	Known CAD: 42.8	NR	NR
Fernandez-Reyes, 2004 ³⁶	moderate risk: cTnT 0.04-0.1 ng/mL, 11	NR	NR	NR	NR	NR	NR
Fernandez-Reyes, 2004 ³⁶	high risk: cTnT >0.1 ng/mL, 12	NR	NR	NR	NR	NR	NR

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Fernandez-Reyes, 2004 ³⁶	changing group: cTnT values change during follow-up, 16	NR	NR	NR	NR	NR	NR
Fernandez-Reyes, 2004 ³⁶	low risk: cTnT <0.04 ng/mL, 23	NR	NR	NR	NR	NR	NR
Fernandez-Reyes, 2004 ³⁶	Total sample, 58	69.9	50	On dialysis: 100	Known CAD: 22	NR	NR
Flores, 2006 ³⁷	Total sample, 467	Median: 80	67	NR	Known CAD: 19	Stage 4 kidney disease, percent: 50	NR
Flores-Solis, 2012 ³⁸	Patients with ONCP (other non-cardiac pathologies),	76	67	NR	NR	NR	NR
Flores-Solis, 2012 ³⁸	Patients with OCP (other cardiac pathologies), 140	78	67	NR	NR	NR	NR

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Flores-Solis, 2012 ³⁸	Total sample, 484	77	68	NR	NR	Stage 3 kidney disease, percent: 58, Stage 4 kidney disease, percent: 31, Stage 5 kidney disease, percent: 11	NR
Flores-Solis, 2012 ³⁸	Patients with ACS, 54	77	76	NR	NR	NR	NR
Gaiki, 2012 ³⁹	cTnl (-), 25	NR	NR	NR	NR	NR	
Gaiki, 2012 ³⁹	cTnl (+), 26	NR	NR	NR	NR	NR	
Gaiki, 2012 ³⁹	Total sample, 51	61.94NR	53	On dialysis: 100	Known CAD: 31	NR	White: 18, African American: 61, Hispanic: 14, Other race/ethnicity: 8
Geerse, 2012 ⁴⁰	Total sample, 206	65.3NR	52	On dialysis: 100	Known CAD: 40	NR	NR
Geerse, 2012 ⁴⁰	>0.10 ug/L troponin, 25	NR	NR	On dialysis: 100	NR	NR	NR
Geerse, 2012 ⁴⁰	0.05-0.10 ug/L troponin, 28	NR	NR	On dialysis: 100	NR	NR	NR

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Geerse, 2012 ⁴⁰	<0.01 ug/L troponin, 59	NR	NR	On dialysis: 100	NR	NR	NR
Geerse, 2012 ⁴⁰	0.01-0.05 ug/L troponin, 94	NR	NR	On dialysis: 100	NR	NR	NR
Goicoechea, 2004 ⁴¹	cTnT<0.01 ng/ml w/ CKD, 108	Median: 68	64	NR	Known CAD: 19	NR	NR
Goicoechea, 2004 ⁴¹	cTnT>0.01 w/ CKD, 20	Median: 77	45	NR	Known CAD: 35	NR	NR
Goicoechea, 2004 ⁴¹	Control (no CKD), 48	Median: 55.5	65	On dialysis: 0NR	Known CAD: 8	NR	NR
Gruberg, 2002 ⁴²	cTnl >0.15 ng/mL, 50	73	76	On dialysis: 0	Known CAD: 100	NR	NR
Gruberg, 2002 ⁴²	cTnl <0.15 ng/mL, 66	69	68.2	On dialysis: 0	Known CAD: 100	NR	NR
Hallen, 2011 ⁴³	Total sample, 109	62	75	On dialysis: 100	Known CAD: 27	NR	NR

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Hallen, 2011 ⁴³	cTnT <0.01 ug/L, 43	NR	NR	NR	NR	NR	NR
Hallen, 2011 ⁴³	cTnT >0.01 ug/L, 64	NR	NR	NR	NR	NR	NR
Han, 2005 ⁴⁴	Pts with no ACS, 27	48.1	63	On dialysis: 51.9	Known CAD: 25.9	NR	White: 18.5, African American: 77.8, Other race/ethnicity: 3.7
Han, 2005 ⁴⁴	Pts with ACS, 34	61	50	On dialysis: 33.3	Known CAD: 26.5	NR	White: 20.6, African American: 79.4, Other race/ethnicity: 0
Han, 2005 ⁴⁴	Total sample, 64	54.9	57.8	On dialysis: 43.7	Known CAD: 40.6	NR	White: 18.8, African American: 79.7, Other race/ethnicity: 1.6
Han, 2009 ⁴⁵	cTnT >0.1 ug/L, 21	54.6	52	On dialysis: 100	NR	NR	NR
Han, 2009 ⁴⁵	cTnT <0.1 ug/L, 86	47.8	44	On dialysis: 100	NR	NR	NR
Hasegawa, 2012 ⁴⁶	Quartile 4 - >33 pg/mL,	Median: 73	NR	NR	NR	Stage 3 kidney disease, percent: 8.3, Stage 4 kidney disease, percent: 33.3, Stage 5 kidney disease, percent: 58.3	

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Hasegawa, 2012 ⁴⁶	Quartile 3 - 19-32 pg/mL, 110	Median: 73	61	On dialysis: 0	NR	Stage 3 kidney disease, percent: 23.6, Stage 4 kidney disease, percent: 52.7, Stage 5 kidney disease, percent: 23.6	Other race/ethnicity: 100
Hasegawa, 2012 ⁴⁶	Quartile 2 - 10-18 pg/mL, 111	Median: 68	67	On dialysis: 0	NR	Stage 3 kidney disease, percent: 35.1, Stage 4 kidney disease, percent: 49.5, Stage 5 kidney disease, percent: 15.3	Other race/ethnicity: 100
Hasegawa, 2012 ⁴⁶	Quartile 1 - <9 pg/mL, 113	Median: 63	58	On dialysis: 0	NR	Stage 3 kidney disease, percent: 78.8, Stage 4 kidney disease, percent: 17.7, Stage 5 kidney disease, percent: 3.5	Other race/ethnicity: 100
Havekes, 2006 ⁴⁷	Total sample, 847	59	60	On dialysis: 100	NR	Stage 5 kidney disease, percent: 100	NR
Heeschen, 2000 ⁴⁸	ESRD patients, 26	Median: 45.8	62	On dialysis: 100	Known CAD: 0	Stage 5 kidney disease, percent: 100	NR
Helleskov Madsen, 2008 ⁴⁹	Total sample, 109	61.8	75	On dialysis: 100	Known CAD: 26.6	Stage 5 kidney disease, percent: 100	NR
Hickman, 2009 ⁵⁰	Total sample, 143	59.67	63	On dialysis: 100	NR	Stage 5 kidney disease, percent: 100	White: 89.3, African American: 3.6, Other race/ethnicity: 7.1

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Hickson, 2008 ⁵¹	Total sample, 644	51	56	On dialysis: 62	Known CAD: 34	NR	White: 98
Hickson, 2009 ⁵²	Total sample, 603	51	57	On dialysis: 67.6	Known CAD: 29	NR	White: 98
Hocher, 2003 ⁵³	survivors, 172	63.5	49	On dialysis: 100	Known CAD: 33	Stage 5 kidney disease, percent: 100	NR
Hocher, 2003 ⁵³	Total sample, 245	NR	50	On dialysis: 100	Known CAD: 41	Stage 5 kidney disease, percent: 100	NR
Hocher, 2003 ⁵³	Nonsurvivors, 73	70.4	53	On dialysis: 100	Known CAD: 45	Stage 5 kidney disease, percent: 100	NR
Hocher, 2004 ⁵⁴	Women, 122	NR	NR	NR	NR	Stage 5 kidney disease, percent: 100	NR
Hocher, 2004 ⁵⁴	Men, 123	NR	NR	NR	NR	Stage 5 kidney disease, percent: 100	NR
Hocher, 2004 ⁵⁴	Total sample, 245	63.5	50	On dialysis: 100	Known CAD: 64	Stage 5 kidney disease, percent: 100	NR
Hocher, 2008 ⁵⁵	Men, 112	63	100	On dialysis: 100	Known CAD: 32	Stage 5 kidney disease, percent: 100	NR

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Hocher, 2008 ⁵⁵	Women, 118	68	0	On dialysis: 100	Known CAD: 23	Stage 5 kidney disease, percent: 100	NR
Hocher, 2008 ⁵⁵	Total sample, 230	65.6	49	On dialysis: 100	Known CAD: 27	Stage 5 kidney disease, percent: 100	NR
Hojs, 2005 ⁵⁶	Total sample, 90	56.2	61	On dialysis: 100	NR	Stage 5 kidney disease, percent: 100	NR
Holden, 2012 ⁵⁷	Total sample, 103	62.9	69	On dialysis: 100	Known CAD: 47.1	NR	NR
Hung, 2004 ⁵⁸	Hypotension Prone, 29	61.4	34	On dialysis: 100	NR	Stage 5 kidney disease, percent: 100	NR
Hung, 2004 ⁵⁸	Hypotension Resistant, 41	58.3	41	On dialysis: 100	NR	Stage 5 kidney disease, percent: 100	NR
Hussein, 2004 ⁵⁹	Total sample, 93	50	49	On dialysis: 100	Known CAD: 20	Stage 5 kidney disease, percent: 100	NR
Ie, 2004 ⁶⁰	Total sample, 49	57	NR	On dialysis: 100	NR	NR	NR
Iliou, 2003 ⁶¹	cTnT>0.15, 18	63.1	63	On dialysis: 100	Known CAD: 21.7	Stage 5 kidney disease, percent: 100	NR

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Iliou, 2003 ⁶¹	cTnT≤0.1 ng/ml, 210	58.5	58.2	On dialysis: 100	Known CAD: 20	Stage 5 kidney disease, percent: 100	NR
Iliou, 2003 ⁶¹	cTnT≤0.15, 240	59.6	57.1	On dialysis: 100	Known CAD: 23.1	Stage 5 kidney disease, percent: 100	NR
Iliou, 2003 ⁶¹	Total sample, 258	60.2	58.1	On dialysis: 100	Known CAD: 22.9	Stage 5 kidney disease, percent: 100	White: 72, African American: 15.5, Other race/ethnicity: 12.5
Iliou, 2003 ⁶¹	cTnT>0.1 ng/ml, 48	67.5	56.2	On dialysis: 100	Known CAD: 35.4	Stage 5 kidney disease, percent: 100	NR
Ilva, 2008 ⁶²	Total sample, 364	74.8	14	NR	Known CAD: 13	NR	NR
Ishii, 2001 ⁶³	Total sample, 100	54	61	On dialysis: 100	NR	Stage 5 kidney disease, percent: 100	NR
Jensen, 2012 ⁶⁴	hsTnT < or = 14 ng/L, 128	67	54	NR	NR	NR	NR
Jensen, 2012 ⁶⁴	hsTnT > 14 ng/L, 65	74	62	NR	NR	NR	NR
Kalaji, 2012 ⁶⁵	Total sample, 145	Median: 45	55.2	On dialysis: 100	Known CAD: 9	Stage 5 kidney disease, percent: 100	NR

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Kang, 2009 ⁶⁶	elevated cTnI levels, 50	67	44	On dialysis: 100	Known CAD: 22	Stage 5 kidney disease, percent: 100	NR
Kang, 2009 ⁶⁶	lower cTnI levels, 71	66	44	On dialysis: 100	Known CAD: 15	Stage 5 kidney disease, percent: 100	NR
Kanwar, 2006 ⁶⁷	Total sample, 173	62	53	On dialysis: 100	NR	NR	White: 57
Katerinis, 2008 ⁶⁸	elevated cTnI, 4	70.2	100	On dialysis: 100	Known CAD: 100	Stage 5 kidney disease, percent: 100	NR
Katerinis, 2008 ⁶⁸	normal cTnI, 46	62.2	61	On dialysis: 100	Known CAD: 35	Stage 5 kidney disease, percent: 100	NR
Kertai, 2004 ⁶⁹	cTNT \geq 0.1ng/ml, 339	NR	79	NR	Known CAD: 19	NR	NR
Kertai, 2004 ⁶⁹	cTNT <0.1ng/ml, 54	NR	83	NR	Known CAD: 43	NR	NR
Khan, 2001 ⁷⁰	cTnI <0.03 ng/mL, 102	59	62	On dialysis: 100	Known CAD: 13	Stage 5 kidney disease, percent: 100	NR
Khan, 2001 ⁷⁰	cTnI >0.03 ng/mL, 24	62.2	58	On dialysis: 100	Known CAD: 3	Stage 5 kidney disease, percent: 100	NR

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Kontos, 2005 ⁷¹	Normal renal function, >60 mL/min,	54	NR	NR	NR	NR	NR
Kontos, 2005 ⁷¹	Severe renal failure, <30 mL/min, 329	65	47	NR	NR	NR	NR
Kontos, 2005 ⁷¹	Total sample, 3774	58	50	NR	NR	NR	NR
Kontos, 2005 ⁷¹	Moderate renal failure, 30-59 mL/min, 755	72	45	NR	NR	NR	NR
Kontos, 2005 ⁷²	CrCl >60, 2259	53	52	NR	NR	NR	NR
Kontos, 2005 ⁷²	CrCl <30, 233	64	45	NR	NR	NR	NR
Kontos, 2005 ⁷²	CrCl 30-59, 582	70	42	NR	NR	NR	NR
Kontos, 2008 ⁷³	Total sample, 4343	58	51	NR	NR	NR	White: 36, African American: 64
Kostrubiec, 2010 ⁷⁴	Normal cTnl or cTnT, 122	NR	NR	NR	NR	NR	NR

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Kostrubiec, 2010 ⁷⁴	Total sample, 212	64	38	NR	Known CAD: 22	NR	NR
Kostrubiec, 2010 ⁷⁴	Elevated cTnl or cTnT, 90	NR	NR	NR	NR	NR	NR
Lamb, 2007 ⁷⁵	Total sample, 222	67	65	On dialysis: 0	Known CAD: 42NR	Stage 3 kidney disease, percent: 25, Stage 4 kidney disease, percent: 32, Stage 5 kidney disease, percent: 43	White: 100
Lang, 2001 ⁷⁶	Total sample, 100	56.6	62	On dialysis: 100	NR	Stage 5 kidney disease, percent: 100	NR
Le Goff, 2007 ⁷⁷	cTnT >0.1 ug/L, 22	NR	NR	NR	NR	NR	NR
Le Goff, 2007 ⁷⁷	cTnT 0.031-0.1 ug/L, 32	NR	NR	NR	NR	NR	NR
Le Goff, 2007 ⁷⁷	cTnT <0.03 ug/L, 7	NR	NR	NR	NR	NR	NR
Le Goff, 2007 ⁷⁷	Total sample, 86	60	53	On dialysis: 100	Known CAD: 53	Stage 5 kidney disease, percent: 100	NR

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Lowbeer, 2002 ⁷⁸	survivors, 11	52	36	On dialysis: 100	Known CAD: 0	Stage 5 kidney disease, percent: 100	NR
Lowbeer, 2002 ⁷⁸	non-survivors, 15	64	60	On dialysis: 100	Known CAD: 33	Stage 5 kidney disease, percent: 100	NR
Lowbeer, 2002 ⁷⁸	Total sample, 26	58	50	On dialysis: 100	Known CAD: 19	Stage 5 kidney disease, percent: 100	NR
Lowbeer, 2003 ⁷⁹	Total sample, 115	52	62	On dialysis: 100	Known CAD: 29	Stage 5 kidney disease, percent: 100	NR
Lowbeer, 2003 ⁷⁹	HD, 49	NR	NR	NR	NR	NR	NR
Lowbeer, 2003 ⁷⁹	PD, 64	NR	NR	NR	NR	NR	NR
Mallamaci, 2002 ⁸⁰	cTnT <0.048 ug/L,	NR	NR	NR	NR	NR	NR
Mallamaci, 2002 ⁸⁰	cTnT >0.098 ug/L,	NR	NR	NR	NR	NR	NR
Mallamaci, 2002 ⁸⁰	cTnT 0.049-0.098 ug/L,	NR	NR	NR	NR	NR	NR

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Mallamaci, 2002 ⁸⁰	Total sample, 199	58.8	56	On dialysis: 100	NR	NR	NR
Martin, 1998 ⁸¹	Total sample, 56	62	50	NR	NR	NR	White: 55, African American: 43, Other race/ethnicity: 2
McCullough, 2002 ⁸²	Quartile 1: >99.4 mL/min/72kg, 189	47.9	37.6	On dialysis: 0	Known CAD: 22.2	NR	White: 16.4, African American: 78.3, Other race/ethnicity: 5.3
McCullough, 2002 ⁸²	Quartile 2: 99.3-72.7 mL/min/72kg, 189	60.9	48.7	On dialysis: 0	Known CAD: 27	NR	White: 20.1, African American: 76.2, Other race/ethnicity: 3.7
McCullough, 2002 ⁸²	Quartile 4: <47.0 mL/min/72kg, 189	75	45	On dialysis: 0	Known CAD: 36	NR	White: 12.7, African American: 85.7, Other race/ethnicity: 1.6
McCullough, 2002 ⁸²	Quartile 3: 72.8-47.0 mL/min/72kg, 190	70.9	48.9	On dialysis: 0	Known CAD: 35.3	NR	White: 14.7, African American: 83.7, Other race/ethnicity: 1.6
McCullough, 2002 ⁸²	End stage renal disease on dialysis, 51	65.2	54.9	On dialysis: 100	Known CAD: 49	NR	White: 11.8, African American: 86.3, Other race/ethnicity: 2

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
McGill, 2010 ⁸³	Total sample, 143	NR	NR	On dialysis: 100	NR	NR	NR
McMurray, 2011 ⁸⁴	>0.028 ng/mL, 217	65	67	NR	NR	NR	White: 64, African American: 28, Other race/ethnicity: 8
McMurray, 2011 ⁸⁴	<.028 ng/mL, 230	69	55	NR	NR	NR	White: 62, African American: 23, Other race/ethnicity: 15
McMurray, 2011 ⁸⁴	Undetectable TnT, 548	68	30	NR	NR	NR	White: 70, African American: 20, Other race/ethnicity: 10
Melloni, 2008 ⁸⁵	>3 x ULN cTn ratio, 20843	Median: 70	59.2	NR	NR	NR	White: 81.9
Melloni, 2008 ⁸⁵	Total sample, 31586	Median: 70	58.6	NR	NR	NR	White: 80.4
Melloni, 2008 ⁸⁵	1-3 x ULN cTn ratio, 5214	Median: 71	55.3	NR	NR	NR	White: 77.4
Melloni, 2008 ⁸⁵	<1 x ULN cTn ratio, 5529	Median: 66	59.8	NR	NR	NR	White: 77.2
Mockel, 1999 ⁸⁶	ESRD, 20	51.5	50	On dialysis: 100	NR	NR	NR

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Mockel, 1999 ⁸⁶	pre-ESRD, 20	63.5	60	On dialysis: 0	NR	NR	NR
Morton, 1998 ⁸⁷	Total sample, 112	61.1	62	On dialysis: 100	Known CAD: 47	Stage 5 kidney disease, percent: 100	NR
Musso, 1999 ⁸⁸	Controls, 117	50	50	On dialysis: 0	NR	NR	NR
Musso, 1999 ⁸⁸	CRF - medical, 12	65	58	On dialysis: 0	NR	NR	NR
Musso, 1999 ⁸⁸	CRF - transplant, 17	44	100	On dialysis: 0	NR	NR	NR
Musso, 1999 ⁸⁸	CRF - dialysis, 20	51	50	On dialysis: 100	NR	NR	NR
Noeller, 2003 ⁸⁹	Age >=65, 301	NR	57	NR	Known CAD: 24	NR	White: 65
Noeller, 2003 ⁸⁹	Age <65, 321	NR	61	NR	Known CAD: 7	NR	White: 51
Ooi, 1999 ⁹⁰	cTnT <0.1, 111	Median: 61	53	On dialysis: 100	Known CAD: 28	Stage 5 kidney disease, percent: 100	NR
Ooi, 1999 ⁹⁰	cTnT >0.2, 24	Median: 62.8	79	On dialysis: 100	Known CAD: 50	Stage 5 kidney disease, percent: 100	NR

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Ooi, 1999 ⁹⁰	cTnT 0.1-0.2, 37	Median: 64.5	70	On dialysis: 100	Known CAD: 30	Stage 5 kidney disease, percent: 100	NR
Ooi, 2001 ⁹¹	cTnT >0.200, 26	NR	77	On dialysis: 100	Known CAD: 31	Stage 5 kidney disease, percent: 100	NR
Ooi, 2001 ⁹¹	cTnT <0.010 ug/L, 26	NR	50	On dialysis: 100	Known CAD: 8	Stage 5 kidney disease, percent: 100	NR
Ooi, 2001 ⁹¹	cTnT 0.100-0.199, 36	NR	67	On dialysis: 100	Known CAD: 39	Stage 5 kidney disease, percent: 100	NR
Ooi, 2001 ⁹¹	cTnT 0.05-0.099, 62	NR	65	On dialysis: 100	Known CAD: 37	Stage 5 kidney disease, percent: 100	NR
Ooi, 2001 ⁹¹	cTnT 0.010-0.049, 94	NR	52	On dialysis: 100	Known CAD: 35	Stage 5 kidney disease, percent: 100	NR
Orea-Tejeda, 2010 ⁹²	cTnT >0.02 ng/mL and eGFR<60, 21	63.19	47.6	NR	NR	NR	NR
Peetz, 2003 ⁹³	women, 41	65	0	On dialysis: 100	Known CAD: 31.7	Stage 5 kidney disease, percent: 100	NR
Peetz, 2003 ⁹³	men, 63	63	100	On dialysis: 100	Known CAD: 39.1	Stage 5 kidney disease, percent: 100	NR
Petrovic, 2009 ⁹⁴	Total sample, 115	53.3	62	On dialysis: 100	NR	NR	NR
Porter, 1998 ⁹⁵	Total sample, 30	66.1	40	NR	Known CAD: 100	NR	NR

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Porter, 2000 ⁹⁶	those available for analysis and the end of the f/u period, 27	48.1	41	On dialysis: 100	Known CAD: 15	Stage 5 kidney disease, percent: 100	NR
Roberts, 2004 ⁹⁷	Negative cTnl, 79	59.2	64.6	On dialysis: 100	Known CAD: 25.3	NR	NR
Roberts, 2004 ⁹⁷	Detectable cTnl, 9	58.6	55.6	On dialysis: 100	Known CAD: 33.3	NR	NR
Roberts, 2009 ⁹⁸	1-4/5 measurements cTnT >0.04 ug/L, 20	66.6	50	NR	NR	NR	NR
Roberts, 2009 ⁹⁸	0/5 measurements cTnT >0.04 ug/L, 28	56.2	50	NR	NR	NR	NR
Roberts, 2009 ⁹⁸	5/5 measurements cTnT >0.04 ug/L, 33	64.6	64	NR	NR	NR	NR
Roppolo, 1999 ⁹⁹	Total sample, 49	58.5	NR	NR	NR	NR	NR
Sahinarslan, 2008 ¹⁰⁰	cTnT >0.1 ug/L, 17	NR	NR	NR	NR	NR	NR

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Sahinarslan, 2008 ¹⁰⁰	cTnT <0.1 ug/L, 61	NR	NR	NR	NR	NR	NR
Sahinarslan, 2008 ¹⁰⁰	Total sample, 78	53.2	69	On dialysis: 100	NR	NR	NR
Satyan, 2007 ¹⁰¹	cTnT 0.056-0.106 ng/mL, 37	62.4	59	On dialysis: 100	Known CAD: 54	NR	White: 8, African American: 89, Other race/ethnicity: 3
Satyan, 2007 ¹⁰¹	cTnT 0.106-0.569 ng/mL, 37	53.6	62	On dialysis: 100	Known CAD: 54	NR	White: 8, African American: 92, Other race/ethnicity: 0
Satyan, 2007 ¹⁰¹	cTnT 0.01-0.022 ng/mL, 38	47.9	58	On dialysis: 100	Known CAD: 29	NR	White: 5, African American: 95, Other race/ethnicity: 0
Satyan, 2007 ¹⁰¹	cTnT 0.022-0.056 ng/mL, 38	59.5	71	On dialysis: 100	Known CAD: 53	NR	White: 13, African American: 84, Other race/ethnicity: 3
Scheven, 2012 ¹⁰²	hs cTnT >0.01 ug/L, 544	64.2	78.9	NR	NR	NR	NR
Scheven, 2012 ¹⁰²	hs cTnT <0.01 ug/L, 7577	49.3	47.7	NR	NR	NR	NR

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Scott, 2003 ¹⁰³	71,	68.7	NR	On dialysis: 100	NR	Stage 5 kidney disease, percent: 100	NR
Sharma, 2005 ¹⁰⁴	Total sample, 118	52	64	On dialysis: 54	Known CAD: 30	Stage 5 kidney disease, percent: 100	NR
Sharma, 2006 ¹⁰⁵	Total sample, 114	52	67	On dialysis: 58	Known CAD: 30	NR	White: 45, African American: 29, Other race/ethnicity: 1
Sharma, 2006 ¹⁰⁵	cTnT >0.06 ng/mL, 51	NR	NR	NR	NR	NR	NR
Sharma, 2006 ¹⁰⁵	cTnT <0.06 ng/mL, 62	NR	NR	NR	NR	NR	NR
Sharma, 2006 ¹⁰⁶	Total sample, 126	52	63	On dialysis: 55	Known CAD: 38	Stage 5 kidney disease, percent: 100	White: 50, African American: 25, Other race/ethnicity: 25
Sharma, 2006 ¹⁰⁶	cTnT>0.1, 38	54	NR	NR	Known CAD: 32	Stage 5 kidney disease, percent: 100	NR
Sharma, 2006 ¹⁰⁶	cTnT>0.04 ug/L, 52	54	NR	NR	Known CAD: 22	Stage 5 kidney disease, percent: 100	NR
Sharma, 2006 ¹⁰⁶	<0.04 ug/L, 74	51	NR	NR	Known CAD: 22	Stage 5 kidney disease, percent: 100	NR

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Sharma, 2006 ¹⁰⁶	cTnT<0.1, 88	51	NR	NR	Known CAD: 27	Stage 5 kidney disease, percent: 100	NR
Shroff, 2012 ¹⁰⁷	cTnI<0.04 ng/mL, 281	48.3	60	On dialysis: 58	Known CAD: 20	NR	White: 85, African American: 6
Shroff, 2012 ¹⁰⁷	cTnI>0.04 ng/mL, 95	52.2	55	On dialysis: 65	Known CAD: 32	NR	White: 88, African American: 4
Sommerer, 2007 ¹⁰⁸	Total sample, 134	Median: 66	59.7	On dialysis: 100	Known CAD: 20.9	Stage 5 kidney disease, percent: 100	NR
Stolar, 1999 ¹⁰⁹	Total sample, 94	62.9	59	On dialysis: 100	NR	Stage 5 kidney disease, percent: 100	NR
Sukonthasarn, 2007 ¹¹⁰	AMI group, 23	71.7	34.8	NR	Known CAD: 0	Stage 3 kidney disease, percent: 21.7, Stage 4 kidney disease, percent: 47.8, Stage 5 kidney disease, percent: 30.4	African American: 100
Sukonthasarn, 2007 ¹¹⁰	Control group, 23	65.7	34.8	NR	Known CAD: 8.7	Stage 3 kidney disease, percent: 34.8, Stage 4 kidney disease, percent: 34.8, Stage 5 kidney disease, percent: 30.4	African American: 100

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Svensson, 2009 ¹¹¹	Total sample, 206	67	65	On dialysis: 100	Known CAD: 100	Stage 5 kidney disease, percent: 100	NR
Trape, 2008 ¹¹²	Total sample, 52	Median: 74	48	On dialysis: 100	Known CAD: 46	NR	NR
Troyanov, 2005 ¹¹³	Total sample, 101	66	57	On dialysis: 100	Known CAD: 37	NR	NR
Van Lente, 1999 ¹¹⁴	Creatinine >20mg/L, 51	70.1	59	On dialysis: 9	NR	NR	NR
Vichairuangthum, 2006 ¹¹⁵	cTnT >0.4 ng/mL, 14	63.21	36	On dialysis: 100	NR	NR	NR
Vichairuangthum, 2006 ¹¹⁵	cTnT <0.08 ng/mL, 16	59.6	50	On dialysis: 100	NR	NR	NR
Vichairuangthum, 2006 ¹¹⁵	cTnT >0.08 ng/mL, 47	54.6	47	On dialysis: 100	NR	NR	NR

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Vichairuangthum, 2006 ¹¹⁵	cTnT <0.4 ng/mL, 49	53.84	51	On dialysis: 100	NR	NR	NR
Wang, 2006 ¹¹⁶	Total sample, 222	56	50	On dialysis: 100	Known CAD: 23.4	Stage 5 kidney disease, percent: 100	NR
Wang, 2007 ¹¹⁷	cTnT <0.01 ug/L, 77	52.1	40.3	On dialysis: 100	Known CAD: 6.5	NR	NR
Wang, 2007 ¹¹⁷	cTnT 0.01-0.099 ug/L, 78	57	50	On dialysis: 100	Known CAD: 23.1	NR	NR
Wang, 2007 ¹¹⁷	cTnT >0.099 ug/L, 83	57.9	62.7	On dialysis: 100	Known CAD: 30.1	NR	NR
Wang, 2010 ¹¹⁸	Total sample, 230	56	50.9	On dialysis: 100	Known CAD: 22.6	Stage 5 kidney disease, percent: 100	NR
Wang, 2010 ¹¹⁹	Total sample, 230	56	51	On dialysis: 100	Known CAD: 23	NR	NR
Wang, 2010 ¹¹⁹	cTnT 0.01-0.099 ug/L, 70	NR	NR	NR	NR	NR	NR

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Wang, 2010 ¹¹⁹	cTnT >=0.1 ug/L, 79	NR	NR	NR	NR	NR	NR
Wang, 2010 ¹¹⁹	cTnT <0.01 ug/L, 81	NR	NR	NR	NR	NR	NR
Wayand, 2000 ¹²⁰	Cardiac Symptoms, 28	67.3	NR	On dialysis: 100	NR	NR	NR
Wayand, 2000 ¹²⁰	No Cardiac Symptoms, 31	51	NR	On dialysis: 100	NR	NR	NR
Wood, 2003 ¹²¹	cTnT >0.1ng/mL, 25	59	68	On dialysis: 0	Known CAD: 36	Stage 5 kidney disease, percent: 100	NR
Wood, 2003 ¹²¹	cTnT <0.1ng/mL, 71	50.1	66.2	On dialysis: 0	Known CAD: 19.7	Stage 5 kidney disease, percent: 100	NR
Wood, 2003 ¹²¹	Total sample, 96	52.4	66.7	On dialysis: 0	Known CAD: 24	Stage 5 kidney disease, percent: 100	NR
Yakupoglu, 2002 ¹²²	cTnl <2.3 ng/mL, 30	NR	NR	NR	NR	Stage 5 kidney disease, percent: 100	NR
Yakupoglu, 2002 ¹²²	Total sample, 38	55.9	42	On dialysis: 100	NR	Stage 5 kidney disease, percent: 100	NR

Author, year	Group, N	Mean Age	Males, percent	Dialysis status, percent	Known CAD, percent	CKD stage, percent	Race/ethnicity, percent
Yakupoglu, 2002 ¹²²	cTnl >2.3 ng/mL, 8	NR	NR	NR	NR	Stage 5 kidney disease, percent: 100	NR

References

1. Abaci A, Ekici E, Oguzhan A, et al. Cardiac troponins T and I in patients with end-stage renal disease: the relation with left ventricular mass and their prognostic value. *Clin Cardiol.* 2004 Dec;27(12):704-9. PMID: 15628116.
2. Abbas NA, John RI, Webb MC, et al. Cardiac troponins and renal function in nondialysis patients with chronic kidney disease. *Clin Chem.* 2005 Nov;51(11):2059-66. PMID: 16166165.
3. Acharji S, Baber U, Mehran R, et al. Prognostic significance of elevated baseline troponin in patients with acute coronary syndromes and chronic kidney disease treated with different antithrombotic regimens: a substudy from the ACUITY trial. *Circ Cardiovasc Interv.* 2012 Apr;5(2):157-65. PMID: 22354934.
4. Alcalai R, Planer D, Culhaoglu A, et al. Acute coronary syndrome vs nonspecific troponin elevation: clinical predictors and survival analysis. *Arch Intern Med.* 2007 Feb 12;167(3):276-81. PMID: 17296884.
5. Apple FS, Sharkey SW, Hoefft P, et al. Prognostic value of serum cardiac troponin I and T in chronic dialysis patients: a 1-year outcomes analysis. *Am J Kidney Dis.* 1997 Mar;29(3):399-403. PMID: 9041216.
6. Apple FS, Christenson RH, Valdes R, Jr., et al. Simultaneous rapid measurement of whole blood myoglobin, creatine kinase MB, and cardiac troponin I by the triage cardiac panel for detection of myocardial infarction. *Clin Chem.* 1999 Feb;45(2):199-205. PMID: 9931041.
7. Apple FS, Murakami MM, Pearce LA, et al. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. *Circulation.* 2002 Dec 3;106(23):2941-5. PMID: 12460876.
8. Apple FS, Murakami MM, Pearce LA, et al. Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. *Clin Chem.* 2004 Dec;50(12):2279-85. PMID: 15364888.
9. Apple FS, Pearce LA, Doyle PJ, et al. Cardiac troponin risk stratification based on 99th percentile reference cutoffs in patients with ischemic symptoms suggestive of acute coronary syndrome: influence of estimated glomerular filtration rates. *Am J Clin Pathol.* 2007 Apr;127(4):598-603. PMID: 17369136.

10. Artunc F, Mueller C, Breidhardt T, et al. Sensitive troponins--which suits better for hemodialysis patients? Associated factors and prediction of mortality. *PLoS One*. 2012;7(10):e47610. PMID: 23077650.
11. Aviles RJ, Askari AT, Lindahl B, et al. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. *N Engl J Med*. 2002 Jun 27;346(26):2047-52. PMID: 12087140.
12. Bagheri N, Taziki O, Falaknazi K. C- Reactive protein, cardiac troponin T and low albumin are predictors of mortality in hemodialysis patients. *Saudi J Kidney Dis Transpl*. 2009 Sep;20(5):789-93. PMID: 19736474.
13. Barthelemy O, Cayla G, Silvain J, et al. Optimal time for catheterization in NSTEMI-ACS patients with impaired renal function: Insights from the ABOARD Study. *Int J Cardiol*. 2012 Jul 12; PMID: 22795712.
14. Beciani M, Tedesco A, Violante A, et al. Cardiac troponin I (2nd generation assay) in chronic haemodialysis patients: prevalence and prognostic value. *Nephrol Dial Transplant*. 2003 May;18(5):942-6. PMID: 12686669.
15. Bhagavan NV, Goldstein AP, Honda SA, et al. Role of cardiac troponin I in the evaluation of myocardial injury. *J Clin Lab Anal*. 1998;12(5):276-9. PMID: 9773957.
16. Boulier A, Jaussent I, Terrier N, et al. Measurement of circulating troponin Ic enhances the prognostic value of C-reactive protein in haemodialysis patients. *Nephrol Dial Transplant*. 2004 Sep;19(9):2313-8. PMID: 15252159.
17. Bozbas H, Korkmaz ME, Atar I, et al. Serum levels of cardiac enzymes before and after renal transplantation. *Clin Cardiol*. 2004 Oct;27(10):559-62. PMID: 15553307.
18. Brunet P, Oddeze C, Paganelli F, et al. Cardiac troponins I and T in hemodialysis patients without acute coronary syndrome. *Int J Cardiol*. 2008 Sep 26;129(2):205-9. PMID: 17662483.
19. Bueti J, Krahn J, Karpinski M, et al. Troponin I testing in dialysis patients presenting to the emergency room: does troponin I predict the 30-day outcome? *Nephron Clin Pract*. 2006;103(4):c129-36. PMID: 16636580.
20. Chew HC. Cardiac troponin T in acute coronary syndrome with renal insufficiency. *Asian Cardiovasc Thorac Ann*. 2008 Aug;16(4):284-7. PMID: 18670019.
21. Choy JB, Armstrong PW, Ulan RA, et al. Do cardiac troponins provide prognostic insight in hemodialysis patients? *Can J Cardiol*. 2003 Jul;19(8):907-11. PMID: 12876611.
22. Chrysochou C, Manzoor S, Wright J, et al. Role of renal function and cardiac biomarkers (NT-proBNP and Troponin) in determining mortality and cardiac outcome in atheromatous renovascular disease. *Kidney Blood Press Res*. 2009;32(5):373-9. PMID: 19887825.
23. Claes K, Bammens B, Evenepoel P, et al. Troponin I is a predictor of acute cardiac events in the immediate postoperative renal transplant period. *Transplantation*. 2010 Feb 15;89(3):341-6. PMID: 20145526.
24. Codognotto M, Piccoli A, Zaninotto M, et al. Effect of a dialysis session on the prognostic values of NT-proBNP, troponins, endothelial damage and inflammation biomarkers. *J Nephrol*. 2010 Jul-Aug;23(4):465-71. PMID: 20540041.
25. Connolly GM, Cunningham R, McNamee PT, et al. Troponin T is an independent predictor of mortality in renal transplant recipients. *Nephrol Dial Transplant*. 2008 Mar;23(3):1019-25. PMID: 18065785.

26. Conway B, McLaughlin M, Sharpe P, et al. Use of cardiac troponin T in diagnosis and prognosis of cardiac events in patients on chronic haemodialysis. *Nephrol Dial Transplant*. 2005 Dec;20(12):2759-64. PMID: 16188899.
27. Deegan PB, Lafferty ME, Blumsohn A, et al. Prognostic value of troponin T in hemodialysis patients is independent of comorbidity. *Kidney Int*. 2001 Dec;60(6):2399-405. PMID: 11737616.
28. deFilippi C, Wasserman S, Rosanio S, et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. *JAMA*. 2003 Jul 16;290(3):353-9. PMID: 12865376.
29. deFilippi C, Seliger SL, Kelley W, et al. Interpreting cardiac troponin results from high-sensitivity assays in chronic kidney disease without acute coronary syndrome. *Clin Chem*. 2012 Sep;58(9):1342-51. PMID: 22791885.
30. Dierkes J, Domrose U, Westphal S, et al. Cardiac troponin T predicts mortality in patients with end-stage renal disease. *Circulation*. 2000 Oct 17;102(16):1964-9. PMID: 11034946.
31. Duman D, Tokay S, Toprak A, et al. Elevated cardiac troponin T is associated with increased left ventricular mass index and predicts mortality in continuous ambulatory peritoneal dialysis patients. *Nephrol Dial Transplant*. 2005 May;20(5):962-7. PMID: 15741207.
32. Facila L, Nunez J, Bodi V, et al. [Prognostic value of serum creatinine in non-ST-elevation acute coronary syndrome]. *Rev Esp Cardiol*. 2006 Mar;59(3):209-16. PMID: 16712744.
33. Farkouh ME, Robbins MJ, Zafar MU, et al. Association between troponin I levels and mortality in stable hemodialysis patients. *Am J Med*. 2003 Feb 15;114(3):224-6. PMID: 12637137.
34. Fehr T, Knoflach A, Ammann P, et al. Differential use of cardiac troponin T versus I in hemodialysis patients. *Clin Nephrol*. 2003 Jan;59(1):35-9. PMID: 12572929.
35. Feringa HH, Bax JJ, de Jonge R, et al. Impact of glomerular filtration rate on minor troponin T elevations for risk assessment in patients undergoing operation for abdominal aortic aneurysm or lower extremity arterial obstruction. *Am J Cardiol*. 2006 Dec 1;98(11):1515-8. PMID: 17126662.
36. Fernandez-Reyes MJ, Mon C, Heras M, et al. Predictive value of troponin T levels for ischemic heart disease and mortality in patients on hemodialysis. *J Nephrol*. 2004 Sep-Oct;17(5):721-7. PMID: 15593041.
37. Flores LM, Hernandez Dominguez JL, Otero A, et al. [Cardiac troponin I determination in patients with chronic renal failure]. *Nefrologia*. 2006;26(1):107-12. PMID: 16649431.
38. Flores-Solis LM, Hernandez-Dominguez JL, Otero-Gonzalez A, et al. Cardiac troponin I and creatine kinase MB isoenzyme in patients with chronic renal failure. *Nefrologia*. 2012;32(6):809-18. PMID: 23169364.
39. Gaiki MR, DeVita MV, Michelis MF, et al. Troponin I as a prognostic marker of cardiac events in asymptomatic hemodialysis patients using a sensitive troponin I assay. *Int Urol Nephrol*. 2012 Dec;44(6):1841-5. PMID: 22311387.
40. Geerse DA, van Berkel M, Vogels S, et al. Moderate elevations of high-sensitivity cardiac troponin I and B-type natriuretic peptide in chronic hemodialysis patients are associated with mortality. *Clin Chem Lab Med*. 2012 Dec 10;50(12):1-8. PMID: 23241607.

41. Goicoechea M, Garca de Vinuesa S, Gomez-Campdera F, et al. Clinical significance of cardiac troponin T levels in chronic kidney disease patients: predictive value for cardiovascular risk. *Am J Kidney Dis.* 2004 May;43(5):846-53. PMID: 15112175.
42. Gruberg L, Fuchs S, Waksman R, et al. Prognostic value of cardiac troponin I elevation after percutaneous coronary intervention in patients with chronic renal insufficiency: a 12-month outcome analysis. *Catheter Cardiovasc Interv.* 2002 Feb;55(2):174-9. PMID: 11835642.
43. Hallen J, Madsen L, Ladefoged S, et al. Incremental value of a combination of cardiac troponin T, N-terminal pro-brain natriuretic peptide and C-reactive protein for prediction of mortality in end-stage renal disease. *Scand J Urol Nephrol.* 2011 Mar;45(2):151-8. PMID: 21091090.
44. Han JH, Lindsell CJ, Ryan RJ, et al. Changes in cardiac troponin T measurements are associated with adverse cardiac events in patients with chronic kidney disease. *Am J Emerg Med.* 2005 Jul;23(4):468-73. PMID: 16032613.
45. Han SH, Choi HY, Kim DK, et al. Elevated cardiac troponin T predicts cardiovascular events in asymptomatic continuous ambulatory peritoneal dialysis patients without a history of cardiovascular disease. *Am J Nephrol.* 2009;29(2):129-35. PMID: 18719346.
46. Hasegawa M, Ishii J, Kitagawa F, et al. Prognostic value of highly sensitive troponin T on cardiac events in patients with chronic kidney disease not on dialysis. *Heart Vessels.* 2012 Aug 23 PMID: 22914904.
47. Havekes B, van Manen JG, Krediet RT, et al. Serum troponin T concentration as a predictor of mortality in hemodialysis and peritoneal dialysis patients. *Am J Kidney Dis.* 2006 May;47(5):823-9. PMID: 16632021.
48. Heesch C, Deu A, Langenbrink L, et al. Analytical and diagnostic performance of troponin assays in patients suspicious for acute coronary syndromes. *Clin Biochem.* 2000 Jul;33(5):359-68. PMID: 11018687.
49. Helleskov Madsen L, Ladefoged S, Hildebrandt P, et al. Comparison of four different cardiac troponin assays in patients with end-stage renal disease on chronic haemodialysis. *Acute Card Care.* 2008;10(3):173-80. PMID: 18608043.
50. Hickman PE, McGill DA, Talaulikar G, et al. Prognostic efficacy of cardiac biomarkers for mortality in dialysis patients. *Intern Med J.* 2009 Dec;39(12):812-8. PMID: 20233242.
51. Hickson LJ, Cosio FG, El-Zoghby ZM, et al. Survival of patients on the kidney transplant wait list: relationship to cardiac troponin T. *Am J Transplant.* 2008 Nov;8(11):2352-9. PMID: 18785956.
52. Hickson LT, El-Zoghby ZM, Lorenz EC, et al. Patient survival after kidney transplantation: relationship to pretransplant cardiac troponin T levels. *Am J Transplant.* 2009 Jun;9(6):1354-61. PMID: 19459818.
53. Hocher B, Ziebig R, Altermann C, et al. Different impact of biomarkers as mortality predictors among diabetic and nondiabetic patients undergoing hemodialysis. *J Am Soc Nephrol.* 2003 Sep;14(9):2329-37. PMID: 12937310.
54. Hocher B, Ziebig R, Krause R, et al. Relaxin is an independent risk factor predicting death in male patients with end-stage kidney disease. *Circulation.* 2004 May 18;109(19):2266-8. PMID: 15136497.
55. Hocher B, Kalk P, Godes M, et al. Gender-dependent impact of risk factors for cardiovascular and non-cardiovascular mortality in end-stage renal disease patients on haemodialysis. *Kidney Blood Press Res.* 2008;31(5):360-6. PMID: 19023219.

56. Hojs R, Ekart R, Hojs Fabjan T, et al. Cardiac troponin T (cTnT) in hemodialysis patients with asymptomatic and symptomatic atherosclerosis. *Arch Med Res*. 2005 Jul-Aug;36(4):367-71. PMID: 15950076.
57. Holden RM, Beseau D, Booth SL, et al. FGF-23 is associated with cardiac troponin T and mortality in hemodialysis patients. *Hemodial Int*. 2012 Jan;16(1):53-8. PMID: 22099949.
58. Hung SY, Hung YM, Fang HC, et al. Cardiac troponin I and creatine kinase isoenzyme MB in patients with intradialytic hypotension. *Blood Purif*. 2004;22(4):338-43. PMID: 15218282.
59. Hussein M, Mooij J, Roujouleh H, et al. Cardiac troponin-I and its prognostic significance in a dialysis population. *Hemodial Int*. 2004 Oct 1;8(4):332-7. PMID: 19379438.
60. Ie EH, Klootwijk PJ, Weimar W, et al. Significance of acute versus chronic troponin T elevation in dialysis patients. *Nephron Clin Pract*. 2004;98(3):c87-92. PMID: 15528943.
61. Iliou MC, Fumeron C, Benoit MO, et al. Prognostic value of cardiac markers in ESRD: Chronic Hemodialysis and New Cardiac Markers Evaluation (CHANCE) study. *Am J Kidney Dis*. 2003 Sep;42(3):513-23. PMID: 12955679.
62. Ilva T, Lassus J, Siirila-Waris K, et al. Clinical significance of cardiac troponins I and T in acute heart failure. *Eur J Heart Fail*. 2008;10(8):772-9.
63. Ishii J, Nomura M, Okuma T, et al. Risk stratification using serum concentrations of cardiac troponin T in patients with end-stage renal disease on chronic maintenance dialysis. *Clin Chim Acta*. 2001 Oct;312(1-2):69-79. PMID: 11580911.
64. Jensen JK, Ueland T, Aukrust P, et al. Highly sensitive troponin T in patients with acute ischemic stroke. *Eur Neurol*. 2012;68(5):287-93. PMID: 23051820.
65. Kalaji FR, Albitar S. Predictive value of cardiac troponin T and I in hemodialysis patients. *Saudi J Kidney Dis Transpl*. 2012 Sep;23(5):939-45. PMID: 22982904.
66. Kang EW, Na HJ, Hong SM, et al. Prognostic value of elevated cardiac troponin I in ESRD patients with sepsis. *Nephrol Dial Transplant*. 2009 May;24(5):1568-73. PMID: 19145004.
67. Kanwar M, Hashem M, Rosman H, et al. Usefulness of clinical evaluation, troponins, and C-reactive protein in predicting mortality among stable hemodialysis patients. *Am J Cardiol*. 2006 Nov 1;98(9):1283-7. PMID: 17056347.
68. Katerinis I, Nguyen QV, Magnin JL, et al. Cardiac findings in asymptomatic chronic hemodialysis patients with persistently elevated cardiac troponin I levels. *Ren Fail*. 2008;30(4):357-62. PMID: 18569907.
69. Kertai MD, Boersma E, Klein J, et al. Long-term prognostic value of asymptomatic cardiac troponin T elevations in patients after major vascular surgery. *Eur J Vasc Endovasc Surg*. 2004 Jul;28(1):59-66. PMID: 15177233.
70. Khan IA, Wattanasuwan N, Mehta NJ, et al. Prognostic value of serum cardiac troponin I in ambulatory patients with chronic renal failure undergoing long-term hemodialysis: a two-year outcome analysis. *J Am Coll Cardiol*. 2001 Oct;38(4):991-8. PMID: 11583870.
71. Kontos MC, Garg R, Anderson FP, et al. Outcomes in patients admitted for chest pain with renal failure and troponin I elevations. *Am Heart J*. 2005 Oct;150(4):674-80. PMID: 16209963.

72. Kontos MC, Garg R, Anderson FP, et al. Predictive power of ejection fraction and renal failure in patients admitted for chest pain without ST elevation in the troponin era. *Am Heart J.* 2005 Oct;150(4):666-73. PMID: 16209962.
73. Kontos MC, Jamal SM, Ornato JP, et al. Comparison of the modification of diet in renal disease and the Cockcroft-Gault equations for predicting mortality in patients admitted for exclusion of myocardial ischemia. *Am J Cardiol.* 2008 Jul 15;102(2):140-5. PMID: 18602510.
74. Kostrubiec M, Labyk A, Pedowska-Wloszek J, et al. Assessment of renal dysfunction improves troponin-based short-term prognosis in patients with acute symptomatic pulmonary embolism. *J Thromb Haemost.* 2010 Apr;8(4):651-8. PMID: 20088923.
75. Lamb EJ, Kenny C, Abbas NA, et al. Cardiac troponin I concentration is commonly increased in nondialysis patients with CKD: experience with a sensitive assay. *Am J Kidney Dis.* 2007 Apr;49(4):507-16. PMID: 17386318.
76. Lang K, Schindler S, Forberger C, et al. Cardiac troponins have no prognostic value for acute and chronic cardiac events in asymptomatic patients with end-stage renal failure. *Clin Nephrol.* 2001 Jul;56(1):44-51. PMID: 11499658.
77. Le Goff C, Bovy C, Aldenhoff MC, et al. Three-year prognostic interest of cardiac troponin T (cTnT) and amino-terminal pro-B-natriuretic peptide (NT-proBNP) in hemodialyzed patients. *Immuno-Analyse et Biologie Specialisee.* 2007;22(6):377-83.
78. Lowbeer C, Gutierrez A, Gustafsson SA, et al. Elevated cardiac troponin T in peritoneal dialysis patients is associated with CRP and predicts all-cause mortality and cardiac death. *Nephrol Dial Transplant.* 2002 Dec;17(12):2178-83. PMID: 12454230.
79. Lowbeer C, Stenvinkel P, Pecoits-Filho R, et al. Elevated cardiac troponin T in predialysis patients is associated with inflammation and predicts mortality. *J Intern Med.* 2003 Feb;253(2):153-60. PMID: 12542555.
80. Mallamaci F, Zoccali C, Parlongo S, et al. Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. *Am J Kidney Dis.* 2002 Jul;40(1):68-75. PMID: 12087563.
81. Martin GS, Becker BN, Schulman G. Cardiac troponin-I accurately predicts myocardial injury in renal failure. *Nephrol Dial Transplant.* 1998 Jul;13(7):1709-12. PMID: 9681716.
82. McCullough PA, Nowak RM, Foreback C, et al. Performance of multiple cardiac biomarkers measured in the emergency department in patients with chronic kidney disease and chest pain. *Acad Emerg Med.* 2002 Dec;9(12):1389-96. PMID: 12460842.
83. McGill D, Talaulikar G, Potter JM, et al. Over time, high-sensitivity TnT replaces NT-proBNP as the most powerful predictor of death in patients with dialysis-dependent chronic renal failure. *Clin Chim Acta.* 2010 Jul 4;411(13-14):936-9. PMID: 20298685.
84. McMurray JJ, Uno H, Jarolim P, et al. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). *Am Heart J.* 2011 Oct;162(4):748-55 e3. PMID: 21982669.
85. Melloni C, Alexander KP, Milford-Beland S, et al. Prognostic value of troponins in patients with non-ST-segment elevation acute coronary syndromes and chronic kidney disease. *Clin Cardiol.* 2008 Mar;31(3):125-9. PMID: 18383049.

86. Mockel M, Schindler R, Knorr L, et al. Prognostic value of cardiac troponin T and I elevations in renal disease patients without acute coronary syndromes: a 9-month outcome analysis. *Nephrol Dial Transplant*. 1999 Jun;14(6):1489-95. PMID: 10383013.
87. Morton AR, Collier CP, Ali N, et al. Cardiac troponin I in patients receiving renal replacement therapy. *ASAIO J*. 1998 Sep-Oct;44(5):M433-5. PMID: 9804466.
88. Musso P, Cox I, Vidano E, et al. Cardiac troponin elevations in chronic renal failure: prevalence and clinical significance. *Clin Biochem*. 1999 Mar;32(2):125-30. PMID: 10211629.
89. Noeller TP, Meldon SW, Peacock WF, et al. Troponin T in elders with suspected acute coronary syndromes. *Am J Emerg Med*. 2003 Jul;21(4):293-7. PMID: 12898485.
90. Ooi DS, Veinot JP, Wells GA, et al. Increased mortality in hemodialyzed patients with elevated serum troponin T: a one-year outcome study. *Clin Biochem*. 1999 Nov;32(8):647-52. PMID: 10638948.
91. Ooi DS, Zimmerman D, Graham J, et al. Cardiac troponin T predicts long-term outcomes in hemodialysis patients. *Clin Chem*. 2001 Mar;47(3):412-7. PMID: 11238290.
92. Orea-Tejeda A, Sanchez-Gonzalez LR, Castillo-Martinez L, et al. Prognostic value of cardiac troponin T elevation is independent of renal function and clinical findings in heart failure patients. *Cardiol J*. 2010;17(1):42-8. PMID: 20104456.
93. Peetz D, Schutt S, Sucke B, et al. Prognostic value of troponin T, troponin I, and CK-MBmass in patients with chronic renal failure. *Med Klin (Munich)*. 2003 Apr 15;98(4):188-92. PMID: 12715142.
94. Petrovic D, Stojimirovic BB. Cardiac troponins: outcome predictors in hemodialysis patients. *J Artif Organs*. 2009;12(4):258-63. PMID: 20035399.
95. Porter GA, Norton T, Bennett WB. Troponin T, a predictor of death in chronic haemodialysis patients. *Eur Heart J*. 1998 Nov;19 Suppl N:N34-7. PMID: 9857937.
96. Porter GA, Norton T, Bennett WM. Long term follow up of the utility of troponin T to assess cardiac risk in stable chronic hemodialysis patients. *Clin Lab*. 2000;46(9-10):469-76. PMID: 11034532.
97. Roberts MA, Fernando D, Macmillan N, et al. Single and serial measurements of cardiac troponin I in asymptomatic patients on chronic hemodialysis. *Clin Nephrol*. 2004 Jan;61(1):40-6. PMID: 14964456.
98. Roberts MA, Hare DL, Macmillan N, et al. Serial increased cardiac troponin T predicts mortality in asymptomatic patients treated with chronic haemodialysis. *Ann Clin Biochem*. 2009 Jul;46(Pt 4):291-5. PMID: 19454539.
99. Roppolo LP, Fitzgerald R, Dillow J, et al. A comparison of troponin T and troponin I as predictors of cardiac events in patients undergoing chronic dialysis at a Veteran's Hospital: a pilot study. *J Am Coll Cardiol*. 1999 Aug;34(2):448-54. PMID: 10440158.
100. Sahinarslan A, Guz G, Okyay K, et al. Prognostic value of troponin T and homocysteine in patients with end-stage renal disease. *Turk Kardiyol Dern Ars*. 2008 Sep;36(6):382-7. PMID: 19155641.

101. Satyan S, Light RP, Agarwal R. Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. *Am J Kidney Dis.* 2007 Dec;50(6):1009-19. PMID: 18037101.
102. Scheven L, de Jong PE, Hillege HL, et al. High-sensitive troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate. *Eur Heart J.* 2012 Sep;33(18):2272-81. PMID: 22740385.
103. Scott B, Deman A, Peeters P, et al. Cardiac troponin T and malondialdehyde modified plasma lipids in haemodialysis patients. *Nephrol Dial Transplant.* 2003 Apr;18(4):737-42. PMID: 12637643.
104. Sharma R, Pellerin D, Gaze DC, et al. Dobutamine stress echocardiography and cardiac troponin T for the detection of significant coronary artery disease and predicting outcome in renal transplant candidates. *Eur J Echocardiogr.* 2005 Oct;6(5):327-35. PMID: 15985387.
105. Sharma R, Gaze DC, Pellerin D, et al. Ischemia-modified albumin predicts mortality in ESRD. *Am J Kidney Dis.* 2006 Mar;47(3):493-502. PMID: 16490629.
106. Sharma R, Gaze DC, Pellerin D, et al. Cardiac structural and functional abnormalities in end stage renal disease patients with elevated cardiac troponin T. *Heart.* 2006 Jun;92(6):804-9. PMID: 16216854.
107. Shroff GR, Akkina SK, Miedema MD, et al. Troponin I levels and postoperative myocardial infarction following renal transplantation. *Am J Nephrol.* 2012;35(2):175-80. PMID: 22286592.
108. Sommerer C, Beimler J, Schwenger V, et al. Cardiac biomarkers and survival in haemodialysis patients. *Eur J Clin Invest.* 2007 May;37(5):350-6. PMID: 17461980.
109. Stolar JC, Georges B, Shita A, et al. The predictive value of cardiac troponin T measurements in subjects on regular haemodialysis. *Nephrol Dial Transplant.* 1999 Aug;14(8):1961-7. PMID: 10462278.
110. Sukonthasarn A, Ponglopisit S. Diagnostic level of cardiac troponin T in patients with chronic renal dysfunction, a pilot study. *J Med Assoc Thai.* 2007 Sep;90(9):1749-58. PMID: 17957915.
111. Svensson M, Gorst-Rasmussen A, Schmidt EB, et al. NT-pro-BNP is an independent predictor of mortality in patients with end-stage renal disease. *Clin Nephrol.* 2009;71(4):380-6.
112. Trape J, Perez A, Naval I, et al. Nt-proBNP in haemodialysis patients: a preliminary study. *Scand J Clin Lab Invest.* 2008;68(5):415-20. PMID: 19172698.
113. Troyanov S, Ly QH, Schampaert E, et al. Diagnostic specificity and prognostic value of cardiac troponins in asymptomatic chronic haemodialysis patients: a three year prospective study. *Heart.* 2005 Sep;91(9):1227-8. PMID: 16103574.
114. Van Lente F, McErlean ES, DeLuca SA, et al. Ability of troponins to predict adverse outcomes in patients with renal insufficiency and suspected acute coronary syndromes: a case-matched study. *J Am Coll Cardiol.* 1999 Feb;33(2):471-8. PMID: 9973028.
115. Vichairuangthum K, Leowattana W, Ong-Ajyooth L, et al. The relationship between serum concentration of cardiac troponin I in chronic renal failure patients and cardiovascular events. *J Med Assoc Thai.* 2006 May;89(5):714-20. PMID: 16756060.

116. Wang AY, Lam CW, Yu CM, et al. Troponin T, left ventricular mass, and function are excellent predictors of cardiovascular congestion in peritoneal dialysis. *Kidney Int.* 2006 Aug;70(3):444-52. PMID: 16871255.
117. Wang AY, Lam CW, Wang M, et al. Prognostic value of cardiac troponin T is independent of inflammation, residual renal function, and cardiac hypertrophy and dysfunction in peritoneal dialysis patients. *Clin Chem.* 2007 May;53(5):882-9. PMID: 17395709.
118. Wang AYM, Lam CW, Chan IH, et al. Sudden cardiac death in end-stage renal disease patients: A 5-year prospective analysis. *NDT Plus.* 2010;3:iii291.
119. Wang AY, Lam CW, Chan IH, et al. Sudden cardiac death in end-stage renal disease patients: a 5-year prospective analysis. *Hypertension.* 2010 Aug;56(2):210-6. PMID: 20606110.
120. Wayand D, Baum H, Schatzle G, et al. Cardiac troponin T and I in end-stage renal failure. *Clin Chem.* 2000 Sep;46(9):1345-50. PMID: 10973864.
121. Wood GN, Keevil B, Gupta J, et al. Serum troponin T measurement in patients with chronic renal impairment predicts survival and vascular disease: a 2 year prospective study. *Nephrol Dial Transplant.* 2003 Aug;18(8):1610-5. PMID: 12897102.
122. Yakupoglu U, Ozdemir FN, Arat Z, et al. Can troponin-I predict cardiovascular mortality due to myocardial injury in hemodialysis patients? *Transplant Proc.* 2002 Sep;34(6):2033-4. PMID: 12270303.

Table 3. Key Question 1 Outcomes

Author, year	Data group	Test	ACS Definition	Total Sample	AUC	Values
Alcalai, 2007 ¹	Age <70 and creatinine <1.13 mg/dL, cTnT >1.0 ng/mL subgroup data	Assay: cTnT Manufacturer: NR Type: NR cut off normal: 0.1 mcg/L timing: NR 99th upper ref: NR	Adjudicated by: panel of 2 cardiologists Definition: ESC/ACC			PPV: 89; 95% CI: 79 to 95
Alcalai, 2007 ¹	Age <70 and creatinine <1.13 mg/dL, cTnT 0.1-1.0 ng/mL subgroup data	Assay: cTnT Manufacturer: NR Type: NR cut off normal: 0.1 mcg/L timing: NR 99th upper ref: NR	Adjudicated by: panel of 2 cardiologists Definition: ESC/ACC			PPV: 73; 95% CI: 65 to 80
Alcalai, 2007 ¹	Age <70 and creatinine <1.13 mg/dL, cTnT Any Positive Results subgroup data	Assay: cTnT Manufacturer: NR Type: NR cut off normal: 0.1 mcg/L	Adjudicated by: panel of 2 cardiologists Definition: ESC/ACC			PPV: 78; 95% CI: 72 to 84

Author, year	Data group	Test	ACS Definition	Total Sample	AUC	Values
		timing: NR 99th upper ref: NR				
Alcalai, 2007 ¹	Age <70 and creatinine \geq 1.13 mg/dL, cTnT >1.0 ng/mL subgroup data	Assay: cTnT Manufacturer: NR Type: NR cut off normal: 0.1 mcg/L timing: NR 99th upper ref: NR	Adjudicated by: panel of 2 cardiologists adjudicated: yes Definition: ESC/ACC			PPV: 59; 95% CI: 36 to 79
Alcalai, 2007 ¹	Age <70 and creatinine \geq 1.13 mg/dL, cTnT 0.1-1.0 ng/mL subgroup data	Assay: cTnT Manufacturer: NR Type: NR cut off normal: 0.1 mcg/L timing: NR 99th upper ref: NR	Adjudicated by: panel of 2 cardiologists Definition: ESC/ACC			PPV: 73; 95% CI: 65 to 80
Alcalai, 2007 ¹	Age <70 and creatinine \geq 1.13 mg/dL, cTnT Any positive results subgroup data	Assay: cTnT Manufacturer: NR Type: NR	ICD-9 code: icd9 Adjudicated by: panel of 2 cardiologists Definition: ESC/ACC			PPV: 44; 95% CI: 35 to 55
Alcalai, 2007 ¹	Age >70 and creatinine <1.13 mg/dL, cTnT \geq 1.0 ng/mL subgroup data	Assay: cTnT Manufacturer: NR Type: NR cut off normal: 0.1 mcg/L timing: NR 99th upper ref: NR	Adjudicated by: panel of 2 cardiologists Definition: ESC/ACC			PPV: 90; 95% CI: 68 to 99
Alcalai, 2007 ¹	Age >70 and creatinine <1.13 mg/dL, cTnT 0.1-1.0 ng/mL subgroup data	Assay: cTnT Manufacturer: NR Type: NR cut off normal: 0.1 mcg/L timing: NR 99th upper ref: NR	Adjudicated by: panel of 2 cardiologists Definition: ESC/ACC			PPV: 42; 95% CI: 31 to 54
Alcalai, 2007 ¹	Age >70 and creatinine <1.13 mg/dL, cTnT any positive results subgroup data	Assay: cTnT Manufacturer: NR Type: NR cut off normal: 0.1 mcg/L timing: NR 99th upper ref: NR	Adjudicated by: panel of 2 cardiologists Definition: ESC/ACC			PPV: 52; 95% CI: 42 to 63

Author, year	Data group	Test	ACS Definition	Total Sample	AUC	Values
Alcalai, 2007 ¹	Age >70 and creatinine \geq 1.13 mg/dL, cTnT >1.0 ng/mL subgroup data	Assay: cTnT Manufacturer: NR Type: NR cut off normal: 0.1 mcg/L timing: NR 99th upper ref: NR	Adjudicated by: panel of 2 cardiologists Definition: ESC/ACC			PPV: 59; 95% CI: 43 to 73
Alcalai, 2007 ¹	Age >70 and creatinine \geq 1.13 mg/dL, cTnT 0.1-1.0 ng/mL subgroup data	Assay: cTnT Manufacturer: NR Type: NR cut off normal: 0.1 mcg/L timing: NR 99th upper ref: NR	Adjudicated by: panel of 2 cardiologists Definition: ESC/ACC			PPV: 27; 95% CI: 20 to 37
Alcalai, 2007 ¹	Age >70 and creatinine \geq 1.13 mg/dL, cTnT any positive results subgroup data	Assay: cTnT Manufacturer: NR Type: NR cut off normal: 0.1 mcg/L timing: NR 99th upper ref: NR	Adjudicated by: panel of 2 cardiologists Definition: ESC/ACC			PPV: 37; 95% CI: 29 to 45
Apple, 1999 ²	Total sample	Assay: cTnI Manufacturer: other Manufacturer: BioSite Diagnostics Type: other Type: Triage Cardiac Panel cut off normal: 0.4 mcg/L timing: Samples taken every 8 hours for 24 hours 99th upper ref: 0.4 mcg/L	NR		AUC: 0.961; 95% CI: 0.931 to 0.979	AUC: 0.961; 95% CI: 0.931 to 0.979
Bhagavan, 1998 ³	subgroup data	Assay: cTnI Manufacturer: other Manufacturer: Baxter Type: Stratus cut off normal: 0.6 mcg/L timing: every 8 hours at and after admission 99th upper ref: NR	NR			Sens: 90 Spec: 81 NPV: 98
Fehr, 2003 ⁴	ACS, cTnI subgroup data	Assay: cTnI Manufacturer: DPC Type: Immulite cut off normal: 1 mcg/L timing: Beginning of hemodialysis session	NR			Sens: 45 Spec: 100

Author, year	Data group	Test	ACS Definition	Total Sample	AUC	Values
		99th upper ref: NR				
Fehr, 2003 ⁴	ACS, cTnT subgroup data	Assay: cTnT Manufacturer: Roche Type: Elecsys cut off normal: 0.1 mcg/L timing: Beginning of hemodialysis session 99th upper ref: NR	NR			Sens: 100 Spec: 42
Flores, 2006 ⁵	Total sample	Assay: cTnI Manufacturer: Beckman Type: Access cut off normal: 0.5 ng/mL timing: NR	NR			FP: 20 Sens: 70; 95% CI: 57 to 83 Spec: 92; 95% CI: 90 to 95 PPV: 51; 95% CI: 39 to 63 NPV: 97; 95% CI: 95 to 98
Flores-Solis, 2012 ⁶		Assay: cTnI Manufacturer: other Type: other Type: Vidas cut off normal: 0.11 ng/mL other timing: other timing: Upon hospitalization and 6 months follow-up 99th upper ref: 0.01 ng/mL	Definition: European Society for Cardiology 2007		AUC: 0.83; 95% CI: 0.76 to 0.9	TP: 36 FP: 53 FN: 20 TN: 367 Sens: 0.64 Spec: 0.87 PPV: 0.4 NPV: 0.95 AUC: 0.83; 95% CI: 0.76 to 0.9
Flores-Solis, 2012 ⁶		Assay: cTnI Manufacturer: Beckman Type: Access cut off normal: 0.50 ng/mL timing: Upon hospitalization and 6 months followup 99th upper ref: 0.04 ng/mL	Definition: European Society for Cardiology 2007	484	AUC: 0.85; 95% CI: 0.91 to 0.78	TP: 24 FP: 24 FN: 32 TN: 403 Sens: 0.43 Spec: 0.94 PPV: 0.5 NPV: 0.93 AUC: 0.85; 95% CI: 0.91 to 0.78

Author, year	Data group	Test	ACS Definition	Total Sample	AUC	Values
Martin, 1998 ⁷	Total sample	Assay: cTnI Manufacturer: Dade-Behring Type: Stratus cut off normal: 0.8 mcg/L timing: 48 hours after admission 99th upper ref: NR	NR			Sens: 94; 95% CI: 82 to 106 Spec: 100 PPV: 100 NPV: 94
McCullough, 2002 ⁸	End-stage Renal Disease on Dialysis subgroup data	Assay: cTnI Manufacturer: other Manufacturer: Biosite Incorporated Type: other Type: Triage Cardiac System Package Insert cut off normal: 0.4 mcg/L timing: 9 hrs after onset 99th upper ref: NR	Adjudicated by: Panel of 2 cardiologists Definition: Thrombolysis in Myocardial Infarction Study Group		AUC: 0.99 sd: 0.01	AUC: 0.99 sd: 0.01
McCullough, 2002 ⁸	Quartile 1 >99.4 mL/min/72kg subgroup data	Assay: cTnI Manufacturer: other Manufacturer: Biosite Incorporated Type: other Type: Triage Cardiac System Package Insert cut off normal: 0.4 mcg/L timing: 9 hrs after onset 99th upper ref: NR	Adjudicated by: Panel of 2 cardiologists Definition: Thrombolysis in Myocardial Infarction Study Group		AUC: 0.93 sd: 0.04	AUC: 0.93 sd: 0.04
McCullough, 2002 ⁸	Quartile 1 >99.4 mL/min/72kg subgroup data	Assay: cTnI Manufacturer: other Manufacturer: Biosite Incorporated Type: other Type: Triage Cardiac System Package Insert cut off normal: 0.4 mcg/L timing: 9 hrs after onset 99th upper ref: NR	Adjudicated by: Panel of 2 cardiologists Definition: Thrombolysis in Myocardial Infarction Study Group		AUC: 1 sd: 0	AUC: 1 sd: 0

Author, year	Data group	Test	ACS Definition	Total Sample	AUC	Values
McCullough, 2002 ⁸	Quartile 2 99.3-72.7 mL/min/72kg subgroup data	Assay: cTnI Manufacturer: other Manufacturer: Biosite Incorporated Type: other Type: Triage Cardiac System Package Insert cut off normal: 0.4 mcg/L timing: 9 hrs after onset 99th upper ref: NR	Adjudicated by: Panel of 2 cardiologists Definition: Thrombolysis in Myocardial Infarction Study Group		AUC: 0.94 sd: 0.02	AUC: 0.94 sd: 0.02
McCullough, 2002 ⁸	Quartile 3: 72.8-47.0mL/min/72kg subgroup data	Assay: cTnI Manufacturer: other Manufacturer: Biosite Incorporated Type: other Type: Triage Cardiac System Package Insert cut off normal: 0.4 mcg/L timing: 9 hrs after onset 99th upper ref: NR	Adjudicated by: Panel of 2 cardiologists Definition: Thrombolysis in Myocardial Infarction Study Group Study Group		AUC: 0.97 sd: 0.01	AUC: 0.97 sd: 0.01
Noeller, 2003 ⁹	Age <65 subgroup data	Assay: cTnT Manufacturer: Roche Type: CARDIAC-ELISA ES300 cut off normal: 0.1 mcg/L timing: 16 hrs after onset 99th upper ref: NR	NR			Sens: 45 Spec: 94 PPV: 77 NPV: 78
Noeller, 2003 ⁹	Age >=65 subgroup data	Assay: cTnT Manufacturer: Roche Type: CARDIAC-ELISA ES300 cut off normal: 0.1 mcg/L timing: 16 hrs after onset 99th upper ref: NR	Definition: ICD-9 code			Sens: 44 Spec: 83 PPV: 62 NPV: 71
Noeller, 2003 ⁹	Creatinine <1.5 mg/dL, age <65 subgroup data	Assay: cTnT Manufacturer: Roche Type: CARDIAC-ELISA ES300 cut off normal: 0.1 mcg/L timing: 16 hrs after onset 99th upper ref: NR	Definition: ICD-9 code			Sens: 45 Spec: 96 Negative likelihood ratio: 83 PPV: 78

Author, year	Data group	Test	ACS Definition	Total Sample	AUC	Values
Noeller, 2003 ⁹	Creatinine <1.5 mg/dL, age >=65 subgroup data	Assay: cTnT Manufacturer: Roche Type: CARDIAC-ELISA ES300 cut off normal: 0.1 mcg/L timing: 16 hrs after onset 99th upper ref: NR	Definition: ICD-9 code			Sens: 41 Spec: 89 PPV: 69 NPV: 71
Noeller, 2003 ⁹	Creatinine >=1.5 mg/dL, age <65 subgroup data	Assay: cTnT Manufacturer: Roche Type: CARDIAC-ELISA ES300 cut off normal: 0.1 mcg/L timing: 16 hrs after onset 99th upper ref: NR	Definition: ICD-9 code			Sens: 43 Spec: 69 PPV: 38 NPV: 73
Noeller, 2003 ⁹	Creatinine >=1.5 mg/dL, age >=65 subgroup data	Assay: cTnT Manufacturer: Roche Type: CARDIAC-ELISA ES300 cut off normal: 0.1 mcg/L timing: 16 hrs after onset 99th upper ref: NR	Definition: ICD-9 code			Sens: 52 Spec: 66 PPV: 48 NPV: 69
Roppolo, 1999 ¹⁰	cTnI >0.5 ng/mL subgroup data	Assay: cTnI Manufacturer: Dade-Behring Type: Opus cut off normal: 0.5 mcg/L timing: 1 week before admission 99th upper ref: NR	Definition: ECG changes, wall motion abnormality by multigated angiogram; echocardiography, angiography or autopsy			Sens: 50; 95% CI: 10 to 90 Spec: 100 PPV: 100 NPV: 93.5; 95% CI: 86.4 to 100
Roppolo, 1999 ¹⁰	cTnT >0.1 ng/mL subgroup data	Assay: cTnT Manufacturer: Dade-Behring Type: Opus cut off normal: 0.1 mcg/L timing: 1 week before admission 99th upper ref: NR	Definition: ECG changes, wall motion abnormality by multigated angiogram; echocardiography, angiography or autopsy			Sens: 100 Spec: 55.8; 95% CI: 5.3 to 100 PPV: 24; 95% CI: 7.6 to 40.4 NPV: 100
Roppolo, 1999 ¹⁰	cTnT >0.2 ng/mL subgroup data	Assay: cTnT Manufacturer: Dade-Behring Type: Opus cut off normal: 0.2 mcg/L timing: 1 week before	Definition: ECG changes, wall motion abnormality by multigated angiogram;			Sens: 83.3; 95% CI: 53.5 to 100 Spec: 90; 95% CI: 82 to 99.4 PPV: 55.6; 95%

Author, year	Data group	Test	ACS Definition	Total Sample	AUC	Values
		admission 99th upper ref: NR	echocardiography, angiography or autopsy			CI: 23.1 to 88.1 NPV: 97.5; 95% CI: 92.7 to 100
Sukonthasarn, 2007 ¹¹	CrCl <15ml/min/1.73m ² subgroup data	Assay: cTnT Manufacturer: Roche Type: Elecsys cut off normal: 0.1 mcg/L timing: 24 hours after admission 99th upper ref: NR	Definition: European Society of Cardiology		AUC: 0.645	Sens: 85.71 Spec: 48 AUC: 0.645
Sukonthasarn, 2007 ¹¹	CrCl <60ml/min/1.73m ² , except hemodialysis subgroup data	Assay: cTnT Manufacturer: Roche Type: Elecsys cut off normal: 0.1 mcg/L timing: 24 hours after admission 99th upper ref: NR	Definition: European Society of Cardiology		AUC: 0.976	Sens: 91.3 Spec: 100 AUC: 0.976
Sukonthasarn, 2007 ¹¹	CrCl <60ml/min/1.73m ² subgroup data	Assay: cTnT Manufacturer: Roche Type: Elecsys cut off normal: 0.1 mcg/L timing: 24 hours after admission 99th upper ref: NR	Definition: European Society of Cardiology		AUC: 0.94	Sens: 90.9 Spec: 84.5 AUC: 0.94
Sukonthasarn, 2007 ¹¹	CrCl 15-29 ml/min/1.73m ² subgroup data	Assay: cTnT Manufacturer: Roche Type: Elecsys cut off normal: 0.1 mcg/L timing: 24 hours after admission 99th upper ref: NR	Definition: European Society of Cardiology		AUC: 0.987	Sens: 97.5 Spec: 92.9 AUC: 0.987
Sukonthasarn, 2007 ¹¹	CrCl 15-59 ml/min/1.73m ² subgroup data	Assay: cTnT Manufacturer: Roche Type: Elecsys cut off normal: 0.1 mcg/L timing: 24 hours after admission 99th upper ref: NR	Definition: European Society of Cardiology		AUC: 0.983	Sens: 100 Spec: 96.6 AUC: 0.983

Author, year	Data group	Test	ACS Definition	Total Sample	AUC	Values
Sukonthasarn, 2007 ¹¹	CrCl 30-59 ml/min/1.73m ² subgroup data	Assay: cTnT Manufacturer: Roche Type: Elecsys cut off normal: 0.1 mcg/L timing: 24 hours after admission 99th upper ref: NR	Definition: European Society of Cardiology		AUC: 0.987	Sens: 90 Spec: 96.8 AUC: 0.987
Sukonthasarn, 2007 ¹¹	Group 2: Renal insufficiency on dialysis subgroup data	Assay: cTnI Manufacturer: other Manufacturer: Accu Type: Access cut off normal: 0.1 ng/mL timing: 8 hour intervals after admission 99th upper ref: NR	Definition: ICD-9 code	32		TP: 19 FP: 1 FN: 5 TN: 7 Sens: 73%; 95% CI: 98 to 55 Spec: 83%; 95% CI: 120 to 70
Troyanov, 2005 ¹²	Total sample	Assay: cTnI Manufacturer: other Manufacturer: AxSYM Type: other Type: MEIA cut off normal: 0.3 mcg/L timing: NR 99th upper ref: 1 mcg/L	NR	101		Spec: 99%
Troyanov, 2005 ¹²	Total sample	Assay: cTnT Manufacturer: Roche Type: Elecsys cut off normal: 0.4 mcg/L timing: NR 99th upper ref: 0.1 mcg/L	Definition: ICD-9 code	101		Sens: 84%

References

1. Alcalai R, Planer D, Culhaoglu A, et al. Acute coronary syndrome vs nonspecific troponin elevation: clinical predictors and survival analysis. *Arch Intern Med.* 2007 Feb 12;167(3):276-81. PMID: 17296884.
2. Apple FS, Christenson RH, Valdes R, Jr., et al. Simultaneous rapid measurement of whole blood myoglobin, creatine kinase MB, and cardiac troponin I by the triage cardiac panel for detection of myocardial infarction. *Clin Chem.* 1999 Feb;45(2):199-205. PMID: 9931041.

3. Bhagavan NV, Goldstein AP, Honda SA, et al. Role of cardiac troponin I in the evaluation of myocardial injury. *J Clin Lab Anal.* 1998;12(5):276-9. PMID: 9773957.
4. Fehr T, Knoflach A, Ammann P, et al. Differential use of cardiac troponin T versus I in hemodialysis patients. *Clin Nephrol.* 2003 Jan;59(1):35-9. PMID: 12572929.
5. Flores LM, Hernandez Dominguez JL, Otero A, et al. [Cardiac troponin I determination in patients with chronic renal failure]. *Nefrologia.* 2006;26(1):107-12. PMID: 16649431.
6. Flores-Solis LM, Hernandez-Dominguez JL, Otero-Gonzalez A, et al. Cardiac troponin I and creatine kinase MB isoenzyme in patients with chronic renal failure. *Nefrologia.* 2012;32(6):809-18. PMID: 23169364.
7. Martin GS, Becker BN, Schulman G. Cardiac troponin-I accurately predicts myocardial injury in renal failure. *Nephrol Dial Transplant.* 1998 Jul;13(7):1709-12. PMID: 9681716.
8. McCullough PA, Nowak RM, Foreback C, et al. Performance of multiple cardiac biomarkers measured in the emergency department in patients with chronic kidney disease and chest pain. *Acad Emerg Med.* 2002 Dec;9(12):1389-96. PMID: 12460842.
9. Noeller TP, Meldon SW, Peacock WF, et al. Troponin T in elders with suspected acute coronary syndromes. *Am J Emerg Med.* 2003 Jul;21(4):293-7. PMID: 12898485.
10. Roppolo LP, Fitzgerald R, Dillow J, et al. A comparison of troponin T and troponin I as predictors of cardiac events in patients undergoing chronic dialysis at a Veteran's Hospital: a pilot study. *J Am Coll Cardiol.* 1999 Aug;34(2):448-54. PMID: 10440158.
11. Sukonthasarn A, Ponglopisit S. Diagnostic level of cardiac troponin T in patients with chronic renal dysfunction, a pilot study. *J Med Assoc Thai.* 2007 Sep;90(9):1749-58. PMID: 17957915.
12. Troyanov S, Ly QH, Schampaert E, et al. Diagnostic specificity and prognostic value of cardiac troponins in asymptomatic chronic haemodialysis patients: a three year prospective study. *Heart.* 2005 Sep;91(9):1227-8. PMID: 16103574.

Table 4. Outcomes reported for Key Question 2,3, and 4

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Abaci, 2004 ¹	All-cause mortality	Years: 2			Pts with event: 25 / 25 persons Results: unadjusted		
Abaci, 2004 ¹	All-cause mortality	Years: 2	Assay: cTnI Manufacturer: other Manufacturer: Abbott; other; AxSYM	> 0.5 mcg/L	Pts with event: 10 / 25 persons Results: unadjusted	N: 31 log rank: 5.15 p value: 0.0232; ref group: other; ref group: All TnI	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Abaci, 2004 ¹	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.03 mcg/L	Pts with event: 6 / 25 persons Results: unadjusted	N: 75	
Abaci, 2004 ¹	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 13 / 25 persons Results: unadjusted	N: 27 log rank: 23.85 p value: <0.0001; ref group: Other;; ref group: All TnT	
Abaci, 2004 ¹	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	0.03-0.1 mcg/mL	Pts with event: 6 / 25 persons Results: unadjusted		
Abaci, 2004 ¹	Cardio mortality	Years: 2			Pts with event: 12 / 12 persons Results: unadjusted		
Abaci, 2004 ¹	Cardio mortality	Years: 2	Assay: cTnI Manufacturer: other Manufacturer: Abbott; other; Axsym	> 0.5 mcg/L	Pts with event: 7 / 12 persons Results: unadjusted		
Abaci, 2004 ¹	Cardio mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.03 mcg/L	Pts with event: 3 / 12 persons Results: unadjusted		
Abaci, 2004 ¹	Cardio mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 5 / 12 persons Results: unadjusted		
Abaci, 2004 ¹	Cardio mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	0.03-0.1 ug/mL	Pts with event: 4 / 12 persons Results: unadjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Abbas, 2005 ²	All-cause mortality		Assay: cTnI Manufacturer: Bayer; other; ADVIA Centaur	< 0.07 mcg/L	Pts with event: 1 / 177 persons Results: adjusted	N: 177 OR: 1	
Abbas, 2005 ²	All-cause mortality		Assay: cTnI Manufacturer: Bayer; other; ADVIA Centaur	> 0.07 mcg/L	Pts with event: 7 / 38 persons Results: adjusted	N: 38 OR: 2.439 95% CI: 0.771 to 6.977 p value: 0.0786; ref group: Grp3	
Abbas, 2005 ²	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.01 mcg/L	Pts with event: 0 / 127 persons Results: adjusted	N: 127 OR: 1	
Abbas, 2005 ²	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.01 mcg/L	Pts with event: 16 / 95 persons Results: adjusted	N: 95 OR: 3.471 95% CI: 1.274 to 10.394 p value: 0.0075; ref group: Grp1	
Acharji, 2012 ³	All-cause mortality	Days: 30		Greater than upper limit of lab normal	% Pts with event: 11.9% / 1291 persons	N: 1291 RH: 2.05 95% CI: 1.48 to 2.83 p value: <0.0001; ref group: Grp2	
Acharji, 2012 ³	All-cause mortality	Days: 30		Lower than upper limit of lab normal	% Pts with event: 5.6% / 888 persons	N: 888	
Acharji, 2012 ³	All-cause mortality	Years: 1		Greater than upper limit of lab normal	% Pts with event: 20.9% / 1291 persons	N: 1291 RH: 1.72 95% CI: 1.36 to 2.17 p value: <0.0001; ref group: Grp2	
Acharji, 2012 ³	All-cause mortality	Years: 1		Lower than upper limit of lab normal	% Pts with event: 13.1% / 888 persons	N: 888 RH: 1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Apple, 1997 ⁴	Cardio mortality	Years: 1	Assay: cTnI Manufacturer: NR; NR	< 0.8 mcg/L	Pts with event: 1 / 13 persons Results: unadjusted		
Apple, 1997 ⁴	Cardio mortality	Years: 1	Assay: cTnI Manufacturer: NR; NR	> 0.8 mcg/L	Pts with event: 3 / 3 persons Results: unadjusted		
Apple, 1997 ⁴	Cardio mortality	Years: 1	Assay: cTnT Manufacturer: other Manufacturer: Boehringer; other; ELISA	< 0.2 mcg/L	Pts with event: 0 / 4 persons Results: unadjusted		
Apple, 1997 ⁴	Cardio mortality	Years: 1	Assay: cTnT Manufacturer: other Manufacturer: Boehringer; other; ELISA	> 0.2 mcg/L	Pts with event: 4 / 12 persons Results: unadjusted		
Apple, 1997 ⁴	Other composite (unstable angina)	Years: 1	Assay: cTnI Manufacturer: NR	< 0.8 mcg/L	Pts with event: 2 / 13 persons Results: unadjusted		
Apple, 1997 ⁴	Other composite (unstable angina)	Years: 1	Assay: cTnI Manufacturer: NR	> 0.8 mcg/L	Pts with event: 0 / 3 persons Results: unadjusted		
Apple, 1997 ⁴	Other composite (unstable angina)	Years: 1	Assay: cTnT Manufacturer: other Manufacturer: Boehringer; other; ELISA	< 0.2 mcg/L	Pts with event: 1 / 4 persons Results: unadjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Apple, 1997 ⁴	Other composite (unstable angina)	Years: 1	Assay: cTnT Manufacturer: other Manufacturer: Boehringer; other; ELISA	> 0.2 mcg/L	Pts with event: 1 / 12 persons Results: unadjusted		
Apple, 2002 ⁵	All-cause mortality	Years: 3	Assay: cTnI Manufacturer: Dade Behring; dimension	< 0.1 mcg/L	% Pts with event: 44% / 688 persons Results: adjusted	N: 688 RR: 1	
Apple, 2002 ⁵	All-cause mortality	Years: 3	Assay: cTnI Manufacturer: Dade Behring; dimension	> 0.1 mcg/L	% Pts with event: 60% / 45 persons Results: adjusted	N: 45 RR: 2.1 95% CI: 1.3 to 3.3 p value: 0.005; ref group: Grp1	
Apple, 2002 ⁵	All-cause mortality	Years: 3	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.01 mcg/L	% Pts with event: 8.4% / 132 persons Results: adjusted	N: 132 RR: 1	
Apple, 2002 ⁵	All-cause mortality	Years: 3	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.04 mcg/L	% Pts with event: 28% / 346 persons Results: adjusted	N: 346 RR: 1	
Apple, 2002 ⁵	All-cause mortality	Years: 3	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	% Pts with event: 42% / 585 persons Results: adjusted	N: 585 RR: 1	
Apple, 2002 ⁵	All-cause mortality	Years: 3	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.01 mcg/L	% Pts with event: 51% / 601 persons Results: adjusted	N: 601 RR: 4.3 95% CI: 2.1 to 8.7 p value: <0.001; ref group: Grp1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Apple, 2002 ⁵	All-cause mortality	Years: 3	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.04 mcg/L	% Pts with event: 57% / 387 persons Results: adjusted	N: 387 RR: 2.1 95% CI: 1.6 to 3 p value: <0.001; ref group: Grp1	
Apple, 2002 ⁵	All-cause mortality	Years: 3	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	% Pts with event: 56% / 148 persons Results: adjusted	N: 148 RR: 2.2 95% CI: 1.6 to 3 p value: <0.001; ref group: Grp1	
Apple, 2004 ⁶	All-cause mortality	Years: 2	Assay: cTnl Manufacturer: Beckman; other; AccuTnl	< 0.04 mcg/L	% Pts with event: 26% / 323 persons Results: adjusted	N: 323 RR: 1	
Apple, 2004 ⁶	All-cause mortality	Years: 2	Assay: cTnl Manufacturer: Beckman; other; AccuTnl	> 0.04 mcg/L	% Pts with event: 47% / 76 persons Results: adjusted	N: 76 RR: 1.8 95% CI: 1.1 to 2.7 p value: 0.01; ref group: Grp1	
Apple, 2004 ⁶	All-cause mortality	Years: 2	Assay: cTnl Manufacturer: Dade Behring; dimension	< 0.1 mcg/L	% Pts with event: 28% / 379 persons Results: adjusted	N: 379 RR: 1	
Apple, 2004 ⁶	All-cause mortality	Years: 2	Assay: cTnl Manufacturer: Dade Behring; dimension	> 0.1 mcg/L	% Pts with event: 61% / 20 persons Results: adjusted	N: 20 RR: 2.7 95% CI: 1.5 to 5 p value: 0.004; ref group: Grp1	
Apple, 2004 ⁶	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.01 mcg/L	% Pts with event: 11% / 60 persons Results: adjusted	N: 60 RR: 1	
Apple, 2004 ⁶	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.03 mcg/L	% Pts with event: 14% / 139 persons	N: 139 RR: 1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Apple, 2004 ⁶	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.01 mcg/L	% Pts with event: 33% / 339 persons Results: adjusted	N: 339 RR: 2.8 95% CI: 1.5 to 5 p value: 0.01; ref group: Grp1	
Apple, 2004 ⁶	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.03 mcg/L 0.074 mcg/L	% Pts with event: 36% / 129 persons	N: 129 RR: 2.4 95% CI: 1.4 to 4.3 p value: <0.0001; ref group: Grp1	
Apple, 2004 ⁶	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.074 mcg/L	% Pts with event: 41% / 131 persons	N: 131 RR: 3.2 95% CI: 1.9 to 5.6 p value: <0.0001; ref group: Grp1	
Apple, 2007 ⁷	MACE < 1 year		Assay: cTnl Manufacturer: Beckman	< 0.1 males/0.04 females mcg/L	No. of events: 9 / 46 persons Results: unadjusted		
Apple, 2007 ⁷	MACE < 1 year		Assay: cTnl Manufacturer: Beckman	> 0.1males/0.04females mcg/L	No. of events: 8 / 18 persons Results: unadjusted		
Apple, 2007 ⁷	MACE < 1 year		Assay: cTnl Manufacturer: Dade Behring; dimension	< 0.06 mcg/L	No. of events: 8 / 46 persons Results: unadjusted		
Apple, 2007 ⁷	MACE < 1 year		Assay: cTnl Manufacturer: Dade Behring; dimension	> 0.06 mcg/L	No. of events: 10 / 25 persons Results: unadjusted		
Apple, 2007 ⁷	MACE < 1 year		Assay: cTnl Manufacturer: other; Tosoh; other; AIA	< .07 males/0.06 females mcg/L	No. of events: 3 / 22 persons Results: unadjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Apple, 2007 ⁷	MACE < 1 year		Assay: cTnl Manufacturer: other Manufacturer: Tosoh; other; AIA	> .07 males/0.06 females mcg/L	No. of events: 5 / 19 persons Results: unadjusted		
Apple, 2007 ⁷	MACE < 1 year		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.01 mcg/L	No. of events: 2 / 17 persons Results: unadjusted		
Apple, 2007 ⁷	MACE < 1 year		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.01 mcg/L	No. of events: 14 / 45 persons Results: unadjusted		
Apple, 2007 ⁷	MACE < 1 year		Assay: cTnl Manufacturer: Beckman; access	< 0.1males/ 0.04females mcg/L	No. of events: 5 / 61 persons Results: unadjusted		
Apple, 2007 ⁷	MACE < 1 year		Assay: cTnl Manufacturer: Beckman; access	> 0.1males/ 0.04females mcg/L	No. of events: 4 / 13 persons Results: unadjusted		
Apple, 2007 ⁷	MACE < 1 year		Assay: cTnl Manufacturer: Dade Behring; dimension	< 0.06 mcg/L	No. of events: 5 / 67 persons Results: unadjusted		
Apple, 2007 ⁷	MACE < 1 year		Assay: cTnl Manufacturer: Dade Behring; dimension	> 0.06 mcg/L	No. of events: 4 / 16 persons Results: unadjusted		
Apple, 2007 ⁷	MACE < 1 year		Assay: cTnl Manufacturer: other Manufacturer: Tosoh; other; AIA	< .07 males/0.06 females mcg/L	No. of events: 2 / 41 persons Results: unadjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Apple, 2007 ⁷	MACE < 1 year		Assay: cTnl Manufacturer: other Manufacturer: Tosoh; other; AIA	> .07 males/0.06 females mcg/L	No. of events: 5 / 16 persons Results: unadjusted		
Apple, 2007 ⁷	MACE < 1 year		Assay: cTnT Manufacturer: Roche; access	< 0.1 mcg/L	No. of events: 5 / 49 persons Results: unadjusted		
Apple, 2007 ⁷	MACE < 1 year		Assay: cTnT Manufacturer: Roche; access	> 0.1 mcg/L	No. of events: 4 / 24 persons Results: unadjusted		
Apple, 2007 ⁷	MACE < 1 year		Assay: cTnl Manufacturer: Beckman; access	< 0.1males/ 0.04females mcg/L	Pts with event: 11 / 252 persons Results: unadjusted		
Apple, 2007 ⁷	MACE < 1 year		Assay: cTnl Manufacturer: Beckman; access	> 0.1males/ 0.04females mcg/L	Pts with event: 0 / 26 persons Results: unadjusted		
Apple, 2007 ⁷	MACE < 1 year		Assay: cTnl Manufacturer: Dade Behring; dimension	< 0.06 mcg/L	Pts with event: 11 / 299 persons Results: unadjusted		
Apple, 2007 ⁷	MACE < 1 year		Assay: cTnl Manufacturer: Dade Behring; dimension	> 0.06 mcg/L	Pts with event: 0 / 31 persons Results: unadjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Apple, 2007 ⁷	MACE < 1 year		Assay: cTnl Manufacturer: other Manufacturer: Tosoh; other; AIA200	< .07males/ 0.06females mcg/L	Pts with event: 9 / 181 persons Results: unadjusted		
Apple, 2007 ⁷	MACE < 1 year		Assay: cTnl Manufacturer: other Manufacturer: Tosoh; other; AIA200	> 0.07males /0.06females mcg/L	Pts with event: 1 / 22 persons Results: unadjusted		
Apple, 2007 ⁷	MACE < 1 year		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	Pts with event: 9 / 243 persons Results: unadjusted		
Apple, 2007 ⁷	MACE < 1 year		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 2 / 37 persons Results: unadjusted		
Artunc, 2012 ⁸	All-cause mortality	Days: 710Followup p NR			Results: unadjusted		AUC value: 0.665 Sensitivity value: 0.61 Specificity value: 0.7
Artunc, 2012 ⁸	All-cause mortality	Days: 710Followup p NR			Results: unadjusted		AUC value: 0.684 Sensitivity value: 0.91 Specificity value: 0.41

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Artunc, 2012 ⁸	All-cause mortality	Days: 710 Followup NR	Assay: hs cTnI Manufacturer: other Manufacturer: Siemens; other; ADIVA Centaur	<10 pg/mL	% Pts with event: 14.8% Results: unadjusted	RH: 1	AUC value: 0.665 Sensitivity value: 0.61 Specificity value: 0.7
Artunc, 2012 ⁸	All-cause mortality	Days: 710 Followup NR	Assay: hs cTnI Manufacturer: other Manufacturer: Siemens; other; ADIVA Centaur	>22 pg/mL	% Pts with event: 29.9% Results: unadjusted	RH: 2.87 to 6.51	AUC value: 0.665 Sensitivity value: 0.61 Specificity value: 0.7
Artunc, 2012 ⁸	All-cause mortality	Days: 710 Followup NR	Assay: hs cTnI Manufacturer: other Manufacturer: Siemens; other; ADIVA Centaur	10-22 pg/mL	% Pts with event: 15.5% Results: unadjusted	RH: 1.23 95% CI: 0.472 to 3	AUC value: 0.665 Sensitivity value: 0.61 Specificity value: 0.7
Artunc, 2012 ⁸	All-cause mortality	Days: 710 Followup NR	Assay: hs cTnT Manufacturer: Roche; Elecsys	<37 pg/mL	% Pts with event: 7% Results: unadjusted	RH: 1	AUC value: 0.684 Sensitivity value: 0.91 Specificity value: 0.41
Artunc, 2012 ⁸	All-cause mortality	Days: 710 Followup NR	Assay: hs cTnT Manufacturer: Roche; Elecsys	>68 pg/mL	% Pts with event: 29.1% Results: unadjusted	RH: 6.01 to 20.6 p value: <.001; ref group: Grp1	AUC value: 0.684 Sensitivity value: 0.91 Specificity value: 0.41

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Artunc, 2012 ⁸	All-cause mortality	Days: 710 Followup NR	Assay: hs cTnT Manufacturer: Roche; Elecsys	38-67 pg/mL	% Pts with event: 23% Results: unadjusted	RH: 5.14 95% CI: 1.91 to 17.6 p value: <.01; ref group: Grp1	AUC value: 0.684 Sensitivity value: 0.91 Specificity value: 0.41
Aviles, 2002 ⁹	MACE < 1 year	Days: 30	Assay: cTnT Manufacturer: Roche; Elecsys	< ng/L< 0.03 mcg/L	Pts with event: 42 / 553 persons Results: adjusted	OR: 2.7 95% CI: 1.9 to 3.8 p value: <0.001; ref group: Grp3	
Aviles, 2002 ⁹	MACE < 1 year	Days: 30	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	Pts with event: 70 / 783 persons Results: adjusted	OR: 2.5 95% CI: 1.8 to 3.3 p value: <0.001; ref group: Grp1	
Aviles, 2002 ⁹	MACE < 1 year	Days: 30	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.03 mcg/L	Pts with event: 214 / 1180 persons Results: adjusted	OR: 1	
Aviles, 2002 ⁹	MACE < 1 year	Days: 30	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 186 / 950 persons Results: adjusted	OR: 1	
Aviles, 2002 ⁹	MACE < 1 year	Days: 30	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	Pts with event: 20 / 805 persons Results: adjusted	OR: 2.3 95% CI: 1.3 to 4.1 p value: 0.003; ref group: Grp1	
Aviles, 2002 ⁹	MACE < 1 year	Days: 30	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.03 mcg/L	Pts with event: 58 / 1117 persons Results: adjusted	OR: 1	
Aviles, 2002 ⁹	MACE < 1 year	Days: 30	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.03 mcg/L	Pts with event: 8 / 618 persons Results: adjusted	OR: 4.8 95% CI: 2.3 to 10.4 p value: <0.001; ref group: Grp3	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Aviles, 2002 ⁹	MACE < 1 year	Days: 30	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 46 / 930 persons Results: adjusted	OR: 1	
Aviles, 2002 ⁹	MACE < 1 year	Days: 30	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.03 mcg/L	Pts with event: 36 / 690 persons Results: adjusted	OR: 2.4 95% CI: 1.6 to 3.6 p value: <0.001; ref group: Grp3	
Aviles, 2002 ⁹	MACE < 1 year	Days: 30	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	Pts with event: 60 / 917 persons Results: adjusted	OR: 1.8 95% CI: 1.3 to 2.6 p value: <0.001; ref group: Grp1	
Aviles, 2002 ⁹	MACE < 1 year	Days: 30	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.03 mcg/L	Pts with event: 115 / 1113 persons Results: adjusted	OR: 1	
Aviles, 2002 ⁹	MACE < 1 year	Days: 30	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 91 / 886 persons Results: adjusted	OR: 1	
Aviles, 2002 ⁹	MACE < 1 year	Days: 30	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.03 mcg/L	Pts with event: 22 / 660 persons Results: adjusted	OR: 2.6 95% CI: 1.6 to 4.4 p value: <0.001; ref group: Grp3	
Aviles, 2002 ⁹	MACE < 1 year	Days: 30	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	% Pts with event: 47% / 883 persons Results: adjusted	OR: 1.4 95% CI: 0.9 to 2.1 p value: 0.16; ref group: Grp1	
Aviles, 2002 ⁹	MACE < 1 year	Days: 30	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.03 mcg/L	Pts with event: 86 / 1102 persons Results: adjusted	OR: 1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Aviles, 2002 ⁹	MACE < 1 year	Days: 30	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 61 / 879 persons Results: adjusted	OR: 1	
Bagheri, 2009 ¹⁰	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	<0.05 mg/L	% Pts with event: 24.2% / 46 persons Results: unadjusted		
Bagheri, 2009 ¹⁰	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	>0.05 mg/L	/ 62 persons Results: unadjusted		
Bagheri, 2009 ¹⁰	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	>0.05 mg/L	% Pts with event: 6.9% / 20 persons Results: unadjusted		
Beciani, 2003 ¹¹	Cardio mortality - Subsequent MI-Revascularization	Years: 1	Assay: cTnI Manufacturer: Dade Behring; opusplus	>0.15 ng/ml	Pts with event: 9 % Pts with event: 64% / 14 persons		
Beciani, 2003 ¹¹	Cardio mortality - Subsequent MI-Revascularization	Years: 1	Assay: cTnI Manufacturer: Dade Behring; opusplus	<0.15 ng/ml	Pts with event: 7 % Pts with event: 9.7% / 72 persons		
Beciani, 2003 ¹¹	Cardio mortality - Subsequent MI-Revascularization	Years: 1	Assay: cTnI Manufacturer: Dade Behring; opusplus	</>0.15 ng/ml	Pts with event: 3 % Pts with event: 20% / 15 persons		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Boulier, 2004 ¹²	All-cause mortality	Days: 418	Assay: cTnl Manufacturer: Beckman; access	< 0.03 mcg/L	Results: adjusted	RR: 1	
Boulier, 2004 ¹²	All-cause mortality	Days: 418	Assay: cTnl Manufacturer: Beckman; access	> 0.03 mcg/L	Results: adjusted	RR: 1.3 95% CI: 0.2 to 11.1; ref group: Grp1	
Boulier, 2004 ¹²	All-cause mortality	Days: 418	Assay: cTnl Manufacturer: Beckman; access	< 0.03 mcg/L	Results: adjusted	N: WITHOUT CHD RR: 1	
Boulier, 2004 ¹²	All-cause mortality	Days: 418	Assay: cTnl Manufacturer: Beckman; access	> 0.03 mcg/L	Results: adjusted	N: WITHOUT CHD RR: 9.3 95% CI: 2.5 to 35; ref group: Grp1	
Boulier, 2004 ¹²	All-cause mortality		Assay: cTnl Manufacturer: Beckman; access	< 0.03 mcg/L	Results: adjusted	N: 143 RR: 1 p value: 0.0009	
Boulier, 2004 ¹²	All-cause mortality		Assay: cTnl Manufacturer: Beckman; access	> 0.03 mcg/L	Results: adjusted	N: 48 RR: 3.9 95% CI: 1.7 to 8.6 p value: 0.0009; ref group: Grp1	
Boulier, 2004 ¹²	Cardio mortality		Assay: cTnl Manufacturer: Beckman; access	< 0.03 mcg/L	Results: adjusted	N: 143 RR: 1 p value: 0.009	
Boulier, 2004 ¹²	Cardio mortality		Assay: cTnl Manufacturer: Beckman; access	> 0.03 mcg/L	Results: adjusted	N: 48 RR: 5.4 95% CI: 1.5 to 19 p value: 0.009; ref group: Grp1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Bozbas, 2004 ¹³	All-cause mortality	Days: 30	Assay: cTnl Manufacturer: DPC; immulite	> 2.3 mcg/L	Pts with event: 0 / 34 persons		
Bozbas, 2004 ¹³	Subsequent MI	Days: 30	Assay: cTnl Manufacturer: DPC; immulite	> 2.3 mcg/L	Pts with event: 0 / 34 persons		
Brunet, 2008 ¹⁴	All-cause mortality	Years: 2.5	Assay: cTnl Manufacturer: Beckman; access	< 0.5 mcg/L	Pts with event: 41 % Pts with event: 40% / 103 persons		
Brunet, 2008 ¹⁴	All-cause mortality	Years: 2.5	Assay: cTnl Manufacturer: Beckman; access	> 0.5 mcg/L	Pts with event: 0 % Pts with event: 0% / 2 persons		
Brunet, 2008 ¹⁴	All-cause mortality	Years: 2.5	Assay: cTnl Manufacturer: Dade Behring; dimension	> 0.6 mcg/L	Pts with event: 1 % Pts with event: 33% / 3 persons		
Brunet, 2008 ¹⁴	All-cause mortality	Years: 2.5	Assay: cTnl Manufacturer: Dade Behring; Troponin I Stat	< 0.6 mcg/L	Pts with event: 40 % Pts with event: 39% / 102 persons		
Brunet, 2008 ¹⁴	All-cause mortality	Years: 2.5	Assay: cTnl Manufacturer: Roche; Elecsys	< 0.1 mcg/L	Pts with event: 24 % Pts with event: 31% / 77 persons		
Brunet, 2008 ¹⁴	All-cause mortality	Years: 2.5	Assay: cTnl Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 17 % Pts with event: 61% / 28 persons		
Brunet, 2008 ¹⁴	All-cause mortality	Years: 2.5	Assay: cTnl Manufacturer: Beckman; access	< 0.06 mcg/L	Pts with event: 30 % Pts with event: 35% / 86 persons		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Brunet, 2008 ¹⁴	All-cause mortality	Years: 2.5	Assay: cTnl Manufacturer: Beckman; access	> 0.06 mcg/L	Pts with event: 11 % Pts with event: 58% / 19 persons		
Brunet, 2008 ¹⁴	All-cause mortality	Years: 2.5	Assay: cTnl Manufacturer: Dade Behring; dimension	< 0.14 mcg/L	Pts with event: 38 % Pts with event: 39% / 98 persons		
Brunet, 2008 ¹⁴	All-cause mortality	Years: 2.5	Assay: cTnl Manufacturer: Dade Behring; dimension	> 0.14 mcg/L	Pts with event: 3 % Pts with event: 43% / 7 persons		
Brunet, 2008 ¹⁴	All-cause mortality	Years: 2.5	Assay: cTnl Manufacturer: Roche; Elecsys	< 0.03 mcg/L	Pts with event: 11 % Pts with event: 27% / 41 persons		
Brunet, 2008 ¹⁴	All-cause mortality	Years: 2.5	Assay: cTnl Manufacturer: Roche; Elecsys	> 0.03 mcg/L	Pts with event: 30 % Pts with event: 47% / 64 persons		
Brunet, 2008 ¹⁴	MACE >= 1 year	Years: 2.5	Assay: cTnl Manufacturer: Beckman; access	< 0.5 mcg/L	Pts with event: 14 % Pts with event: 14% / 103 persons		
Brunet, 2008 ¹⁴	MACE >= 1 year	Years: 2.5	Assay: cTnl Manufacturer: Beckman; access	> 0.5 mcg/L	Pts with event: 1 % Pts with event: 50% / 2 persons		
Brunet, 2008 ¹⁴	MACE >= 1 year	Years: 2.5	Assay: cTnl Manufacturer: Roche; Elecsys	< 0.1 mcg/L	Pts with event: 4 % Pts with event: 5% / 77 persons		
Brunet, 2008 ¹⁴	MACE >= 1 year	Years: 2.5	Assay: cTnl Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 11 % Pts with event: 39% / 28 persons		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Brunet, 2008 ¹⁴	MACE >= 1 year	Years: 2.5	Assay: cTnl Manufacturer: Dade Behring; dimension	< 0.14 mcg/L	Pts with event: 13 % Pts with event: 13% / 98 persons		
Brunet, 2008 ¹⁴	MACE >= 1 year	Years: 2.5	Assay: cTnl Manufacturer: Dade Behring; dimension	< 0.6 mcg/L	Pts with event: 13 % Pts with event: 13% / 102 persons		
Brunet, 2008 ¹⁴	MACE >= 1 year	Years: 2.5	Assay: cTnl Manufacturer: Dade Behring; dimension	> 0.14 mcg/L	Pts with event: 2 % Pts with event: 29% / 7 persons		
Brunet, 2008 ¹⁴	MACE >= 1 year	Years: 2.5	Assay: cTnl Manufacturer: Dade Behring; dimension	> 0.6 mcg/L	Pts with event: 2 % Pts with event: 67% / 3 persons		
Brunet, 2008 ¹⁴	MACE >= 1 year	Years: 2.5	Assay: cTnl Manufacturer: Roche; Elecsys	< 0.03 mcg/L	Pts with event: 2 % Pts with event: 5% / 41 persons		
Brunet, 2008 ¹⁴	MACE >= 1 year	Years: 2.5	Assay: cTnl Manufacturer: Roche; Elecsys	> 0.03 mcg/L	Pts with event: 13 % Pts with event: 20% / 64 persons		
Brunet, 2008 ¹⁴	MACE >= 1 year	Years: 2.5	Assay: cTnl Manufacturer: Beckman; access	< 0.06 mcg/L	Pts with event: 10 % Pts with event: 12% / 86 persons		
Brunet, 2008 ¹⁴	MACE >= 1 year	Years: 2.5	Assay: cTnl Manufacturer: Beckman; access	> 0.06 mcg/L	Pts with event: 5 % Pts with event: 26% / 19 persons		
Bueti, 2006 ¹⁵	MACE < 1 year- Revascularization		Assay: cTnl	< 0.1 ng/L			

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Bueti, 2006 ¹⁵	MACE < 1 year-Revascularization		Assay: cTnl	> 0.1 ng/L		OR: 10.7 95% CI: 3.6 to 31; ref group: < 0.1 ng/L	
Bueti, 2006 ¹⁵	MACE < 1 year-Revascularization	Days: 30	Assay: cTnl Manufacturer: Bayer; other; Immuno 1	< 0.1 ng/L	Results: unadjusted	Likelihood ratio: 0.32 95% CI: 0.16 to 0.63	
Bueti, 2006 ¹⁵	MACE < 1 year-Revascularization	Days: 30	Assay: cTnl Manufacturer: Bayer; other; Immuno 1	> 0.1 ng/L < 0.3 ng/L	Results: unadjusted	Likelihood ratio: 0.7 95% CI: 0.09 to 5.5	
Bueti, 2006 ¹⁵	MACE < 1 year-Revascularization	Days: 30	Assay: cTnl Manufacturer: Bayer; other; Immuno 1	> 0.3 ng/L < 1 ng/L	Results: unadjusted	Likelihood ratio: 4.33 95% CI: 1.04 to 18	
Bueti, 2006 ¹⁵	MACE < 1 year-Revascularization	Days: 30	Assay: cTnl Manufacturer: Bayer; other; Immuno 1	> 1 ng/L < 2 ng/L	Results: unadjusted	Likelihood ratio: 5.77 95% CI: 0.85 to 39	
Bueti, 2006 ¹⁵	MACE < 1 year-Revascularization	Days: 30	Assay: cTnl Manufacturer: Bayer; other; Immuno 1	> 2 ng/L	Results: unadjusted	Likelihood ratio: 11.7 95% CI: 4.4 to 31	
Bueti, 2006 ¹⁵	MACE < 1 year-Revascularization	Days: 30			Results: unadjusted		
Bueti, 2006 ¹⁵	MACE < 1 year-Revascularization	Days: 30	Assay: cTnl Manufacturer: Bayer; other; Immuno 1	< 0.1 ng/L	Results: unadjusted	OR: 1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Bueti, 2006 ¹⁵	MACE < 1 year-Revascularization	Days: 30	Assay: cTnl Manufacturer: Bayer; other; Immuno 1	> 0.1 ng/L	Results: unadjusted	OR: 15.2 95% CI: 5.26 to 43.6 p value: 4e-007; ref group: Grp1	
Chew, 2008 ¹⁶	All-cause mortality	Followup NR	Assay: cTnT Manufacturer: NR; NR	< 0.1 mcg/L	/ 106 persons Results: unadjusted		
Chew, 2008 ¹⁶	All-cause mortality	Followup NR	Assay: cTnT Manufacturer: NR; NR	> 0.1 mcg/L	/ 121 persons Results: unadjusted		
Choy, 2003 ¹⁷	All-cause mortality		Assay: cTnl Manufacturer: Dade Behring	< 0.5 mcg/L	Pts with event: 11 / 96 persons		
Choy, 2003 ¹⁷	All-cause mortality		Assay: cTnl Manufacturer: Dade Behring	> 0.5 mcg/L	Pts with event: 1 / 17 persons		
Choy, 2003 ¹⁷	All-cause mortality		Assay: cTnT Manufacturer: Roche	> 0.1 mcg/L	Pts with event: 10 / 48 persons		
Choy, 2003 ¹⁷	All-cause mortality		Assay: cTnT Manufacturer: Roche; NR	< 0.1 mcg/L	Pts with event: 3 / 65 persons	N: 48 OR: 13.6 95% CI: 2.5 to 73.2 p value: 0.002; ref group: Grp1	
Choy, 2003 ¹⁷	All-cause mortality		Manufacturer: Roche; NR		Pts with event: 13 / 113 persons	N: 65 OR: 1	
Choy, 2003 ¹⁷	Subsequent MI		Assay: cTnl Manufacturer: Dade Behring; NR	< 0.5 mcg/L	Pts with event: 0 / 96 persons		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Choy, 2003 ¹⁷	Subsequent MI		Assay: cTnI Manufacturer: Dade Behring; NR	> 0.5 mcg/L	Pts with event: 1 / 17 persons		
Choy, 2003 ¹⁷	Subsequent MI		Assay: cTnT Manufacturer: Roche; NR	> 0.1 mcg/L	Pts with event: 0 / 48 persons		
Choy, 2003 ¹⁷	Subsequent MI		Assay: cTnT Manufacturer: Roche; NR	> 0.1 mcg/L	Pts with event: 0 / 65 persons		
Chrysochou, 2009 ¹⁸	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	<0.03 ng/mL	Results: unadjusted	N: 71 RH: 1	
Chrysochou, 2009 ¹⁸	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	>0.03 ng/mL	Results: unadjusted	N: 11 RH: 3.9 95% CI: 1.8 to 8.5 p value: 0.001; ref group: Grp1	
Chrysochou, 2009 ¹⁸	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	<0.03 ng/mL	Pts with event: 11 / 71 persons Results: unadjusted		
Chrysochou, 2009 ¹⁸	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	>0.03 ng/mL	No. of events: 4 / 11 persons Results: unadjusted		
Claes, 2010 ¹⁹	MACE < 1 year	Weeks: 2					AUC value: 0.85 Sensitivity value: 0.55 Specificity value: 0.98

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Claes, 2010 ¹⁹	MACE < 1 year	Weeks: 2	Assay: cTnI Manufacturer: other Manufacturer: Siemens; Heterogeneous Immunoassay	< 0.02 mcg/L			AUC value: 0.85 Sensitivity value: 0.55 Specificity value: 0.98
Claes, 2010 ¹⁹	MACE < 1 year	Weeks: 2	Assay: cTnI Manufacturer: other Manufacturer: Siemens; Heterogeneous Immunoassay	> 0.02 mcg/L< 0.06 mcg/L			AUC value: 0.85 Sensitivity value: 0.55 Specificity value: 0.98
Claes, 2010 ¹⁹	MACE < 1 year	Weeks: 2	Assay: cTnI Manufacturer: other Manufacturer: Siemens; Heterogeneous Immunoassay	> 0.06 mcg/L< 0.13 mcg/L			AUC value: 0.85 Sensitivity value: 0.55 Specificity value: 0.98
Claes, 2010 ¹⁹	MACE < 1 year	Weeks: 2	Assay: cTnI Manufacturer: other Manufacturer: Siemens; Heterogeneous Immunoassay	> 0.13 mcg/L			AUC value: 0.85 Sensitivity value: 0.55 Specificity value: 0.98

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Codognotto, 2010 ²⁰	All-cause mortality	Years: 3	Assay: cTnI Manufacturer: other Manufacturer: Siemens; lithium-heparin plasma	< 0.15 mcg/L	% Pts with event: 20.6% Results: adjusted		
Codognotto, 2010 ²⁰	All-cause mortality	Years: 3	Assay: cTnI Manufacturer: other Manufacturer: Siemens; lithium-heparin plasma	> 0.15 mcg/L	% Pts with event: 43.3% Results: adjusted		
Codognotto, 2010 ²⁰	All-cause mortality	Years: 3	Assay: cTnT Manufacturer: Roche; NR	< 0.01 mcg/L	% Pts with event: 13.2% Results: adjusted		
Codognotto, 2010 ²⁰	All-cause mortality	Years: 3	Assay: cTnT Manufacturer: Roche; NR	> 0.01 mcg/L	% Pts with event: 40.2% Results: adjusted		
Connolly, 2008 ²¹	All-cause mortality	Days: 1626	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.03 mcg/L	Pts with event: 49 / 351 persons Results: adjusted	N: 351 Exponent Beta: 1	
Connolly, 2008 ²¹	All-cause mortality	Days: 1626	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.03 mcg/L	Pts with event: 12 / 21 persons Results: adjusted	N: 21 Exponent Beta: 2.669 95% CI: 1.201 to 6.056 p value: <0.016; ref group: Grp1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Connolly, 2008 ²¹	Cardio mortality	Days: 1626	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.03 mcg/L	Pts with event: 17 / 351 persons Results: unadjusted		
Connolly, 2008 ²¹	Cardio mortality	Days: 1626	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.03 mcg/L	Pts with event: 7 / 21 persons Results: unadjusted		
Conway, 2005 ²²	MACE \geq 1 year- MACE < 1 year-Other composite (unstable angina)		Assay: cTnT Manufacturer: Roche; other; ECLIA	> 0.03 mcg/L < 0.1 mcg/L	Pts with event: 9 / 22 persons Results: unadjusted		
Conway, 2005 ²²	MACE \geq 1 year- MACE < 1 year-Other composite (unstable angina)		Assay: cTnT Manufacturer: Roche; other; ECLIA	< 0.03 mcg/L	Pts with event: 4 / 40 persons Results: unadjusted		
Conway, 2005 ²²	MACE \geq 1 year- MACE < 1 year-Other composite (unstable angina)		Assay: cTnT Manufacturer: Roche; other; ECLIA	> 0.1 mcg/L	Pts with event: 7 / 13 persons Results: unadjusted		
Deegan, 2001 ²³	All-cause mortality				Results: unadjusted		AUC value: 0.857 95% CI: 0.755 to 0.928 Sensitivity value: 0.6 Specificity value: 0.85

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Deegan, 2001 ²³	All-cause mortality		Assay: cTnT Manufacturer: other Manufacturer: Boehringer Mannheim; Elecsys	< 0.1 mcg/L	Pts with event: 7 % Pts with event: 15% / 53 persons Results: unadjusted	N: 53	AUC value: 0.857 95% CI: 0.755 to 0.928 Sensitivity value: 0.6 Specificity value: 0.85
Deegan, 2001 ²³	All-cause mortality		Assay: cTnT Manufacturer: other Manufacturer: Boehringer Mannheim; Elecsys	> 0.1 mcg/L	Pts with event: 13 % Pts with event: 65% / 20 persons Results: unadjusted	N: 20 RH: 4.1 ; ref group: Grp1	AUC value: 0.857 95% CI: 0.755 to 0.928 Sensitivity value: 0.6 Specificity value: 0.85
Deegan, 2001 ²³	Cardio mortality		Assay: cTnT Manufacturer: other Manufacturer: Boehringer Mannheim; Elecsys	< 0.1 mcg/L	Pts with event: 5 / 53 persons Results: unadjusted		
Deegan, 2001 ²³	Cardio mortality		Assay: cTnT Manufacturer: other Manufacturer: Boehringer Mannheim; Elecsys	> 0.1 mcg/L	Pts with event: 7 / 20 persons Results: unadjusted		
deFilippi, 2003 ²⁴	All-cause mortality	Days: 827	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.029 mcg/L	Pts with event: 16 % Pts with event: 28% / 57 persons Results: adjusted	N: 57 hazard ratio: Reference	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
deFilippi, 2003 ²⁴	All-cause mortality	Days: 827	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.117 mcg/L	Pts with event: 36 % Pts with event: 65% / 55 persons Results: adjusted	N: 55 hazard ratio: 2.8 95% CI: 5 to 1.5 p value: 0.001; ref group: Grp1	
deFilippi, 2003 ²⁴	All-cause mortality	Days: 827	Assay: cTnT Manufacturer: Roche; Elecsys	0.029-0.064ng/mL	Pts with event: 30 % Pts with event: 54% / 56 persons Results: adjusted	N: 56 hazard ratio: 1.6 95% CI: 3 to 0.9 p value: 0.14; ref group: Grp1	
deFilippi, 2003 ²⁴	All-cause mortality	Days: 827	Assay: cTnT Manufacturer: Roche; Elecsys	0.065-0.116ng/mL	Pts with event: 34 % Pts with event: 62% / 55 persons Results: adjusted	N: 55 hazard ratio: 2.3 95% CI: 4.2 to 1.3 p value: 0.006; ref group: Grp1	
deFilippi, 2012 ²⁵	All-cause mortality	Years: 4.8	Assay: hscTnI Manufacturer: other Manufacturer: Siemens; other; Dimension Vista 1500	< 11.6 ng/L		RH: 6.34 95% CI: 2.18 to 18.5; ref group: Grp1	
deFilippi, 2012 ²⁵	All-cause mortality	Years: 4.8	Assay: hscTnI Manufacturer: other Manufacturer: Siemens; other; Dimension Vista 1500	< 4 ng/L		RH: 1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
deFilippi, 2012 ²⁵	All-cause mortality	Years: 4.8	Assay: hscTnI Manufacturer: other Manufacturer: Siemens; other; Dimension Vista 1500	> 4 ng/L < 11.6 ng/L		RH: 2.07 95% CI: 0.62 to 6.88; ref group: Grp1	
deFilippi, 2012 ²⁵	All-cause mortality	Years: 4.8	Assay: hscTnI Manufacturer: Roche; Elecsys	> 13.2 ng/L < 24.3 mcg/L		RH: 1.19 95% CI: 0.36 to 3.9; ref group: Grp1	
deFilippi, 2012 ²⁵	All-cause mortality	Years: 4.8	Assay: hscTnT Manufacturer: Roche; Elecsys	< 13.2 ng/L		RH: 1	
deFilippi, 2012 ²⁵	All-cause mortality	Years: 4.8	Assay: hscTnT Manufacturer: Roche; Elecsys	> 24.4 ng/L		RH: 5.2 95% CI: 13.73 to 1.97; ref group: Grp1	
Dierkes, 2000 ²⁶	All-cause mortality	Years: 2		< 0.04 mcg/L	Pts with event: 0 / 17 persons Results: adjusted		
Dierkes, 2000 ²⁶	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; NR	> 0.04 mcg/L	Pts with event: 18 / 40 persons Results: adjusted		
Dierkes, 2000 ²⁶	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; NR	> 0.1 mcg/L	Pts with event: 10 / 12 persons Results: adjusted	RH: 7.31 95% CI: 1.85 to 28.83	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Duman, 2005 ²⁷	All-cause mortality		Assay: cTnI Manufacturer: other Manufacturer: Diagnostic Product corp; immulite	> 0.06 mcg/L	No. of events: 3 / 4 persons Results: adjusted		
Duman, 2005 ²⁷	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.01 mcg/L	No. of events: 10 / 15 persons Results: adjusted	N: 36 OR: 1 SE:	
Duman, 2005 ²⁷	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.035 mcg/L	Pts with event: No. of events: 17 / 29 persons Results: adjusted	N: 29 OR: 4.31 SE: 0.67 95% CI: 1.16 to 16.04 p value: 0.02; ref group: Grp1	
Duman, 2005 ²⁷	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.01 mcg/L	No. of events: 16 / 23 persons Results: unadjusted	N: 36 OR: 1 SE:	
Duman, 2005 ²⁷	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.035 mcg/L	No. of events: 16 / 23 persons Results: unadjusted	N: 29 OR: 8.94 SE: 0.71 95% CI: 2.23 to 35.88 p value: 0.002; ref group: Grp1	
Farkouh, 2003 ²⁸	All-cause mortality		Assay: cTnI Manufacturer: Dade Behring; other: Stratus-II enzyme immunoassay	< 1 mcg/L	Pts with event: 15 / 127 persons Results: adjusted	N: 127 RH: 1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Farkouh, 2003 ²⁸	All-cause mortality		Assay: cTnI Manufacturer: Dade Behring; other; Stratus-II enzyme immunoassay	> 1 mcg/L	Pts with event: 4 / 10 persons Results: adjusted	N: 10 RH: 9.6 95% CI: 2.8 to 33 p value: <0.01; ref group: Grp1	
Feringa, 2006 ²⁹	All-cause mortality	Years: 4	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.03 ng/L	Results: adjusted	RH: 1	
Feringa, 2006 ²⁹	All-cause mortality	Years: 4	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.03 ng/L < 0.09 ng/L	Results: adjusted	RH: 4.27 95% CI: 1.75 to 10.4 p value: <0.001; ref group: Grp1	
Feringa, 2006 ²⁹	All-cause mortality	Years: 4	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 ng/L	Results: adjusted	RH: 5.54 95% CI: 2.92 to 10.52 p value: <0.001; ref group: Grp1	
Feringa, 2006 ²⁹	MACE >= 1 year- MACE < 1 year	Years: 4	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.03 ng/L	Results: adjusted	RH: 1	
Feringa, 2006 ²⁹	MACE >= 1 year- MACE < 1 year	Years: 4	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.03 ng/L < 0.09 ng/L	Results: adjusted	RH: 8.09 95% CI: 2.72 to 24.05 p value: <0.001; ref group: Grp1	
Feringa, 2006 ²⁹	MACE >= 1 year- MACE < 1 year	Years: 4	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 ng/L	Results: adjusted	RH: 7.05 95% CI: 3.44 to 14.47 p value: <0.001; ref group: Grp1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Fernandez-Reyes, 2004 ³⁰	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.01 mcg/L	Results: unadjusted	N: 53 RR: 1.07 Cox hazard model: 95% CI: 1.03 to 1.12 p value: 0.01	
Fernandez-Reyes, 2004 ³⁰	Other composite (Heart Failure)	Years: 2.5	Assay: cTnT Manufacturer: Roche; Elecsys	<0.04 ng/mL	Pts with event: 2 / 23 persons		
Fernandez-Reyes, 2004 ³⁰	Other composite (Heart Failure)	Years: 2.5	Assay: cTnT Manufacturer: Roche; Elecsys	>0.04 ng/mL	Pts with event: 1 / 12 persons		
Fernandez-Reyes, 2004 ³⁰	Other composite (Heart Failure)	Years: 2.5	Assay: cTnT Manufacturer: Roche; Elecsys	0.04-0.1 ng/mL	Pts with event: 1 / 11 persons		
Fernandez-Reyes, 2004 ³⁰	Other composite (Ischemic Heart Disease)	Years: 2.5			Pts with event: 5 / 16 persons		
Fernandez-Reyes, 2004 ³⁰	Other composite (Ischemic Heart Disease)	Years: 2.5	Assay: cTnT Manufacturer: Roche; Elecsys	<0.04 ng/mL	Pts with event: 0 / 23 persons		
Fernandez-Reyes, 2004 ³⁰	Other composite (Ischemic Heart Disease)	Years: 2.5	Assay: cTnT Manufacturer: Roche; Elecsys	>0.04 ng/mL	Pts with event: 3 / 12 persons		
Fernandez-Reyes, 2004 ³⁰	Other composite (Ischemic Heart Disease)	Years: 2.5	Assay: cTnT Manufacturer: Roche; Elecsys	0.04-0.1 ng/mL	Pts with event: 1 / 11 persons		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Flores, 2006 ³¹	Subsequent MI	Followup NR	Assay: cTnl Manufacturer: Beckman; access	<0.05 ng/mL	Pts with event: 0 / 47 persons Results: unadjusted		
Flores, 2006 ³¹	Subsequent MI	Followup NR	Assay: cTnl Manufacturer: Beckman; access	> 0.05 ng/mL	Pts with event: 14 / 47 persons Results: unadjusted		
Flores, 2006 ³¹	Subsequent MI	Followup NR	Assay: cTnl Manufacturer: Beckman; access	>0.5 ng/mL	Pts with event: 33 / 47 persons Results: unadjusted		
Gaiki, 2012 ³²	All-cause mortality	Years: 2	Assay: hscTnl Manufacturer: other Manufacturer: Ortho Clinical Diagnostics ; Vitro ES	<0.035 ng/mL	No. of events: 6 / 25 persons Results: unadjusted		
Gaiki, 2012 ³²	All-cause mortality	Years: 2	Assay: hscTnl Manufacturer: other Manufacturer: Ortho Clinical Diagnostics ; Vitro ES	>0.035 ng/mL	No. of events: 8 / 25 persons Results: unadjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Gaiki, 2012 ³²	Other composite (Composite of ACS, Revascularization, cardiac arrest, sudden death)	Years: 2	Assay: hscTnl Manufacturer: other Manufacturer: Ortho Clinical Diagnostics ; Vitro ES	<0.035	No. of events: 0 / 25 persons Results: unadjusted		
Gaiki, 2012 ³²	Other composite (Composite of ACS, Revascularization, cardiac arrest, sudden death)	Years: 2	Assay: hscTnl Manufacturer: other Manufacturer: Ortho Clinical Diagnostics ; Vitro ES	>0.035 ng/mL	No. of events: 6 / 25 persons Results: unadjusted		
Geerse, 2012 ³³	All-cause mortality		Assay: cTnl Manufacturer: other Manufacturer: Siemens Medical Solutions Diagnostics ; other; Advia Centaur	< 0.01 mcg/L	% Pts with event: 10.1% / 59 persons Results: adjusted	N: 59 RH: 1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Geerse, 2012 ³³	All-cause mortality		Assay: cTnl Manufacturer: other Manufacturer: Siemens Medical Solutions Diagnostics ; other; Advia Centaur	> 0.01 mcg/L< 0.05 mcg/L	% Pts with event: 36.6% / 94 persons Results: adjusted	N: 94 RH: 2.55 95% CI: 1.05 to 6.21 p value: 0.039; ref group: Grp1	
Geerse, 2012 ³³	All-cause mortality		Assay: cTnl Manufacturer: other Manufacturer: Siemens Medical Solutions Diagnostics ; other; Advia Centaur	> 0.05 mcg/L< 0.1 mcg/L	% Pts with event: 50.4% / 28 persons Results: adjusted	N: 28 RH: 3.57 95% CI: 1.31 to 9.71 p value: 0.013; ref group: Grp1	
Geerse, 2012 ³³	All-cause mortality		Assay: cTnl Manufacturer: other Manufacturer: Siemens Medical Solutions Diagnostics ; other; Advia Centaur	> 0.1 mcg/L	% Pts with event: 72.3% / 25 persons Results: adjusted	N: 25 RH: 6.35 95% CI: 2.43 to 16.49 p value: <0.001; ref group: Grp1	
Geerse, 2012 ³³	Cardio mortality			< 0.01 mcg/L	% Pts with event: 5.05% / 59 persons		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Geerse, 2012 ³³	Cardio mortality			> 0.01 mcg/L < 0.05 mcg/L	% Pts with event: 21.2% / 94 persons		
Geerse, 2012 ³³	Cardio mortality			> 0.05 mcg/L < 0.1 mcg/L	% Pts with event: 32.3% / 28 persons		
Geerse, 2012 ³³	Cardio mortality			> 0.1 mcg/L	% Pts with event: 56.2% / 25 persons		
Goicoechea, 2004 ³⁴	MACE >= 1 year- MACE < 1 year- Revascularization				Results: unadjusted		
Goicoechea, 2004 ³⁴	MACE >= 1 year- MACE < 1 year- Revascularization		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.01 ng/L	Results: unadjusted	N: 156 RH: 1 p value: 0	
Goicoechea, 2004 ³⁴	MACE >= 1 year- MACE < 1 year- Revascularization		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.01 ng/L	Results: unadjusted	N: 20 RH: 12.34 95% CI: 4.91 to 31.02 p value: 0; ref group: Grp1	
Gruberg, 2002 ³⁵	All-cause mortality		Assay: cTnI Manufacturer: Beckman; other; Chemiluminescent Immunoenzymatic Assay	< 0.15 mcg/L	% Pts with event: 9.9% / 66 persons Results: adjusted	OR:	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Gruberg, 2002 ³⁵	All-cause mortality		Assay: cTnl Manufacturer: Beckman; other; Chemiluminescent Immunoenzymatic Assay	> 0.15 mcg/L	% Pts with event: 28% / 50 persons Results: adjusted	OR: 2.26 95% CI: 1.07 to 4.77 p value: 0.03; ref group: Grp1	
Gruberg, 2002 ³⁵	MACE >= 1 year		Assay: cTnl Manufacturer: Beckman; other; Chemiluminescent Immunoenzymatic Assay	< 0.15 mcg/L	% Pts with event: 30.1% / 66 persons		
Gruberg, 2002 ³⁵	MACE >= 1 year		Assay: cTnl Manufacturer: Beckman; other; Chemiluminescent Immunoenzymatic Assay	> 0.15 mcg/L	% Pts with event: 40.3% / 50 persons		
Gruberg, 2002 ³⁵	Revascularization		Assay: cTnl Manufacturer: Beckman; other; Chemiluminescent Immunoenzymatic Assay	< 0.15 mcg/L	% Pts with event: 20% / 66 persons		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Gruberg, 2002 ³⁵	Revascularization		Assay: cTnI Manufacturer: Beckman; other; Chemiluminescent Immunoenzymatic Assay	> 0.15 mcg/L	% Pts with event: 19% / 50 persons		
Gruberg, 2002 ³⁵	Subsequent MI		Assay: cTnI Manufacturer: Beckman; other; Chemiluminescent Immunoenzymatic Assay	< 0.15 mcg/L	% Pts with event: 13.8% / 66 persons		
Gruberg, 2002 ³⁵	Subsequent MI		Assay: cTnI Manufacturer: Beckman; other; Chemiluminescent Immunoenzymatic Assay	> 0.15 mcg/L	% Pts with event: 25% / 50 persons		
Hallen, 2011 ³⁶	All-cause mortality	Days: 926	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.01 mcg/L	Pts with event: 43 / 64 persons Results: adjusted	N: 64 RH: 3.2 95% CI: 1.2 to 8.5 p value: <0.017; ref group: Grp1	
Hallen, 2011 ³⁶	All-cause mortality	Days: 926	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.01 mcg/L	Pts with event: 7 / 43 persons Results: adjusted	N: 43 RH: 1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Han, 2005 ³⁷	Other composite (ACE)				Results: unadjusted		AUC value: 0.6 95% CI: 0.45 to 0.74 Sensitivity value: 27 Specificity value: 96
Han, 2005 ³⁷	Other composite (ACE)		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.01 mcg/L	Results: unadjusted		AUC value: 0.6 95% CI: 0.45 to 0.74 Sensitivity value: 27 Specificity value: 96
Han, 2009 ³⁸	Other composite (Cardiac Events)	Years: 3	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	Pts with event: 4 / 86 persons Results: adjusted	N: 86 RH: 1	
Han, 2009 ³⁸	Other composite (Cardiac Events)	Years: 3	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 9 / 21 persons Results: adjusted	N: 21 RH: 5.89 95% CI: 1.24 to 28 p value: <0.05; ref group: Grp1	
Hasegawa, 2012 ³⁹	Other composite (Cardiac Events)		Assay: hscTnT Manufacturer: Roche; NR	<9 pg/mL	% Pts with event: 0.88% / 113 persons Results: adjusted	N: 113 RH: 1	
Hasegawa, 2012 ³⁹	Other composite (Cardiac Events)		Assay: hscTnT Manufacturer: Roche; NR	>33 pg/mL	% Pts with event: 41.4% / 108 persons Results: adjusted	N: 108 RH: 6.18 95% CI: 1.38 to 27.69; ref group: Grp1	
Hasegawa, 2012 ³⁹	Other composite (Cardiac Events)		Assay: hscTnT Manufacturer: Roche; NR	10-18 pg/mL	% Pts with event: 11.5% / 111 persons Results: adjusted	N: 111 RH: 2.54 95% CI: 0.54 to 11.93; ref group: Grp1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Hasegawa, 2012 ³⁹	Other composite (Cardiac Events)		Assay: hscTnT Manufacturer: Roche; NR	19-32 pg/mL	% Pts with event: 19% / 110 persons Results: adjusted	N: 110 RH: 3 95% CI: 0.66 to 13.7; ref group: Grp1	
Havekes, 2006 ⁴⁰	All-cause mortality	Followup NR	Assay: cTnT Manufacturer: Roche; NR	> 0.05 mcg/L < 0.1 mcg/L	Results: adjusted	N: 188 RH: 1.2 95% CI: 0.9 to 1.7; ref group: Grp1	
Havekes, 2006 ⁴⁰	All-cause mortality	Followup NR	Assay: cTnT Manufacturer: Roche; NR	> 0.1 mcg/L	Results: adjusted	N: 93 RH: 2.2 95% CI: 1.5 to 3.3; ref group: Grp1	
Havekes, 2006 ⁴⁰	All-cause mortality	Followup NR	Assay: cTnT Manufacturer: Roche; other; 3rd generation immunochemical test	< 0.04 mcg/L	Results: adjusted	N: 566 RH: 1	
Havekes, 2006 ⁴⁰	Cardio mortality	Followup NR	Assay: cTnT Manufacturer: Roche; NR	< 0.04 mcg/L	Results: adjusted	N: 566 RH: 1	
Havekes, 2006 ⁴⁰	Cardio mortality	Followup NR	Assay: cTnT Manufacturer: Roche; NR	> 0.04 mcg/L < 0.1 mcg/L	Results: adjusted	N: 188 RH: 1 95% CI: 0.6 to 1.7; ref group: Grp1	
Havekes, 2006 ⁴⁰	Cardio mortality	Followup NR	Assay: cTnT Manufacturer: Roche; NR	> 0.1 mcg/L	Results: adjusted	N: 93 RH: 1.9 95% CI: 0.9 to 3.7; ref group: Grp1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Heeschen, 2000 ⁴¹	MACE < 1 year-Revascularization	Days: 30	Assay: cTnl Manufacturer: other Manufacturer: Abbott; other; AxSYM	< 1 mcg/L	Pts with event: 0 / 24 persons Results: unadjusted		
Heeschen, 2000 ⁴¹	MACE < 1 year-Revascularization	Days: 30	Assay: cTnl Manufacturer: other Manufacturer: Abbott; other; AxSYM	> 1 mcg/L	Pts with event: 0 / 2 persons Results: unadjusted		
Heeschen, 2000 ⁴¹	MACE < 1 year-Revascularization	Days: 30	Assay: cTnT Manufacturer: other Manufacturer: Boehringer; Elecsys	< 0.06 mcg/L	Pts with event: 0 / 12 persons Results: unadjusted		
Heeschen, 2000 ⁴¹	MACE < 1 year-Revascularization	Days: 30	Manufacturer: other Manufacturer: Boehringer; Elecsys	> 0.06 mcg/L	Pts with event: 0 / 14 persons Results: unadjusted		
Helleskov Madsen, 2008 ⁴²	All-cause mortality	Days: 970	Assay: cTnl Manufacturer: Beckman; access	< 0.06 mcg/L	Pts with event: 28 / 97 persons Results: adjusted	RR: 1	
Helleskov Madsen, 2008 ⁴²	All-cause mortality	Days: 970	Assay: cTnl Manufacturer: Beckman; access	> 0.06 mcg/L	Pts with event: 6 / 12 persons Results: adjusted	RR: 1.9 95% CI: 0.6 to 6.4; ref group: Grp3	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Helleskov Madsen, 2008 ⁴²	All-cause mortality	Days: 970	Assay: cTnI Manufacturer: Dade Behring; dimension	< 0.14 mcg/L	Pts with event: 30 / 101 persons Results: adjusted	RR: 1	
Helleskov Madsen, 2008 ⁴²	All-cause mortality	Days: 970	Assay: cTnI Manufacturer: Dade Behring; dimension	> 0.14 mcg/L	Pts with event: 4 / 8 persons Results: adjusted	RR: 2 95% CI: 0.7 to 5.8 p value: ns; ref group: Grp3	
Helleskov Madsen, 2008 ⁴²	All-cause mortality	Days: 970	Assay: cTnI Manufacturer: other Manufacturer: TOSOH; AIA-600II	< 0.1 mcg/L	Pts with event: 32 / 107 persons Results: adjusted	RR: 1	
Helleskov Madsen, 2008 ⁴²	All-cause mortality	Days: 970	Assay: cTnI Manufacturer: other Manufacturer: TOSOH; AIA-600II	> 0.1 mcg/L	Pts with event: 2 / 2 persons Results: adjusted	RR: 2.8 95% CI: 0.6 to 13.4 p value: ns; ref group: Grp1	
Helleskov Madsen, 2008 ⁴²	All-cause mortality	Days: 970	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.03 mcg/L	Pts with event: 5 / 52 persons Results: adjusted	RR: 1	
Helleskov Madsen, 2008 ⁴²	All-cause mortality	Days: 970	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.03 mcg/L	Pts with event: 29 / 57 persons Results: adjusted	RR: 7.7 95% CI: 2.7 to 21.9; ref group: Grp1	
Hickman, 2009 ⁴³	All-cause mortality		Assay: cTnI Manufacturer: other Manufacturer: Abbott; Architect ci8200		Results: unadjusted	OR: ref	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Hickman, 2009 ⁴³	All-cause mortality		Assay: cTnl Manufacturer: other Manufacturer: Abbott; Architect ci8200	< 0.01 mcg/L	Pts with event: 1 / 34 persons Results: unadjusted		
Hickman, 2009 ⁴³	All-cause mortality		Assay: cTnl Manufacturer: other Manufacturer: Abbott; Architect ci8200	< 0.043 mcg/L	Results: unadjusted	N: 104 OR: ref	
Hickman, 2009 ⁴³	All-cause mortality		Assay: cTnl Manufacturer: other Manufacturer: Abbott; Architect ci8200	> 0.011 mcg/L< 0.02 mcg/L	Pts with event: 3 / 35 persons Results: unadjusted		
Hickman, 2009 ⁴³	All-cause mortality		Assay: cTnl Manufacturer: other Manufacturer: Abbott; Architect ci8200	> 0.021 mcg/L< 0.043 mcg/L	Pts with event: 10 / 35 persons Results: unadjusted		
Hickman, 2009 ⁴³	All-cause mortality		Assay: cTnl Manufacturer: other Manufacturer: Abbott; Architect ci8200	> 0.043 mcg/L	Results: unadjusted	N: 34 OR: 4.5 95% CI: 1.86 to 10.91 p value: <0.001; ref group: Grp2	
Hickman, 2009 ⁴³	All-cause mortality		Assay: cTnl Manufacturer: other Manufacturer: Abbott; Architect ci8200	> 0.043 mcg/L	Pts with event: 14 / 34 persons Results: unadjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Hickman, 2009 ⁴³	All-cause mortality		Assay: cTnI Manufacturer: other Manufacturer: Abbott; Architect ci8200	detectable	Results: unadjusted	OR: 6.37 95% CI: 0.82 to 49.58 p value: 0.087; ref group: Grp2	
Hickman, 2009 ⁴³	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.01 mcg/L	Pts with event: 1 / 35 persons Results: unadjusted		
Hickman, 2009 ⁴³	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.098 mcg/L	Results: unadjusted	N: 107 OR: ref	
Hickman, 2009 ⁴³	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.011 mcg/L< 0.042 mcg/L	Pts with event: 6 / 36 persons Results: unadjusted		
Hickman, 2009 ⁴³	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.043 mcg/L< 0.097 mcg/L	Pts with event: 7 / 36 persons Results: unadjusted		
Hickman, 2009 ⁴³	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.098 mcg/L	Results: unadjusted	N: 36 OR: 4.23 95% CI: 1.76 to 10.14 p value: 0.001; ref group: Grp2	
Hickman, 2009 ⁴³	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.098 mcg/L	Pts with event: 14 / 36 persons Results: unadjusted		
Hickman, 2009 ⁴³	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	detectable	Results: unadjusted	OR: 11.33 95% CI: 1.48 to 86.79 p value: 0.004; ref group: Grp2	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Hickman, 2009 ⁴³	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	not detectable	Results: unadjusted	OR: ref	
Hickson, 2008 ⁴⁴	All-cause mortality				Results: unadjusted		Sensitivity value: 70% Specificity value: 69%
Hickson, 2008 ⁴⁴	All-cause mortality		Assay: cTnT Manufacturer: Roche; NR	< 0.03 mcg/L	% Pts with event: 2% / 437 persons Results: unadjusted		Sensitivity value: 70% Specificity value: 69%
Hickson, 2008 ⁴⁴	All-cause mortality		Assay: cTnT Manufacturer: Roche; NR	> 0.03 mcg/L	% Pts with event: 12% / 207 persons Results: unadjusted		Sensitivity value: 70% Specificity value: 69%
Hickson, 2008 ⁴⁴	All-cause mortality		Assay: cTnT Manufacturer: Roche; NR	< 0.01 mcg/L	Results: adjusted	RH: ref	
Hickson, 2008 ⁴⁴	All-cause mortality		Assay: cTnT Manufacturer: Roche; NR	< 0.01 mcg/L	% Pts with event: 2% / 253 persons Results: unadjusted	N: 253 RH: ref	
Hickson, 2008 ⁴⁴	All-cause mortality		Assay: cTnT Manufacturer: Roche; NR	> >=0.01 mcg/L	% Pts with event: 15% / 81 persons Results: unadjusted	N: 81 RH: 4.085 95% CI: 11.74 to 1.42 p value: 0.009; ref group: Grp1	
Hickson, 2008 ⁴⁴	All-cause mortality		Assay: cTnT Manufacturer: Roche; NR	> 0.01 mcg/L < 0.03 mcg/L	% Pts with event: 3% / 184 persons Results: unadjusted	N: 184 p value: NS; ref group: Grp1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Hickson, 2008 ⁴⁴	All-cause mortality		Assay: cTnT Manufacturer: Roche; NR	> 0.04 mcg/L 0.09 mcg/L	% Pts with event: 10% / 126 persons Results: unadjusted	N: 126 RH: 3.011 95% CI: 8.61 to 1.05 p value: 0.04; ref group: Grp1	
Hickson, 2008 ⁴⁴	All-cause mortality		Assay: cTnT Manufacturer: Roche; NR	cTnT were analyzed as after grouping values at four levels: <0.01, 0.01-0.03, 0.04-0.09, >=0.01 ng/mL	Results: adjusted	RH: 1.642 95% CI: 1.07 to 2.51 p value: 0.022; ref group: Grp1	
Hickson, 2009 ⁴⁵	MACE >= 1 year		Assay: cTnT Manufacturer: Roche; NR	analyzed as groups: 0.01-0.03, 0.04-0.09, >=0.1 ng/mL	Results: adjusted	RH: 1.584 95% CI: 1.125 to 2.225 p value: 0.008; ref group: Grp1	
Hickson, 2009 ⁴⁵	MACE >= 1 year		Assay: cTnT Manufacturer: Roche; NR	< 0.01 mcg/L	Results: adjusted	RH: ref	
Hickson, 2009 ⁴⁵	MACE >= 1 year		Assay: cTnT Manufacturer: Roche; NR	analyzed as groups: 0.01-0.03, 0.04-0.09; >=0.1 ng/mL	Results: unadjusted	RH: 1.693 95% CI: 1.693 to 2.473 p value: 0.006; ref group: Grp1	
Hickson, 2009 ⁴⁵	MACE >= 1 year		Assay: cTnT Manufacturer: Roche; NR	< 0.01 mcg/L	Results: unadjusted	RH: ref	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Hickson, 2009 ⁴⁵	MACE >= 1 year		Assay: cTnT Manufacturer: Roche; NR	> >=0.1 mcg/L	Results: unadjusted	N: 64 RH: 6.126 95% CI: 2.124 to 17.665 p value: 0.001; ref group: Grp1	
Hickson, 2009 ⁴⁵	MACE >= 1 year		Assay: cTnT Manufacturer: Roche; NR	> 0.04 mcg/L < 0.1 mcg/L	Results: unadjusted	N: 115 RH: 4.478 95% CI: 1.656 to 12.109 p value: 0.003; ref group: Grp1	
Hickson, 2009 ⁴⁵	MACE >= 1 year		Assay: cTnT Manufacturer: Roche; NR	> 0.01 mcg/L < 0.03 mcg/L	Results: unadjusted	N: 160 RH: 2.52 95% CI: 0.897 to 7.079 p value: 0.08; ref group: Grp1	
Hickson, 2009 ⁴⁵	MACE >= 1 year		Assay: cTnT Manufacturer: Roche; NR	< 0.01 mcg/L	Results: unadjusted	N: 264 RH: ref	
Hocher, 2003 ⁴⁶	All-cause mortality	Days: 775	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.054 mcg/L		N: 84 RR: 1 ; ref group: other; ref group: all diabetic Pts	
Hocher, 2003 ⁴⁶	All-cause mortality	Days: 775	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.054 mcg/L		N: 43 RR: 1.464 95% CI: 0.667 to 3.216 p value: 0.342; ref group: Grp1	
Hocher, 2003 ⁴⁶	All-cause mortality	Days: 775	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.054 mcg/L		N: 161 RR: 1 ; ref group: other; ref group: all non-diabetic Pts	
Hocher, 2003 ⁴⁶	All-cause mortality	Days: 775	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.054 mcg/L		N: 30 RR: 3.998 95% CI: 1.583 to 10.098 p value: 0.003; ref group: Grp1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Hocher, 2003 ⁴⁶	All-cause mortality	Days: 775	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.054 mcg/L		N: 245 RR: 1 ; ref group: other; ref group: total sample	
Hocher, 2003 ⁴⁶	All-cause mortality	Days: 775	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.054 mcg/L		N: 73 RR: 2.75 95% CI: 1.538 to 4.916 p value: 0.001; ref group: Grp1	
Hocher, 2003 ⁴⁶	Cardio mortality	Days: 775	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.054 mcg/L		N: 84 RR: 1	
Hocher, 2003 ⁴⁶	Cardio mortality	Days: 775	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.054 mcg/L		N: 28 RR: 1.195 95% CI: 0.45 to 3.173 p value: 0.72; ref group: Grp1	
Hocher, 2003 ⁴⁶	Cardio mortality	Days: 775	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.054 mcg/L		N: 161 RR: 1 ; ref group: other; ref group: all non-diabetic Pts	
Hocher, 2003 ⁴⁶	Cardio mortality	Days: 775	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.054 mcg/L		N: 13 RR: 5.378 95% CI: 1.108 to 26.1 p value: 0.037; ref group: Grp1	
Hocher, 2003 ⁴⁶	Cardio mortality	Days: 775	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.054 mcg/L		N: 245 RR: 1 ; ref group: other; ref group: total sample	
Hocher, 2003 ⁴⁶	Cardio mortality	Days: 775	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.054 mcg/L		N: 41 RR: 2.478 95% CI: 1.129 to 5.436 p value: 0.024; ref group: Grp1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Hocher, 2004 ⁴⁷	All-cause mortality	Days: 1140	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.039 mcg/L	Results: unadjusted	RR: 1	
Hocher, 2004 ⁴⁷	All-cause mortality	Days: 1140	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.039 mcg/L	Results: unadjusted	RR: 9.06 95% CI: 2.62 to 31.35 p value: 0.001; ref group: Grp1	
Hocher, 2004 ⁴⁷	All-cause mortality	Days: 1140	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.039 mcg/L	Results: unadjusted	RR: 1	
Hocher, 2004 ⁴⁷	All-cause mortality	Days: 1140	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.039 mcg/L	Results: unadjusted	RR: 3.22 95% CI: 1.6 to 6.49 p value: 0.001; ref group: Grp1	
Hocher, 2004 ⁴⁷	Cardio mortality	Days: 1140			Results: unadjusted	RR: 17.17 95% CI: 2.13 to 138.29 p value: 0.008; ref group: Grp1	
Hocher, 2004 ⁴⁷	Cardio mortality	Days: 1140	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.039 mcg/L	Results: unadjusted	N: 123 RR: 1 ; ref group: other; ref group: total sample	
Hocher, 2004 ⁴⁷	Cardio mortality	Days: 1140	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.039 mcg/L	Results: unadjusted	RR: 1 ; ref group: Grp1	
Hocher, 2004 ⁴⁷	Cardio mortality	Days: 1140				RR: 4.2 95% CI: 1.6 to 11.07 p value: 0.004; ref group: Grp1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Hocher, 2004 ⁴⁷	Cardio mortality	Days: 1140	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.039 mcg/L		N: 122 ; ref group: other; ref group: total sample	
Hocher, 2004 ⁴⁷	Cardio mortality	Days: 1140	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.039 mcg/L		RR: 1 ; ref group: Grp1	
Hocher, 2008 ⁴⁸	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.053 mcg/L	Results: adjusted	RR: 1 p value: 0.048	
Hocher, 2008 ⁴⁸	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.053 mcg/L	Results: adjusted	RR: 2.01 95% CI: 1.01 to 4.01 p value: 0.048; ref group: Grp1	
Hocher, 2008 ⁴⁸	All-cause mortality	Weeks: 52	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.034 mcg/L	Results: adjusted	RR: 1 p value: <0.001	
Hocher, 2008 ⁴⁸	All-cause mortality	Weeks: 52	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.034 mcg/L	Results: adjusted	RR: 3.54 95% CI: 1.92 to 6.54 p value: <0.001; ref group: Grp1	
Hocher, 2008 ⁴⁸	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.039 mcg/L	Results: adjusted	RR: 1 p value: <0.001	
Hocher, 2008 ⁴⁸	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.039 mcg/L	Results: adjusted	RR: 2.66 95% CI: 1.69 to 4.18 p value: <0.001; ref group: Grp1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Hocher, 2008 ⁴⁸	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.053 mcg/L	Results: adjusted	RR: 1 p value: 0.23	
Hocher, 2008 ⁴⁸	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.053 mcg/L	Results: adjusted	RR: 1.69 95% CI: 0.72 to 3.96 p value: 0.23; ref group: Grp1	
Hocher, 2008 ⁴⁸	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.034 mcg/L	Results: adjusted	RR: 1 p value: 0.004	
Hocher, 2008 ⁴⁸	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.034 mcg/L	Results: adjusted	RR: 5.16 95% CI: 1.67 to 15.88 p value: 0.004; ref group: Grp1	
Hocher, 2008 ⁴⁸	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.039 mcg/L	Results: adjusted	RR: 1 p value: 0.001	
Hocher, 2008 ⁴⁸	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.039 mcg/L	Results: adjusted	RR: 2.99 95% CI: 1.53 to 5.86 p value: 0.001; ref group: Grp1	
Hojs, 2005 ⁴⁹	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.05 mcg/L	Pts with event: 3 / 51 persons Results: unadjusted		
Hojs, 2005 ⁴⁹	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	Pts with event: 5 / 66 persons Results: unadjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Hojs, 2005 ⁴⁹	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.05 mcg/L	Pts with event: 11 / 39 persons Results: unadjusted		
Hojs, 2005 ⁴⁹	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 9 / 24 persons Results: unadjusted		
Holden, 2012 ⁵⁰	All-cause mortality	Years: 3.5	Assay: cTnT Manufacturer: Roche; E170 Analyzer - immunoassay		Results: adjusted	RH: 0.76 95% CI: 0.24 to 2.4 p value: 0.2; ref group: Grp1	
Holden, 2012 ⁵⁰	All-cause mortality	Years: 3.5	Assay: cTnT Manufacturer: Roche; E170 Analyzer - immunoassay		Results: adjusted	RH: 1	
Hung, 2004 ⁵¹	MACE < 1 year		Assay: cTnI Manufacturer: DPC; immulite	< 0.2 ng/L	Results: adjusted	OR: 1 p value: 0.012	
Hung, 2004 ⁵¹	MACE < 1 year		Assay: cTnI Manufacturer: DPC; immulite	> 0.2 ng/L	Results: adjusted	OR: 15 95% CI: 1.8 to 125.5 p value: 0.012; ref group: Grp1	
Hung, 2004 ⁵¹	MACE < 1 year		Assay: cTnI Manufacturer: DPC; immulite	< 0.2 ng/L	Results: unadjusted	OR: 1 p value: 0.019	
Hung, 2004 ⁵¹	MACE < 1 year		Assay: cTnI Manufacturer: DPC; immulite	> 0.2 ng/L	Results: unadjusted	OR: 8 95% CI: 1.4 to 45.5 p value: 0.019; ref group: Grp1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Hussein, 2004 ⁵²	All-cause mortality		Assay: cTnI Manufacturer: other Manufacturer: Abbott; NR	< 0 ng/L	Pts with event: 8 / 84 persons Results: unadjusted		
Hussein, 2004 ⁵²	All-cause mortality		Assay: cTnI Manufacturer: other Manufacturer: Abbott; NR	> 0 ng/L	Pts with event: 4 / 9 persons Results: unadjusted		
Ie, 2004 ⁵³	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.03 ng/L	Pts with event: 0 % Pts with event: 0% / 9 persons		
Ie, 2004 ⁵³	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.03 mcg/L	Pts with event: 16 / 40 persons		
Ie, 2004 ⁵³	MACE >= 1 year	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.03 mcg/L	Pts with event: 5 No. of events: 7 / 30 persons		
Ie, 2004 ⁵³	MACE >= 1 year	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.03 ng/L	Pts with event: 0 No. of events: 0 / 19 persons		
Iliou, 2003 ⁵⁴	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	Pts with event: 41 % Pts with event: 20.6% / 199 persons Results: adjusted	N: 199 RR: 1	
Iliou, 2003 ⁵⁴	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.15 mcg/L	Pts with event: 49 % Pts with event: 24.5% / 200 persons Results: adjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Iliou, 2003 ⁵⁴	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 23 % Pts with event: 23.4% / 47 persons Results: adjusted	N: 47 RR: 1.83 95% CI: 1.1 to 3.1 p value: 0.03; ref group: Grp1	
Iliou, 2003 ⁵⁴	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.15 mcg/L	Pts with event: 15 % Pts with event: 32.6% / 46 persons Results: adjusted		
Iliou, 2003 ⁵⁴	Cardio mortality	Years: 1	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	Pts with event: 8 % Pts with event: 3.8% / 210 persons Results: adjusted	N: 199 RR: 1	
Iliou, 2003 ⁵⁴	Cardio mortality	Years: 1	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.15 mcg/L	Pts with event: 15 % Pts with event: 7.1% / 212 persons Results: adjusted		
Iliou, 2003 ⁵⁴	Cardio mortality	Years: 1	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 9 % Pts with event: 18.7% / 48 persons Results: adjusted	N: 47 RR: 2.9 95% CI: 1.05 to 7.9 p value: 0.04; ref group: Grp1	
Iliou, 2003 ⁵⁴	Cardio mortality	Years: 1	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.15 mcg/L	Pts with event: 2 % Pts with event: 4.3% / 46 persons Results: adjusted		
Iliou, 2003 ⁵⁴	MACE >= 1 year	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	Pts with event: 34 % Pts with event: 17.1% / 199 persons Results: adjusted	N: 199 RR: 1	
Iliou, 2003 ⁵⁴	MACE >= 1 year	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.15 mcg/L	Pts with event: 42 % Pts with event: 21% / 200 persons Results: adjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Iliou, 2003 ⁵⁴	MACE >= 1 year	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 15 % Pts with event: 31.9% / 47 persons Results: adjusted	N: 47 RR: 1.9 95% CI: 1.02 to 3.4 p value: 0.04; ref group: Grp1	
Iliou, 2003 ⁵⁴	MACE >= 1 year	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.15 mcg/L	Pts with event: 7 % Pts with event: 15.2% / 46 persons Results: adjusted		
Ilva, 2008 ⁵⁵	All-cause mortality		Assay: cTnI Manufacturer: other Manufacturer: Abbott; other; Architect STAT	< 0.032 mcg/L	/ 67 persons Results: unadjusted	N: 67 RR:	
Ilva, 2008 ⁵⁵	All-cause mortality		Assay: cTnI Manufacturer: other Manufacturer: Abbott; other; Architect STAT	> 0.032 mcg/L	/ 96 persons Results: unadjusted	N: 96 (59% - cTnI) RR: 1.4 95% CI: 0.7 to 2.8 p value: ns; ref group: Grp3	
Ilva, 2008 ⁵⁵	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.03 mcg/L	/ 90 persons Results: unadjusted	N: 90 RR:	
Ilva, 2008 ⁵⁵	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.03 mcg/L	/ 73 persons Results: unadjusted	N: 73 (45% - cTnT) RR: 1.3 95% CI: 0.7 to 2.5 p value: ns; ref group: Grp1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Ishii, 2001 ⁵⁶	All-cause mortality	Years: 2					AUC value: 0.517 95% CI: 0.36 to 0.674 Sensitivity value: 17.60% Specificity value: 96.30%
Ishii, 2001 ⁵⁶	All-cause mortality	Years: 2					AUC value: 0.517 95% CI: 0.36 to 0.674 Sensitivity value: 17.60% Specificity value: 96.30%
Ishii, 2001 ⁵⁶	All-cause mortality	Years: 2	Assay: cTnl Manufacturer: Beckman; access	< 0.1 mcg/L	Pts with event: 16 % Pts with event: 17% / 94 persons		AUC value: 0.517 95% CI: 0.36 to 0.674 Sensitivity value: 17.60% Specificity value: 96.30%
Ishii, 2001 ⁵⁶	All-cause mortality	Years: 2	Assay: cTnl Manufacturer: Beckman; access	> 0.1 mcg/L	Pts with event: 3 % Pts with event: 50% / 6 persons		AUC value: 0.517 95% CI: 0.36 to 0.674 Sensitivity value: 17.60% Specificity value: 96.30%

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Ishii, 2001 ⁵⁶	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	Pts with event: 7 % Pts with event: 9% / 75 persons Results: adjusted	N: 75 RH: REF	AUC value: 0.857 95% CI: 0.773 to 0.941 Sensitivity value: 62.30% Specificity value: 86.70%
Ishii, 2001 ⁵⁶	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 12 % Pts with event: 48% / 25 persons Results: adjusted	N: 25 RH: 3.71 95% CI: 2.66 to 4.77 p value: <0.05; ref group: Grp1	AUC value: 0.857 95% CI: 0.773 to 0.941 Sensitivity value: 62.30% Specificity value: 86.70%
Ishii, 2001 ⁵⁶	Cardio mortality	Years: 2			Results: adjusted		AUC value: 0.861 95% CI: 0.749 to 0.972 Sensitivity value: 69.50% Specificity value: 82.50%
Ishii, 2001 ⁵⁶	Cardio mortality	Years: 2	Assay: Access		Results: adjusted		AUC value: 0.861 95% CI: 0.749 to 0.972 Sensitivity value: 69.50% Specificity value: 82.50%

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Ishii, 2001 ⁵⁶	Cardio mortality	Years: 2	Assay: cTnT Manufacturer: Roche; other; ECLusys	< 0.1 mcg/L	Pts with event: 3 % Pts with event: 4% / 75 persons Results: adjusted	N: 75 RH: REF	AUC value: 0.861 95% CI: 0.749 to 0.972 Sensitivity value: 69.50% Specificity value: 82.50%
Ishii, 2001 ⁵⁶	Cardio mortality	Years: 2	Assay: cTnT Manufacturer: Roche; other; ECLusys	> 0.1 mcg/L	Pts with event: 7 % Pts with event: 28% / 25 persons Results: adjusted	N: 25 RH: 6.24 95% CI: 4.89 to 7.59 p value: <0.001; ref group: Grp1	AUC value: 0.861 95% CI: 0.749 to 0.972 Sensitivity value: 69.50% Specificity value: 82.50%
Ishii, 2001 ⁵⁶	Cardio mortality	Years: 2					AUC value: 0.609 95% CI: 0.394 to 0.824 Sensitivity value: 30.30% Specificity value: 94.40%
Ishii, 2001 ⁵⁶	Cardio mortality	Years: 2	Assay: cTnI Manufacturer: Beckman	> 0.1 mcg/L	Pts with event: 3 % Pts with event: 50% / 6 persons		AUC value: 0.609 95% CI: 0.394 to 0.824 Sensitivity value: 30.30% Specificity value: 94.40%

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Ishii, 2001 ⁵⁶	Cardio mortality	Years: 2	Assay: cTnI Manufacturer: Beckman; access	< 0.1 mcg/L	Pts with event: 7 % Pts with event: 7% / 94 persons		AUC value: 0.609 95% CI: 0.394 to 0.824 Sensitivity value: 30.30% Specificity value: 94.40%
Jensen, 2012 ⁵⁷	All-cause mortality	Years: 4.4	Assay: cTnT Manufacturer: Roche; Elecsys	< or = to 14 ng/L		N: 128 RH: 1	
Jensen, 2012 ⁵⁷	All-cause mortality	Years: 4.4	Assay: cTnT Manufacturer: Roche; Elecsys	> 14 ng/L		N: 65 RH: 1.32 95% CI: 0.62 to 2.81 p value: 0.48; ref group: Grp1	
Jensen, 2012 ⁵⁷	Cardio mortality	Years: 4.4	Assay: cTnT Manufacturer: Roche; Elecsys	> 14 ng/L		N: 65 RH: 1.34 95% CI: 0.44 to 4.1 p value: 0.61; ref group: Grp1	
Kalaji, 2012 ⁵⁸	All-cause mortality	Days: 551					
Kalaji, 2012 ⁵⁸	All-cause mortality	Days: 551	Assay: cTnT Manufacturer: Roche; Elecsys			Results: adjusted	
Kalaji, 2012 ⁵⁸	All-cause mortality	Days: 551	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 ng/L	No. of events: 27 / 115 persons Results: adjusted	N: 115	
Kalaji, 2012 ⁵⁸	All-cause mortality	Days: 551	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 ng/L	No. of events: 13 / 30 persons Results: adjusted	N: 30 RH: 1.9 95% CI: 0.9 to 3.9 p value: 0.07; ref group: Grp1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kalaji, 2012 ⁵⁸	All-cause mortality	Days: 551	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.01 mcg/L	% Pts with event: 7.1% No. of events: 1 / 14 persons Results: adjusted	N: 14 RH: 1	
Kalaji, 2012 ⁵⁸	All-cause mortality	Days: 551	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.03 mcg/L	% Pts with event: 15.4% No. of events: 6 / 39 persons Results: adjusted	N: 39 RH: 1	
Kalaji, 2012 ⁵⁸	All-cause mortality	Days: 551	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.01 mcg/L	% Pts with event: 29.8% No. of events: 39 / 131 persons Results: adjusted	N: 131 RH: 3.9 95% CI: 0.5 to 28.6 p value: NS; ref group: Grp1	
Kalaji, 2012 ⁵⁸	All-cause mortality	Days: 551	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.03 mcg/L	% Pts with event: 32.1% No. of events: 34 / 106 persons Results: adjusted	N: 106 RH: 1.9 95% CI: 0.8 to 4.7 p value: NS; ref group: Grp1	
Kalaji, 2012 ⁵⁸	All-cause mortality	Days: 551	Assay: cTnl Manufacturer: other Manufacturer: Siemens; other; Immulite Troponin I kit	<0.2 ng/mL	% Pts with event: 25.5% No. of events: 24 / 94 persons Results: adjusted	N: 94 RH: 1	
Kalaji, 2012 ⁵⁸	All-cause mortality	Days: 551	Assay: cTnl Manufacturer: other Manufacturer: Siemens; other; Immulite Troponin I kit	>0.2 ng/mL	% Pts with event: 31.4% No. of events: 16 / 51 persons Results: adjusted	N: 51 RH: 1.6 95% CI: 0.8 to 3 p value: NS; ref group: Grp1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kang, 2009 ⁵⁹	All-cause mortality	Followup NR	Assay: cTnl Manufacturer: Beckman; AccuTnl	< 0.2 mcg/L	% Pts with event: 23.9% / 46 persons Results: adjusted	N: 46 hazard ratio: 1 p value: 0.001	
Kang, 2009 ⁵⁹	All-cause mortality	Followup NR	Assay: cTnl Manufacturer: Beckman; AccuTnl	> 0.2 mcg/L	% Pts with event: 55% / 20 persons Results: adjusted	N: 20 hazard ratio: 5.9 95% CI: 2.06 to 16.87 p value: 0.001; ref group: Grp1	
Kang, 2009 ⁵⁹	All-cause mortality	Days: 90	Assay: cTnl Manufacturer: Beckman; AccuTnl	< 0.2 mcg/L	% Pts with event: 35.2% / 71 persons Results: adjusted	N: 71 OR: 1	
Kang, 2009 ⁵⁹	All-cause mortality	Days: 90	Assay: cTnl Manufacturer: Beckman; AccuTnl	> 0.2 mcg/L	% Pts with event: 60% / 50 persons Results: adjusted	N: 50 OR: 5.13 95% CI: 1.73 to 15.18 p value: 0.003; ref group: Grp1	
Kang, 2009 ⁵⁹	Cardio mortality	Followup NR	Assay: cTnl Manufacturer: Beckman; AccuTnl	< 0.2 mcg/L	Results: adjusted	N: 46 hazard ratio: 1	
Kang, 2009 ⁵⁹	Cardio mortality	Followup NR	Assay: cTnl Manufacturer: Beckman; AccuTnl	> 0.2 mcg/L	Results: adjusted	N: 20 hazard ratio: 5.17 95% CI: 1.16 to 23.16 p value: 0.032; ref group: Grp1	
Kanwar, 2006 ⁶⁰	All-cause mortality		Assay: cTnl Manufacturer: Beckman; NR	< 0.01 mcg/L	Pts with event: 4 / 23 persons		
Kanwar, 2006 ⁶⁰	All-cause mortality		Assay: cTnl Manufacturer: Beckman; NR	> 0.01 mcg/L	Pts with event: 9 / 35 persons		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kanwar, 2006 ⁶⁰	All-cause mortality		Assay: cTnl Manufacturer: Beckman; NR	< 0.01 mcg/L	Pts with event: 7 / 34 persons		
Kanwar, 2006 ⁶⁰	All-cause mortality		Assay: cTnl Manufacturer: Beckman; NR	> 0.01 mcg/L	Pts with event: 46 / 81 persons		
Katerinis, 2008 ⁶¹	All-cause mortality		Assay: cTnl Manufacturer: Beckman; AccuTnl	< 0.09 mcg/L	Pts with event: 0 / 46 persons Results: unadjusted		
Katerinis, 2008 ⁶¹	All-cause mortality		Assay: cTnl Manufacturer: Beckman; AccuTnl	> 0.09 mcg/L	Pts with event: 1 / 4 persons Results: unadjusted		
Katerinis, 2008 ⁶¹	MACE >= 1 year		Assay: cTnl Manufacturer: Beckman; AccuTnl	< 0.09 mcg/L	Pts with event: 0 / 46 persons		
Katerinis, 2008 ⁶¹	MACE >= 1 year		Assay: cTnl Manufacturer: Beckman; AccuTnl	> 0.09 mcg/L	Pts with event: 0 / 4 persons		
Kertai, 2004 ⁶²	All-cause mortality	Years: 4	Assay: cTnT Manufacturer: Roche; other; Trop T	< 0.1 ng/L	Pts with event: 9 / 42 persons Results: unadjusted	RH: 1	
Kertai, 2004 ⁶²	All-cause mortality	Years: 4	Assay: cTnT Manufacturer: Roche; other; Trop T	> 0.1 ng/L	Pts with event: 4 / 16 persons Results: unadjusted	RH: 0.9 95% CI: 0.3 to 3.3; ref group: Grp1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Khan, 2001 ⁶³	All-cause mortality	Years: 2	Assay: cTnl Manufacturer: Sanofi; access	< 0.03 mcg/L	Pts with event: 20 / 102 persons Results: unadjusted		
Khan, 2001 ⁶³	All-cause mortality	Years: 2	Assay: cTnl Manufacturer: Sanofi; access	> 0.03 mcg/L	Pts with event: 4 / 24 persons Results: unadjusted		
Khan, 2001 ⁶³	Cardio mortality	Years: 2	Assay: cTnl Manufacturer: Sanofi; access	< 0.03 mcg/L	Pts with event: 4 / 102 persons		
Khan, 2001 ⁶³	Cardio mortality	Years: 2	Assay: cTnl Manufacturer: Sanofi; access	> 0.03 mcg/L	Pts with event: 1 / 24 persons		
Khan, 2001 ⁶³	hospital readmission	Years: 2	Assay: cTnl Manufacturer: Sanofi; access	< 0.03 mcg/L	No. of events: 177 / 102 persons		
Khan, 2001 ⁶³	hospital readmission	Years: 2	Assay: cTnl Manufacturer: Sanofi; access	> 0.03 mcg/L	No. of events: 30 / 24 persons		
Khan, 2001 ⁶³	hospital readmission	Years: 2	Assay: cTnl Manufacturer: Sanofi; access	< 0.03 mcg/L	No. of events: 53 / 102 persons		
Khan, 2001 ⁶³	hospital readmission	Years: 2	Assay: cTnl Manufacturer: Sanofi; access	> 0.03 mcg/L	No. of events: 8 / 24 persons		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kontos, 2005 ⁶⁴	All-cause mortality	Years: 1	Assay: cTnI Manufacturer: other Manufacturer: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One	For Opus assay: ≤ 1.0 ng/mL	% Pts with event: 14%		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kontos, 2005 ⁶⁴	All-cause mortality	Years: 1	Assay: cTnl Manufacturer: other Manufacturer: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One	For Opus assay: ≥ 2.5 ng/mL. For Bayer assay: ≥ 0.9 ng/mL	% Pts with event: 18%	RR: 1.4 95% CI: 2.4 to 0.8; ref group: Grp2	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kontos, 2005 ⁶⁴	All-cause mortality	Years: 1	Assay: cTnl Manufacturer: other Manufacturer: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One	For Opus assay: 1.0 ng/mL - 2.5 ng/mL. For Bayer assay: 0.3 ng/mL - 0.9 ng/mL	% Pts with event: 29%	RR: 2.6 95% CI: 5.2 to 1.2; ref group: Grp2	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kontos, 2005 ⁶⁴	All-cause mortality	Years: 1	Assay: cTnl Manufacturer: other Manufacturer: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One	For Opus assay: <=1.0 ng/mL	% Pts with event: 4.9%		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kontos, 2005 ⁶⁴	All-cause mortality	Years: 1	Assay: cTnl Manufacturer: other Manufacturer: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One	For Opus assay: >=2.5 ng/mL. For Bayer assay: >=0.9 ng/mL	% Pts with event: 9.7%	RR: 2.1 95% CI: 3.3 to 1.3; ref group: Grp2	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kontos, 2005 ⁶⁴	All-cause mortality	Years: 1	Assay: cTnl Manufacturer: other Manufacturer: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One	For Opus assay: 1.0 ng/mL - 2.5 ng/mL. For Bayer assay: 0.3 ng/mL - 0.9 ng/mL	% Pts with event: 7.1%	RR: 1.5 95% CI: 3.1 to 0.7; ref group: Grp2	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kontos, 2005 ⁶⁴	All-cause mortality	Years: 1	Assay: cTnl Manufacturer: other Manufacturer: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One	For Opus assay: <=1.0 ng/mL	% Pts with event: 26%	95% CI: to	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kontos, 2005 ⁶⁴	All-cause mortality	Years: 1	Assay: cTnl Manufacturer: other Manufacturer: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One	For Opus assay: ≥ 2.5 ng/mL. For Bayer assay: ≥ 0.9 ng/mL	% Pts with event: 57%	RR: 3.8 95% CI: 6.8 to 2; ref group: Grp2	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kontos, 2005 ⁶⁴	All-cause mortality	Years: 1	Assay: cTnl Manufacturer: other Manufacturer: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One	For Opus assay: 1.0 ng/mL - 2.5 ng/mL. For Bayer assay: 0.3 ng/mL - 0.9 ng/mL	% Pts with event: 43%	RR: 2.1 95% CI: 4.8 to 0.9; ref group: Grp2	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kontos, 2005 ⁶⁴	Cardio mortality	Years: 1	Assay: cTnl Manufacturer: other Manufacturer: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One	For Opus assay: <=1.0 ng/mL	% Pts with event: 7.7%		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kontos, 2005 ⁶⁴	Cardio mortality	Years: 1	Assay: cTnl Manufacturer: other Manufacturer: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One	For Opus assay: 1.0 ng/mL - 2.5 ng/mL. For Bayer assay: 0.3 ng/mL - 0.9 ng/mL	% Pts with event: 17%	RR: 2.5 95% CI: 5.9 to 1; ref group: Grp2	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kontos, 2005 ⁶⁴	Cardio mortality	Years: 1	Manufacturer: other Manufacturer: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One	For Opus assay: >=2.5 ng/mL. For Bayer assay: >=0.9 ng/mL	% Pts with event: 15%	RR: 2.1 95% CI: 4 to 1.1; ref group: Grp2	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kontos, 2005 ⁶⁴	Cardio mortality	Years: 1	Assay: cTnl Manufacturer: other Manufacturer: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One	For Opus assay: 1.0 ng/mL - 2.5 ng/mL. For Bayer assay: 0.3 ng/mL - 0.9 ng/mL	% Pts with event: 5.4%	RR: 2.7 95% CI: 6.5 to 1.1; ref group: Grp2	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kontos, 2005 ⁶⁴	Cardio mortality	Years: 1	Assay: cTnl Manufacturer: other Manufacturer: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One	For Opus assay: ≥ 2.5 ng/mL. For Bayer assay: ≥ 0.9 ng/mL	% Pts with event: 7.2%	RR: 3.7 95% CI: 6.6 to 2; ref group: Grp2	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kontos, 2005 ⁶⁴	Cardio mortality	Years: 1	Assay: cTnl Manufacturer: other Manufacturer: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One	For Opus assay: <=1.0 ng/mL	% Pts with event: 2%		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kontos, 2005 ⁶⁴	Cardio mortality	Years: 1	Assay: cTnl Manufacturer: other Manufacturer: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One	For Opus assay: <=1.0 ng/mL	% Pts with event: 12%		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kontos, 2005 ⁶⁴	Cardio mortality	Years: 1	Assay: cTnl Manufacturer: other Manufacturer: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One	For Opus assay: ≥ 2.5 ng/mL. For Bayer assay: ≥ 0.9 ng/mL	% Pts with event: 40%	RR: 4.8 95% CI: 9.3 to 2.3; ref group: Grp2	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kontos, 2005 ⁶⁴	Cardio mortality	Years: 1	Assay: cTnl Manufacturer: other Manufacturer: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One	For Opus assay: 1.0 ng/mL - 2.5 ng/mL. For Bayer assay: 0.3 ng/mL - 0.9 ng/mL	% Pts with event: 18%	RR: 1.6 95% CI: 4.5 to 0.5; ref group: Grp2	
Kontos, 2005 ⁶⁵	All-cause mortality	Years: 1	Assay: cTnl	Negative: optimal diagnostic values...similar to those recommended by a consensus panel	% Pts with event: 3.6% / 1635 persons Results: unadjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kontos, 2005 ⁶⁵	All-cause mortality	Years: 1	Assay: cTnI	Positive: optimal diagnostic values...similar to those recommended by a consensus panel	% Pts with event: 5.9% / 270 persons Results: unadjusted		
Kontos, 2005 ⁶⁵	All-cause mortality	Years: 1	Assay: cTnI	Negative: optimal diagnostic values...similar to those recommended by a consensus panel	% Pts with event: 17% / 52 persons Results: unadjusted		
Kontos, 2005 ⁶⁵	All-cause mortality	Years: 1	Assay: cTnI	Positive: optimal diagnostic values...similar to those recommended by a consensus panel	% Pts with event: 47% / 34 persons Results: unadjusted		
Kontos, 2005 ⁶⁵	All-cause mortality	Years: 1	Assay: cTnI	Negative: optimal diagnostic values...similar to those recommended by a consensus panel	Pts with event: 19 / 95 persons Results: unadjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kontos, 2005 ⁶⁵	All-cause mortality	Years: 1	Assay: cTnI	Positive: optimal diagnostic values...similar to those recommended by a consensus panel	Pts with event: 28 / 39 persons Results: unadjusted		
Kontos, 2005 ⁶⁵	All-cause mortality	Years: 1	Assay: cTnI	Negative: optimal diagnostic values...similar to those recommended by a consensus panel	% Pts with event: 17% / 120 persons Results: unadjusted		
Kontos, 2005 ⁶⁵	All-cause mortality	Years: 1	Assay: cTnI	Positive: optimal diagnostic values...similar to those recommended by a consensus panel	% Pts with event: 24% / 45 persons Results: unadjusted		
Kontos, 2005 ⁶⁵	All-cause mortality	Years: 1	Assay: cTnI	Negative: optimal diagnostic values...similar to those recommended by a consensus panel	% Pts with event: 6.6% / 228 persons Results: unadjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kontos, 2005 ⁶⁵	All-cause mortality	Years: 1	Assay: cTnI	Positive: optimal diagnostic values...similar to those recommended by a consensus panel	% Pts with event: 15% / 55 persons Results: unadjusted		
Kontos, 2005 ⁶⁵	All-cause mortality	Years: 1	Assay: cTnI	Negative: optimal diagnostic values...similar to those recommended by a consensus panel	% Pts with event: 5.4% / 297 persons Results: unadjusted		
Kontos, 2005 ⁶⁵	All-cause mortality	Years: 1	Assay: cTnI	Positive: optimal diagnostic values...similar to those recommended by a consensus panel	% Pts with event: 19% / 57 persons Results: unadjusted		
Kontos, 2005 ⁶⁵	All-cause mortality	Years: 1	Assay: cTnI	Negative: optimal diagnostic values...similar to those recommended by a consensus panel	% Pts with event: 25% / 101 persons Results: unadjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kontos, 2005 ⁶⁵	All-cause mortality	Years: 1	Assay: cTnI	Positive: optimal diagnostic values...similar to those recommended by a consensus panel	% Pts with event: 53% / 45 persons Results: unadjusted		
Kontos, 2008 ⁶⁶	All-cause mortality	Days: 30	Assay: cTnI	negative	% Pts with event: 3.8% Results: unadjusted		
Kontos, 2008 ⁶⁶	All-cause mortality	Days: 30	Assay: cTnI	positive	% Pts with event: 10% Results: unadjusted		
Kontos, 2008 ⁶⁶	All-cause mortality	Years: 1	Assay: cTnI	negative	% Pts with event: 15% Results: unadjusted		
Kontos, 2008 ⁶⁶	All-cause mortality	Years: 1	Assay: cTnI	positive	% Pts with event: 26% Results: unadjusted		
Kontos, 2008 ⁶⁶	All-cause mortality	Days: 30	Assay: cTnI	negative	% Pts with event: 8.6% Results: unadjusted		
Kontos, 2008 ⁶⁶	All-cause mortality	Days: 30	Assay: cTnI	positive	% Pts with event: 26% Results: unadjusted		
Kontos, 2008 ⁶⁶	All-cause mortality	Years: 1	Assay: cTnI	negative	% Pts with event: 32% Results: unadjusted		
Kontos, 2008 ⁶⁶	All-cause mortality	Years: 1	Assay: cTnI	positive	% Pts with event: 53% Results: unadjusted		
Kontos, 2008 ⁶⁶	All-cause mortality	Days: 30	Assay: cTnI	negative	% Pts with event: 0.8% Results: unadjusted		
Kontos, 2008 ⁶⁶	All-cause mortality	Days: 30	Assay: cTnI	positive	% Pts with event: 3.9% Results: unadjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Kontos, 2008 ⁶⁶	All-cause mortality	Years: 1	Assay: cTnl	negative	% Pts with event: 5.1% Results: unadjusted		
Kontos, 2008 ⁶⁶	All-cause mortality	Years: 1	Assay: cTnl	positive	% Pts with event: 9.9% Results: unadjusted		
Kontos, 2008 ⁶⁶	All-cause mortality	Days: 30	Assay: cTnl	negative	% Pts with event: 3.3% Results: unadjusted		
Kontos, 2008 ⁶⁶	All-cause mortality	Days: 30	Assay: cTnl	positive	% Pts with event: 10% Results: unadjusted		
Kontos, 2008 ⁶⁶	All-cause mortality	Days: 30	Assay: cTnl	negative	% Pts with event: 9.6% Results: unadjusted		
Kontos, 2008 ⁶⁶	All-cause mortality	Years: 1	Assay: cTnl	negative	% Pts with event: 30% Results: unadjusted		
Kontos, 2008 ⁶⁶	All-cause mortality	Years: 1	Assay: cTnl	positive	% Pts with event: 54% Results: unadjusted		
Kontos, 2008 ⁶⁶	All-cause mortality	Days: 30	Assay: cTnl	negative	% Pts with event: 1% Results: unadjusted		
Kontos, 2008 ⁶⁶	All-cause mortality	Days: 30	Assay: cTnl	positive	% Pts with event: 4.7% Results: unadjusted		
Kostrubiec, 2010 ⁶⁷	All-cause mortality	Days: 30		GFR < 35 and Troponin +	Pts with event: 10 / 21 persons		
Lamb, 2007 ⁶⁸	All-cause mortality				Results: adjusted		Sensitivity value: 31 95% CI: 17 to 48 Specificity value: 85 95% CI: 79 to 90

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Lamb, 2007 ⁶⁸	All-cause mortality				Results: adjusted		Sensitivity value: 51 95% CI: 35 to 68 Specificity value: 80 95% CI: 73 to 85
Lamb, 2007 ⁶⁸	All-cause mortality				Results: adjusted		Sensitivity value: 67 95% CI: 50 to 81 Specificity value: 62 95% CI: 55 to 69
Lamb, 2007 ⁶⁸	All-cause mortality				Results: adjusted		AUC value: 0.75 p value: <0.001 95% CI: 0.663 to 0.838 Sensitivity value: 60 95% CI: 42 to 76 Specificity value: 73 95% CI: 66 to 80
Lamb, 2007 ⁶⁸	All-cause mortality		Assay: cTnl Manufacturer: Bayer; Advair Centaur (standard)	< 0.07 mcg/L	Pts with event: 27 / 177 persons Results: adjusted	N: 177 RH: REF	Sensitivity value: 31 95% CI: 17 to 48 Specificity value: 85 95% CI: 79 to 90
Lamb, 2007 ⁶⁸	All-cause mortality		Assay: cTnl Manufacturer: Bayer; Advair Centaur (standard)	> 0.07 mcg/L	Pts with event: 12 / 38 persons Results: adjusted	N: 38 RH: 1.4 95% CI: 0.7 to 3 p value: 0.3; ref group: Grp1	Sensitivity value: 31 95% CI: 17 to 48 Specificity value: 85 95% CI: 79 to 90

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Lamb, 2007 ⁶⁸	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.01 mcg/L	Pts with event: 13 / 127 persons Results: adjusted	N: 127 RH: REF	Sensitivity value: 67 95% CI: 50 to 81 Specificity value: 62 95% CI: 55 to 69
Lamb, 2007 ⁶⁸	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.03 mcg/L	Pts with event: 19 / 165 persons Results: adjusted	N: 165 RH: REF	Sensitivity value: 51 95% CI: 35 to 68 Specificity value: 80 95% CI: 73 to 85
Lamb, 2007 ⁶⁸	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.01 mcg/L	Pts with event: 26 / 95 persons Results: adjusted	N: 95 RH: 2 95% CI: 1 to 3.9 p value: 0.05; ref group: Grp1	Sensitivity value: 67 95% CI: 50 to 81 Specificity value: 62 95% CI: 55 to 69
Lamb, 2007 ⁶⁸	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.03 mcg/L	Pts with event: 20 / 57 persons Results: adjusted	N: 57 RH: 2.1 95% CI: 1.1 to 4 p value: 0.03; ref group: Grp1	Sensitivity value: 51 95% CI: 35 to 68 Specificity value: 80 95% CI: 73 to 85
Lamb, 2007 ⁶⁸	All-cause mortality		Assay: hscTnI Manufacturer: Bayer; other; Advia Centaur (Ultra)	< 0.04 mcg/L	Pts with event: 14 / 129 persons Results: adjusted	N: 129 RH: REF	AUC value: 0.75 p value: <0.001 95% CI: 0.663 to 0.838 Sensitivity value: 60 95% CI: 42 to 76 Specificity value: 73 95% CI: 66 to 80

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Lamb, 2007 ⁶⁸	All-cause mortality		Assay: hscTnl Manufacturer: Bayer; other; Advia Centaur (Ultra)	> 0.04 mcg/L	Pts with event: 21 / 63 persons Results: adjusted	N: 63 RH: 1.9 95% CI: 0.9 to 3.9 p value: 0.08; ref group: Grp1	AUC value: 0.75 p value: <0.001 95% CI: 0.663 to 0.838 Sensitivity value: 60 95% CI: 42 to 76 Specificity value: 73 95% CI: 66 to 80
Lang, 2001 ⁶⁹	All-cause mortality	Years: 2					Sensitivity value: 5 Specificity value: 93
Lang, 2001 ⁶⁹	All-cause mortality	Years: 2	Assay: cTnl Manufacturer: Dade Behring; other; Stratus Cardiac Troponin I	< 0.4 mcg/L	Pts with event: 17 / 93 persons		Sensitivity value: 5 Specificity value: 93
Lang, 2001 ⁶⁹	All-cause mortality	Years: 2	Assay: cTnl Manufacturer: Dade Behring; other; Stratus Cardiac Troponin I	> 0.4 mcg/L	Pts with event: 1 / 7 persons		Sensitivity value: 5 Specificity value: 93
Lang, 2001 ⁶⁹	All-cause mortality	Years: 2	Assay: cTnl Manufacturer: other Manufacturer: Astra; other; Cardiac STATus Troponin I rapid test	< 0.1 mcg/L	Pts with event: 10 / 73 persons		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Lang, 2001 ⁶⁹	All-cause mortality	Years: 2	Assay: cTnI Manufacturer: other Manufacturer: Astra; other; Cardiac STATus Troponin I rapid test	> 0.1 mcg/L	Pts with event: 8 / 27 persons		
Lang, 2001 ⁶⁹	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: other Manufacturer: Boehringer Mannheim; other; ELISA	< 0.1 mcg/L	Pts with event: 11 / 78 persons		
Lang, 2001 ⁶⁹	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: other Manufacturer: Boehringer Mannheim; other; ELISA	> 0.1 mcg/L	Pts with event: 7 / 22 persons		
Lang, 2001 ⁶⁹	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: other Manufacturer: Boehringer Mannheim; other; TropT-sensitive rapid test	< 0.1 mcg/L	Pts with event: 6 / 59 persons		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Lang, 2001 ⁶⁹	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: other Manufacturer: Boehringer Mannheim; other; TropT-sensitive rapid test	> 0.1 mcg/L	Pts with event: 12 / 41 persons		
Lang, 2001 ⁶⁹	Cardio mortality	Years: 2	Assay: cTnT Manufacturer: other Manufacturer: Boehringer Mannheim; other; ELISA	< 0.1 mcg/L	Pts with event: 8 / 78 persons		
Lang, 2001 ⁶⁹	Cardio mortality	Years: 2	Assay: cTnT Manufacturer: other Manufacturer: Boehringer Mannheim; other; ELISA	> 0.1 mcg/L	Pts with event: 5 / 22 persons		
Lang, 2001 ⁶⁹	Cardio mortality	Years: 2	Assay: cTnI Manufacturer: Dade Behring; other; Stratus Cardiac Troponin I	< 0.4 mcg/L	Pts with event: 12 / 93 persons		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Lang, 2001 ⁶⁹	Cardio mortality	Years: 2	Assay: cTnl Manufacturer: Dade Behring; other; Stratus Cardiac Troponin I	> 0.4 mcg/L	Pts with event: 1 / 7 persons		
Lang, 2001 ⁶⁹	Cardio mortality	Years: 2	Assay: cTnl Manufacturer: other Manufacturer: Astra; other; Cardiac STATus Troponin I rapid test	< 0.1 mcg/L	Pts with event: 5 / 73 persons		
Lang, 2001 ⁶⁹	Cardio mortality	Years: 2	Assay: cTnl Manufacturer: other Manufacturer: Astra; other; Cardiac STATus Troponin I rapid test	> 0.1 mcg/L	Pts with event: 8 / 27 persons		
Lang, 2001 ⁶⁹	Cardio mortality	Years: 2	Assay: cTnT Manufacturer: other Manufacturer: Boehringer Mannheim; other; TropT-sensitive rapid test	< 0.1 mcg/L	Pts with event: 3 / 59 persons		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Lang, 2001 ⁶⁹	Cardio mortality	Years: 2	Assay: cTnT Manufacturer: other Manufacturer: Boehringer Mannheim; other; TropT- sensitive rapid test	> 0.1 mcg/L	Pts with event: 10 / 41 persons		
Lang, 2001 ⁶⁹	Subsequent MI	Years: 2	Assay: cTnT Manufacturer: other Manufacturer: Boehringer Mannheim; other; TropT- sensitive rapid test	< 0.1 mcg/L	Pts with event: 4 / 59 persons		
Lang, 2001 ⁶⁹	Subsequent MI	Years: 2	Assay: cTnT Manufacturer: other Manufacturer: Boehringer Mannheim; other; TropT- sensitive rapid test	> 0.1 mcg/L	Pts with event: 10 / 41 persons		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Lang, 2001 ⁶⁹	Subsequent MI	Years: 2	Assay: cTnI Manufacturer: Dade Behring; other; Stratus Cardiac Troponin I	< 0.4 mcg/L	Pts with event: 13 / 93 persons		
Lang, 2001 ⁶⁹	Subsequent MI	Years: 2	Assay: cTnI Manufacturer: Dade Behring; other; Stratus Cardiac Troponin I	> 0.4 mcg/L	Pts with event: 1 / 7 persons		
Lang, 2001 ⁶⁹	Subsequent MI	Years: 2	Assay: cTnI Manufacturer: other Manufacturer: Astra; other; Cardiac STATus Troponin I rapid test	< 0.1 mcg/L	Pts with event: 5 / 73 persons		
Lang, 2001 ⁶⁹	Subsequent MI	Years: 2	Assay: cTnI Manufacturer: other Manufacturer: Astra; other; Cardiac STATus Troponin I rapid test	> 0.1 mcg/L	Pts with event: 9 / 27 persons		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Lang, 2001 ⁶⁹	Subsequent MI	Years: 2	Assay: cTnT Manufacturer: other Manufacturer: Boehringer Mannheim; other; ELISA	< 0.1 mcg/L	Pts with event: 9 / 78 persons		
Lang, 2001 ⁶⁹	Subsequent MI	Years: 2	Assay: cTnT Manufacturer: other Manufacturer: Boehringer Mannheim; other; ELISA	> 0.1 mcg/L	Pts with event: 5 / 22 persons		
Le Goff, 2007 ⁷⁰	All-cause mortality	Years: 3			% Pts with event: 73.2% / 22 persons Results: adjusted		
Le Goff, 2007 ⁷⁰	All-cause mortality	Years: 3	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.03 mcg/L	Pts with event: 61 / 86 persons Results: adjusted		
Le Goff, 2007 ⁷⁰	All-cause mortality	Years: 3	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.031 mcg/L < 0.1 mcg/L	% Pts with event: 43% / 7 persons Results: adjusted		
Le Goff, 2007 ⁷⁰	All-cause mortality	Years: 3	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	% Pts with event: 53% / 32 persons Results: adjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Le Goff, 2007 ⁷⁰	Cardio mortality	Years: 3			% Pts with event: 32% / 22 persons Results: adjusted		
Le Goff, 2007 ⁷⁰	Cardio mortality	Years: 3	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.03 mcg/L	% Pts with event: 61% / 86 persons Results: adjusted		
Le Goff, 2007 ⁷⁰	Cardio mortality	Years: 3	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.031 mcg/L < 0.1 mcg/L	% Pts with event: 14% / 7 persons Results: adjusted		
Le Goff, 2007 ⁷⁰	Cardio mortality	Years: 3	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	% Pts with event: 9% / 32 persons Results: adjusted		
Lowbeer, 2002 ⁷¹	All-cause mortality		Assay: cTnT Manufacturer: other Manufacturer: Boehringer; other; ELISA	< 0.04 mcg/L	Pts with event: 3 / 12 persons	N: 16	
Lowbeer, 2002 ⁷¹	All-cause mortality		Assay: cTnT Manufacturer: other Manufacturer: Boehringer; other; ELISA	> 0.04 mcg/L	Pts with event: 12 / 14 persons	N: 10 Exponent Beta: 6.54 SE: 0.54 p value: 0.00056; ref group: Grp1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Lowbeer, 2002 ⁷¹	Cardio mortality		Assay: cTnT Manufacturer: other Manufacturer: Boehringer; other; ELISA	< 0.04 mcg/L	Pts with event: 3 / 12 persons		
Lowbeer, 2002 ⁷¹	Cardio mortality		Assay: cTnT Manufacturer: other Manufacturer: Boehringer; other; ELISA	> 0.04 mcg/L	Pts with event: 8 / 14 persons		
Lowbeer, 2003 ⁷²	Other composite (Survival)	Years: 2.7	Assay: cTnT Manufacturer: Roche; Elecsys		/ 49 persons		
Lowbeer, 2003 ⁷²	Other composite (Survival)	Years: 2.7	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	% Pts with event: 72% / 35 persons		
Lowbeer, 2003 ⁷²	Other composite (Survival)	Years: 2.7	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	% Pts with event: 65% / 14 persons		
Lowbeer, 2003 ⁷²	Other composite (Survival)		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	% Pts with event: 75% / 44 persons		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Lowbeer, 2003 ⁷²	Other composite (Survival)		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	% Pts with event: 45% / 20 persons		
Lowbeer, 2003 ⁷²	Other composite (Survival)	Years: 2.7	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	% Pts with event: 74.4% / 81 persons Results: adjusted	N: 81 RH: 1	
Lowbeer, 2003 ⁷²	Other composite (Survival)	Years: 2.7	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	% Pts with event: 45.5% / 34 persons Results: adjusted	N: 34 RH: 2.66 95% CI: 1.07 to 10.95 p value: <0.05; ref group: Grp1	
Mallamaci, 2002 ⁷³	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.01 mcg/L	Pts with event: 0 / 12 persons Results: adjusted		
Mallamaci, 2002 ⁷³	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.048 mcg/L	Results: adjusted	RH: 1 95% CI: to	
Mallamaci, 2002 ⁷³	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.049 mcg/L < 0.098 mcg/L	Results: adjusted	RH: 1.15 95% CI: 0.53 to 2.51 p value: 0.73; ref group: Grp2	
Mallamaci, 2002 ⁷³	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.098 mcg/L	Results: adjusted	RH: 2.39 95% CI: 1.13 to 5.06 p value: 0.02; ref group: Grp2	
Mallamaci, 2002 ⁷³	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.048 mcg/L	Results: adjusted	RH: 1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Mallamaci, 2002 ⁷³	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.049 mcg/L < 0.098 mcg/L	Results: adjusted	RH: 1.19 95% CI: 0.5 to 2.82 p value: 0.69; ref group: Grp1	
Mallamaci, 2002 ⁷³	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.098 mcg/L	Results: adjusted	RH: 2.35 95% CI: 1.01 to 5.49 p value: 0.048; ref group: Grp1	
Martin, 1998 ⁷⁴	All-cause mortality		Assay: cTnI Manufacturer: Dade Behring; stratus	< 0.8 mcg/L	Pts with event: 5 % Pts with event: 15% / 33 persons Results: unadjusted		
Martin, 1998 ⁷⁴	All-cause mortality		Assay: cTnI Manufacturer: Dade Behring; stratus	> 0.8 mcg/L	Pts with event: 4 % Pts with event: 29% / 14 persons Results: unadjusted		
McGill, 2010 ⁷⁵	All-cause mortality	Years: 3.9	Assay: hscTnT Manufacturer: Roche; E411 analyzer	Ln hs-cTnT, cut off 3 ng/L	Results: adjusted	N: 143 RH: 1.404 95% CI: 1.001 to 1.968 p value: 0.049	
McMurray, 2011 ⁷⁶	Cardio mortality	Years: 2.4	Assay: cTnT Manufacturer: Roche; 4th generation TnT assay	<0.028 ng/mL		N: 230 RH: 1.42 95% CI: 1.05 to 1.93 p value: 0.0001; ref group: Grp1	
McMurray, 2011 ⁷⁶	Cardio mortality	Years: 2.4	Assay: cTnT Manufacturer: Roche; 4th generation TnT assay	>0.028 ng/mL		N: 217 RH: 1.5 95% CI: 2.13 to 10.6 p value: 0.0001; ref group: Grp1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
McMurray, 2011 ⁷⁶	Cardio mortality	Years: 2.4	Assay: cTnT Manufacturer: Roche; 4th generation TnT assay	Undetectable		N: 548 RH: 1	
Melloni, 2008 ⁷⁷	All-cause mortality	Followup NR	Assay: cTnI	<1 x ULN	% Pts with event: 3.3% / 5529 persons		
Melloni, 2008 ⁷⁷	All-cause mortality	Followup NR	Assay: cTnI	>3 x ULN	% Pts with event: 7.4% / 20843 persons		
Melloni, 2008 ⁷⁷	All-cause mortality	Followup NR	Assay: cTnI	1-3 x ULN	% Pts with event: 5.4% / 5214 persons		
Melloni, 2008 ⁷⁷	All-cause mortality	Followup NR	Assay: cTnT	<1 x ULN	% Pts with event: 3.7% / 5529 persons		
Melloni, 2008 ⁷⁷	All-cause mortality	Followup NR	Assay: cTnT	>3 x ULN	% Pts with event: 7.3% / 20843 persons		
Melloni, 2008 ⁷⁷	All-cause mortality	Followup NR	Assay: cTnT	1-3 x ULN	% Pts with event: 3.5% / 5214 persons		
Melloni, 2008 ⁷⁷	All-cause mortality	Followup NR	Assay: cTnI	<1 x ULN	% Pts with event: 1.7% / 5529 persons		
Melloni, 2008 ⁷⁷	All-cause mortality	Followup NR	Assay: cTnI	>3 x ULN	% Pts with event: 2.1% / 20843 persons		
Melloni, 2008 ⁷⁷	All-cause mortality	Followup NR	Assay: cTnI	1-3 x ULN	% Pts with event: 2.1% / 5214 persons		
Melloni, 2008 ⁷⁷	All-cause mortality	Followup NR	Assay: cTnT	<1 x ULN	% Pts with event: 1% / 5529 persons		
Melloni, 2008 ⁷⁷	All-cause mortality	Followup NR	Assay: cTnT	> 3 x ULN	% Pts with event: 2.6% / 20843 persons		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Melloni, 2008 ⁷⁷	All-cause mortality	Followup NR	Assay: cTnT	1-3 x ULN	% Pts with event: 2.2% / 5214 persons		
Melloni, 2008 ⁷⁷	All-cause mortality	Followup NR	Assay: cTnI	<1 x ULN	% Pts with event: 10.1% / 5529 persons		
Melloni, 2008 ⁷⁷	All-cause mortality	Followup NR	Assay: cTnI	>3 x ULN	% Pts with event: 14.6% / 20843 persons		
Melloni, 2008 ⁷⁷	All-cause mortality	Followup NR	Assay: cTnI	1-3 x ULN	% Pts with event: 9.6% / 5214 persons		
Melloni, 2008 ⁷⁷	All-cause mortality	Followup NR	Assay: cTnT	<1 x ULN	% Pts with event: 7% / 5529 persons		
Melloni, 2008 ⁷⁷	All-cause mortality	Followup NR	Assay: cTnT	>3 x ULN	% Pts with event: 14% / 20843 persons		
Melloni, 2008 ⁷⁷	All-cause mortality	Followup NR	Assay: cTnT	1-3 x ULN	% Pts with event: 5.7% / 5214 persons		
Mockel, 1999 ⁷⁸	All-cause mortality	Years: 1	Assay: cTnI Manufacturer: Dade Behring; opusplus	< 0.5 mcg/L	Pts with event: 2 / 16 persons		
Mockel, 1999 ⁷⁸	All-cause mortality	Years: 1	Assay: cTnI Manufacturer: Dade Behring; opusplus	> 0.5 mcg/L	Pts with event: 1 / 4 persons		
Mockel, 1999 ⁷⁸	All-cause mortality	Years: 1	Assay: cTnI Manufacturer: Dade Behring; stratus	< 0.4 mcg/L	Pts with event: 4 / 28 persons		
Mockel, 1999 ⁷⁸	All-cause mortality	Years: 1	Assay: cTnI Manufacturer: Dade Behring; stratus	> 0.4 mcg/L	Pts with event: 1 / 2 persons		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Mockel, 1999 ⁷⁸	All-cause mortality	Years: 1	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	Pts with event: 1 / 20 persons		
Mockel, 1999 ⁷⁸	All-cause mortality	Years: 1	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 4 / 10 persons		
Mockel, 1999 ⁷⁸	MACE < 1 year	Years: 1	Assay: cTnI Manufacturer: Dade Behring; opusplus	> 0.5 mcg/L		N: 7 OR: 4.57 95% CI: 0.4 to 5.2 p value: 0.22	
Mockel, 1999 ⁷⁸	MACE < 1 year	Years: 1	Assay: cTnI Manufacturer: Dade Behring; stratus	> 0.4 mcg/L		N: 7 OR: 3.22 95% CI: 0.6 to 17 p value: 0.168	
Mockel, 1999 ⁷⁸	MACE < 1 year	Years: 1	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L		N: 7 OR: 1.63 95% CI: 0.18 to 5.9 p value: 0.969	
Morton, 1998 ⁷⁹	All-cause mortality				Results: unadjusted		Specificity value: 100% (for >1.5)
Morton, 1998 ⁷⁹	All-cause mortality		Assay: cTnI Manufacturer: Sanofi; access	< 0.15 mcg/L	/ 108 persons Results: unadjusted		Specificity value: 100% (for >1.5)
Morton, 1998 ⁷⁹	All-cause mortality		Assay: cTnI Manufacturer: Sanofi; access	> 0.15 mcg/L < 1.5 mcg/L	/ 4 persons Results: unadjusted		Specificity value: 100% (for >1.5)
Morton, 1998 ⁷⁹	All-cause mortality		Assay: cTnI Manufacturer: Sanofi; access	> 1.5 mcg/L	Pts with event: 0 % Pts with event: 0% / 0 persons Results: unadjusted		Specificity value: 100% (for >1.5)

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Musso, 1999 ⁸⁰	All-cause mortality		Assay: cTnI Manufacturer: Dade Behring; stratus	< 0.4 mcg/L	Pts with event: 2 / 47 persons Results: unadjusted		
Musso, 1999 ⁸⁰	All-cause mortality		Assay: cTnI Manufacturer: Dade Behring; stratus	> 0.4 mcg/L	Pts with event: 0 / 2 persons Results: unadjusted		
Musso, 1999 ⁸⁰	All-cause mortality		Assay: cTnI Manufacturer: Sanofi; access	< 0.04 mcg/L	Pts with event: 2 / 49 persons Results: unadjusted		
Musso, 1999 ⁸⁰	All-cause mortality		Assay: cTnI Manufacturer: Sanofi; access	> 0.4 mcg/L	Pts with event: 0 / 0 persons Results: unadjusted		
Musso, 1999 ⁸⁰	All-cause mortality		Assay: cTnT Manufacturer: other Manufacturer: Boehringer; other; Enzymum	< 0.1 mcg/L	Pts with event: 2 / 26 persons Results: unadjusted		
Musso, 1999 ⁸⁰	All-cause mortality		Assay: cTnT Manufacturer: other Manufacturer: Boehringer; other; Enzymum	> 0.1 mcg/L	Pts with event: 0 / 23 persons Results: unadjusted		
Musso, 1999 ⁸⁰	MACE >= 1 year		Assay: cTnI Manufacturer: Dade Behring; stratus	< 0.4 mcg/L	Pts with event: 0 / 47 persons Results: unadjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Musso, 1999 ⁸⁰	MACE >= 1 year		Assay: cTnI Manufacturer: Dade Behring; stratus	> 0.4 mcg/L	Pts with event: 0 / 2 persons Results: unadjusted		
Musso, 1999 ⁸⁰	MACE >= 1 year		Assay: cTnI Manufacturer: Sanofi; access	< 0.4 mcg/L	Pts with event: 0 / 49 persons Results: unadjusted		
Musso, 1999 ⁸⁰	MACE >= 1 year		Assay: cTnI Manufacturer: Sanofi; access	> 0.4 mcg/L	Pts with event: 0 / 0 persons Results: unadjusted		
Musso, 1999 ⁸⁰	MACE >= 1 year		Assay: cTnT Manufacturer: other Manufacturer: Boehringer; other; Enzymum	< 0.1 mcg/L	Pts with event: 0 / 26 persons Results: unadjusted		
Musso, 1999 ⁸⁰	MACE >= 1 year		Assay: cTnT Manufacturer: other Manufacturer: Boehringer; other; Enzymum	> 0.1 mcg/L	Pts with event: 0 / 23 persons Results: unadjusted		
Ooi, 1999 ⁸¹	All-cause mortality	Years: 1	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	% Pts with event: 10% / 111 persons Results: unadjusted	RR: 1	
Ooi, 1999 ⁸¹	All-cause mortality	Years: 1	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	% Pts with event: 33% / 61 persons Results: unadjusted	RR: 3.3 95% CI: 1.7 to 6.4 p value: <0.001; ref group: Grp1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Ooi, 1999 ⁸¹	Cardio mortality	Years: 1	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	% Pts with event: 5% / 111 persons Results: unadjusted	RR: 1	
Ooi, 1999 ⁸¹	Cardio mortality	Years: 1	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	% Pts with event: 10% / 61 persons Results: unadjusted	RR: 1.8 95% CI: 0.6 to 5.4 p value: ns; ref group: Grp1	
Ooi, 2001 ⁸²	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.01 mcg/L	Pts with event: 1 % Pts with event: 6% / 17 persons Results: unadjusted	N: 17 RR: 1	
Ooi, 2001 ⁸²	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.01 mcg/L 0.099 mcg/L	Pts with event: 52 % Pts with event: 43% / 121 persons Results: unadjusted	N: 121 RR: 7.3 95% CI: 1.1 to 49 p value: <0.005; ref group: Grp1	
Ooi, 2001 ⁸²	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 34 % Pts with event: 59% / 58 persons Results: unadjusted	N: 58 RR: 10 95% CI: 1.5 to 68 p value: <0.001; ref group: Grp1	
Ooi, 2001 ⁸²	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.01 mcg/L	Pts with event: 0 / 17 persons Results: unadjusted		
Ooi, 2001 ⁸²	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.01 mcg/L 0.099 mcg/L	Pts with event: 17 % Pts with event: 14% / 121 persons Results: unadjusted		
Ooi, 2001 ⁸²	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 14 % Pts with event: 24% / 58 persons Results: unadjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Orea-Tejeda, 2010 ⁸³	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys		Results: adjusted		
Orea-Tejeda, 2010 ⁸³	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	>=0.02 ng/mL	% Pts with event: 83.5% / 21 persons Results: adjusted		
Peetz, 2003 ⁸⁴	MACE < 1 year				Results: unadjusted		AUC value: 0.574 Sensitivity value: 16% Specificity value: 93.70%
Peetz, 2003 ⁸⁴	MACE < 1 year		Assay: cTnI Manufacturer: Dade Behring; stratus	< 0.4 mcg/L	Results: unadjusted	N: 101 (97.1%)	AUC value: 0.574 Sensitivity value: 16% Specificity value: 93.70%
Peetz, 2003 ⁸⁴	MACE < 1 year		Assay: cTnI Manufacturer: Dade Behring; stratus	> 0.4 mcg/L	Results: unadjusted	N: 3 (2.9%)	AUC value: 0.574 Sensitivity value: 16% Specificity value: 93.70%
Peetz, 2003 ⁸⁴	MACE < 1 year				Results: unadjusted		AUC value: 0.708 Sensitivity value: 53.50% Specificity value: 72.50%

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Peetz, 2003 ⁸⁴	MACE < 1 year		Assay: cTnI Manufacturer: Bayer; acs180	< 0.15 mcg/L	Results: unadjusted	N: 70 (69.6%) OR: REF	AUC value: 0.708 Sensitivity value: 53.50% Specificity value: 72.50%
Peetz, 2003 ⁸⁴	MACE < 1 year		Assay: cTnI Manufacturer: Bayer; acs180	> 0.15 mcg/L	Results: unadjusted	N: 34 (32.4%) OR: 4 p value: 0.22; ref group: Grp1	AUC value: 0.708 Sensitivity value: 53.50% Specificity value: 72.50%
Peetz, 2003 ⁸⁴	MACE < 1 year				Results: unadjusted		AUC value: 0.726 Sensitivity value: 58.4 Specificity value: 77.9
Peetz, 2003 ⁸⁴	MACE < 1 year		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	Results: unadjusted	N: 36 (34.6%) OR: REF	AUC value: 0.726 Sensitivity value: 58.4 Specificity value: 77.9
Peetz, 2003 ⁸⁴	MACE < 1 year		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Results: unadjusted	N: 68 (65.7%) OR: 16 p value: <0.01; ref group: Grp1	AUC value: 0.726 Sensitivity value: 58.4 Specificity value: 77.9

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Petrovic, 2009 ⁸⁵	All-cause mortality		Assay: cTnl Manufacturer: other Manufacturer: Abbott; ADV AxSYM cTnl Immunoassay	<0.15 ng/mL	% Pts with event: 2.41% Results: unadjusted		
Petrovic, 2009 ⁸⁵	All-cause mortality		Assay: cTnl Manufacturer: other Manufacturer: Abbott; ADV AxSYM cTnl Immunoassay	>0.15 ng/mL	% Pts with event: 15.62% Results: unadjusted		
Petrovic, 2009 ⁸⁵	All-cause mortality				Results: unadjusted		AUC value: 0.637 95% CI: 0.542 to 0.725 Sensitivity value: 0.5172 95% CI: 32.5 to 70.5 Specificity value: 0.814 95% CI: 71.6 to 89

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Petrovic, 2009 ⁸⁵	All-cause mortality				Results: unadjusted		AUC value: 0.744 95% CI: 0.654 to 0.821 Sensitivity value: 0.7586 95% CI: 56.5 to 89.7 Specificity value: 0.7209 95% CI: 61.4 to 81.2
Petrovic, 2009 ⁸⁵	All-cause mortality			<0.15 ng/mL	% Pts with event: 0% Results: unadjusted		
Petrovic, 2009 ⁸⁵	All-cause mortality			>0.15 ng/mL	% Pts with event: 31.11% Results: unadjusted		
Petrovic, 2009 ⁸⁵	All-cause mortality		Assay: cTnl Manufacturer: other Manufacturer: Abbott; ADV AxSYM cTnl Immunoassay	<0.15 ng/mL	% Pts with event: 14.46% Results: unadjusted		
Petrovic, 2009 ⁸⁵	All-cause mortality		Assay: cTnl Manufacturer: other Manufacturer: Abbott; ADV AxSYM cTnl Immunoassay	<0.15 ng/mL	% Pts with event: 16.87% Results: unadjusted		AUC value: 0.637 95% CI: 0.542 to 0.725 Sensitivity value: 0.5172 95% CI: 32.5 to 70.5 Specificity value: 0.814 95% CI: 71.6 to 89

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Petrovic, 2009 ⁸⁵	All-cause mortality		Assay: cTnl Manufacturer: other Manufacturer: Abbott; ADV AxSYM cTnl Immunoassay	<0.15 ng/mL	% Pts with event: 7.23% Results: unadjusted		
Petrovic, 2009 ⁸⁵	All-cause mortality		Assay: cTnl Manufacturer: other Manufacturer: Abbott; ADV AxSYM cTnl Immunoassay	>0.15 ng/mL	% Pts with event: 25% Results: unadjusted		
Petrovic, 2009 ⁸⁵	All-cause mortality		Assay: cTnl Manufacturer: other Manufacturer: Abbott; ADV AxSYM cTnl Immunoassay	>0.15 ng/mL	% Pts with event: 34.37% Results: unadjusted		
Petrovic, 2009 ⁸⁵	All-cause mortality		Assay: cTnl Manufacturer: other Manufacturer: Abbott; ADV AxSYM cTnl Immunoassay	>0.15 ng/mL	% Pts with event: 46.87% Results: unadjusted		AUC value: 0.637 95% CI: 0.542 to 0.725 Sensitivity value: 0.5172 95% CI: 32.5 to 70.5 Specificity value: 0.814 95% CI: 71.6 to 89

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Petrovic, 2009 ⁸⁵	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	% Pts with event: 0% Results: unadjusted		
Petrovic, 2009 ⁸⁵	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	% Pts with event: 2.86% Results: unadjusted		
Petrovic, 2009 ⁸⁵	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	% Pts with event: 2.86% Results: unadjusted		AUC value: 0.744 95% CI: 0.654 to 0.821 Sensitivity value: 0.7586 95% CI: 56.5 to 89.7 Specificity value: 0.7209 95% CI: 61.4 to 81.2
Petrovic, 2009 ⁸⁵	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	% Pts with event: 15.56% Results: unadjusted		
Petrovic, 2009 ⁸⁵	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	% Pts with event: 46.67% Results: unadjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Petrovic, 2009 ⁸⁵	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	% Pts with event: 60% Results: unadjusted		AUC value: 0.744 95% CI: 0.654 to 0.821 Sensitivity value: 0.7586 95% CI: 56.5 to 89.7 Specificity value: 0.7209 95% CI: 61.4 to 81.2
Porter, 1998 ⁸⁶	All-cause mortality						Sensitivity value: 0.25 Specificity value: 0.909
Porter, 1998 ⁸⁶	All-cause mortality						Sensitivity value: 0.875 Specificity value: 0.864
Porter, 1998 ⁸⁶	All-cause mortality				Results: unadjusted		Sensitivity value: 0.125 Specificity value: 0.955
Porter, 1998 ⁸⁶	All-cause mortality		Assay: cTnI Manufacturer: Dade Behring; NR	< 0.4 mcg/L	Pts with event: 4 / 28 persons Results: unadjusted		Sensitivity value: 0.125 Specificity value: 0.955

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Porter, 1998 ⁸⁶	All-cause mortality		Assay: cTnI Manufacturer: Dade Behring; NR	< 0.5 mcg/L	Pts with event: 2 / 16 persons		Sensitivity value: 0.25 Specificity value: 0.909
Porter, 1998 ⁸⁶	All-cause mortality		Assay: cTnI Manufacturer: Dade Behring; NR	> 0.4 mcg/L	Pts with event: 1 / 2 persons Results: unadjusted		Sensitivity value: 0.125 Specificity value: 0.955
Porter, 1998 ⁸⁶	All-cause mortality		Assay: cTnI Manufacturer: Dade Behring; NR	> 0.5 mcg/L	Pts with event: 1 / 4 persons		Sensitivity value: 0.25 Specificity value: 0.909
Porter, 1998 ⁸⁶	All-cause mortality		Assay: cTnT Manufacturer: Roche; other; Enzymum	< 0.1 mcg/L	Pts with event: 1 / 20 persons		Sensitivity value: 0.875 Specificity value: 0.864
Porter, 1998 ⁸⁶	All-cause mortality		Assay: cTnT Manufacturer: Roche; other; Enzymum	> 0.1 mcg/L	Pts with event: 4 / 10 persons		Sensitivity value: 0.875 Specificity value: 0.864
Porter, 2000 ⁸⁷	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	Pts with event: 2 / 17 persons Results: unadjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Porter, 2000 ⁸⁷	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 5 / 10 persons Results: unadjusted		
Porter, 2000 ⁸⁷	MACE >= 1 year	Years: 2			Results: unadjusted		Sensitivity value: 18.2 Specificity value: 87.5
Porter, 2000 ⁸⁷	MACE >= 1 year	Years: 2			Results: unadjusted		Sensitivity value: 9.1 Specificity value: 87.5
Porter, 2000 ⁸⁷	MACE >= 1 year	Years: 2	Assay: cTnI Manufacturer: Dade Behring; stratus	< 0.4 mcg/L	Pts with event: 10 / 24 persons Results: unadjusted		Sensitivity value: 9.1 Specificity value: 87.5
Porter, 2000 ⁸⁷	MACE >= 1 year	Years: 2	Assay: cTnI Manufacturer: Dade Behring; stratus	> 0.4 mcg/L	Pts with event: 1 / 3 persons Results: unadjusted		Sensitivity value: 9.1 Specificity value: 87.5
Porter, 2000 ⁸⁷	MACE >= 1 year	Years: 2	Assay: cTnI Manufacturer: other Manufacturer: Abbott; other; AxSym	< 0.5 mcg/L	Pts with event: 9 / 23 persons Results: unadjusted		Sensitivity value: 18.2 Specificity value: 87.5
Porter, 2000 ⁸⁷	MACE >= 1 year	Years: 2	Assay: cTnI Manufacturer: other Manufacturer: Abbott; other; AxSym	> 0.5 mcg/L	Pts with event: 2 / 4 persons Results: unadjusted		Sensitivity value: 18.2 Specificity value: 87.5

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Porter, 2000 ⁸⁷	MACE >/= 1 year	Years: 2			Results: unadjusted		Sensitivity value: 81.8 Specificity value: 88.2
Porter, 2000 ⁸⁷	MACE >/= 1 year	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	Pts with event: 2 / 17 persons Results: unadjusted		Sensitivity value: 81.8 Specificity value: 88.2
Porter, 2000 ⁸⁷	MACE >/= 1 year	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 9 / 10 persons Results: unadjusted		Sensitivity value: 81.8 Specificity value: 88.2
Roberts, 2004 ⁸⁸	MACE < 1 year- Revascularization- Other composite		Assay: cTnI Manufacturer: other Manufacturer: Abott; other; Abott AXSYM	< 0.3 mcg/L	Pts with event: 5 / 79 persons Results: unadjusted	N: 79 RR: 1	
Roberts, 2004 ⁸⁸	MACE < 1 year- Revascularization- Other composite		Assay: cTnI Manufacturer: other Manufacturer: Abott; other; Abott AXSYM	> 0.3 mcg/L	Pts with event: 5 / 9 persons Results: unadjusted	N: 9 RR: 8.8 95% CI: 1.8 to 31.8; ref group: Grp1	
Roberts, 2009 ⁸⁹	All-cause mortality	Years: 1.8	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.04 mcg/L	Pts with event: 0 / 28 persons		
Roberts, 2009 ⁸⁹	All-cause mortality	Years: 1.8	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.04 mcg/L	Pts with event: 2 / 20 persons		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Roberts, 2009 ⁸⁹	All-cause mortality	Years: 1.8	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.04 mcg/L	Pts with event: 7 / 33 persons		
Roberts, 2009 ⁸⁹	Cardio mortality	Years: 1.8	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.04 mcg/L	Pts with event: 0 / 26 persons		
Roberts, 2009 ⁸⁹	Cardio mortality	Years: 1.8	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.04 mcg/L	Pts with event: 1 / 17 persons		
Roberts, 2009 ⁸⁹	Cardio mortality	Years: 1.8	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.04 mcg/L	Pts with event: 6 / 29 persons		
Roppolo, 1999 ⁹⁰	MACE < 1 year		Assay: cTnl Manufacturer: Dade Behring; opus	> 0.5 mcg/L	Pts with event: 3 / 3 persons Results: unadjusted		
Roppolo, 1999 ⁹⁰	MACE < 1 year		Assay: cTnT Manufacturer: Dade Behring; opus	> 0.1 mcg/L	Pts with event: 6 / 24 persons Results: unadjusted		
Roppolo, 1999 ⁹⁰	MACE < 1 year		Assay: cTnT Manufacturer: Dade Behring; opus	> 0.2 mcg/L	Pts with event: 5 / 9 persons Results: unadjusted		
Sahinarslan, 2008 ⁹¹	All-cause mortality	Years: 5	Assay: cTnT Manufacturer: NR; NR	< 0.1 mcg/L	% Pts with event: 16.4% / 61 persons Results: unadjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Sahinarslan, 2008 ⁹¹	All-cause mortality	Years: 5	Assay: cTnT Manufacturer: NR; NR	> 0.1 mcg/L	% Pts with event: 52.9% / 17 persons Results: unadjusted		
Sahinarslan, 2008 ⁹¹	MACE >= 1 year	Years: 5	Assay: cTnT Manufacturer: NR; NR	< 0.1 mcg/L	% Pts with event: 24.6% / 61 persons Results: adjusted	N: 61 OR: 1	
Sahinarslan, 2008 ⁹¹	MACE >= 1 year	Years: 5	Assay: cTnT Manufacturer: NR; NR	> 0.1 mcg/L	% Pts with event: 64.7% / 17 persons Results: adjusted	N: 17 OR: 3.215 95% CI: 0.405 to 25.53 p value: 0.269; ref group: Grp1	
Satyan, 2007 ⁹²	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.01 mcg/L < 0.022 mcg/L	Results: adjusted	N: 38 RH: 1	
Satyan, 2007 ⁹²	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.022 mcg/L < 0.056 mcg/L	Results: adjusted	N: 38 RH: 1.57 95% CI: 0.46 to 5.35 p value: 0.5; ref group: Grp1	
Satyan, 2007 ⁹²	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.056 mcg/L < 0.106 mcg/L	Results: adjusted	N: 37 RH: 2.32 95% CI: 0.69 to 7.86 p value: 0.2; ref group: Grp1	
Satyan, 2007 ⁹²	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.106 mcg/L < 0.569 mcg/L	Results: adjusted	N: 37 RH: 3.39 95% CI: 1.04 to 11.07 p value: 0.04; ref group: Grp1	
Satyan, 2007 ⁹²	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.01 mcg/L < 0.022 mcg/L	Results: adjusted	N: 38 RH: 1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Satyan, 2007 ⁹²	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.022 mcg/L < 0.056 mcg/L	Results: adjusted	N: 38 RH: 0.81 95% CI: 0.16 to 4.06 p value: 0.8; ref group: Grp1	
Satyan, 2007 ⁹²	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.056 mcg/L < 0.106 mcg/L	Results: adjusted	N: 37 RH: 2.12 95% CI: 0.47 to 9.54 p value: 0.34; ref group: Grp1	
Satyan, 2007 ⁹²	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.106 mcg/L < 0.569 mcg/L	Results: adjusted	N: 37 RH: 2.14 95% CI: 0.48 to 9.6 p value: 0.32; ref group: Grp1	
Scott, 2003 ⁹³	All-cause mortality	Years: 1	Assay: cTnT Manufacturer: other Manufacturer: Boehringer Mannheim; other; Cardiac reader	< 0.1 mcg/L	Pts with event: % Pts with event: 17% / 42 persons Results: unadjusted	N: 42 Coefficient: REF SE: 2.185	
Scott, 2003 ⁹³	All-cause mortality	Years: 1	Assay: cTnT Manufacturer: other Manufacturer: Boehringer Mannheim; other; Cardiac reader	> 0.1 mcg/L	% Pts with event: 41% / 29 persons Results: unadjusted	N: 29 (40.8%) Coefficient: 4.988 SE: 2.185 95% CI: 10645.93 to 2.023 p value: 0.0025; ref group: Grp1	
Sharma, 2005 ⁹⁴	All-cause mortality	Years: 2.12	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	Pts with event: 0 / 87 persons Results: unadjusted	N: 87	AUC value: 0.76 p value: 0.02 95% CI: 0.617 to 0.935

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Sharma, 2005 ⁹⁴	All-cause mortality	Years: 2.12	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 5 / 31 persons Results: unadjusted	N: 31 AUC: 0.76 95% CI: 0.617 to 0.935 p value: 0.02; ref group: Grp1	
Sharma, 2006 ⁹⁵	All-cause mortality	Years: 2.25			Results: unadjusted		AUC value: 0.82 p value: 0.02 95% CI: 0.99 to 0.64 Sensitivity value: 75 Specificity value: 72
Sharma, 2006 ⁹⁵	All-cause mortality	Years: 2.25			Results: unadjusted		AUC value: 0.82 p value: 0.02 95% CI: 0.99 to 0.64 Sensitivity value: 75 Specificity value: 72
Sharma, 2006 ⁹⁵	All-cause mortality	Years: 2.25			Results: unadjusted		AUC value: 0.82 p value: 0.02 95% CI: 0.99 to 0.64 Sensitivity value: 75 Specificity value: 72
Sharma, 2006 ⁹⁵	All-cause mortality	Years: 2.25	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.06 mcg/L	Results: unadjusted	N: 51 OR: 7.14 95% CI: 5.71 to 10.22 p value: 0.004; ref group: Grp2	AUC value: 0.82 p value: 0.02 95% CI: 0.99 to 0.64 Sensitivity value: 75 Specificity value: 72
Sharma, 2006 ⁹⁵	All-cause mortality	Years: 2.25	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.06 mcg/L	Results: unadjusted	N: 62	AUC value: 0.82 p value: 0.02 95% CI: 0.99 to 0.64 Sensitivity value: 75 Specificity value: 72

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Sharma, 2006 ⁹⁶	All-cause mortality	Years: 2.5	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.04 mcg/L	Pts with event: 3 / 74 persons Results: unadjusted		
Sharma, 2006 ⁹⁶	All-cause mortality	Years: 2.5	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	Pts with event: 6 / 88 persons Results: unadjusted		
Sharma, 2006 ⁹⁶	All-cause mortality	Years: 2.5	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.04 mcg/L	Pts with event: 17 / 52 persons Results: unadjusted		
Sharma, 2006 ⁹⁶	All-cause mortality	Years: 2.5	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 14 / 38 persons Results: unadjusted		
Shroff, 2012 ⁹⁷	All-cause mortality	Years: 1	Assay: cTnI Manufacturer: other Manufacturer: Ortho Clinical Diagnostics ; Vitros	<0.04 ng/mL	Pts with event: 5 / 281 persons Results: unadjusted		
Shroff, 2012 ⁹⁷	All-cause mortality	Years: 1	Assay: cTnI Manufacturer: other Manufacturer: Ortho Clinical Diagnostics ; Vitros	>0.04 ng>mL	Pts with event: 3 / 95 persons Results: unadjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Shroff, 2012 ⁹⁷	MACE < 1 year	Years: 1	Assay: cTnl Manufacturer: other Manufacturer: Ortho Clinical Diagnostics ; Vitros	<0.04 ng/mL	No. of events: 4 / 281 persons Results: unadjusted		
Shroff, 2012 ⁹⁷	MACE < 1 year	Years: 1	Assay: cTnl Manufacturer: other Manufacturer: Ortho Clinical Diagnostics ; Vitros	>0.04 ng>mL	No. of events: 5 / 95 persons Results: unadjusted		
Sommerer, 2007 ⁹⁸	MACE >/= 1 year		Assay: cTnl Manufacturer: Roche; Elecsys	> 0.026 mcg/L	Results: adjusted	N: 53 (39.6%) OR: 2.12 SE: 95% CI: 1.24 to 3.62 p value: 0.006; ref group: Grp1	
Sommerer, 2007 ⁹⁸	MACE >/= 1 year		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.026 mcg/L	Results: adjusted	N: 81 OR: REF SE:	
Stolear, 1999 ⁹⁹	All-cause mortality		Assay: cTnT Manufacturer: other Manufacturer: Boehringer Mannheim; Elecsys	< 0.1 mcg/L	Pts with event: 6 % Pts with event: 13% / 47 persons Results: adjusted	N: 47	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Stolear, 1999 ⁹⁹	All-cause mortality		Assay: cTnT Manufacturer: other Manufacturer: Boehringer Mannheim; Elecsys	> 0.1 mcg/L	Pts with event: 18 % Pts with event: 38% / 47 persons Results: adjusted	N: 47 beta coefficient in Cox model: 2.74 SE: 0.69 p value: 0.0001; ref group: Grp1	
Stolear, 1999 ⁹⁹	All-cause mortality		Assay: cTnT Manufacturer: other Manufacturer: Boehringer; other; TROP T RA -rapid beside assay	< 0.2 mcg/L	Pts with event: 2 / 44 persons Results: adjusted		
Stolear, 1999 ⁹⁹	All-cause mortality		Assay: cTnT Manufacturer: other Manufacturer: Boehringer; other; TROP TRA - rapid assay	> 0.2 mcg/L	Pts with event: 22 / 50 persons Results: adjusted		
Stolear, 1999 ⁹⁹	Subsequent MI		Assay: cTnT Manufacturer: other Manufacturer: Boehringer; Elecsys	< 0.1 mcg/L	Pts with event: 0 / 47 persons Results: unadjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Stolar, 1999 ⁹⁹	Subsequent MI		Assay: cTnT Manufacturer: other Manufacturer: Boehringer; Elecsys	> 0.1 mcg/L	Pts with event: 2 / 47 persons Results: unadjusted		
Svensson, 2009 ¹⁰⁰	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: NR; NR	NR	Results: adjusted	N: 206 HR: 1.76 95% CI: 0.32 to 9.69 p value: 0.52; ref group: other; ref group: Total sample	
Trape, 2008 ¹⁰¹	All-cause mortality	Years: 1	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	Pts with event: 4 / 39 persons Results: unadjusted		
Trape, 2008 ¹⁰¹	All-cause mortality	Years: 1	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 5 / 13 persons Results: unadjusted		
Trape, 2008 ¹⁰¹	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	Pts with event: 11 / 39 persons Results: unadjusted		
Trape, 2008 ¹⁰¹	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 8 / 13 persons Results: unadjusted		
Trape, 2008 ¹⁰¹	All-cause mortality	Years: 3	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	Pts with event: 18 / 39 persons Results: unadjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Trape, 2008 ¹⁰¹	All-cause mortality	Years: 3	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 10 / 13 persons Results: unadjusted		
Troyanov, 2005 ¹⁰²	Other composite (ACS occurrence)	Years: 3	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.4 mcg/L		N: 29 Unadjusted hazard ratio: 2.98 95% CI: 8.57 to 1.04 p value: 0.04	
Troyanov, 2005 ¹⁰²	Other composite (ACS occurrence)	Years: 3	Assay: cTnI Manufacturer: other Manufacturer: Abbot Laboratories; other; MEIA, AxSYM	> 0.3 mcg/L		N: 29 un adjusted hazard ratio: 3.37 95% CI: 7.25 to 1.56 p value: 0.001	
Van Lente, 1999 ¹⁰³	MACE < 1 year-Revascularization				Results: unadjusted		AUC value: 0.59 p value: <0.01 Sensitivity value: 0.45 Specificity value: 0.72
Van Lente, 1999 ¹⁰³	MACE < 1 year-Revascularization				Results: unadjusted		AUC value: 0.53 p value: <0.02 Sensitivity value: 0.33 Specificity value: 0.78
Van Lente, 1999 ¹⁰³	MACE < 1 year-Revascularization		Assay: cTnI Manufacturer: Dade Behring; stratus	threshold 0.6 microgram /L	Results: unadjusted		AUC value: 0.53 p value: <0.02 Sensitivity value: 0.33 Specificity value: 0.78

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Van Lente, 1999 ¹⁰³	MACE < 1 year-Revascularization		Assay: cTnT Manufacturer: other Manufacturer: Boehringer; other; Enzymun	threshold 0.10 mcg/L	Results: unadjusted		AUC value: 0.59 p value: <0.01 Sensitivity value: 0.45 Specificity value: 0.72
Vichairuangthum, 2006 ¹⁰⁴	Cardio mortality		Assay: cTnI Manufacturer: other Manufacturer: Johnson & Johnson; other; Vitros ECI	< 0.08 mcg/L	Pts with event: 0 / 16 persons Results: unadjusted		
Vichairuangthum, 2006 ¹⁰⁴	Cardio mortality		Assay: cTnI Manufacturer: other Manufacturer: Johnson & Johnson; other; Vitros ECI	< 0.4 mcg/L	Pts with event: 2 / 49 persons Results: unadjusted		
Vichairuangthum, 2006 ¹⁰⁴	Cardio mortality		Assay: cTnI Manufacturer: other Manufacturer: Johnson & Johnson; other; Vitros ECI	> 0.08 mcg/L	Pts with event: 2 / 47 persons Results: unadjusted		
Vichairuangthum, 2006 ¹⁰⁴	Cardio mortality		Assay: cTnI Manufacturer: other Manufacturer: Johnson & Johnson; other; Vitros ECI	> 0.4 mcg/L	Pts with event: 0 / 14 persons Results: unadjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Vichairuangthum, 2006 ¹⁰⁴	MACE >= 1 year		Assay: cTnl Manufacturer: other Manufacturer: Johnson & Johnson; other; Vitros ECi	< 0.08 mcg/L	Pts with event: 0 / 16 persons Results: unadjusted		
Vichairuangthum, 2006 ¹⁰⁴	MACE >= 1 year		Assay: cTnl Manufacturer: other Manufacturer: Johnson & Johnson; other; Vitros ECi	< 0.4 mcg/L	Pts with event: 5 / 49 persons Results: unadjusted		
Vichairuangthum, 2006 ¹⁰⁴	MACE >= 1 year		Assay: cTnl Manufacturer: other Manufacturer: Johnson & Johnson; other; Vitros ECi	> 0.08 mcg/L	Pts with event: 10 / 47 persons Results: unadjusted		
Vichairuangthum, 2006 ¹⁰⁴	MACE >= 1 year		Assay: cTnl Manufacturer: other Manufacturer: Johnson & Johnson; other; Vitros ECi	> 0.4 mcg/L	Pts with event: 5 / 14 persons Results: unadjusted		
Vichairuangthum, 2006 ¹⁰⁴	Subsequent MI		Assay: cTnl Manufacturer: other Manufacturer: Johnson & Johnson; other; Vitros ECi	< 0.08 mcg/L	Pts with event: 0 / 16 persons Results: unadjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Vichairuangthum, 2006 ¹⁰⁴	Subsequent MI		Assay: cTnI Manufacturer: other Manufacturer: Johnson & Johnson; other; Vitros ECI	< 0.4 mcg/L	Pts with event: 0 / 49 persons Results: unadjusted		
Vichairuangthum, 2006 ¹⁰⁴	Subsequent MI		Assay: cTnI Manufacturer: other Manufacturer: Johnson & Johnson; other; Vitros ECI	> 0.08 mcg/L	Pts with event: 1 / 47 persons Results: unadjusted		
Vichairuangthum, 2006 ¹⁰⁴	Subsequent MI		Assay: cTnI Manufacturer: other Manufacturer: Johnson & Johnson; other; Vitros ECI	> 0.4 mcg/L	Pts with event: 1 / 14 persons Results: unadjusted		
Wang, 2006 ¹⁰⁵	Other composite (cardiovascular congestion)	Years: 3	Assay: cTnT Manufacturer: Roche; other; Roche Modular Analyzer	per 1 ug/L increase (continuous)	Pts with event: 85 / 222 persons Results: adjusted	N: 85 RH: 2.98 95% CI: 1.19 to 7.42 p value: 0.019; ref group: other; ref group: total population	
Wang, 2007 ¹⁰⁶	All-cause mortality				Results: adjusted		Sensitivity value: 0.76 95% CI: 0.64 to 0.85 Specificity value: 0.71 95% CI: 0.63 to 0.78

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Wang, 2007 ¹⁰⁶	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.01 mcg/L	Pts with event: 9 / 77 persons Results: adjusted		Sensitivity value: 0.76 95% CI: 0.64 to 0.85 Specificity value: 0.71 95% CI: 0.63 to 0.78
Wang, 2007 ¹⁰⁶	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.01 mcg/L 0.099 mcg/L	Pts with event: 15 / 78 persons Results: adjusted		Sensitivity value: 0.76 95% CI: 0.64 to 0.85 Specificity value: 0.71 95% CI: 0.63 to 0.78
Wang, 2007 ¹⁰⁶	All-cause mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 46 / 83 persons Results: adjusted		Sensitivity value: 0.76 95% CI: 0.64 to 0.85 Specificity value: 0.71 95% CI: 0.63 to 0.78
Wang, 2007 ¹⁰⁶	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.01 mcg/L	Pts with event: 6 / 77 persons Results: adjusted		
Wang, 2007 ¹⁰⁶	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.01 mcg/L 0.099 mcg/L	Pts with event: 9 / 78 persons Results: adjusted		
Wang, 2007 ¹⁰⁶	Cardio mortality		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 29 / 83 persons Results: adjusted		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Wang, 2007 ¹⁰⁶	MACE >/= 1 year		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.01 mcg/L< 0.099 mcg/L	Pts with event: 37 / 78 persons Results: adjusted		Sensitivity value: 0.61 95% CI: 0.52 to 0.69 Specificity value: 0.78 95% CI: 0.69 to 0.85
Wang, 2007 ¹⁰⁶	MACE >/= 1 year		Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Pts with event: 66 / 83 persons Results: adjusted		Sensitivity value: 0.61 95% CI: 0.52 to 0.69 Specificity value: 0.78 95% CI: 0.69 to 0.85
Wang, 2007 ¹⁰⁶	MACE >/= 1 year		Assay: cTnT Manufacturer: Roche; Elecsys	< 0.01 mcg/L	Pts with event: 26 / 77 persons Results: adjusted		Sensitivity value: 0.61 95% CI: 0.52 to 0.69 Specificity value: 0.78 95% CI: 0.69 to 0.85
Wang, 2007 ¹⁰⁶	MACE >/= 1 year				Results: adjusted		Sensitivity value: 0.61 95% CI: 0.52 to 0.69 Specificity value: 0.78 95% CI: 0.69 to 0.85
Wang, 2010 ¹⁰⁷	Cardio mortality	Years: 5	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.01 mcg/L	Results: adjusted	N: 81 RH: 1	
Wang, 2010 ¹⁰⁷	Cardio mortality	Years: 5	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	Results: adjusted	N: 79 RH: 2.58 95% CI: 0.78 to 8.57 p value: 0.13; ref group: Grp1	

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Wang, 2010 ¹⁰⁷	Cardio mortality	Years: 5	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.01 mcg/L < 0.099 mcg/L	Results: adjusted	N: 70 RH: 1.91 95% CI: 0.58 to 6.32 p value: 0.29; ref group: Grp1	
Wang, 2010 ¹⁰⁸	Other composite	Years: 5	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.01 mcg/L	% Pts with event: 8.1% / 81 persons		
Wang, 2010 ¹⁰⁸	Other composite	Years: 5	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.01 mcg/L < 0.099 mcg/L	% Pts with event: 18.7% / 70 persons		
Wang, 2010 ¹⁰⁸	Other composite	Years: 5	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	% Pts with event: 28.5% / 79 persons		
Wayand, 2000 ¹⁰⁹	All-cause mortality	Years: 2					AUC value: 0.477 Sensitivity value: 0.57 Specificity value: 0.67
Wayand, 2000 ¹⁰⁹	All-cause mortality	Years: 2	Assay: cTnI Manufacturer: Dade Behring; stratus	< 0.4 mcg/L	Pts with event: 3 / 31 persons		AUC value: 0.477 Sensitivity value: 0.57 Specificity value: 0.67
Wayand, 2000 ¹⁰⁹	All-cause mortality	Years: 2	Assay: cTnI Manufacturer: Dade Behring; stratus	> 0.4 mcg/L	Pts with event: 2 / 28 persons		AUC value: 0.477 Sensitivity value: 0.57 Specificity value: 0.67

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Wayand, 2000 ¹⁰⁹	All-cause mortality	Years: 2					AUC value: 0.703 p value: 0.213 Sensitivity value: 0.57 Specificity value: 0.88
Wayand, 2000 ¹⁰⁹	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; other; Enzymum Troponin T - ES700	< 0.1 mcg/L	Pts with event: 1 / 31 persons		AUC value: 0.703 p value: 0.213 Sensitivity value: 0.57 Specificity value: 0.88
Wayand, 2000 ¹⁰⁹	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; other; Enzymum Troponin T - ES700	> 0.1 mcg/L	Pts with event: 4 / 28 persons		AUC value: 0.703 p value: 0.213 Sensitivity value: 0.57 Specificity value: 0.88
Wood, 2003 ¹¹⁰	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	% Pts with event: 14% No. of events: 10 / 71 persons Results: adjusted	N: 71 RH:	
Wood, 2003 ¹¹⁰	All-cause mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	% Pts with event: 52% No. of events: 11 / 25 persons Results: adjusted	N: 25 RH: 1.72 95% CI: 1.08 to 2.74 p value: 0.02; ref group: Grp1	
Wood, 2003 ¹¹⁰	Cardio mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	< 0.1 mcg/L	No. of events: 5 / 71 persons		
Wood, 2003 ¹¹⁰	Cardio mortality	Years: 2	Assay: cTnT Manufacturer: Roche; Elecsys	> 0.1 mcg/L	No. of events: 6 / 25 persons		

Author, year	Outcome	Followup time	Assay	Cutpoint	Incidence of outcome	Measures of Association	AUC
Yakupoglu, 2002 ¹¹¹	Cardio mortality		Assay: cTnl Manufacturer: other Manufacturer: Diagnostic Products; immulite	< 2.3 mcg/L	Pts with event: 10 % Pts with event: 33% / 30 persons Results: unadjusted		
Yakupoglu, 2002 ¹¹¹	Cardio mortality		Assay: cTnl Manufacturer: other Manufacturer: Diagnostic Products; immulite	> 2.3 mcg/L	Pts with event: 6 % Pts with event: 75% / 8 persons Results: unadjusted		
Yakupoglu, 2002 ¹¹¹	Other composite (Survival)		Assay: cTnl Manufacturer: other Manufacturer: Diagnostic Products; immulite	< 2.3 mcg/L	% Pts with event: 66.1% / 30 persons Results: unadjusted		
Yakupoglu, 2002 ¹¹¹	Other composite (Survival)		Assay: cTnl Manufacturer: other Manufacturer: Diagnostic Products; immulite	> 2.3 mcg/L	% Pts with event: 25% / 8 persons Results: unadjusted		

References

1. Abaci A, Ekici E, Oguzhan A, et al. Cardiac troponins T and I in patients with end-stage renal disease: the relation with left ventricular mass and their prognostic value. *Clin Cardiol.* 2004 Dec;27(12):704-9. PMID: 15628116.
2. Abbas NA, John RI, Webb MC, et al. Cardiac troponins and renal function in nondialysis patients with chronic kidney disease. *Clin Chem.* 2005 Nov;51(11):2059-66. PMID: 16166165.
3. Acharji S, Baber U, Mehran R, et al. Prognostic significance of elevated baseline troponin in patients with acute coronary syndromes and chronic kidney disease treated with different antithrombotic regimens: a substudy from the ACUITY trial. *Circ Cardiovasc Interv.* 2012 Apr;5(2):157-65. PMID: 22354934.
4. Apple FS, Sharkey SW, Hoefft P, et al. Prognostic value of serum cardiac troponin I and T in chronic dialysis patients: a 1-year outcomes analysis. *Am J Kidney Dis.* 1997 Mar;29(3):399-403. PMID: 9041216.
5. Apple FS, Murakami MM, Pearce LA, et al. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. *Circulation.* 2002 Dec 3;106(23):2941-5. PMID: 12460876.
6. Apple FS, Murakami MM, Pearce LA, et al. Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. *Clin Chem.* 2004 Dec;50(12):2279-85. PMID: 15364888.
7. Apple FS, Pearce LA, Doyle PJ, et al. Cardiac troponin risk stratification based on 99th percentile reference cutoffs in patients with ischemic symptoms suggestive of acute coronary syndrome: influence of estimated glomerular filtration rates. *Am J Clin Pathol.* 2007 Apr;127(4):598-603. PMID: 17369136.
8. Artunc F, Mueller C, Breidhardt T, et al. Sensitive troponins--which suits better for hemodialysis patients? Associated factors and prediction of mortality. *PLoS One.* 2012;7(10):e47610. PMID: 23077650.
9. Aviles RJ, Askari AT, Lindahl B, et al. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. *N Engl J Med.* 2002 Jun 27;346(26):2047-52. PMID: 12087140.
10. Bagheri N, Taziki O, Falaknazi K. C- Reactive protein, cardiac troponin T and low albumin are predictors of mortality in hemodialysis patients. *Saudi J Kidney Dis Transpl.* 2009 Sep;20(5):789-93. PMID: 19736474.
11. Beciani M, Tedesco A, Violante A, et al. Cardiac troponin I (2nd generation assay) in chronic haemodialysis patients: prevalence and prognostic value. *Nephrol Dial Transplant.* 2003 May;18(5):942-6. PMID: 12686669.
12. Boulrier A, Jaussent I, Terrier N, et al. Measurement of circulating troponin Ic enhances the prognostic value of C-reactive protein in haemodialysis patients. *Nephrol Dial Transplant.* 2004 Sep;19(9):2313-8. PMID: 15252159.
13. Bozbas H, Korkmaz ME, Atar I, et al. Serum levels of cardiac enzymes before and after renal transplantation. *Clin Cardiol.* 2004 Oct;27(10):559-62. PMID: 15553307.
14. Brunet P, Oddeze C, Paganelli F, et al. Cardiac troponins I and T in hemodialysis patients without acute coronary syndrome. *Int J Cardiol.* 2008 Sep 26;129(2):205-9. PMID: 17662483.

15. Bueti J, Krahn J, Karpinski M, et al. Troponin I testing in dialysis patients presenting to the emergency room: does troponin I predict the 30-day outcome? *Nephron Clin Pract.* 2006;103(4):c129-36. PMID: 16636580.
16. Chew HC. Cardiac troponin T in acute coronary syndrome with renal insufficiency. *Asian Cardiovasc Thorac Ann.* 2008 Aug;16(4):284-7. PMID: 18670019.
17. Choy JB, Armstrong PW, Ulan RA, et al. Do cardiac troponins provide prognostic insight in hemodialysis patients? *Can J Cardiol.* 2003 Jul;19(8):907-11. PMID: 12876611.
18. Chrysochou C, Manzoor S, Wright J, et al. Role of renal function and cardiac biomarkers (NT-proBNP and Troponin) in determining mortality and cardiac outcome in atheromatous renovascular disease. *Kidney Blood Press Res.* 2009;32(5):373-9. PMID: 19887825.
19. Claes K, Bammens B, Evenepoel P, et al. Troponin I is a predictor of acute cardiac events in the immediate postoperative renal transplant period. *Transplantation.* 2010 Feb 15;89(3):341-6. PMID: 20145526.
20. Codognotto M, Piccoli A, Zaninotto M, et al. Effect of a dialysis session on the prognostic values of NT-proBNP, troponins, endothelial damage and inflammation biomarkers. *J Nephrol.* 2010 Jul-Aug;23(4):465-71. PMID: 20540041.
21. Connolly GM, Cunningham R, McNamee PT, et al. Troponin T is an independent predictor of mortality in renal transplant recipients. *Nephrol Dial Transplant.* 2008 Mar;23(3):1019-25. PMID: 18065785.
22. Conway B, McLaughlin M, Sharpe P, et al. Use of cardiac troponin T in diagnosis and prognosis of cardiac events in patients on chronic haemodialysis. *Nephrol Dial Transplant.* 2005 Dec;20(12):2759-64. PMID: 16188899.
23. Deegan PB, Lafferty ME, Blumsohn A, et al. Prognostic value of troponin T in hemodialysis patients is independent of comorbidity. *Kidney Int.* 2001 Dec;60(6):2399-405. PMID: 11737616.
24. deFilippi C, Wasserman S, Rosanio S, et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. *JAMA.* 2003 Jul 16;290(3):353-9. PMID: 12865376.
25. deFilippi C, Seliger SL, Kelley W, et al. Interpreting cardiac troponin results from high-sensitivity assays in chronic kidney disease without acute coronary syndrome. *Clin Chem.* 2012 Sep;58(9):1342-51. PMID: 22791885.
26. Dierkes J, Domrose U, Westphal S, et al. Cardiac troponin T predicts mortality in patients with end-stage renal disease. *Circulation.* 2000 Oct 17;102(16):1964-9. PMID: 11034946.
27. Duman D, Tokay S, Toprak A, et al. Elevated cardiac troponin T is associated with increased left ventricular mass index and predicts mortality in continuous ambulatory peritoneal dialysis patients. *Nephrol Dial Transplant.* 2005 May;20(5):962-7. PMID: 15741207.
28. Farkouh ME, Robbins MJ, Zafar MU, et al. Association between troponin I levels and mortality in stable hemodialysis patients. *Am J Med.* 2003 Feb 15;114(3):224-6. PMID: 12637137.

29. Feringa HH, Bax JJ, de Jonge R, et al. Impact of glomerular filtration rate on minor troponin T elevations for risk assessment in patients undergoing operation for abdominal aortic aneurysm or lower extremity arterial obstruction. *Am J Cardiol.* 2006 Dec 1;98(11):1515-8. PMID: 17126662.
30. Fernandez-Reyes MJ, Mon C, Heras M, et al. Predictive value of troponin T levels for ischemic heart disease and mortality in patients on hemodialysis. *J Nephrol.* 2004 Sep-Oct;17(5):721-7. PMID: 15593041.
31. Flores LM, Hernandez Dominguez JL, Otero A, et al. [Cardiac troponin I determination in patients with chronic renal failure]. *Nefrologia.* 2006;26(1):107-12. PMID: 16649431.
32. Gaiki MR, DeVita MV, Michelis MF, et al. Troponin I as a prognostic marker of cardiac events in asymptomatic hemodialysis patients using a sensitive troponin I assay. *Int Urol Nephrol.* 2012 Dec;44(6):1841-5. PMID: 22311387.
33. Geerse DA, van Berkel M, Vogels S, et al. Moderate elevations of high-sensitivity cardiac troponin I and B-type natriuretic peptide in chronic hemodialysis patients are associated with mortality. *Clin Chem Lab Med.* 2012 Dec 10;1-8. PMID: 23241607.
34. Goicoechea M, Garca de Vinuesa S, Gomez-Campdera F, et al. Clinical significance of cardiac troponin T levels in chronic kidney disease patients: predictive value for cardiovascular risk. *Am J Kidney Dis.* 2004 May;43(5):846-53. PMID: 15112175.
35. Gruberg L, Fuchs S, Waksman R, et al. Prognostic value of cardiac troponin I elevation after percutaneous coronary intervention in patients with chronic renal insufficiency: a 12-month outcome analysis. *Catheter Cardiovasc Interv.* 2002 Feb;55(2):174-9. PMID: 11835642.
36. Hallen J, Madsen L, Ladefoged S, et al. Incremental value of a combination of cardiac troponin T, N-terminal pro-brain natriuretic peptide and C-reactive protein for prediction of mortality in end-stage renal disease. *Scand J Urol Nephrol.* 2011 Mar;45(2):151-8. PMID: 21091090.
37. Han JH, Lindsell CJ, Ryan RJ, et al. Changes in cardiac troponin T measurements are associated with adverse cardiac events in patients with chronic kidney disease. *Am J Emerg Med.* 2005 Jul;23(4):468-73. PMID: 16032613.
38. Han SH, Choi HY, Kim DK, et al. Elevated cardiac troponin T predicts cardiovascular events in asymptomatic continuous ambulatory peritoneal dialysis patients without a history of cardiovascular disease. *Am J Nephrol.* 2009;29(2):129-35. PMID: 18719346.
39. Hasegawa M, Ishii J, Kitagawa F, et al. Prognostic value of highly sensitive troponin T on cardiac events in patients with chronic kidney disease not on dialysis. *Heart Vessels.* 2012 Aug 23; PMID: 22914904.
40. Havekes B, van Manen JG, Krediet RT, et al. Serum troponin T concentration as a predictor of mortality in hemodialysis and peritoneal dialysis patients. *Am J Kidney Dis.* 2006 May;47(5):823-9. PMID: 16632021.
41. Heeschen C, Deu A, Langenbrink L, et al. Analytical and diagnostic performance of troponin assays in patients suspicious for acute coronary syndromes. *Clin Biochem.* 2000 Jul;33(5):359-68. PMID: 11018687.
42. Helleskov Madsen L, Ladefoged S, Hildebrandt P, et al. Comparison of four different cardiac troponin assays in patients with end-stage renal disease on chronic haemodialysis. *Acute Card Care.* 2008;10(3):173-80. PMID: 18608043.

43. Hickman PE, McGill DA, Talaulikar G, et al. Prognostic efficacy of cardiac biomarkers for mortality in dialysis patients. *Intern Med J*. 2009 Dec;39(12):812-8. PMID: 20233242.
44. Hickson LJ, Cosio FG, El-Zoghby ZM, et al. Survival of patients on the kidney transplant wait list: relationship to cardiac troponin T. *Am J Transplant*. 2008 Nov;8(11):2352-9. PMID: 18785956.
45. Hickson LT, El-Zoghby ZM, Lorenz EC, et al. Patient survival after kidney transplantation: relationship to pretransplant cardiac troponin T levels. *Am J Transplant*. 2009 Jun;9(6):1354-61. PMID: 19459818.
46. Hocher B, Ziebig R, Altermann C, et al. Different impact of biomarkers as mortality predictors among diabetic and nondiabetic patients undergoing hemodialysis. *J Am Soc Nephrol*. 2003 Sep;14(9):2329-37. PMID: 12937310.
47. Hocher B, Ziebig R, Krause R, et al. Relaxin is an independent risk factor predicting death in male patients with end-stage kidney disease. *Circulation*. 2004 May 18;109(19):2266-8. PMID: 15136497.
48. Hocher B, Kalk P, Godes M, et al. Gender-dependent impact of risk factors for cardiovascular and non-cardiovascular mortality in end-stage renal disease patients on haemodialysis. *Kidney Blood Press Res*. 2008;31(5):360-6. PMID: 19023219.
49. Hojs R, Ekart R, Hojs Fabjan T, et al. Cardiac troponin T (cTnT) in hemodialysis patients with asymptomatic and symptomatic atherosclerosis. *Arch Med Res*. 2005 Jul-Aug;36(4):367-71. PMID: 15950076.
50. Holden RM, Beseau D, Booth SL, et al. FGF-23 is associated with cardiac troponin T and mortality in hemodialysis patients. *Hemodial Int*. 2012 Jan;16(1):53-8. PMID: 22099949.
51. Hung SY, Hung YM, Fang HC, et al. Cardiac troponin I and creatine kinase isoenzyme MB in patients with intradialytic hypotension. *Blood Purif*. 2004;22(4):338-43. PMID: 15218282.
52. Hussein M, Mooij J, Roujouleh H, et al. Cardiac troponin-I and its prognostic significance in a dialysis population. *Hemodial Int*. 2004 Oct 1;8(4):332-7. PMID: 19379438.
53. Ie EH, Klootwijk PJ, Weimar W, et al. Significance of acute versus chronic troponin T elevation in dialysis patients. *Nephron Clin Pract*. 2004;98(3):c87-92. PMID: 15528943.
54. Iliou MC, Fumeron C, Benoit MO, et al. Prognostic value of cardiac markers in ESRD: Chronic Hemodialysis and New Cardiac Markers Evaluation (CHANCE) study. *Am J Kidney Dis*. 2003 Sep;42(3):513-23. PMID: 12955679.
55. Ilva T, Lassus J, Siirila-Waris K, et al. Clinical significance of cardiac troponins I and T in acute heart failure. *Eur J Heart Fail*. 2008;10(8):772-9.
56. Ishii J, Nomura M, Okuma T, et al. Risk stratification using serum concentrations of cardiac troponin T in patients with end-stage renal disease on chronic maintenance dialysis. *Clin Chim Acta*. 2001 Oct;312(1-2):69-79. PMID: 11580911.
57. Jensen JK, Ueland T, Aukrust P, et al. Highly sensitive troponin T in patients with acute ischemic stroke. *Eur Neurol*. 2012;68(5):287-93. PMID: 23051820.
58. Kalaji FR, Albitar S. Predictive value of cardiac troponin T and I in hemodialysis patients. *Saudi J Kidney Dis Transpl*. 2012 Sep;23(5):939-45. PMID: 22982904.

59. Kang EW, Na HJ, Hong SM, et al. Prognostic value of elevated cardiac troponin I in ESRD patients with sepsis. *Nephrol Dial Transplant*. 2009 May;24(5):1568-73. PMID: 19145004.
60. Kanwar M, Hashem M, Rosman H, et al. Usefulness of clinical evaluation, troponins, and C-reactive protein in predicting mortality among stable hemodialysis patients. *Am J Cardiol*. 2006 Nov 1;98(9):1283-7. PMID: 17056347.
61. Katerinis I, Nguyen QV, Magnin JL, et al. Cardiac findings in asymptomatic chronic hemodialysis patients with persistently elevated cardiac troponin I levels. *Ren Fail*. 2008;30(4):357-62. PMID: 18569907.
62. Kertai MD, Boersma E, Klein J, et al. Long-term prognostic value of asymptomatic cardiac troponin T elevations in patients after major vascular surgery. *Eur J Vasc Endovasc Surg*. 2004 Jul;28(1):59-66. PMID: 15177233.
63. Khan IA, Wattanasuwan N, Mehta NJ, et al. Prognostic value of serum cardiac troponin I in ambulatory patients with chronic renal failure undergoing long-term hemodialysis: a two-year outcome analysis. *J Am Coll Cardiol*. 2001 Oct;38(4):991-8. PMID: 11583870.
64. Kontos MC, Garg R, Anderson FP, et al. Outcomes in patients admitted for chest pain with renal failure and troponin I elevations. *Am Heart J*. 2005 Oct;150(4):674-80. PMID: 16209963.
65. Kontos MC, Garg R, Anderson FP, et al. Predictive power of ejection fraction and renal failure in patients admitted for chest pain without ST elevation in the troponin era. *Am Heart J*. 2005 Oct;150(4):666-73. PMID: 16209962.
66. Kontos MC, Jamal SM, Ornato JP, et al. Comparison of the modification of diet in renal disease and the Cockcroft-Gault equations for predicting mortality in patients admitted for exclusion of myocardial ischemia. *Am J Cardiol*. 2008 Jul 15;102(2):140-5. PMID: 18602510.
67. Kostrubiec M, Labyk A, Pedowska-Wloszek J, et al. Assessment of renal dysfunction improves troponin-based short-term prognosis in patients with acute symptomatic pulmonary embolism. *J Thromb Haemost*. 2010 Apr;8(4):651-8. PMID: 20088923.
68. Lamb EJ, Kenny C, Abbas NA, et al. Cardiac troponin I concentration is commonly increased in nondialysis patients with CKD: experience with a sensitive assay. *Am J Kidney Dis*. 2007 Apr;49(4):507-16. PMID: 17386318.
69. Lang K, Schindler S, Forberger C, et al. Cardiac troponins have no prognostic value for acute and chronic cardiac events in asymptomatic patients with end-stage renal failure. *Clin Nephrol*. 2001 Jul;56(1):44-51. PMID: 11499658.
70. Le Goff C, Bovy C, Aldenhoff MC, et al. Three-year prognostic interest of cardiac troponin T (cTnT) and amino-terminal pro-B-natriuretic peptide (NT-proBNP) in hemodialyzed patients. *Immuno-Analyse et Biologie Specialisee*. 2007;22(6):377-83.
71. Lowbeer C, Gutierrez A, Gustafsson SA, et al. Elevated cardiac troponin T in peritoneal dialysis patients is associated with CRP and predicts all-cause mortality and cardiac death. *Nephrol Dial Transplant*. 2002 Dec;17(12):2178-83. PMID: 12454230.
72. Lowbeer C, Stenvinkel P, Pecoits-Filho R, et al. Elevated cardiac troponin T in predialysis patients is associated with inflammation and predicts mortality. *J Intern Med*. 2003 Feb;253(2):153-60. PMID: 12542555.
73. Mallamaci F, Zoccali C, Parlongo S, et al. Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. *Am J Kidney Dis*. 2002 Jul;40(1):68-75. PMID: 12087563.

74. Martin GS, Becker BN, Schulman G. Cardiac troponin-I accurately predicts myocardial injury in renal failure. *Nephrol Dial Transplant*. 1998 Jul;13(7):1709-12. PMID: 9681716.
75. McGill D, Talaulikar G, Potter JM, et al. Over time, high-sensitivity TnT replaces NT-proBNP as the most powerful predictor of death in patients with dialysis-dependent chronic renal failure. *Clin Chim Acta*. 2010 Jul 4;411(13-14):936-9. PMID: 20298685.
76. McMurray JJ, Uno H, Jarolim P, et al. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). *Am Heart J*. 2011 Oct;162(4):748-55 e3. PMID: 21982669.
77. Melloni C, Alexander KP, Milford-Beland S, et al. Prognostic value of troponins in patients with non-ST-segment elevation acute coronary syndromes and chronic kidney disease. *Clin Cardiol*. 2008 Mar;31(3):125-9. PMID: 18383049.
78. Mockel M, Schindler R, Knorr L, et al. Prognostic value of cardiac troponin T and I elevations in renal disease patients without acute coronary syndromes: a 9-month outcome analysis. *Nephrol Dial Transplant*. 1999 Jun;14(6):1489-95. PMID: 10383013.
79. Morton AR, Collier CP, Ali N, et al. Cardiac troponin I in patients receiving renal replacement therapy. *ASAIO J*. 1998 Sep-Oct;44(5):M433-5. PMID: 9804466.
80. Musso P, Cox I, Vidano E, et al. Cardiac troponin elevations in chronic renal failure: prevalence and clinical significance. *Clin Biochem*. 1999 Mar;32(2):125-30. PMID: 10211629.
81. Ooi DS, Veinot JP, Wells GA, et al. Increased mortality in hemodialyzed patients with elevated serum troponin T: a one-year outcome study. *Clin Biochem*. 1999 Nov;32(8):647-52. PMID: 10638948.
82. Ooi DS, Zimmerman D, Graham J, et al. Cardiac troponin T predicts long-term outcomes in hemodialysis patients. *Clin Chem*. 2001 Mar;47(3):412-7. PMID: 11238290.
83. Orea-Tejeda A, Sanchez-Gonzalez LR, Castillo-Martinez L, et al. Prognostic value of cardiac troponin T elevation is independent of renal function and clinical findings in heart failure patients. *Cardiol J*. 2010;17(1):42-8. PMID: 20104456.
84. Peetz D, Schutt S, Sucke B, et al. Prognostic value of troponin T, troponin I, and CK-MBmass in patients with chronic renal failure. *Med Klin (Munich)*. 2003 Apr 15;98(4):188-92. PMID: 12715142.
85. Petrovic D, Stojimirovic BB. Cardiac troponins: outcome predictors in hemodialysis patients. *J Artif Organs*. 2009;12(4):258-63. PMID: 20035399.
86. Porter GA, Norton T, Bennett WB. Troponin T, a predictor of death in chronic haemodialysis patients. *Eur Heart J*. 1998 Nov;19 Suppl N:N34-7. PMID: 9857937.
87. Porter GA, Norton T, Bennett WM. Long term follow up of the utility of troponin T to assess cardiac risk in stable chronic hemodialysis patients. *Clin Lab*. 2000;46(9-10):469-76. PMID: 11034532.
88. Roberts MA, Fernando D, Macmillan N, et al. Single and serial measurements of cardiac troponin I in asymptomatic patients on chronic hemodialysis. *Clin Nephrol*. 2004 Jan;61(1):40-6. PMID: 14964456.

89. Roberts MA, Hare DL, Macmillan N, et al. Serial increased cardiac troponin T predicts mortality in asymptomatic patients treated with chronic haemodialysis. *Ann Clin Biochem.* 2009 Jul;46(Pt 4):291-5. PMID: 19454539.
90. Roppolo LP, Fitzgerald R, Dillow J, et al. A comparison of troponin T and troponin I as predictors of cardiac events in patients undergoing chronic dialysis at a Veteran's Hospital: a pilot study. *J Am Coll Cardiol.* 1999 Aug;34(2):448-54. PMID: 10440158.
91. Sahinarslan A, Guz G, Okay K, et al. Prognostic value of troponin T and homocysteine in patients with end-stage renal disease. *Turk Kardiyol Dern Ars.* 2008 Sep;36(6):382-7. PMID: 19155641.
92. Satyan S, Light RP, Agarwal R. Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. *Am J Kidney Dis.* 2007 Dec;50(6):1009-19. PMID: 18037101.
93. Scott B, Deman A, Peeters P, et al. Cardiac troponin T and malondialdehyde modified plasma lipids in haemodialysis patients. *Nephrol Dial Transplant.* 2003 Apr;18(4):737-42. PMID: 12637643.
94. Sharma R, Pellerin D, Gaze DC, et al. Dobutamine stress echocardiography and cardiac troponin T for the detection of significant coronary artery disease and predicting outcome in renal transplant candidates. *Eur J Echocardiogr.* 2005 Oct;6(5):327-35. PMID: 15985387.
95. Sharma R, Gaze DC, Pellerin D, et al. Ischemia-modified albumin predicts mortality in ESRD. *Am J Kidney Dis.* 2006 Mar;47(3):493-502. PMID: 16490629.
96. Sharma R, Gaze DC, Pellerin D, et al. Cardiac structural and functional abnormalities in end stage renal disease patients with elevated cardiac troponin T. *Heart.* 2006 Jun;92(6):804-9. PMID: 16216854.
97. Shroff GR, Akkina SK, Miedema MD, et al. Troponin I levels and postoperative myocardial infarction following renal transplantation. *Am J Nephrol.* 2012;35(2):175-80. PMID: 22286592.
98. Sommerer C, Beimler J, Schwenger V, et al. Cardiac biomarkers and survival in haemodialysis patients. *Eur J Clin Invest.* 2007 May;37(5):350-6. PMID: 17461980.
99. Stolear JC, Georges B, Shita A, et al. The predictive value of cardiac troponin T measurements in subjects on regular haemodialysis. *Nephrol Dial Transplant.* 1999 Aug;14(8):1961-7. PMID: 10462278.
100. Svensson M, Gorst-Rasmussen A, Schmidt EB, et al. NT-pro-BNP is an independent predictor of mortality in patients with end-stage renal disease. *Clin Nephrol.* 2009;71(4):380-6.
101. Trape J, Perez A, Naval I, et al. Nt-proBNP in haemodialysis patients: a preliminary study. *Scand J Clin Lab Invest.* 2008;68(5):415-20. PMID: 19172698.
102. Troyanov S, Ly QH, Schampaert E, et al. Diagnostic specificity and prognostic value of cardiac troponins in asymptomatic chronic haemodialysis patients: a three year prospective study. *Heart.* 2005 Sep;91(9):1227-8. PMID: 16103574.
103. Van Lente F, McErlean ES, DeLuca SA, et al. Ability of troponins to predict adverse outcomes in patients with renal insufficiency and suspected acute coronary syndromes: a case-matched study. *J Am Coll Cardiol.* 1999 Feb;33(2):471-8. PMID: 9973028.

104. Vichairuangthum K, Leowattana W, Ong-Ajyooth L, et al. The relationship between serum concentration of cardiac troponin I in chronic renal failure patients and cardiovascular events. *J Med Assoc Thai.* 2006 May;89(5):714-20. PMID: 16756060.
105. Wang AY, Lam CW, Yu CM, et al. Troponin T, left ventricular mass, and function are excellent predictors of cardiovascular congestion in peritoneal dialysis. *Kidney Int.* 2006 Aug;70(3):444-52. PMID: 16871255.
106. Wang AY, Lam CW, Wang M, et al. Prognostic value of cardiac troponin T is independent of inflammation, residual renal function, and cardiac hypertrophy and dysfunction in peritoneal dialysis patients. *Clin Chem.* 2007 May;53(5):882-9. PMID: 17395709.
107. Wang AYM, Lam CW, Chan IH, et al. Sudden cardiac death in end-stage renal disease patients: A 5-year prospective analysis. *NDT Plus.* 2010;3:iii291.
108. Wang AY, Lam CW, Chan IH, et al. Sudden cardiac death in end-stage renal disease patients: a 5-year prospective analysis. *Hypertension.* 2010 Aug;56(2):210-6. PMID: 20606110.
109. Wayand D, Baum H, Schatzle G, et al. Cardiac troponin T and I in end-stage renal failure. *Clin Chem.* 2000 Sep;46(9):1345-50. PMID: 10973864.
110. Wood GN, Keevil B, Gupta J, et al. Serum troponin T measurement in patients with chronic renal impairment predicts survival and vascular disease: a 2 year prospective study. *Nephrol Dial Transplant.* 2003 Aug;18(8):1610-5. PMID: 12897102.
111. Yakupoglu U, Ozdemir FN, Arat Z, et al. Can troponin-I predict cardiovascular mortality due to myocardial injury in hemodialysis patients? *Transplant Proc.* 2002 Sep;34(6):2033-4. PMID: 12270303.

Table 5a. Study quality data for articles included in KQ1

Reporting									
Author, year	Main hypothesis/objective described	Main outcome described	Patient characteristics described	Interventions of interest described	Principal confounders described	Main findings described	Random variability estimate	Loss to follow up described	Actual probability values
Alcalai, 2007 ¹	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes
Alcalai, 2007 ¹	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Apple, 1999 ²	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No
Apple, 1999 ²	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No
Bhagavan, 1998 ³	Yes	Yes	No	Yes	No	Yes	Yes	No	No

Author, year	Main hypothesis/objective described	Main outcome described	Patient characteristics described	Interventions of interest described	Principal confounders described	Main findings described	Random variability estimate	Loss to follow up described	Actual probability values
Bhagavan, 1998 ³	Yes	Yes	No	Yes	No	Yes	No	No	No
Fehr, 2003 ⁴	Yes	No	No	Yes	No	Yes	Yes	No	Yes
Fehr, 2003 ⁴	Yes	No	No	Yes	No	Yes	No	No	No
Flores, 2006 ⁵	Yes	No	Yes	Yes	No	Yes	No	Yes	No
Flores, 2006 ⁵	Yes	Yes	Yes	Yes	No	Yes	No	Yes	No
Flores-Solis, 2012 ⁶	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No
Flores-Solis, 2012 ⁶	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No
Martin, 1998 ⁷	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No
Martin, 1998 ⁷	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No
McCullough, 2002 ⁸	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
McCullough, 2002 ⁸	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Noeller, 2003 ⁹	Yes	Yes	Yes	Yes	No	Yes	No	Yes	Yes
Noeller, 2003 ⁹	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Roppolo, 1999 ¹⁰	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No
Roppolo, 1999 ¹⁰	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No
Sukonthasarn, 2007 ¹¹	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes
Sukonthasarn, 2007 ¹¹	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes

Author, year	Main hypothesis/objective described	Main outcome described	Patient characteristics described	Interventions of interest described	Principal confounders described	Main findings described	Random variability estimate	Loss to follow up described	Actual probability values
Troyanov, 2005 ¹²	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes
Troyanov, 2005 ¹²	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes

Internal Validity -Bias

Author, year	Blinding those measuring outcomes	Data dredging	Adjust for different followup	Appropriate statistical tests used	Main outcome measures accurate	Intervention groups from same population	Intervention groups recruited same time	Adequate adjustment for confounding in analyses	Losses to followup taken into account
Alcalai, 2007 ¹	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes some	Yes
Alcalai, 2007 ¹	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Unable to determine	Yes
Apple, 1999 ²	Yes	Yes	Unable to determine	Yes	Yes	No	Yes	Yes	Unable to determine
Apple, 1999 ²	Unable to determine	Yes	Unable to determine	Yes	Yes	No	Yes	Yes	Unable to determine
Bhagavan, 1998 ³	No	Yes	Unable to determine	Yes	Yes	Unable to determine	Unable to determine	No	Unable to determine
Bhagavan, 1998 ³	Unable to determine	Yes	Unable to determine	Yes	Yes	Unable to determine	Unable to determine	Unable to determine	Unable to determine
Fehr, 2003 ⁴	Not feasible	Yes	Unable to determine	Yes	Unable to determine	Unable to determine	Unable to determine	No	No
Fehr, 2003 ⁴	Unable to determine	Yes	Unable to determine	Yes	Yes	Unable to determine	Unable to determine	Unable to determine	Unable to determine

Author, year	Blinding those measuring outcomes	Data dredging	Adjust for different followup	Appropriate statistical tests used	Main outcome measures accurate	Intervention groups from same population	Intervention groups recruited same time	Adequate adjustment for confounding in analyses	Losses to followup taken into account
Flores, 2006 ⁵	Unable to determine	Unable to determine	NA	Yes	Yes	Yes	Yes	Unable to determine	NA
Flores, 2006 ⁵	Not feasible	Yes	NA	Yes	Yes	Yes	Yes	No	Yes
Flores-Solis, 2012 ⁶	Not feasible	Yes	NA	Yes	Yes	Yes	Yes	NA	NA
Flores-Solis, 2012 ⁶	Unable to determine	Yes	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes
Martin, 1998 ⁷	Yes	Unable to determine	Yes	Yes	Yes	Yes	Yes	NA	Yes
Martin, 1998 ⁷	Unable to determine	Yes	Unable to determine	Yes	Yes	Yes	Yes	NA	Yes
McCullough, 2002 ⁸	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes some	Yes
McCullough, 2002 ⁸	Yes	Yes	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes
Noeller, 2003 ⁹	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Noeller, 2003 ⁹	Yes	Yes	Unable to determine	Yes	Yes	Yes	Unable to determine	Yes some	Yes
Roppolo, 1999 ¹⁰	No	Yes	NA	Yes	Yes	Yes	Yes	No	Yes
Roppolo, 1999 ¹⁰	Unable to determine	Yes	Yes	Yes	Yes	Yes	Unable to determine	NA	Yes

Author, year	Blinding those measuring outcomes	Data dredging	Adjust for different followup	Appropriate statistical tests used	Main outcome measures accurate	Intervention groups from same population	Intervention groups recruited same time	Adequate adjustment for confounding in analyses	Losses to followup taken into account
Sukonthasarn, 2007 ¹¹	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	No	Unable to determine
Sukonthasarn, 2007 ¹¹	Unable to determine	Yes	Unable to determine	Yes	Yes	Yes	Yes	Unable to determine	Unable to determine
Troyanov, 2005 ¹²	No	Yes	No	Yes	Yes	Yes	Yes	Yes some	Unable to determine
Troyanov, 2005 ¹²	Unable to determine	Yes	Unable to determine	Yes	Yes	Yes	Unable to determine	Yes some	Yes

External validity - Power

Author, year	Population asked representative	Population prepared participate representative	Staff places facilities representative	Power calculation reported	Industry support	Overall quality
Alcalai, 2007 ¹	Yes	Yes	Yes	No	NR support	Fair
Alcalai, 2007 ¹	Yes	Yes	Yes	No	NR support	Good
Apple, 1999 ²	Yes	Yes	Unable to determine	No	Yes industry support	Fair
Apple, 1999 ²	Unable to determine	Yes	Unable to determine	No	NR support	Fair
Bhagavan, 1998 ³	Unable to determine	Unable to determine	Unable to determine	No	NR support	Fair
Bhagavan, 1998 ³	Unable to determine	Unable to determine	Unable to determine	No	NR support	Fair
Fehr, 2003 ⁴	Unable to determine	Unable to determine	Unable to determine	No	NR support	Poor
Fehr, 2003 ⁴	Unable to determine	Unable to determine	Unable to determine	No	NR support	Poor

Author, year	Population asked representative	Population prepared participate representative	Staff places facilities representative	Power calculation reported	Industry support	Overall quality
Flores, 2006 ⁵	No	No	Unable to determine	No	NR support	Poor
Flores, 2006 ⁵	Unable to determine	Unable to determine	Unable to determine	No	NR support	Fair
Flores-Solis, 2012 ⁶	Yes	Yes	Yes	Yes	No industry support	Fair
Flores-Solis, 2012 ⁶	Unable to determine	Unable to determine	Yes	Yes	No industry support	Good
Martin, 1998 ⁷	Yes	Yes	Unable to determine	No	NR support	Fair
Martin, 1998 ⁷	Yes	Yes	Yes	No	NR support	Fair
McCullough, 2002 ⁸	Yes	Yes	Yes	No	Yes industry support	Good
McCullough, 2002 ⁸	Yes	Yes	Unable to determine	No	NR support	Good
Noeller, 2003 ⁹	Yes	Yes	Yes	Yes	NR support	Fair
Noeller, 2003 ⁹	Yes	Yes	Unable to determine	Yes	NR support	Good
Roppolo, 1999 ¹⁰	Yes	Unable to determine	Unable to determine	No	NR support	Good
Roppolo, 1999 ¹⁰	Yes	Yes	Unable to determine	No	NR support	Poor
Sukonthasarn, 2007 ¹¹	Yes	Unable to determine	Yes	No	No industry support	Fair
Sukonthasarn, 2007 ¹¹	Yes	Yes	Yes	No	Yes industry support	Good
TroyaNov, 2005 ¹²	Unable to determine	Unable to determine	Yes	No	Yes industry support	Fair
TroyaNov, 2005 ¹²	Unable to determine	Unable to determine	Unable to determine	No	NR support	Fair

Table 5b. Study quality data for articles included in KQ2 and KQ3

Reporting

Author, year	Main hypothesis/objective described	Main outcome described	Patient characteristics described	Interventions of interest described	Principal confounders described	Main findings described	Random variability estimate	Loss to follow up described	Actual probability values
Acharji, 2012 ¹³	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Chew, 2008 ¹⁴	Yes	Yes	Yes	No	Yes	Yes	No	No	Yes
Kontos, 2008 ¹⁵	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No
Melloni, 2008 ¹⁶	Yes	Yes	Yes	Yes	Yes	Yes	No	No	No
Apple, 2007 ¹⁷	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Flores, 2006 ⁵	Yes	Yes	Yes	Yes	No	Yes	No	Yes	No
Bueti, 2006 ¹⁸	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Kontos, 2005 ¹⁹	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Kontos, 2005 ²⁰	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Han, 2005 ²¹	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No
Aviles, 2002 ²²	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Gruberg, 2002 ²³	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Wayand, 2000 ²⁴	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes
Van Lente, 1999 ²⁵	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes

Internal Validity -Bias

Author, year	Blinding those measuring outcomes	Data dredging	Main outcome measures accurate	Intervention groups from same population	Intervention groups recruited same time	Adequate adjustment for confounding in analyses	Losses to followup taken into account
Acharji, 2012 ¹³	Not feasible	Yes	Yes	Yes	Yes	Yes	Yes
Chew, 2008 ¹⁴	Not feasible	Yes	Yes	Yes	Yes	No	Yes
Kontos, 2008 ¹⁵	No	Yes	Yes	Yes	Yes	No	Yes
Melloni, 2008 ¹⁶	No	Yes	Yes	Yes	Yes	Yes	Yes
Apple, 2007 ¹⁷	No	Yes	Yes	Yes	Yes	No	Yes

Author, year	Blinding those measuring outcomes	Data dredging	Main outcome measures accurate	Intervention groups from same population	Intervention groups recruited same time	Adequate adjustment for confounding in analyses	Losses to followup taken into account
Flores, 2006 ⁵	Not feasible	Yes	Yes	Yes	Yes	No	Yes
Bueti, 2006 ¹⁸	No	Yes	Yes	Yes	Yes	Yes	Yes
Kontos, 2005 ¹⁹	Not feasible	Yes	Yes	Yes	Yes	Yes	Yes
Kontos, 2005 ²⁰	No	Yes	Yes	Yes	Yes	No	Yes
Han, 2005 ²¹	Not feasible	Yes	Yes	Yes	Yes	Yes	Yes
Aviles, 2002 ²²	Yes	Yes	Yes	Yes	Yes	No	Yes
Gruberg, 2002 ²³	No	No	Yes	Yes	Yes	No	Yes
Wayand, 2000 ²⁴	Yes	Yes	Yes	Yes	Yes	No	Yes
Van Lente, 1999 ²⁵	Yes	Yes	Yes	Yes	Yes	Yes	Yes

External validity - Power

Author, year	Population asked representative	Population prepared participate representative	Staff places facilities representative	Power calculation reported	Industry support	Overall quality
Acharji, 2012 ¹³	Yes	Yes	Unable	Yes (in original RCT)	Yes	Good
Chew, 2008 ¹⁴	Unable	Unable	Unable	No	NR	Poor
Kontos, 2008 ¹⁵	Yes	Unable	Unable	No	NR	Good
Melloni, 2008 ¹⁶	Yes	Yes	Yes	No	Yes	Good
Apple, 2007 ¹⁷	Yes	Yes	Unable	No	Yes	Fair
Flores, 2006 ⁵	Unable	Unable	Unable to determine	No	NR	Poor
Bueti, 2006 ¹⁸	Yes	Yes	Yes	No	No	Good

Author, year	Population asked representative	Population prepared participate representative	Staff places facilities representative	Power calculation reported	Industry support	Overall quality
Kontos, 2005 ¹⁹	Yes	Yes	Yes	No	NR	Fair
Kontos, 2005 ²⁰	Yes	Unable	Yes	No	NR	Good
Han, 2005 ²¹	Yes	Yes	Unable to determine	No	NR	Fair
Aviles, 2002 ²²	Yes	Yes	Yes	No	Yes	Good
Gruberg, 2002 ²³	Yes	Yes	Yes	No	NR	Good
Wayand, 2000 ²⁴	Unable to determine	Unable to determine	Yes	No	NR	Fair
Van Lente, 1999 ²⁵	Yes	Yes	Yes	No	Yes	Good

Table 5c. Study quality data for articles included in KQ4

Reporting

Author, year	Main hypothesis/objective described	Main outcome described	Patient characteristics described	Interventions of interest described	Principal confounders described	Main findings described	Random variability estimate	Loss to follow up described	Actual probability values
Abaci, 2004 ²⁶	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Abbas, 2005 ²⁷	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Apple, 1997 ²⁸	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No
Apple, 2002 ²⁹	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Apple, 2004 ³⁰	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

Author, year	Main hypothesis/objective described	Main outcome described	Patient characteristics described	Interventions of interest described	Principal confounders described	Main findings described	Random variability estimate	Loss to follow up described	Actual probability values
Artunc, 2012 ³¹	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes
Bagheri, 2009 ³²	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes
Boulier, 2004 ³³	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Bozbas, 2004 ³⁴	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No
Brunet, 2008 ³⁵	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes
Choy, 2003 ³⁶	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Chrysochou, 2009 ³⁷	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Claes, 2010 ³⁸	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Codognotto, 2010 ³⁹	Yes	Yes	Yes	Yes	No	No	No	Yes	Yes
Connolly, 2008 ⁴⁰	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Conway, 2005 ⁴¹	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Deegan, 2001 ⁴²	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes

Author, year	Main hypothesis/objective described	Main outcome described	Patient characteristics described	Interventions of interest described	Principal confounders described	Main findings described	Random variability estimate	Loss to follow up described	Actual probability values
deFilippi, 2003 ⁴³	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Dierkes, 2000 ⁴⁴	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Duman, 2005 ⁴⁵	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Farkouh, 2003 ⁴⁶	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Feringa, 2006 ⁴⁷	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Fernandez-Reyes, 2004 ⁴⁸	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes
Gaiki, 2012 ⁴⁹	Yes	Yes	Yes	Yes	No	Yes	No	Yes	Yes
Geerse, 2012 ⁵⁰	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No
Goicoechea, 2004 ⁵¹	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Hallen, 2011 ⁵²	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Han, 2009 ⁵³	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No
Hasegawa, 2012 ⁵⁴	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes

Author, year	Main hypothesis/objective described	Main outcome described	Patient characteristics described	Interventions of interest described	Principal confounders described	Main findings described	Random variability estimate	Loss to follow up described	Actual probability values
Havekes, 2006 ⁵⁵	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No
Helleskov Madsen, 2008 ⁵⁶	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Hickman, 2009 ⁵⁷	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Hickson, 2008 ⁵⁸	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Hickson, 2009 ⁵⁹	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Hocher, 2003 ⁶⁰	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Hocher, 2004 ⁶¹	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes
Hocher, 2008 ⁶²	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Hojs, 2005 ⁶³	Yes	Yes	Yes	Yes	No	Yes	No	Yes	Yes
Holden, 2012 ⁶⁴	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Hussein, 2004 ⁶⁵	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Ie, 2004 ⁶⁶	Yes	Yes	Yes	Yes	No	Yes	No	Yes	Yes

Author, year	Main hypothesis/objective described	Main outcome described	Patient characteristics described	Interventions of interest described	Principal confounders described	Main findings described	Random variability estimate	Loss to follow up described	Actual probability values
Iliou, 2003 ⁶⁷	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Ilva, 2008 ⁶⁸	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Ishii, 2001 ⁶⁹	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Kalaji, 2012 ⁷⁰	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes
Kang, 2009 ⁷¹	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Kanwar, 2006 ⁷²	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes
Katerinis, 2008 ⁷³	Yes	Yes	Yes	Yes	No	No	No	Yes	No
Kertai, 2004 ⁷⁴	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Khan, 2001 ⁷⁵	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Lamb, 2007 ⁷⁶	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Lang, 2001 ⁷⁷	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Le Goff, 2007 ⁷⁸	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes

Author, year	Main hypothesis/objective described	Main outcome described	Patient characteristics described	Interventions of interest described	Principal confounders described	Main findings described	Random variability estimate	Loss to follow up described	Actual probability values
Lowbeer, 2002 ⁷⁹	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Lowbeer, 2003 ⁸⁰	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Mallamaci, 2002 ⁸¹	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
McGill, 2010 ⁸²	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes
McMurray, 2011 ⁸³	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes
Mockel, 1999 ⁸⁴	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Morton, 1998 ⁸⁵	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Musso, 1999 ⁸⁶	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes
Ooi, 1999 ⁸⁷	Yes	No	Yes	No	Yes	Yes	Yes	Yes	Yes
Ooi, 2001 ⁸⁸	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Orea-Tejeda, 2010 ⁸⁹	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes
Petrovic, 2009 ⁹⁰	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes

Author, year	Main hypothesis/objective described	Main outcome described	Patient characteristics described	Interventions of interest described	Principal confounders described	Main findings described	Random variability estimate	Loss to follow up described	Actual probability values
Porter, 1998 ⁹¹	Yes	Yes	Yes	Yes	No	Yes	No	Yes	No
Porter, 2000 ⁹²	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No
Roberts, 2009 ⁹³	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes
Sahinarslan, 2008 ⁹⁴	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes
Satyan, 2007 ⁹⁵	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Scheven, 2012 ⁹⁶	Yes	Yes	Yes	No	Yes	Yes	Yes	No	Yes
Scott, 2003 ⁹⁷	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Sharma, 2005 ⁹⁸	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Sharma, 2006 ⁹⁹	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes
Sharma, 2006 ¹⁰⁰	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Shroff, 2012 ¹⁰¹	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Sommerer, 2007 ¹⁰²	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes

Author, year	Main hypothesis/objective described	Main outcome described	Patient characteristics described	Interventions of interest described	Principal confounders described	Main findings described	Random variability estimate	Loss to follow up described	Actual probability values
Stolear, 1999 ¹⁰³	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Svensson, 2009 ¹⁰⁴	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Trape, 2008 ¹⁰⁵	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes
TroyaNov, 2005 ¹²	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes
Vichairuangthum, 2006 ¹⁰⁶	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Wang, 2006 ¹⁰⁷	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Wang, 2007 ¹⁰⁸	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Wang, 2010 ¹⁰⁹	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Wood, 2003 ¹¹⁰	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Yakupoglu, 2002 ¹¹¹	Yes	Yes	No	Yes	No	Yes	Yes	Yes	Yes

Internal Validity -Bias

Author, year	Blinding those measuring outcomes	Data dredging	Adjust for different followup	Appropriate statistical tests used	Main outcome measures accurate	Intervention groups from same population	Intervention groups recruited same time	Adequate adjustment for confounding in analyses	Losses to followup taken into account
Abaci, 2004 ²⁶	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes some	Yes
Abbas, 2005 ²⁷	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Apple, 1997 ²⁸	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	NA	Yes
Apple, 2002 ²⁹	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes some	Yes
Apple, 2004 ³⁰	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes some	Yes
Artunc, 2012 ³¹	Unable to determine	Yes	Yes	Yes	Unable to determine	Yes	Yes	Unable to determine	Yes
Bagheri, 2009 ³²	No	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Boulier, 2004 ³³	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Bozbas, 2004 ³⁴	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Brunet, 2008 ³⁵	No	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Choy, 2003 ³⁶	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Chrysochou, 2009 ³⁷	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Claes, 2010 ³⁸	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Codognotto, 2010 ³⁹	No	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Connolly, 2008 ⁴⁰	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

Author, year	Blinding those measuring outcomes	Data dredging	Adjust for different followup	Appropriate statistical tests used	Main outcome measures accurate	Intervention groups from same population	Intervention groups recruited same time	Adequate adjustment for confounding in analyses	Losses to followup taken into account
Conway, 2005 ⁴¹	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Deegan, 2001 ⁴²	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes some	Yes
deFilippi, 2003 ⁴³	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Dierkes, 2000 ⁴⁴	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes some	Yes
Duman, 2005 ⁴⁵	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Farkouh, 2003 ⁴⁶	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Feringa, 2006 ⁴⁷	No	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Fernandez-Reyes, 2004 ⁴⁸	Unable to determine	Yes	Unable to determine	Yes	Yes	Yes	Yes	No	Unable to determine
Gaiki, 2012 ⁴⁹	No	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Geerse, 2012 ⁵⁰	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes some	Yes
Goicoechea, 2004 ⁵¹	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Hallen, 2011 ⁵²	o	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Han, 2009 ⁵³	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes some	Yes
Hasegawa, 2012 ⁵⁴	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Havekes, 2006 ⁵⁵	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

Author, year	Blinding those measuring outcomes	Data dredging	Adjust for different followup	Appropriate statistical tests used	Main outcome measures accurate	Intervention groups from same population	Intervention groups recruited same time	Adequate adjustment for confounding in analyses	Losses to followup taken into account
Helleskov Madsen, 2008 ⁵⁶	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes some	Yes
Hickman, 2009 ⁵⁷	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Hickson, 2008 ⁵⁸	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Hickson, 2009 ⁵⁹	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Hocher, 2003 ⁶⁰	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Hocher, 2004 ⁶¹	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Hocher, 2008 ⁶²	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Hojs, 2005 ⁶³	Unable to determine	Yes	Yes	Yes	Yes	Yes	Unable to determine	No	Yes
Holden, 2012 ⁶⁴	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Hussein, 2004 ⁶⁵	No	Yes	No	Yes	Yes	Yes	Yes	No	No
Ile, 2004 ⁶⁶	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Iliou, 2003 ⁶⁷	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Ilva, 2008 ⁶⁸	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes some	Yes
Ishii, 2001 ⁶⁹	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

Author, year	Blinding those measuring outcomes	Data dredging	Adjust for different followup	Appropriate statistical tests used	Main outcome measures accurate	Intervention groups from same population	Intervention groups recruited same time	Adequate adjustment for confounding in analyses	Losses to followup taken into account
Kalaji, 2012 ⁷⁰	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Kang, 2009 ⁷¹	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Kanwar, 2006 ⁷²	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Katerinis, 2008 ⁷³	Unable to determine	Yes	Yes	Unable to determine	Yes	Yes	Yes	No	Yes
Kertai, 2004 ⁷⁴	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes some	Yes
Khan, 2001 ⁷⁵	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Lamb, 2007 ⁷⁶	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Lang, 2001 ⁷⁷	Unable to determine	Yes	Unable to determine	Yes	Yes	Yes	Yes	No	Yes
Le Goff, 2007 ⁷⁸	Unable to determine	Yes	Unable to determine	Yes	Yes	Yes	Yes	Yes some	Unable to determine
Lowbeer, 2002 ⁷⁹	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Lowbeer, 2003 ⁸⁰	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Mallamaci, 2002 ⁸¹	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
McGill, 2010 ⁸²	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes some	Yes
McMurray, 2011 ⁸³	No	Yes	Yes	Yes	Unable to determine	Yes	Yes	Yes some	Yes

Author, year	Blinding those measuring outcomes	Data dredging	Adjust for different followup	Appropriate statistical tests used	Main outcome measures accurate	Intervention groups from same population	Intervention groups recruited same time	Adequate adjustment for confounding in analyses	Losses to followup taken into account
Mockel, 1999 ⁸⁴	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Unable to determine
Morton, 1998 ⁸⁵	No	Yes	Unable to determine	Yes	Yes	Yes	Yes	Yes some	Unable to determine
Musso, 1999 ⁸⁶	Unable to determine	Yes	Unable to determine	Yes	Yes	Yes	Unable to determine	No	No
Ooi, 1999 ⁸⁷	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Ooi, 2001 ⁸⁸	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes some	Yes
Orea-Tejeda, 2010 ⁸⁹	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Petrovic, 2009 ⁹⁰	Unable to determine	No	Yes	Yes	Yes	Yes	Yes	Unable to determine	Unable to determine
Porter, 1998 ⁹¹	No	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Porter, 2000 ⁹²	Unable to determine	Yes	Unable to determine	Yes	Yes	Yes	Yes	Unable to determine	Yes
Roberts, 2009 ⁹³	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Sahinarslan, 2008 ⁹⁴	Unable to determine	Yes	Unable to determine	Yes	Yes	Yes	Yes	Yes	Unable to determine
Satyan, 2007 ⁹⁵	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Scheven, 2012 ⁹⁶	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Scott, 2003 ⁹⁷	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes some	Yes

Author, year	Blinding those measuring outcomes	Data dredging	Adjust for different followup	Appropriate statistical tests used	Main outcome measures accurate	Intervention groups from same population	Intervention groups recruited same time	Adequate adjustment for confounding in analyses	Losses to followup taken into account
Sharma, 2005 ⁹⁸	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes some	Yes
Sharma, 2006 ⁹⁹	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Sharma, 2006 ¹⁰⁰	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes some	Yes
Shroff, 2012 ¹⁰¹	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	No	Unable to determine
Sommerer, 2007 ¹⁰²	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Unable to determine	Yes
Stolar, 1999 ¹⁰³	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes some	Yes
Svensson, 2009 ¹⁰⁴	Unable to determine	Yes	Yes	Yes	Yes	Unable to determine	Unable to determine	Yes some	Yes
Trape, 2008 ¹⁰⁵	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
TroyaNov, 2005 ¹²	No	Yes	No	Yes	Yes	Yes	Yes	Yes some	Unable to determine
Vichairuangthum, 2006 ¹⁰⁶	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Wang, 2006 ¹⁰⁷	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Wang, 2007 ¹⁰⁸	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes some	Yes
Wang, 2010 ¹⁰⁹	Unable to determine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Wood, 2003 ¹¹⁰	Unable to determine	Yes	Yes	Yes	Yes	Yes	Unable to determine	Yes some	Yes

Author, year	Blinding those measuring outcomes	Data dredging	Adjust for different followup	Appropriate statistical tests used	Main outcome measures accurate	Intervention groups from same population	Intervention groups recruited same time	Adequate adjustment for confounding in analyses	Losses to followup taken into account
Yakupoglu, 2002 ¹¹¹	Unable to determine	Yes	Unable to determine	Yes	Yes	Yes	Unable to determine	No	Yes

External validity - Power

Author, year	Population asked representative	Population prepared participate representative	Staff places facilities representative	Power calculation reported	Industry support	Overall quality
Abaci, 2004 ²⁶	Unable to determine	Yes	Yes	No	NR support	Fair
Abbas, 2005 ²⁷	Unable to determine	Unable to determine	Yes	No	Yes industry support	Fair
Apple, 1997 ²⁸	Yes	Yes	Unable to determine	No	Yes industry support	Fair
Apple, 2002 ²⁹	Unable to determine	Unable to determine	Yes	No	Yes industry support	Fair
Apple, 2004 ³⁰	Yes	Yes	Yes	No	Yes industry support	Good
Artunc, 2012 ³¹	Yes	Yes	Unable to determine	No	NR support	Fair
Bagheri, 2009 ³²	Unable to determine	Unable to determine	Yes	No	NR support	Fair
Boulier, 2004 ³³	Yes	Unable to determine	Unable to determine	No	Yes industry support	Good
Bozbas, 2004 ³⁴	Unable to determine	Unable to determine	Yes	No	NR support	Poor
Brunet, 2008 ³⁵	Yes	Yes	Yes	No	Yes industry support	Good
Choy, 2003 ³⁶	Yes	Unable to determine	Yes	No	Yes industry support	Good

Author, year	Population asked representative	Population prepared participate representative	Staff places facilities representative	Power calculation reported	Industry support	Overall quality
Chrysochou, 2009 ³⁷	Yes	Unable to determine	Yes	No	NR support	Fair
Claes, 2010 ³⁸	Yes	Unable to determine	Yes	No	NR support	Good
Codognotto, 2010 ³⁹	Unable to determine	Unable to determine	Yes	No	No industry support	Fair
Connolly, 2008 ⁴⁰	Yes	Yes	Yes	No	No industry support	Good
Conway, 2005 ⁴¹	Yes	Unable to determine	Unable to determine	No	NR support	Fair
Deegan, 2001 ⁴²	Yes	Yes	Yes	No	NR support	Fair
deFilippi, 2003 ⁴³	Yes	Yes	Unable to determine	No	Yes industry support	Fair
Dierkes, 2000 ⁴⁴	Unable to determine	Yes	Yes	No	NR support	Good
Duman, 2005 ⁴⁵	Unable to determine	Unable to determine	Unable to determine	No	No industry support	Fair
Farkouh, 2003 ⁴⁶	Unable to determine	Unable to determine	Unable to determine	No	NR support	Fair
Feringa, 2006 ⁴⁷	Yes	Unable to determine	Yes	No	NR support	Good
Fernandez-Reyes, 2004 ⁴⁸	Yes	Unable to determine	Unable to determine	No	NR support	Fair
Gaiki, 2012 ⁴⁹	Yes	Unable to determine	Unable to determine	No	NR support	Fair
Geerse, 2012 ⁵⁰	Yes	Yes	Yes	No	NR support	Fair
Goicoechea, 2004 ⁵¹	Unable to determine	Unable to determine	Yes	No	NR support	Good
Hallen, 2011 ⁵²	Unable to determine	Unable to determine	Unable to determine	No	NR support	Fair
Han, 2009 ⁵³	Unable to determine	Unable to determine	Yes	No	NR support	Fair

Author, year	Population asked representative	Population prepared participate representative	Staff places facilities representative	Power calculation reported	Industry support	Overall quality
Hasegawa, 2012 ⁵⁴	Unable to determine	Unable to determine	Unable to determine	No	NR support	Fair
Havekes, 2006 ⁵⁵	Unable to determine	Unable to determine	Unable to determine	No	No industry support	Fair
Helleskov Madsen, 2008 ⁵⁶	Unable to determine	Unable to determine	Unable to determine	No	No industry support	Good
Hickman, 2009 ⁵⁷	Yes	Yes	Yes	Yes	NR support	Good
Hickson, 2008 ⁵⁸	Unable to determine	Unable to determine	Yes	No	No industry support	Good
Hickson, 2009 ⁵⁹	Unable to determine	Unable to determine	Yes	No	No industry support	Good
Hocher, 2003 ⁶⁰	Yes	Yes	Yes	No	No industry support	Good
Hocher, 2004 ⁶¹	Unable to determine	Unable to determine	Yes	No	No industry support	Good
Hocher, 2008 ⁶²	Unable to determine	Unable to determine	Yes	No	No industry support	Good
Hojs, 2005 ⁶³	Unable to determine	Unable to determine	Unable to determine	No	NR support	Poor
Holden, 2012 ⁶⁴	Yes	Yes	Yes	No	NR support	Good
Hussein, 2004 ⁶⁵	Unable to determine	Unable to determine	Unable to determine	No	NR support	Fair
Ie, 2004 ⁶⁶	Unable to determine	Unable to determine	Unable to determine	No	NR support	Fair
Iliou, 2003 ⁶⁷	Unable to determine	Unable to determine	Yes	No	Yes industry support	Good
Ilva, 2008 ⁶⁸	Yes	Unable to determine	Yes	No	Yes industry support	Good
Ishii, 2001 ⁶⁹	Yes	Yes	Unable to determine	No	Yes industry support	Good

Author, year	Population asked representative	Population prepared participate representative	Staff places facilities representative	Power calculation reported	Industry support	Overall quality
Kalaji, 2012 ⁷⁰	Unable to determine	Unable to determine	Unable to determine	No	NR support	Fair
Kang, 2009 ⁷¹	Unable to determine	Yes	Unable to determine	No	No industry support	Fair
Kanwar, 2006 ⁷²	Yes	Yes	Yes	No	Yes industry support	Good
Katerinis, 2008 ⁷³	Yes	Yes	Yes	No	NR support	Poor
Kertai, 2004 ⁷⁴	Unable to determine	Unable to determine	Yes	No	NR support	Fair
Khan, 2001 ⁷⁵	Unable to determine	Yes	Yes	No	NR support	Good
Lamb, 2007 ⁷⁶	Yes	Yes	Yes	No	Yes industry support	Good
Lang, 2001 ⁷⁷	Unable to determine	Unable to determine	Unable to determine	No	Yes industry support	Fair
Le Goff, 2007 ⁷⁸	Unable to determine	Unable to determine	Yes	No	NR support	Fair
Lowbeer, 2002 ⁷⁹	Unable to determine	Unable to determine	Yes	No	No industry support	Fair
Lowbeer, 2003 ⁸⁰	Unable to determine	Unable to determine	Unable to determine	No	No industry support	Fair
Mallamaci, 2002 ⁸¹	Unable to determine	Yes	Yes	No	NR support	Good
McGill, 2010 ⁸²	Yes	Unable to determine	Yes	No	No industry support	Fair
McMurray, 2011 ⁸³	Unable to determine	Unable to determine	Unable to determine	No	Yes industry support	Fair
Mockel, 1999 ⁸⁴	Unable to determine	Unable to determine	Yes	No	Yes industry support	Fair
Morton, 1998 ⁸⁵	Yes	Yes	Yes	No	No industry support	Good

Author, year	Population asked representative	Population prepared participate representative	Staff places facilities representative	Power calculation reported	Industry support	Overall quality
Musso, 1999 ⁸⁶	Unable to determine	Unable to determine	Unable to determine	No	NR support	Fair
Ooi, 1999 ⁸⁷	Yes	Unable to determine	Unable to determine	No	NR support	Fair
Ooi, 2001 ⁸⁸	Unable to determine	Unable to determine	Unable to determine	No	Yes industry support	Good
Orea-Tejeda, 2010 ⁸⁹	Yes	Unable to determine	Yes	No	No industry support	Fair
Petrovic, 2009 ⁹⁰	Unable to determine	Unable to determine	Yes	No	NR support	Fair
Porter, 1998 ⁹¹	Unable to determine	Unable to determine	Yes	No	NR support	Fair
Porter, 2000 ⁹²	Unable to determine	Unable to determine	Unable to determine	No	Yes industry support	Fair
Roberts, 2009 ⁹³	Yes	Unable to determine	Yes	No	Yes industry support	Fair
Sahinarslan, 2008 ⁹⁴	Unable to determine	Unable to determine	Unable to determine	No	NR support	Fair
Satyan, 2007 ⁹⁵	Yes	Yes	Yes	No	No industry support	Good
Scheven, 2012 ⁹⁶	Yes	Unable to determine	Unable to determine	No	No industry support	Fair
Scott, 2003 ⁹⁷	Yes	Unable to determine	Unable to determine	No	No industry support	Good
Sharma, 2005 ⁹⁸	Yes	Yes	Yes	No	NR support	Good
Sharma, 2006 ⁹⁹	Yes	Yes	Yes	No	NR support	Fair
Sharma, 2006 ¹⁰⁰	Yes	Yes	Unable to determine	No	No industry support	Fair
Shroff, 2012 ¹⁰¹	Yes	Unable to determine	Unable to determine	No	Yes industry support	Fair

Author, year	Population asked representative	Population prepared participate representative	Staff places facilities representative	Power calculation reported	Industry support	Overall quality
Sommerer, 2007 ¹⁰²	Unable to determine	Yes	Unable to determine	No	NR support	Fair
Stolear, 1999 ¹⁰³	Yes	Yes	Unable to determine	No	Yes industry support	Good
Svensson, 2009 ¹⁰⁴	Unable to determine	Unable to determine	Unable to determine	No	Yes industry support	Fair
Trape, 2008 ¹⁰⁵	Unable to determine	Unable to determine	Yes	No	NR support	Good
Troyanov, 2005 ¹²	Unable to determine	Unable to determine	Unable to determine	No	Yes industry support	Fair
Vichairuangthum, 2006 ¹⁰⁶	Unable to determine	Unable to determine	Unable to determine	No	NR support	Fair
Wang, 2006 ¹⁰⁷	Yes	Yes	Yes	No	No industry support	Good
Wang, 2007 ¹⁰⁸	Yes	Yes	Yes	No	No industry support	Good
Wang, 2010 ¹⁰⁹	Yes	Yes	Yes	No	No industry support	Good
Wood, 2003 ¹¹⁰	Unable to determine	Unable to determine	Yes	No	NR support	Fair
Yakupoglu, 2002 ¹¹¹	Unable to determine	Unable to determine	Unable to determine	No	NR support	Fair

Abbreviations: NA = not applicable; NR = not reported

References

1. Alcalai R, Planer D, Culhaoglu A, et al. Acute coronary syndrome vs nonspecific troponin elevation: clinical predictors and survival analysis. Arch Intern Med. 2007 Feb 12;167(3):276-81. PMID: 17296884.

2. Apple FS, Christenson RH, Valdes R, Jr., et al. Simultaneous rapid measurement of whole blood myoglobin, creatine kinase MB, and cardiac troponin I by the triage cardiac panel for detection of myocardial infarction. *Clin Chem*. 1999 Feb;45(2):199-205. PMID: 9931041.
3. Bhagavan NV, Goldstein AP, Honda SA, et al. Role of cardiac troponin I in the evaluation of myocardial injury. *J Clin Lab Anal*. 1998;12(5):276-9. PMID: 9773957.
4. Fehr T, Knoflach A, Ammann P, et al. Differential use of cardiac troponin T versus I in hemodialysis patients. *Clin Nephrol*. 2003 Jan;59(1):35-9. PMID: 12572929.
5. Flores LM, Hernandez Dominguez JL, Otero A, et al. [Cardiac troponin I determination in patients with chronic renal failure]. *Nefrologia*. 2006;26(1):107-12. PMID: 16649431.
6. Flores-Solis LM, Hernandez-Dominguez JL, Otero-Gonzalez A, et al. Cardiac troponin I and creatine kinase MB isoenzyme in patients with chronic renal failure. *Nefrologia*. 2012;32(6):809-18. PMID: 23169364.
7. Martin GS, Becker BN, Schulman G. Cardiac troponin-I accurately predicts myocardial injury in renal failure. *Nephrol Dial Transplant*. 1998 Jul;13(7):1709-12. PMID: 9681716.
8. McCullough PA, Nowak RM, Foreback C, et al. Performance of multiple cardiac biomarkers measured in the emergency department in patients with chronic kidney disease and chest pain. *Acad Emerg Med*. 2002 Dec;9(12):1389-96. PMID: 12460842.
9. Noeller TP, Meldon SW, Peacock WF, et al. Troponin T in elders with suspected acute coronary syndromes. *Am J Emerg Med*. 2003 Jul;21(4):293-7. PMID: 12898485.
10. Roppolo LP, Fitzgerald R, Dillow J, et al. A comparison of troponin T and troponin I as predictors of cardiac events in patients undergoing chronic dialysis at a Veteran's Hospital: a pilot study. *J Am Coll Cardiol*. 1999 Aug;34(2):448-54. PMID: 10440158.
11. Sukonthasarn A, Ponglopisit S. Diagnostic level of cardiac troponin T in patients with chronic renal dysfunction, a pilot study. *J Med Assoc Thai*. 2007 Sep;90(9):1749-58. PMID: 17957915.
12. Troyanov S, Ly QH, Schampaert E, et al. Diagnostic specificity and prognostic value of cardiac troponins in asymptomatic chronic haemodialysis patients: a three year prospective study. *Heart*. 2005 Sep;91(9):1227-8. PMID: 16103574.
13. Acharji S, Baber U, Mehran R, et al. Prognostic significance of elevated baseline troponin in patients with acute coronary syndromes and chronic kidney disease treated with different antithrombotic regimens: a substudy from the ACUITY trial. *Circ Cardiovasc Interv*. 2012 Apr;5(2):157-65. PMID: 22354934.
14. Chew HC. Cardiac troponin T in acute coronary syndrome with renal insufficiency. *Asian Cardiovasc Thorac Ann*. 2008 Aug;16(4):284-7. PMID: 18670019.
15. Kontos MC, Jamal SM, Ornato JP, et al. Comparison of the modification of diet in renal disease and the Cockcroft-Gault equations for predicting mortality in patients admitted for exclusion of myocardial ischemia. *Am J Cardiol*. 2008 Jul 15;102(2):140-5. PMID: 18602510.

16. Melloni C, Alexander KP, Milford-Beland S, et al. Prognostic value of troponins in patients with non-ST-segment elevation acute coronary syndromes and chronic kidney disease. *Clin Cardiol.* 2008 Mar;31(3):125-9. PMID: 18383049.
17. Apple FS, Pearce LA, Doyle PJ, et al. Cardiac troponin risk stratification based on 99th percentile reference cutoffs in patients with ischemic symptoms suggestive of acute coronary syndrome: influence of estimated glomerular filtration rates. *Am J Clin Pathol.* 2007 Apr;127(4):598-603. PMID: 17369136.
18. Bueti J, Krahn J, Karpinski M, et al. Troponin I testing in dialysis patients presenting to the emergency room: does troponin I predict the 30-day outcome? *Nephron Clin Pract.* 2006;103(4):c129-36. PMID: 16636580.
19. Kontos MC, Garg R, Anderson FP, et al. Outcomes in patients admitted for chest pain with renal failure and troponin I elevations. *Am Heart J.* 2005 Oct;150(4):674-80. PMID: 16209963.
20. Kontos MC, Garg R, Anderson FP, et al. Predictive power of ejection fraction and renal failure in patients admitted for chest pain without ST elevation in the troponin era. *Am Heart J.* 2005 Oct;150(4):666-73. PMID: 16209962.
21. Han JH, Lindsell CJ, Ryan RJ, et al. Changes in cardiac troponin T measurements are associated with adverse cardiac events in patients with chronic kidney disease. *Am J Emerg Med.* 2005 Jul;23(4):468-73. PMID: 16032613.
22. Aviles RJ, Askari AT, Lindahl B, et al. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. *N Engl J Med.* 2002 Jun 27;346(26):2047-52. PMID: 12087140.
23. Gruberg L, Fuchs S, Waksman R, et al. Prognostic value of cardiac troponin I elevation after percutaneous coronary intervention in patients with chronic renal insufficiency: a 12-month outcome analysis. *Catheter Cardiovasc Interv.* 2002 Feb;55(2):174-9. PMID: 11835642.
24. Wayand D, Baum H, Schatzle G, et al. Cardiac troponin T and I in end-stage renal failure. *Clin Chem.* 2000 Sep;46(9):1345-50. PMID: 10973864.
25. Van Lente F, McErlean ES, DeLuca SA, et al. Ability of troponins to predict adverse outcomes in patients with renal insufficiency and suspected acute coronary syndromes: a case-matched study. *J Am Coll Cardiol.* 1999 Feb;33(2):471-8. PMID: 9973028.
26. Abaci A, Ekici E, Oguzhan A, et al. Cardiac troponins T and I in patients with end-stage renal disease: the relation with left ventricular mass and their prognostic value. *Clin Cardiol.* 2004 Dec;27(12):704-9. PMID: 15628116.
27. Abbas NA, John RI, Webb MC, et al. Cardiac troponins and renal function in nondialysis patients with chronic kidney disease. *Clin Chem.* 2005 Nov;51(11):2059-66. PMID: 16166165.
28. Apple FS, Sharkey SW, Hoelt P, et al. Prognostic value of serum cardiac troponin I and T in chronic dialysis patients: a 1-year outcomes analysis. *Am J Kidney Dis.* 1997 Mar;29(3):399-403. PMID: 9041216.
29. Apple FS, Murakami MM, Pearce LA, et al. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. *Circulation.* 2002 Dec 3;106(23):2941-5. PMID: 12460876.
30. Apple FS, Murakami MM, Pearce LA, et al. Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. *Clin Chem.* 2004 Dec;50(12):2279-85. PMID: 15364888.

31. Artunc F, Mueller C, Breidhardt T, et al. Sensitive troponins--which suits better for hemodialysis patients? Associated factors and prediction of mortality. *PLoS One*. 2012;7(10):e47610. PMID: 23077650.
32. Bagheri N, Taziki O, Falaknazi K. C- Reactive protein, cardiac troponin T and low albumin are predictors of mortality in hemodialysis patients. *Saudi J Kidney Dis Transpl*. 2009 Sep;20(5):789-93. PMID: 19736474.
33. Boulier A, Jaussent I, Terrier N, et al. Measurement of circulating troponin Ic enhances the prognostic value of C-reactive protein in haemodialysis patients. *Nephrol Dial Transplant*. 2004 Sep;19(9):2313-8. PMID: 15252159.
34. Bozbas H, Korkmaz ME, Atar I, et al. Serum levels of cardiac enzymes before and after renal transplantation. *Clin Cardiol*. 2004 Oct;27(10):559-62. PMID: 15553307.
35. Brunet P, Oddoze C, Paganelli F, et al. Cardiac troponins I and T in hemodialysis patients without acute coronary syndrome. *Int J Cardiol*. 2008 Sep 26;129(2):205-9. PMID: 17662483.
36. Choy JB, Armstrong PW, Ulan RA, et al. Do cardiac troponins provide prognostic insight in hemodialysis patients? *Can J Cardiol*. 2003 Jul;19(8):907-11. PMID: 12876611.
37. Chrysochou C, Manzoor S, Wright J, et al. Role of renal function and cardiac biomarkers (NT-proBNP and Troponin) in determining mortality and cardiac outcome in atheromatous renovascular disease. *Kidney Blood Press Res*. 2009;32(5):373-9. PMID: 19887825.
38. Claes K, Bammens B, Evenepoel P, et al. Troponin I is a predictor of acute cardiac events in the immediate postoperative renal transplant period. *Transplantation*. 2010 Feb 15;89(3):341-6. PMID: 20145526.
39. Codognotto M, Piccoli A, Zaninotto M, et al. Effect of a dialysis session on the prognostic values of NT-proBNP, troponins, endothelial damage and inflammation biomarkers. *J Nephrol*. 2010 Jul-Aug;23(4):465-71. PMID: 20540041.
40. Connolly GM, Cunningham R, McNamee PT, et al. Troponin T is an independent predictor of mortality in renal transplant recipients. *Nephrol Dial Transplant*. 2008 Mar;23(3):1019-25. PMID: 18065785.
41. Conway B, McLaughlin M, Sharpe P, et al. Use of cardiac troponin T in diagnosis and prognosis of cardiac events in patients on chronic haemodialysis. *Nephrol Dial Transplant*. 2005 Dec;20(12):2759-64. PMID: 16188899.
42. Deegan PB, Lafferty ME, Blumsohn A, et al. Prognostic value of troponin T in hemodialysis patients is independent of comorbidity. *Kidney Int*. 2001 Dec;60(6):2399-405. PMID: 11737616.
43. deFilippi C, Wasserman S, Rosanio S, et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. *JAMA*. 2003 Jul 16;290(3):353-9. PMID: 12865376.
44. Dierkes J, Domrose U, Westphal S, et al. Cardiac troponin T predicts mortality in patients with end-stage renal disease. *Circulation*. 2000 Oct 17;102(16):1964-9. PMID: 11034946.
45. Duman D, Tokay S, Toprak A, et al. Elevated cardiac troponin T is associated with increased left ventricular mass index and predicts mortality in continuous ambulatory peritoneal dialysis patients. *Nephrol Dial Transplant*. 2005 May;20(5):962-7. PMID: 15741207.

46. Farkouh ME, Robbins MJ, Zafar MU, et al. Association between troponin I levels and mortality in stable hemodialysis patients. *Am J Med.* 2003 Feb 15;114(3):224-6. PMID: 12637137.
47. Feringa HH, Bax JJ, de Jonge R, et al. Impact of glomerular filtration rate on minor troponin T elevations for risk assessment in patients undergoing operation for abdominal aortic aneurysm or lower extremity arterial obstruction. *Am J Cardiol.* 2006 Dec 1;98(11):1515-8. PMID: 17126662.
48. Fernandez-Reyes MJ, Mon C, Heras M, et al. Predictive value of troponin T levels for ischemic heart disease and mortality in patients on hemodialysis. *J Nephrol.* 2004 Sep-Oct;17(5):721-7. PMID: 15593041.
49. Gaiki MR, DeVita MV, Michelis MF, et al. Troponin I as a prognostic marker of cardiac events in asymptomatic hemodialysis patients using a sensitive troponin I assay. *Int Urol Nephrol.* 2012 Dec;44(6):1841-5. PMID: 22311387.
50. Geerse DA, van Berkel M, Vogels S, et al. Moderate elevations of high-sensitivity cardiac troponin I and B-type natriuretic peptide in chronic hemodialysis patients are associated with mortality. *Clin Chem Lab Med.* 2012 Dec 10;1-8. PMID: 23241607.
51. Goicoechea M, Garca de Vinuesa S, Gomez-Campdera F, et al. Clinical significance of cardiac troponin T levels in chronic kidney disease patients: predictive value for cardiovascular risk. *Am J Kidney Dis.* 2004 May;43(5):846-53. PMID: 15112175.
52. Hallen J, Madsen L, Ladefoged S, et al. Incremental value of a combination of cardiac troponin T, N-terminal pro-brain natriuretic peptide and C-reactive protein for prediction of mortality in end-stage renal disease. *Scand J Urol Nephrol.* 2011 Mar;45(2):151-8. PMID: 21091090.
53. Han SH, Choi HY, Kim DK, et al. Elevated cardiac troponin T predicts cardiovascular events in asymptomatic continuous ambulatory peritoneal dialysis patients without a history of cardiovascular disease. *Am J Nephrol.* 2009;29(2):129-35. PMID: 18719346.
54. Hasegawa M, Ishii J, Kitagawa F, et al. Prognostic value of highly sensitive troponin T on cardiac events in patients with chronic kidney disease not on dialysis. *Heart Vessels.* 2012 Aug 23; PMID: 22914904.
55. Havekes B, van Manen JG, Krediet RT, et al. Serum troponin T concentration as a predictor of mortality in hemodialysis and peritoneal dialysis patients. *Am J Kidney Dis.* 2006 May;47(5):823-9. PMID: 16632021.
56. Helleskov Madsen L, Ladefoged S, Hildebrandt P, et al. Comparison of four different cardiac troponin assays in patients with end-stage renal disease on chronic haemodialysis. *Acute Card Care.* 2008;10(3):173-80. PMID: 18608043.
57. Hickman PE, McGill DA, Talaulikar G, et al. Prognostic efficacy of cardiac biomarkers for mortality in dialysis patients. *Intern Med J.* 2009 Dec;39(12):812-8. PMID: 20233242.
58. Hickson LJ, Cosio FG, El-Zoghby ZM, et al. Survival of patients on the kidney transplant wait list: relationship to cardiac troponin T. *Am J Transplant.* 2008 Nov;8(11):2352-9. PMID: 18785956.
59. Hickson LT, El-Zoghby ZM, Lorenz EC, et al. Patient survival after kidney transplantation: relationship to pretransplant cardiac troponin T levels. *Am J Transplant.* 2009 Jun;9(6):1354-61. PMID: 19459818.
60. Hocher B, Ziebig R, Altermann C, et al. Different impact of biomarkers as mortality predictors among diabetic and nondiabetic patients undergoing hemodialysis. *J Am Soc Nephrol.* 2003 Sep;14(9):2329-37. PMID: 12937310.

61. Hocher B, Ziebig R, Krause R, et al. Relaxin is an independent risk factor predicting death in male patients with end-stage kidney disease. *Circulation*. 2004 May 18;109(19):2266-8. PMID: 15136497.
62. Hocher B, Kalk P, Godes M, et al. Gender-dependent impact of risk factors for cardiovascular and non-cardiovascular mortality in end-stage renal disease patients on haemodialysis. *Kidney Blood Press Res*. 2008;31(5):360-6. PMID: 19023219.
63. Hojs R, Ekart R, Hojs Fabjan T, et al. Cardiac troponin T (cTnT) in hemodialysis patients with asymptomatic and symptomatic atherosclerosis. *Arch Med Res*. 2005 Jul-Aug;36(4):367-71. PMID: 15950076.
64. Holden RM, Beseau D, Booth SL, et al. FGF-23 is associated with cardiac troponin T and mortality in hemodialysis patients. *Hemodial Int*. 2012 Jan;16(1):53-8. PMID: 22099949.
65. Hussein M, Mooij J, Roujouleh H, et al. Cardiac troponin-I and its prognostic significance in a dialysis population. *Hemodial Int*. 2004 Oct 1;8(4):332-7. PMID: 19379438.
66. Ie EH, Klootwijk PJ, Weimar W, et al. Significance of acute versus chronic troponin T elevation in dialysis patients. *Nephron Clin Pract*. 2004;98(3):c87-92. PMID: 15528943.
67. Iliou MC, Fumeron C, Benoit MO, et al. Prognostic value of cardiac markers in ESRD: Chronic Hemodialysis and New Cardiac Markers Evaluation (CHANCE) study. *Am J Kidney Dis*. 2003 Sep;42(3):513-23. PMID: 12955679.
68. Ilva T, Lassus J, Siirila-Waris K, et al. Clinical significance of cardiac troponins I and T in acute heart failure. *Eur J Heart Fail*. 2008;10(8):772-9.
69. Ishii J, Nomura M, Okuma T, et al. Risk stratification using serum concentrations of cardiac troponin T in patients with end-stage renal disease on chronic maintenance dialysis. *Clin Chim Acta*. 2001 Oct;312(1-2):69-79. PMID: 11580911.
70. Kalaji FR, Albitar S. Predictive value of cardiac troponin T and I in hemodialysis patients. *Saudi J Kidney Dis Transpl*. 2012 Sep;23(5):939-45. PMID: 22982904.
71. Kang EW, Na HJ, Hong SM, et al. Prognostic value of elevated cardiac troponin I in ESRD patients with sepsis. *Nephrol Dial Transplant*. 2009 May;24(5):1568-73. PMID: 19145004.
72. Kanwar M, Hashem M, Rosman H, et al. Usefulness of clinical evaluation, troponins, and C-reactive protein in predicting mortality among stable hemodialysis patients. *Am J Cardiol*. 2006 Nov 1;98(9):1283-7. PMID: 17056347.
73. Katerinis I, Nguyen QV, Magnin JL, et al. Cardiac findings in asymptomatic chronic hemodialysis patients with persistently elevated cardiac troponin I levels. *Ren Fail*. 2008;30(4):357-62. PMID: 18569907.
74. Kertai MD, Boersma E, Klein J, et al. Long-term prognostic value of asymptomatic cardiac troponin T elevations in patients after major vascular surgery. *Eur J Vasc Endovasc Surg*. 2004 Jul;28(1):59-66. PMID: 15177233.
75. Khan IA, Wattanasuwan N, Mehta NJ, et al. Prognostic value of serum cardiac troponin I in ambulatory patients with chronic renal failure undergoing long-term hemodialysis: a two-year outcome analysis. *J Am Coll Cardiol*. 2001 Oct;38(4):991-8. PMID: 11583870.
76. Lamb EJ, Kenny C, Abbas NA, et al. Cardiac troponin I concentration is commonly increased in nondialysis patients with CKD: experience with a sensitive assay. *Am J Kidney Dis*. 2007 Apr;49(4):507-16. PMID: 17386318.

77. Lang K, Schindler S, Forberger C, et al. Cardiac troponins have no prognostic value for acute and chronic cardiac events in asymptomatic patients with end-stage renal failure. *Clin Nephrol.* 2001 Jul;56(1):44-51. PMID: 11499658.
78. Le Goff C, Bovy C, Aldenhoff MC, et al. Three-year prognostic interest of cardiac troponin T (cTnT) and amino-terminal pro-B-natriuretic peptide (NT-proBNP) in hemodialyzed patients. *Immuno-Analyse et Biologie Specialisee.* 2007;22(6):377-83.
79. Lowbeer C, Gutierrez A, Gustafsson SA, et al. Elevated cardiac troponin T in peritoneal dialysis patients is associated with CRP and predicts all-cause mortality and cardiac death. *Nephrol Dial Transplant.* 2002 Dec;17(12):2178-83. PMID: 12454230.
80. Lowbeer C, Stenvinkel P, Pecoits-Filho R, et al. Elevated cardiac troponin T in predialysis patients is associated with inflammation and predicts mortality. *J Intern Med.* 2003 Feb;253(2):153-60. PMID: 12542555.
81. Mallamaci F, Zoccali C, Parlongo S, et al. Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. *Am J Kidney Dis.* 2002 Jul;40(1):68-75. PMID: 12087563.
82. McGill D, Talaulikar G, Potter JM, et al. Over time, high-sensitivity TnT replaces NT-proBNP as the most powerful predictor of death in patients with dialysis-dependent chronic renal failure. *Clin Chim Acta.* 2010 Jul 4;411(13-14):936-9. PMID: 20298685.
83. McMurray JJ, Uno H, Jarolim P, et al. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). *Am Heart J.* 2011 Oct;162(4):748-55 e3. PMID: 21982669.
84. Mockel M, Schindler R, Knorr L, et al. Prognostic value of cardiac troponin T and I elevations in renal disease patients without acute coronary syndromes: a 9-month outcome analysis. *Nephrol Dial Transplant.* 1999 Jun;14(6):1489-95. PMID: 10383013.
85. Morton AR, Collier CP, Ali N, et al. Cardiac troponin I in patients receiving renal replacement therapy. *ASAIO J.* 1998 Sep-Oct;44(5):M433-5. PMID: 9804466.
86. Musso P, Cox I, Vidano E, et al. Cardiac troponin elevations in chronic renal failure: prevalence and clinical significance. *Clin Biochem.* 1999 Mar;32(2):125-30. PMID: 10211629.
87. Ooi DS, Veinot JP, Wells GA, et al. Increased mortality in hemodialyzed patients with elevated serum troponin T: a one-year outcome study. *Clin Biochem.* 1999 Nov;32(8):647-52. PMID: 10638948.
88. Ooi DS, Zimmerman D, Graham J, et al. Cardiac troponin T predicts long-term outcomes in hemodialysis patients. *Clin Chem.* 2001 Mar;47(3):412-7. PMID: 11238290.
89. Orea-Tejeda A, Sanchez-Gonzalez LR, Castillo-Martinez L, et al. Prognostic value of cardiac troponin T elevation is independent of renal function and clinical findings in heart failure patients. *Cardiol J.* 2010;17(1):42-8. PMID: 20104456.
90. Petrovic D, Stojimirovic BB. Cardiac troponins: outcome predictors in hemodialysis patients. *J Artif Organs.* 2009;12(4):258-63. PMID: 20035399.
91. Porter GA, Norton T, Bennett WB. Troponin T, a predictor of death in chronic haemodialysis patients. *Eur Heart J.* 1998 Nov;19 Suppl N:N34-7. PMID: 9857937.

92. Porter GA, Norton T, Bennett WM. Long term follow up of the utility of troponin T to assess cardiac risk in stable chronic hemodialysis patients. *Clin Lab*. 2000;46(9-10):469-76. PMID: 11034532.
93. Roberts MA, Hare DL, Macmillan N, et al. Serial increased cardiac troponin T predicts mortality in asymptomatic patients treated with chronic haemodialysis. *Ann Clin Biochem*. 2009 Jul;46(Pt 4):291-5. PMID: 19454539.
94. Sahinarslan A, Guz G, Okyay K, et al. Prognostic value of troponin T and homocysteine in patients with end-stage renal disease. *Turk Kardiyol Dern Ars*. 2008 Sep;36(6):382-7. PMID: 19155641.
95. Satyan S, Light RP, Agarwal R. Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. *Am J Kidney Dis*. 2007 Dec;50(6):1009-19. PMID: 18037101.
96. Scheven L, de Jong PE, Hillege HL, et al. High-sensitive troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate. *Eur Heart J*. 2012 Sep;33(18):2272-81. PMID: 22740385.
97. Scott B, Deman A, Peeters P, et al. Cardiac troponin T and malondialdehyde modified plasma lipids in haemodialysis patients. *Nephrol Dial Transplant*. 2003 Apr;18(4):737-42. PMID: 12637643.
98. Sharma R, Pellerin D, Gaze DC, et al. Dobutamine stress echocardiography and cardiac troponin T for the detection of significant coronary artery disease and predicting outcome in renal transplant candidates. *Eur J Echocardiogr*. 2005 Oct;6(5):327-35. PMID: 15985387.
99. Sharma R, Gaze DC, Pellerin D, et al. Ischemia-modified albumin predicts mortality in ESRD. *Am J Kidney Dis*. 2006 Mar;47(3):493-502. PMID: 16490629.
100. Sharma R, Gaze DC, Pellerin D, et al. Cardiac structural and functional abnormalities in end stage renal disease patients with elevated cardiac troponin T. *Heart*. 2006 Jun;92(6):804-9. PMID: 16216854.
101. Shroff GR, Akkina SK, Miedema MD, et al. Troponin I levels and postoperative myocardial infarction following renal transplantation. *Am J Nephrol*. 2012;35(2):175-80. PMID: 22286592.
102. Sommerer C, Beimler J, Schwenger V, et al. Cardiac biomarkers and survival in haemodialysis patients. *Eur J Clin Invest*. 2007 May;37(5):350-6. PMID: 17461980.
103. Stolar JC, Georges B, Shita A, et al. The predictive value of cardiac troponin T measurements in subjects on regular haemodialysis. *Nephrol Dial Transplant*. 1999 Aug;14(8):1961-7. PMID: 10462278.
104. Svensson M, Gorst-Rasmussen A, Schmidt EB, et al. NT-pro-BNP is an independent predictor of mortality in patients with end-stage renal disease. *Clin Nephrol*. 2009;71(4):380-6.
105. Trape J, Perez A, Naval I, et al. Nt-proBNP in haemodialysis patients: a preliminary study. *Scand J Clin Lab Invest*. 2008;68(5):415-20. PMID: 19172698.
106. Vichairuangthum K, Leowattana W, Ong-Ajyooth L, et al. The relationship between serum concentration of cardiac troponin I in chronic renal failure patients and cardiovascular events. *J Med Assoc Thai*. 2006 May;89(5):714-20. PMID: 16756060.

107. Wang AY, Lam CW, Yu CM, et al. Troponin T, left ventricular mass, and function are excellent predictors of cardiovascular congestion in peritoneal dialysis. *Kidney Int.* 2006 Aug;70(3):444-52. PMID: 16871255.
108. Wang AY, Lam CW, Wang M, et al. Prognostic value of cardiac troponin T is independent of inflammation, residual renal function, and cardiac hypertrophy and dysfunction in peritoneal dialysis patients. *Clin Chem.* 2007 May;53(5):882-9. PMID: 17395709.
109. Wang AYM, Lam CW, Chan IH, et al. Sudden cardiac death in end-stage renal disease patients: A 5-year prospective analysis. *NDT Plus.* 2010;3:iii291.
110. Wood GN, Keevil B, Gupta J, et al. Serum troponin T measurement in patients with chronic renal impairment predicts survival and vascular disease: a 2 year prospective study. *Nephrol Dial Transplant.* 2003 Aug;18(8):1610-5. PMID: 12897102.
111. Yakupoglu U, Ozdemir FN, Arat Z, et al. Can troponin-I predict cardiovascular mortality due to myocardial injury in hemodialysis patients? *Transplant Proc.* 2002 Sep;34(6):2033-4. PMID: 12270303.

Appendix E: Overview of studies included in the meta-analyses

Table 1. Studies included/excluded for cTnT and all-cause mortality for Dialysis patients

Author, year	Included in HR meta-analysis	Included in OR meta-analysis	Excluded from both meta-analyses	Reason for exclusion
Kalaji, 2012 ¹	X	X		
Holden, 2012 ²	X			
Hallen, 2011 ³	X	X		
Codognotto, 2010 ⁴	Derived			
Hickman, 2009 ⁵		X		Not included in HR meta-analysis because presented OR and not enough data to derive HR
Petrovic, 2009 ⁶			X	Insufficient information to derive any HR or OR
Chrysochou, 2009 ⁷			X	Belongs in non-dialysis group.
Bagheri, 2009 ⁸			X	Very poor quality study; unclear measures, did not provide data for all participants
Roberts, 2009 ⁹			X	Definition of a troponin qualitatively different (number of times troponin was elevated)
Trape, 2008 ¹⁰		X		
Sahinarslan, 2008 ¹¹		X		
Helleskov Madsen, 2008 ¹²	X	X		
Satyan, 2007 ¹³	X			

Author, year	Included in HR meta-analysis	Included in OR meta-analysis	Excluded from both meta-analyses	Reason for exclusion
Wang, 2007 ¹⁴		X-Choose 0.1 cutpoint to dichotomize data		
Havekes, 2006 ¹⁵	X			
Sharma, 2006¹⁶ , Sharma, 2005 ¹⁷		X		
Duman, 2005 ¹⁸		X-used same cutpoint as HR meta-analysis		Not included in HR meta-analysis because presented OR and not enough data to derive HR
Abaci, 2004 ¹⁹		X-Choose 0.1 cutpoint to dichotomize data		
Fernandez-Reyes, 2004 ²⁰	X			
le, 2004 ²¹		X		
Iliou, 2003 ²²	X	X		
Choy, 2003 ²³		X		Not included in HR meta-analysis because presented OR and not enough data to derive HR
deFilippi, 2003 ²⁴	X	X-Choose 0.117 cutpoint to dichotomize data		
Scott, 2003 ²⁵			X	Study provided a coefficient for a log rank test; Insufficient information to derive other statistics
Lowbeer, 2002 ²⁶	X	X		
Mallamaci, 2002 ²⁷	X			
Deegan, 2001 ²⁸	derived	X		
Ishii, 2001 ²⁹	X	X		
Lang, 2001 ³⁰		X		
Dierkes, 2000 ³¹	X	X-choose same cutpoint as HR meta-analysis		
Stolear, 1999 ³²	X	X		
Mockel, 1999 ³³			X	Does not report results for dialysis patients separately
Musso, 1999 ³⁴			X	Results are not reported separately for a dialysis population

Author, year	Included in HR meta-analysis	Included in OR meta-analysis	Excluded from both meta-analyses	Reason for exclusion
Apple, 2002 ³⁵ , Apple, 2004 ³⁶	X	X		
Ooi, 1999 ³⁷ , Ooi, 2001 ³⁸	X	X-Choose 0.1 cutpoint to dichotomize data		
Porter, 1998 ³⁹ , Porter, 2000 ⁴⁰		X		
Hocher, 2003 ⁴¹ , Hocher, 2004 ⁴² , Hocher, 2008 ⁴³	X			
Svensson, 2009 ⁴⁴			X	Unclear cut-point
Le Goff, 2007 ⁴⁵			X	Only included patients with NT proBNP >5000
Brunet, 2008 ⁴⁶		X		

Table 2. Studies included/excluded in the meta-analysis for cTnl and all-cause mortality for Dialysis patients.

Study	Refid	Included in HR meta-analysis	Included in OR meta-analysis	Excluded from both meta-analyses	Reason for exclusion
Geerse, 2012 ⁴⁷	55	X	X-dichotomized data at 0.1 cutpoint		
Artunc, 2012 ⁴⁸	129			X	High sensitivity assay
Kalaji, 2012 ¹	165	X	X		
Codognotto, 2010 ⁴	893			X	Insufficient data reported
Hickman, 2009 ⁵	988		X		Not included in HR meta-analysis because study reported an OR, not HR
Petrovic, 2009 ⁶	1029			X	Insufficient data to be included in meta-analysis
Kang, 2009 ⁴⁹	1314	X	X		
Helleskov Madsen, 2008 ¹²	1444	X	X		
Katerinis, 2008 ⁵⁰	1454		X		
Brunet, 2008 ⁴⁶	1675		X-Beckman Access 0.06 cutpoint		
Kanwar, 2006 ⁵¹	1823		X-used CHD(-) group		
Duman, 2005 ¹⁸	2154		X		

Study	Refid	Included in HR meta-analysis	Included in OR meta-analysis	Excluded from both meta-analyses	Reason for exclusion
Abaci, 2004 ¹⁹	2184		X		
Hussein, 2004 ³²	2220		X		
Boulier, 2004 ⁵³	2253	X			
Choy, 2003 ²³	2391		X		
Farkouh, 2003 ⁵⁴	2450	X	X		
Apple, 2002³⁵, Apple, 2004³⁶	2481, 2230	X			
Lowbeer, 2002 ²⁶	2484			X	No data reported for cTnI –just qualitative statement of no difference
Khan, 2001 ⁵⁵	2613		X		
Ishii, 2001 ²⁹	2615		X		
Lang, 2001 ³⁰	2630		X-Dade Stratus data		
Mockel, 1999 ³³	2793			X	Results are not separated by dialysis patients.
Musso, 1999 ³⁴	2800			X	Results are not separated by dialysis patients
Porter, 1998 ³⁹	2823		X-Dade data		
Morton, 1998 ⁵⁶	2836			X	No data for analysis
Iliou, 2003 ²²	2373	X			

Table 3. Studies included/excluded for cTnT and Cardiovascular mortality for Dialysis patients

Study	Refid	Included in HR meta-analysis	Included in OR meta-analysis	Excluded from both meta-analyses	Reason for exclusion
Abaci, 2004 ¹⁹	2184		X-dichotomized on >0.1 cutpoint		
Apple, 1997 ⁵⁷	2934		X		
Deegan, 2001 ²⁸	2599		X		
Duman, 2005 ¹⁸	2154		X		I ran the OR analysis with and without this study. The problem is that it does not report number of events and sample sizes, just an adjusted OR.
Havekes, 2006 ¹⁵	1924	X			
Hoche, 2003 ⁴¹ , Hoche, 2004 ⁴² , Hoche, 2008⁴³	2378; 2290; 1353	X			
Hojs, 2005 ⁵⁸	2104		X		
Iliou, 2003 ²²	2373	X	X-used >0.1 cutpoint		
Ishii, 2001 ²⁹	2615	X	X		

Study	Refid	Included in HR meta-analysis	Included in OR meta-analysis	Excluded from both meta-analyses	Reason for exclusion
Lang, 2001 ³⁰	2630		X-Used ELISA data		
Le Goff, 2007 ⁴⁵	8043			X	
Mallamaci, 2002 ²⁷	2536	X			
Ooi, 1999 ³⁷ , Ooi, 2001 ³⁸	2754; 2666	X	X		
Satyan, 2007 ¹³	1590	X			
Wang, 2007 ¹⁴ , Wang, 2010 ⁵⁹	1743; 6702		X-dichotomized on >0.1 cutpoint		The 2 Wang publications were excluded from the HR meta-analysis because 1743 did not provide a clear cut-point and 6702 had a narrow definition of CVD mortality

Table 4. Studies included/excluded for cTnI and Cardiovascular mortality for Dialysis patients

Study	Refid	Included in HR meta-analysis	Included in OR meta-analysis	Excluded from both meta-analyses	Reason for exclusion
Abaci, 2004 ¹⁹	2184		X		
Apple, 1997 ⁵⁷	2934		X		
Boulier, 2004 ⁵³	2253	X			
Duman, 2005 ¹⁸	2154			X	Insufficient information to derive any values.
Ishii, 2001 ²⁹	2615		X		
Kang, 2009 ⁴⁹	1314	X			
Khan, 2001 ⁵⁵	2613		X		
Lang, 2001 ³⁰	2630		X		
Vichairuangthum, 2006	1903		X		
Yakupoglu, 2002 ⁶⁰	2510		X-excluded in sensitivity analysis		
Geerse, 2012 ⁴⁷	55		X-used 0.1 cutpoint		

Table 5. Studies included/excluded for cTnT and MACE >1 year for Dialysis patients

Study	Refid	Included in HR meta-analysis	Included in OR meta-analysis	Excluded from both meta-analyses	Reason for exclusion
Sahinarslan, 2008 ¹¹	1311		X		
Brunet, 2008 ⁴⁶	1675		X		
Han, 2005 ⁶¹	1418	X	X		

Sommerer, 2007 ⁶²	1725		X-analysis ran with and without study	Sommerer only presents an adjusted odds ratio.
Wang, 2007 ¹⁴	1743		X	
Conway, 2005 ⁶³	2043		X	
Iliou, 2003 ²²	2373	X	X	
Porter, 2000 ⁴⁰	2693		X	
Apple, 1997 ⁵⁷	2934		X	

Table 6. Studies included/excluded for cTnl and MACE >1 year for Dialysis patients

Study	Refid	Included in OR meta-analysis	Included in sensitivity analysis #1	Included in sensitivity analysis #2	Excluded from meta-analyses & reason for exclusion
Katerinis, 2008 ⁵⁰	1454			X	
Brunet, 2008 ⁴⁶	1675	X-Used Beckman 0.06 cutpoint	X	X	
Vichairuangthum, 2006 ⁶⁴	1903	X-Used 0.4 cutpoint	X	X	
Troyanov, 2005 ⁶⁵	2069	X-abstracted data from KM curve	X	X	
Hung, 2004 ⁶⁶	2264		X		
Beciani, 2003 ⁶⁷	2436			X	
Yakupoglu, 2002 ⁶⁰	2510				X – This is cardiovascular mortality.
Porter, 2000 ⁴⁰	2693	X-Used Dade 0.4 cutpoint	X	X	
Apple, 1997 ⁵⁷	2934	X	X	X	

Table 7. Studies included/excluded for cTnl and MACE <1 year for Dialysis patients

Study	Refid	Included in OR meta-analysis	Excluded from meta-analyses & reason for exclusion
Roberts, 2004 ⁶⁸	2320	X	
Peetz, 2003 ⁶⁹	2428		X – I don't think there is sufficient data to derive an odds ratio. Using Digitizelt, we were able to get the point estimate and the upper bound of the confidence interval. However, we are not able to abstract the lower bound of the CI. These numbers are very imprecise, so I would be reluctant to use them.
Heeschen, 2000 ⁷⁰	2696	X	
Roppolo, 1999 ⁷¹	2781	X	

References

1. Kalaji FR, Albitar S. Predictive value of cardiac troponin T and I in hemodialysis patients. *Saudi J Kidney Dis Transpl.* 2012 Sep;23(5):939-45. PMID: 22982904.
2. Holden RM, Beseau D, Booth SL, et al. FGF-23 is associated with cardiac troponin T and mortality in hemodialysis patients. *Hemodial Int.* 2012 Jan;16(1):53-8. PMID: 22099949.
3. Hallen J, Madsen L, Ladefoged S, et al. Incremental value of a combination of cardiac troponin T, N-terminal pro-brain natriuretic peptide and C-reactive protein for prediction of mortality in end-stage renal disease. *Scand J Urol Nephrol.* 2011 Mar;45(2):151-8. PMID: 21091090.
4. Codognotto M, Piccoli A, Zaninotto M, et al. Effect of a dialysis session on the prognostic values of NT-proBNP, troponins, endothelial damage and inflammation biomarkers. *J Nephrol.* 2010 Jul-Aug;23(4):465-71. PMID: 20540041.
5. Hickman PE, McGill DA, Talaulikar G, et al. Prognostic efficacy of cardiac biomarkers for mortality in dialysis patients. *Intern Med J.* 2009 Dec;39(12):812-8. PMID: 20233242.
6. Petrovic D, Stojimirovic BB. Cardiac troponins: outcome predictors in hemodialysis patients. *J Artif Organs.* 2009;12(4):258-63. PMID: 20035399.
7. Chrysochou C, Manzoor S, Wright J, et al. Role of renal function and cardiac biomarkers (NT-proBNP and Troponin) in determining mortality and cardiac outcome in atheromatous renovascular disease. *Kidney Blood Press Res.* 2009;32(5):373-9. PMID: 19887825.
8. Bagheri N, Taziki O, Falaknazi K. C- Reactive protein, cardiac troponin T and low albumin are predictors of mortality in hemodialysis patients. *Saudi J Kidney Dis Transpl.* 2009 Sep;20(5):789-93. PMID: 19736474.
9. Roberts MA, Hare DL, Macmillan N, et al. Serial increased cardiac troponin T predicts mortality in asymptomatic patients treated with chronic haemodialysis. *Ann Clin Biochem.* 2009 Jul;46(Pt 4):291-5. PMID: 19454539.
10. Trape J, Perez A, Naval I, et al. Nt-proBNP in haemodialysis patients: a preliminary study. *Scand J Clin Lab Invest.* 2008;68(5):415-20. PMID: 19172698.
11. Sahinarслан A, Guz G, Okyay K, et al. Prognostic value of troponin T and homocysteine in patients with end-stage renal disease. *Turk Kardiyol Dern Ars.* 2008 Sep;36(6):382-7. PMID: 19155641.
12. Helleskov Madsen L, Ladefoged S, Hildebrandt P, et al. Comparison of four different cardiac troponin assays in patients with end-stage renal disease on chronic haemodialysis. *Acute Card Care.* 2008;10(3):173-80. PMID: 18608043.
13. Satyan S, Light RP, Agarwal R. Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. *Am J Kidney Dis.* 2007 Dec;50(6):1009-19. PMID: 18037101.

14. Wang AY, Lam CW, Wang M, et al. Prognostic value of cardiac troponin T is independent of inflammation, residual renal function, and cardiac hypertrophy and dysfunction in peritoneal dialysis patients. *Clin Chem*. 2007 May;53(5):882-9. PMID: 17395709.
15. Havekes B, van Manen JG, Krediet RT, et al. Serum troponin T concentration as a predictor of mortality in hemodialysis and peritoneal dialysis patients. *Am J Kidney Dis*. 2006 May;47(5):823-9. PMID: 16632021.
16. Sharma R, Gaze DC, Pellerin D, et al. Cardiac structural and functional abnormalities in end stage renal disease patients with elevated cardiac troponin T. *Heart*. 2006 Jun;92(6):804-9. PMID: 16216854.
17. Sharma R, Pellerin D, Gaze DC, et al. Dobutamine stress echocardiography and cardiac troponin T for the detection of significant coronary artery disease and predicting outcome in renal transplant candidates. *Eur J Echocardiogr*. 2005 Oct;6(5):327-35. PMID: 15985387.
18. Duman D, Tokay S, Toprak A, et al. Elevated cardiac troponin T is associated with increased left ventricular mass index and predicts mortality in continuous ambulatory peritoneal dialysis patients. *Nephrol Dial Transplant*. 2005 May;20(5):962-7. PMID: 15741207.
19. Abaci A, Ekici E, Oguzhan A, et al. Cardiac troponins T and I in patients with end-stage renal disease: the relation with left ventricular mass and their prognostic value. *Clin Cardiol*. 2004 Dec;27(12):704-9. PMID: 15628116.
20. Fernandez-Reyes MJ, Mon C, Heras M, et al. Predictive value of troponin T levels for ischemic heart disease and mortality in patients on hemodialysis. *J Nephrol*. 2004 Sep-Oct;17(5):721-7. PMID: 15593041.
21. Ie EH, Klootwijk PJ, Weimar W, et al. Significance of acute versus chronic troponin T elevation in dialysis patients. *Nephron Clin Pract*. 2004;98(3):c87-92. PMID: 15528943.
22. Iliou MC, Fumeron C, Benoit MO, et al. Prognostic value of cardiac markers in ESRD: Chronic Hemodialysis and New Cardiac Markers Evaluation (CHANCE) study. *Am J Kidney Dis*. 2003 Sep;42(3):513-23. PMID: 12955679.
23. Choy JB, Armstrong PW, Ulan RA, et al. Do cardiac troponins provide prognostic insight in hemodialysis patients? *Can J Cardiol*. 2003 Jul;19(8):907-11. PMID: 12876611.
24. deFilippi C, Wasserman S, Rosanio S, et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. *JAMA*. 2003 Jul 16;290(3):353-9. PMID: 12865376.
25. Scott B, Deman A, Peeters P, et al. Cardiac troponin T and malondialdehyde modified plasma lipids in haemodialysis patients. *Nephrol Dial Transplant*. 2003 Apr;18(4):737-42. PMID: 12637643.
26. Lowbeer C, Gutierrez A, Gustafsson SA, et al. Elevated cardiac troponin T in peritoneal dialysis patients is associated with CRP and predicts all-cause mortality and cardiac death. *Nephrol Dial Transplant*. 2002 Dec;17(12):2178-83. PMID: 12454230.
27. Mallamaci F, Zoccali C, Parlongo S, et al. Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. *Am J Kidney Dis*. 2002 Jul;40(1):68-75. PMID: 12087563.

28. Deegan PB, Lafferty ME, Blumsohn A, et al. Prognostic value of troponin T in hemodialysis patients is independent of comorbidity. *Kidney Int.* 2001 Dec;60(6):2399-405. PMID: 11737616.
29. Ishii J, Nomura M, Okuma T, et al. Risk stratification using serum concentrations of cardiac troponin T in patients with end-stage renal disease on chronic maintenance dialysis. *Clin Chim Acta.* 2001 Oct;312(1-2):69-79. PMID: 11580911.
30. Lang K, Schindler S, Forberger C, et al. Cardiac troponins have no prognostic value for acute and chronic cardiac events in asymptomatic patients with end-stage renal failure. *Clin Nephrol.* 2001 Jul;56(1):44-51. PMID: 11499658.
31. Dierkes J, Domrose U, Westphal S, et al. Cardiac troponin T predicts mortality in patients with end-stage renal disease. *Circulation.* 2000 Oct 17;102(16):1964-9. PMID: 11034946.
32. Stolear JC, Georges B, Shita A, et al. The predictive value of cardiac troponin T measurements in subjects on regular haemodialysis. *Nephrol Dial Transplant.* 1999 Aug;14(8):1961-7. PMID: 10462278.
33. Mockel M, Schindler R, Knorr L, et al. Prognostic value of cardiac troponin T and I elevations in renal disease patients without acute coronary syndromes: a 9-month outcome analysis. *Nephrol Dial Transplant.* 1999 Jun;14(6):1489-95. PMID: 10383013.
34. Musso P, Cox I, Vidano E, et al. Cardiac troponin elevations in chronic renal failure: prevalence and clinical significance. *Clin Biochem.* 1999 Mar;32(2):125-30. PMID: 10211629.
35. Apple FS, Murakami MM, Pearce LA, et al. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. *Circulation.* 2002 Dec 3;106(23):2941-5. PMID: 12460876.
36. Apple FS, Murakami MM, Pearce LA, et al. Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. *Clin Chem.* 2004 Dec;50(12):2279-85. PMID: 15364888.
37. Ooi DS, Veinot JP, Wells GA, et al. Increased mortality in hemodialyzed patients with elevated serum troponin T: a one-year outcome study. *Clin Biochem.* 1999 Nov;32(8):647-52. PMID: 10638948.
38. Ooi DS, Zimmerman D, Graham J, et al. Cardiac troponin T predicts long-term outcomes in hemodialysis patients. *Clin Chem.* 2001 Mar;47(3):412-7. PMID: 11238290.
39. Porter GA, Norton T, Bennett WB. Troponin T, a predictor of death in chronic haemodialysis patients. *Eur Heart J.* 1998 Nov;19 Suppl N:N34-7. PMID: 9857937.
40. Porter GA, Norton T, Bennett WM. Long term follow up of the utility of troponin T to assess cardiac risk in stable chronic hemodialysis patients. *Clin Lab.* 2000;46(9-10):469-76. PMID: 11034532.
41. Hocher B, Ziebig R, Altermann C, et al. Different impact of biomarkers as mortality predictors among diabetic and nondiabetic patients undergoing hemodialysis. *J Am Soc Nephrol.* 2003 Sep;14(9):2329-37. PMID: 12937310.
42. Hocher B, Ziebig R, Krause R, et al. Relaxin is an independent risk factor predicting death in male patients with end-stage kidney disease. *Circulation.* 2004 May 18;109(19):2266-8. PMID: 15136497.
43. Hocher B, Kalk P, Godes M, et al. Gender-dependent impact of risk factors for cardiovascular and non-cardiovascular mortality in end-stage renal disease patients on haemodialysis. *Kidney Blood Press Res.* 2008;31(5):360-6. PMID: 19023219.

44. Svensson M, Gorst-Rasmussen A, Schmidt EB, et al. NT-pro-BNP is an independent predictor of mortality in patients with end-stage renal disease. *Clin Nephrol*. 2009;71(4):380-6.
45. Le Goff C, Bovy C, Aldenhoff MC, et al. Three-year prognostic interest of cardiac troponin T (cTnT) and amino-terminal pro-B-natriuretic peptide (NT-proBNP) in hemodialyzed patients. *Immuno-Analyse et Biologie Specialisee*. 2007;22(6):377-83.
46. Brunet P, Oddoze C, Paganelli F, et al. Cardiac troponins I and T in hemodialysis patients without acute coronary syndrome. *Int J Cardiol*. 2008 Sep 26;129(2):205-9. PMID: 17662483.
47. Geerse DA, van Berkel M, Vogels S, et al. Moderate elevations of high-sensitivity cardiac troponin I and B-type natriuretic peptide in chronic hemodialysis patients are associated with mortality. *Clin Chem Lab Med*. 2012 Dec 10;1-8. PMID: 23241607.
48. Artunc F, Mueller C, Breidhardt T, et al. Sensitive troponins--which suits better for hemodialysis patients? Associated factors and prediction of mortality. *PLoS One*. 2012;7(10):e47610. PMID: 23077650.
49. Kang EW, Na HJ, Hong SM, et al. Prognostic value of elevated cardiac troponin I in ESRD patients with sepsis. *Nephrol Dial Transplant*. 2009 May;24(5):1568-73. PMID: 19145004.
50. Katerinis I, Nguyen QV, Magnin JL, et al. Cardiac findings in asymptomatic chronic hemodialysis patients with persistently elevated cardiac troponin I levels. *Ren Fail*. 2008;30(4):357-62. PMID: 18569907.
51. Kanwar M, Hashem M, Rosman H, et al. Usefulness of clinical evaluation, troponins, and C-reactive protein in predicting mortality among stable hemodialysis patients. *Am J Cardiol*. 2006 Nov 1;98(9):1283-7. PMID: 17056347.
52. Hussein M, Mooij J, Roujouleh H, et al. Cardiac troponin-I and its prognostic significance in a dialysis population. *Hemodial Int*. 2004 Oct 1;8(4):332-7. PMID: 19379438.
53. Boulrier A, Jaussent I, Terrier N, et al. Measurement of circulating troponin Ic enhances the prognostic value of C-reactive protein in haemodialysis patients. *Nephrol Dial Transplant*. 2004 Sep;19(9):2313-8. PMID: 15252159.
54. Farkouh ME, Robbins MJ, Zafar MU, et al. Association between troponin I levels and mortality in stable hemodialysis patients. *Am J Med*. 2003 Feb 15;114(3):224-6. PMID: 12637137.
55. Khan IA, Wattanasuwan N, Mehta NJ, et al. Prognostic value of serum cardiac troponin I in ambulatory patients with chronic renal failure undergoing long-term hemodialysis: a two-year outcome analysis. *J Am Coll Cardiol*. 2001 Oct;38(4):991-8. PMID: 11583870.
56. Morton AR, Collier CP, Ali N, et al. Cardiac troponin I in patients receiving renal replacement therapy. *ASAIO J*. 1998 Sep-Oct;44(5):M433-5. PMID: 9804466.
57. Apple FS, Sharkey SW, Hoefl P, et al. Prognostic value of serum cardiac troponin I and T in chronic dialysis patients: a 1-year outcomes analysis. *Am J Kidney Dis*. 1997 Mar;29(3):399-403. PMID: 9041216.
58. Hojs R, Ekart R, Hojs Fabjan T, et al. Cardiac troponin T (cTnT) in hemodialysis patients with asymptomatic and symptomatic atherosclerosis. *Arch Med Res*. 2005 Jul-Aug;36(4):367-71. PMID: 15950076.
59. Wang AY, Lam CW, Chan IH, et al. Sudden cardiac death in end-stage renal disease patients: a 5-year prospective analysis. *Hypertension*. 2010 Aug;56(2):210-6. PMID: 20606110.

60. Yakupoglu U, Ozdemir FN, Arat Z, et al. Can troponin-I predict cardiovascular mortality due to myocardial injury in hemodialysis patients? *Transplant Proc.* 2002 Sep;34(6):2033-4. PMID: 12270303.
61. Han JH, Lindsell CJ, Ryan RJ, et al. Changes in cardiac troponin T measurements are associated with adverse cardiac events in patients with chronic kidney disease. *Am J Emerg Med.* 2005 Jul;23(4):468-73. PMID: 16032613.
62. Sommerer C, Beimler J, Schwenger V, et al. Cardiac biomarkers and survival in haemodialysis patients. *Eur J Clin Invest.* 2007 May;37(5):350-6. PMID: 17461980.
63. Conway B, McLaughlin M, Sharpe P, et al. Use of cardiac troponin T in diagnosis and prognosis of cardiac events in patients on chronic haemodialysis. *Nephrol Dial Transplant.* 2005 Dec;20(12):2759-64. PMID: 16188899.
64. Vichairuangthum K, Leowattana W, Ong-Ajyooth L, et al. The relationship between serum concentration of cardiac troponin I in chronic renal failure patients and cardiovascular events. *J Med Assoc Thai.* 2006 May;89(5):714-20. PMID: 16756060.
65. Troyanov S, Ly QH, Schampaert E, et al. Diagnostic specificity and prognostic value of cardiac troponins in asymptomatic chronic haemodialysis patients: a three year prospective study. *Heart.* 2005 Sep;91(9):1227-8. PMID: 16103574.
66. Hung SY, Hung YM, Fang HC, et al. Cardiac troponin I and creatine kinase isoenzyme MB in patients with intradialytic hypotension. *Blood Purif.* 2004;22(4):338-43. PMID: 15218282.
67. Beciani M, Tedesco A, Violante A, et al. Cardiac troponin I (2nd generation assay) in chronic haemodialysis patients: prevalence and prognostic value. *Nephrol Dial Transplant.* 2003 May;18(5):942-6. PMID: 12686669.
68. Roberts MA, Fernando D, Macmillan N, et al. Single and serial measurements of cardiac troponin I in asymptomatic patients on chronic hemodialysis. *Clin Nephrol.* 2004 Jan;61(1):40-6. PMID: 14964456.
69. Peetz D, Schutt S, Sucke B, et al. Prognostic value of troponin T, troponin I, and CK-MBmass in patients with chronic renal failure. *Med Klin (Munich).* 2003 Apr 15;98(4):188-92. PMID: 12715142.
70. Heesch C, Deu A, Langenbrink L, et al. Analytical and diagnostic performance of troponin assays in patients suspicious for acute coronary syndromes. *Clin Biochem.* 2000 Jul;33(5):359-68. PMID: 11018687.
71. Roppolo LP, Fitzgerald R, Dillow J, et al. A comparison of troponin T and troponin I as predictors of cardiac events in patients undergoing chronic dialysis at a Veteran's Hospital: a pilot study. *J Am Coll Cardiol.* 1999 Aug;34(2):448-54. PMID: 10440158.

Appendix F: Troponin Assays for Background Reference

Troponin assay (cTnI, cTnT, hscTnI, hsCTnT)	Manufacturer	Assay name	Assay Generation	CV (mcg/L)	99th percentile (mcg/L)	Reference population for 99thtile	Source reference
cTnI	Abbot Laboratories	ADV AxSYM cTnI Immunoassay	NR	0.4	0.04	NR	Storti S, Prontera C, Parri MS, et al. Evaluation of the analytical performance of the advanced method for cardiac troponin I for the AxSYM platform: comparison with the old method and the Access system. Clin Chem Lab Med 2006;44(8):1022-29 PMID: 16879072
cTnI	Abbot Laboratories	Architect ci8200	2nd	0.032	0.012	NR	Tate JR, Ferguson W, Bais R, et al. The determination of the 99 th centile level for troponin assays in an Australian reference population. Ann Clin Biochem. 2008;45(Pt 3):275-88 PMID:18482916
cTnI	Abbot Laboratories	Architect STAT	NR	0.03	0.012	N: 480 Age: 16 to 82	Lam Q, Black M, Youdell O, et al. Performance evaluation and subsequent clinical experience with the Abbott Automated Architect STAT Troponin-I assay. Clin Chem. 2006;52(2):298-300 PMID: 16449210
cTnI	Abbot Laboratories	AxSYM	NR	0.8	0.5	NR	Apple FS, Quist HE, Doyle PJ, et al. Plasma 99 th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem. 2003;49(8):1331-6
cTnI	Astra	Cardiac STATus Troponin I Rapid Test					Unable to find single source providing CV in mcg/L and 99 th percentile for same reference group.
cTnI	Baxter	Stratus					Unable to find single source providing CV in mcg/L and 99 th percentile for same reference group.
cTnI	Bayer	ACS: 180	NR	0.37	0.1	Eight serum pool samples (details NR)	Panteghini M, Pagani F, Yeo KT, et al. Evaluation of imprecision for cardiac troponin assays at low-range concentration. Clin Chem. 2004;50(2):327-32 PMID: 14656904

Troponin assay (cTnI, cTnT, hscTnI, hsCTnT)	Manufacturer	Assay name	Assay Generation	CV (mcg/L)	99th percentile (mcg/L)	Reference population for 99thtile	Source reference
cTnI	Bayer	ADVIA Centaur	NR	0.35	0.1	NR	Apple FS, Quist HE, Doyle PJ, et al. Plasma 99 th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem. 2003;49(8):1331-6
cTnI	Bayer	Immuno1	NR	0.34	0.1	Eight serum pool samples (details NR)	Panteghini M, Pagani F, Yeo KT, et al. Evaluation of imprecision for cardiac troponin assays at low-range concentration. Clin Chem. 2004;50(2):327-32 PMID: 14656904
hscTnI	Bayer	Advia Cenatur (Ultra)	NR	0.33	0.07	NR	Foohay L, Neighbor S, Buchmelter T, et al. Troponin clinical applications. Bayer Healthcare Diagnostics Division. 2006 (http://www.medical.siemens.com/siemens/en_GLOBAL/gg_diag_FBAs/files/brochures/TnI_Assay/tni_wp2.pdf)
cTnI	Beckman Coulter	Access Acu	NR	0.06	0.04	NR	IFCC Troponin tables
cTnI	Beckman Coulter	AccuTnI	NR	0.06	0.04	NR	Morrow DA, Rifai N, Sabatine MS, et al. Evaluation of the Accu TnI cardiac troponin I assay for risk assessment in acute coronary syndromes. Clin Chem. 2003;49(8):1396-8 PMID: 12881457
cTnI	Beckman Coulter	Chemiluminescent Immunoenzymatic Assay					"Chemiluminescent Immunoenzymatic Assay" is too broad of a term, need more specific assay name.
cTnI	Bio-Merieux	Vidas	NR	0.11	0.01	N: 747 Age: 20 to 81	IFCC Troponin tables
cTnI	BioSite Diagnostics	Triage Cardiac Panel	NR	0.05	0.05	NR	http://emj.bmj.com/content/suppl/2012/03/21/emermed-2011-200667.DC1/emermed-2011-200667-s6.pdf
hscTnI	Boehringer Mannheim (company bought by Roche)	Elecsys	NR	0.005	0.014	NR	Hoeller R, Rubini Gimenez M, Reichlin T, et al. Normal presenting levels of high-sensitivity troponin and myocardial infarction. Heart. 2013: Epub ahead of print PMID: 23604180

Troponin assay (cTnI, cTnT, hscTnI, hsCTnT)	Manufacturer	Assay name	Assay Generation	CV (mcg/L)	99th percentile (mcg/L)	Reference population for 99thtile	Source reference
cTnT	Boehringer Mannheim	Elecsys	3	0.035	0.01	NR	Fesmire FM, Decker WW, Diercks DB, et al. Clinical policy: critical issues in the evaluation and management of adult patients with non-ST-segment elevation acute coronary syndromes. Ann Emerg Med. 2006;48(30):270-301 PMID: 16934648
cTnT	Boehringer Mannheim	Cardiac Reader					"Cardiac Reader" is too broad of a term, need more specific assay name.
cTnT	Boehringer Mannheim	ELISA	2	0.01	0.1	N: 323, with suspected AMI	Muller-Bardoff M, Hallermayer K, Schroder A, et al. Improved troponin T ELISA specific for cardiac troponin T isoform: assay development and analytical and clinical validation. Clin Chem. 1997;43(3):458-66 PMID: 9068589
cTnT	Boehringer Mannheim	TropT-sensitive Rapid Test					Unable to find single source providing CV in mcg/L and 99 th percentile for same reference group.
cTnT	Boehringer Mannheim	Enzymun					Unable to find single source providing CV in mcg/L and 99 th percentile for same reference group.
cTnT	Boehringer Mannheim	TROP TRA-Rapid Beside Assay					Unable to find single source providing CV in mcg/L and 99 th percentile for same reference group.
cTnI	Dade Behring	Opus	NR	0.9	0.1	Eight serum pool samples (details NR)	Panteghini M, Pagani F, Yeo KT, et al. Evaluation of imprecision for cardiac troponin assays at low-range concentration. Clin Chem. 2004;50(2):327-32 PMID: 14656904
cTnI	Dade Behring	OPUS Plus	1	0.3	0.1	NR	Fesmire FM, Decker WW, Diercks DB, et al. Clinical policy: critical issues in the evaluation and management of adult patients with non-ST-segment elevation acute coronary syndromes. Ann Emerg Med. 2006;48(30):270-301 PMID: 16934648
cTnI	Dade Behring	Opus Magnum Analyzer	NR	3.0 (12% CV)	0.5	NR	Kontos MC, Shah R, Fritz LM, et al. Implication of different cardiac troponin I levels for clinical outcomes and prognosis of acute chest pain patients. J AM Coll Cardiol. 2004;43(6):958-65 PMID: 15028350

Troponin assay (cTnI, cTnT, hscTnI, hsCTnT)	Manufacturer	Assay name	Assay Generation	CV (mcg/L)	99th percentile (mcg/L)	Reference population for 99thtile	Source reference
cTnI	Dade Behring	Stratus	NR	0.1	0.07	Eight serum pool samples (details NR)	Panteghini M, Pagani F, Yeo KT, et al. Evaluation of imprecision for cardiac troponin assays at low-range concentration. Clin Chem. 2004;50(2):327-32 PMID: 14656904
cTnI	Dade Behring	Stratus-II Enzyme Immunoassay	NR	0.6	<0.35 (97.5 percentile, 99 th % NR)	NR	Boriani G, Biffi M, Cervi V, et al. Evaluation of myocardial injury following repeated internal atrial shocks by monitoring serum cardiac troponin I levels. Chest. 2000;118(2):342-7 PMID: 10936122
cTnI	Diagnostic Product Corp	Immulite	1st	0.6	0.2	NR	Fesmire FM, Decker WW, Diercks DB, et al. Clinical policy: critical issues in the evaluation and management of adult patients with non-ST-segment elevation acute coronary syndromes. Ann Emerg Med. 2006;48(30):270-301 PMID: 16934648
cTnI	Johnson and Johnson	Vitros ECi	1st	0.12	0.08	NR	Fesmire FM, Decker WW, Diercks DB, et al. Clinical policy: critical issues in the evaluation and management of adult patients with non-ST-segment elevation acute coronary syndromes. Ann Emerg Med. 2006;48(30):270-301 PMID: 16934648
cTnI	Ortho Clinical Diagnostics	Vitros					Search for "Vitros" brings up every assay in the Vitros assay series.
hscTnI	Ortho Clinical Diagnostics	Vitro ES	NR	0.034	0.034	NR	IFCC Troponin tables (from Erin)
cTnT	Roche	Cardiac-ELISA ES300	2nd	0.06	0.01	N: 750 Age: 58 to 78	Jernberg T, Venge P, Lindahl B. Comparison between second and third generation troponin T assay in patients with symptoms suggestive of an acute coronary syndrome but without ST segment elevation. Cardiology. 2003;100(1):29-35 PMID: 12975543
cTnT	Roche	Immunochemical test					"Immunochemical test" is not a specific assay, refers to broad range of assay types that use immunochemical technology.

Troponin assay (cTnI, cTnT, hscTnI, hsCTnT)	Manufacturer	Assay name	Assay Generation	CV (mcg/L)	99th percentile (mcg/L)	Reference population for 99thtile	Source reference
cTnT	Roche	ECLIA (electrochemiluminescence immunoassay, used in Elecsys)	NR	0.013	0.014	N: 294, with chest pain and suspected AMI	Roche Diagnostics GmbH. Troponin T hs instruction insert for Elecsys and Cobas analyzers (05199620001V4 English). REF 05092744 190;2011 – 02, V4:1 – 5.
cTnT	Roche	ECLusys					Unable to find single source providing CV in mcg/L and 99 th percentile for same reference group.
cTnT	Roche	Enzymun Troponin T – ES700					Unable to find single source providing CV in mcg/L and 99 th percentile for same reference group.
cTnT	Roche	Modular Analyzer					Unable to find single source providing CV in mcg/L and 99 th percentile for same reference group.
cTnT	Roche	Trop T					Unable to find single source providing CV in mcg/L and 99 th percentile for same reference group.
cTnI	Siemens	Dimensional RxL CTNI	NR	0.14	0.07	N: 342 Age: 18 to 83	IFCC Troponin tables (from Erin)
cTnI	Siemens	Lithium-Heparin Plasma					Unable to find single source providing CV in mcg/L and 99 th percentile for same reference group.
cTnI	Siemens	Advia Centaur	NR	0.4	0.4	NR	Thygesen K, Mair J, Giannitsis E, et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J. 2012;33(18):2252-7 PMID: 22723599
cTnI	Siemens	Heterogeneous Immunoassay					“Heterogeneous Immunoassay” is too broad of a term, need more specific assay name.
cTnI	Siemens	Immolute 1000 Troponin I Kit	NR	0.22	0.19	N: 300	IFCC Troponin tables (from Erin)
hscTnI	Siemens	Advia Centaur	NR	0.03	0.04	N: 838, patients with chest pain and non-diagnostic electrocardiogram	Collinson PO, Gaze D, Thokala P, et al. What is the diagnostic accuracy of highly sensitive troponin assays in the emergency room population. Clin Chem. 2012;58(10):A4-A5 (abstract only)

Troponin assay (cTnI, cTnT, hscTnI, hsCTnT)	Manufacturer	Assay name	Assay Generation	CV (mcg/L)	99th percentile (mcg/L)	Reference population for 99th%tile	Source reference
hscTnI	Siemens	Dimension Vista 1500	NR	0.003	0.009	NR	Hoeller R, Rubini Gimenez M, Reichlin T, et al. Normal presenting levels of high-sensitivity troponin and myocardial infarction. Heart. 2013: Epub ahead of print PMID: 23604180
cTnI	Tosoh	AIA-600II	2nd	0.06	<0.06	NR	Apple FS, Quist HE, Doyle PJ, et al. Plasma 99 th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem. 2003;49(8):1331-6
cTnI	Tosoh	AIA	2	0.06	0.06	NR	Fesmire FM, Decker WW, Diercks DB, et al. Clinical policy: critical issues in the evaluation and management of adult patients with non-ST-segment elevation acute coronary syndromes. Ann Emerg Med. 2006;48(3):270-301 PMID: 16934648
cTnI	Tosoh	AIA200					Unable to find single source providing CV in mcg/L and 99 th percentile for same reference group.